Evogene's News http://www.evogene.com/News-Events/News en-us http://www.evogene.com/rss/press-releases 60 Marrone Bio Innovations and Evogene Advance Novel Bacteria and Related Proteins Beyond Discovery into Insecticidal Product Development Phase http://www.evogene.com/News-Events/Press-Releases/2016/Marrone-Bio-Innovations-and-Evogene-Advance-Novel-Bacteria-and-Related-Proteins-Beyond-Discovery-into-Insecticidal-Product-Development-Phase- Davis, California and Rehovot, Israel - March 28, 2017 - Marrone Bio Innovations Inc. (MBI), (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that MBI will advance certain novel bacteria and Evogene-identified related proteins into MBI's bioinsecticide product development pipeline under their previously announced multi-year collaboration for the discovery and development of novel insect control solutions. According to MarketsandMarkets, the bioinsecticides market was estimated to be valued at $1.2 billion in 2015. It is projected to grow at a compound annual growth rate of 18.3% from 2016 to 2021, reaching $3.2 billion by 2021. However, MBI also expects to access the larger chemical insecticide market, valued at $14 billion in 2014, according to Jefferies. MBI has historically brought new biopesticides to the market in approximately 3-5 years or less. The target pests related to MBI's potential new product include the caterpillar (lepidopteran) and sucking bug (hemipteran/homopteran) species. The collaboration, initiated in July 2014, and supported by funding from the Binational Industrial Research and Development (BIRD) Foundation, aims to bring to market new insect control solutions - both seed traits and bio-insecticides - through leveraging the expertise and distinct assets and capabilities of each party. The parties have agreed to share revenues from any products that may result from this collaboration. Utilizing its proprietary computational platform BiomeMiner® and other predictive discovery capabilities, Evogene identified candidate proteins from tens of thousands of proteins within selected insecticidal strains from MBI's extensive and proprietary bacterial collection. The proteins' bioactivity for pest control was then validated in insect assays, with the result that a subset of the candidate proteins demonstrated positive insecticidal results. The advancement announced today represents the completion of the collaboration's discovery phase and a shift by the companies towards product development. The bacteria that were selected to advance into MBI's pipeline contain candidate proteins with positive insecticidal properties, while in parallel Evogene continues its product development efforts to develop seed trait solutions based on such proteins. Pam Marrone, CEO and Founder of Marrone Bio Innovations, said "It is exciting to see validation of the companies' joint work in the discovery phase as we move toward product development activities. MBI already has significant experience with the development of bioinsecticide products, and we will be targeting our future efforts on filling gaps in our portfolio to better address unmet needs in the market." Ofer Haviv, President and CEO of Evogene, stated, "We are very pleased with the successful completion of the discovery stage for this program with both parties now advancing into product development based on Evogene-identified proteins. We look forward to continuing this collaboration with MBI and to the successful development of new insect control solutions by each of us." About Marrone Bio Innovations Smart. Natural. Solutions. Marrone Bio Innovations, Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI's effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. MBI has four products for agriculture on the market (Regalia®, Grandevo®, Venerate® and Majestene®). MBI also distributes Bio-tam 2.0® for Isagro USA in the western U.S. and MBI also markets Zequanox® for invasive mussels for water markets. MBI also has a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations, the team is dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com. About Evogene Ltd. Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. * * * Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertain-ties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI's or Evogene's views as of any subsequent date. Examples of such statements include statements regarding potential products or product candidates that may be identified and developed by MBI or Evogene, including the isolation, development, commercialization, market for, potential benefits and uses of or revenues from any such product or product candidate, the results of any studies or validation tests on any product candidates, MBI's or Evogene's efforts with respect to other potential products, the ongoing strategic partnership between MBI and Evogene and funding by BIRD Foundation. Such forward-looking statements are based on information available to MBI and Evogene as of the date of this release and involve a number of risks and uncertainties, some beyond the either party's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including any difficulty in isolating, developing and commercializing any potential product or product candidate, marketing the potential product with either party's principal customers, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI's or Evogene's performance is contained in their respective filings with the SEC or other appropriate securities authorities. Neither MBI nor Evogene is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise. 28/03/2017 http://www.evogene.com/News-Events/Press-Releases/2016/Marrone-Bio-Innovations-and-Evogene-Advance-Novel-Bacteria-and-Related-Proteins-Beyond-Discovery-into-Insecticidal-Product-Development-Phase- Evogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-Innovative-Approach-for-Improving-Cannabis-for-Medical-Needs-at-CannaTech-Summit Rehovot, Israel - March 07, 2017 - Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that Mr. Yuval Ben-Galim, Evogene's COO, will present at the CannaTech 2017 annual cannabis summit, taking place in Tel-Aviv, Israel on March 21st. The summit will focus on acceleration of cannabis innovation, with wide spectrum of global industry leaders spanning from science to government. Cannabis is now being widely acknowledged for its potential to facilitate medicinal benefits. One of the major limitations in the field is developing various stable cannabis strains that contain the desired active components that meet precise medicinal needs for different diseases and indications. As we recently disclosed, cannabis is one of the crops Evogene is evaluating for the extension of its program focus. At the conference, Mr. Ben-Galim will present Evogene's approach, which utilizes the Company's predictive biology technology platform to develop innovative cannabis strains that are specifically generated for medicinal requirements, to potentially address this challenge. About Evogene Ltd.: Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 07/03/2017 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-Innovative-Approach-for-Improving-Cannabis-for-Medical-Needs-at-CannaTech-Summit Evogene Reports Fourth Quarter and Full Year 2016 Financial Results http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Fourth-Quarter-and-Full-Year-2016-Financial-Results Rehovot, Israel - February 27, 2017 - Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity, announced today its financial results for the fourth quarter and year ended December 31, 2016. Ofer Haviv, Evogene's President and CEO, stated: "This past year was a period of rapid advancement across multiple fronts for Evogene. We believe that our development progress and the validation results we achieved have positioned the Company for a potentially transformative 2017." Some of Evogene's key highlights for 2016 included: In our yield and stress product program with Monsanto, a subset of the Company's discovered genes demonstrated positive results towards yield improvement in corn and soybean trials conducted by Monsanto; In our internal insect control product program, five novel microbial genes displayed insecticidal, toxic activity on target insects via potentially new modes of action; Our herbicide discovery collaboration with BASF is progressing and chemical compounds delivered by Evogene, having been predicted to inhibit the validated collaboration targets, will be tested in BASF's herbicide pipeline; In our internal herbicide discovery program, ten chemical compounds that were computationally predicted to impact six Evogene discovered targets, were validated for herbicidal activity in plants; In our internal bio-stimulants program, ten microbial candidates exhibited positive performance for trait improvement in corn field validation. "We are very proud of these impressive results achieved in 2016 in each of our target markets, which also provide additional proof of the predictive capability of our unique technology infrastructure. We are now evaluating the further enhancement of this discovery infrastructure with additional capabilities such as genome editing, and the extension of our program focus to additional market areas such as bio-pesticides and insecticides, and to new crops such as cannabis," added Mr. Haviv "We enthusiastically look forward to the remainder of this year as we continue to increase the commercial potential of our overall business. In addition to our leadership position in discovery, our progress is indicative of the fact that Evogene is moving downstream towards becoming a significant player in early-stage ag product development," concluded Mr. Haviv. Financial results for the fourth quarter and full year 2016: Cash position: As of December 31, 2016, Evogene had $88.2 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $12.5 million for the year. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its net cash usage for full year 2017 will be in the range of $16 to $18 million. Revenues primarily consist of research and development payments, reflecting R&D cost reimbursement under certain of our collaboration agreements. The majority of these agreements also provide for development milestone payments and royalties or other forms of revenue sharing from successfully developed products, and therefore, longer term, the Company anticipates that its future revenues and profitability will largely reflect the receipt of such payments from its existing and future collaborations. Revenues for the fourth quarter of 2016 were $1.2 million compared to $2.5 million for the same period in 2015. Revenues for the year ended December 31, 2016 were $6.5 million, compared to $11.1 million for the same period in 2015. This decline reflects the net decrease in such research and development payments in accordance with the work plans under Evogene's various collaboration agreements. It includes changes in the scope and type of activities undertaken by the Company as part of its yield and stress collaboration with Monsanto, whereby resource intensive activities, such as novel gene discovery and validation, evolved to focus increasingly on optimization activities supporting Monsanto's ongoing development and advancement efforts of Evogene discovered genes. Cost of revenues includes research and development expenses related to the Company's on-going activities in support of collaboration agreements. Cost of revenues for the fourth quarter of 2016 was $1.1 million compared to $2.0 million for the same period in 2015. Cost of revenues for the year ended December 31, 2016 was $5.6 million, compared to $8.3 million, for the same period in 2015. The net decrease primarily related to the change in the scope and type of activities performed under Evogene's collaboration with Monsanto, as noted above. R&D expenses for the fourth quarter of 2016 were $4.7 million, compared to $4.1 million for the same period in 2015. R&D expenses for the year ended December 31, 2016 were $16.4 million, compared to $14.4 million for the same period in 2015. This increase is largely related to the expansion of activities, primarily focused on the development of computational platforms, as well as discovery and validation activities in our key growth segments - insect control, ag-chemicals and ag-biologicals. Operating loss for the fourth quarter of 2016 was $6.2 million (including a non-cash expense of approximately $0.6 million for share-based compensation), compared with $5.4 million (including a non-cash expense of approximately $1.1 million for share-based compensation), for the same period in 2015. Operating loss for the year ended December 31, 2016, was $21.1 million (including a non-cash expense of approximately $2.9 million for share-based compensation), compared to $17.9 million (including a non-cash expense of approximately $4.4 million for share-based compensation), for the same period in 2015. The increase in operating loss was primarily due to the decrease in revenues discussed above, which were partially offset by the net decline in other expense categories. Net loss for the fourth quarter of 2016 was $6.6 million compared with a net loss of $5.5 million for the same period in 2015. Net loss for the year ended December 31, 2016, was $19.6 million compared with a net loss of $17.2 million for the same period in 2015. Conference call and webcast details: Evogene management will host a conference call today at 9:00 am Eastern time, 16:00 Israel time, to discuss the results. US-based participants are invited to access the call by dialing 1-888-407-2553, and participants from Israel and other countries are invited to access the call at 972-3-918-0610. A replay of the conference call will be available beginning at approximately 1:00 pm Eastern time, 20:00 Israel time today, and will be accessible through March 1, 2017. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5901. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. Financial Tables -xxx - About Evogene Ltd.: Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 27/02/2017 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Fourth-Quarter-and-Full-Year-2016-Financial-Results Evogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-ICL-Innovation-Sign-Collaboration-for-Development-of-Crop-Enhancers Rehovot, and Tel Aviv, Israel - February 14, 2017 - Evogene Ltd. (NASDAQ; TASE: EVGN), a leading company for the improvement of crop productivity, and ICL Innovation, a subsidiary of ICL (NYSE; TASE: ICL), announced today they have entered a multi-year research and development collaboration for the discovery of novel crop enhancers for the improvement of nutrient use efficiency in selected crops. Under the terms of the agreement, Evogene will utilize its computational discovery platform to identify the potential of certain compounds to improve nutrient use efficiency. Successful candidates identified from the collaboration may be integrated into ICL's product pipeline for further development and formulation. Expected commercialization of products derived from the joint efforts may occur as early as five years from initiation of the research and development activities. "This collaboration brings two very unique companies together, each with very distinct capabilities and strong track record," said Ofer Haviv, Evogene's President and CEO. "ICL currently offers one of the industry's most robust and diverse fertilizer portfolios, and we believe that, together with Evogene's market leadership in bringing predictive biology to agricultural innovation, we can introduce novel chemistry-based products for enhancing crop productivity through better utilization of applied specialty fertilizers." "This is Evogene's first collaboration in the area of specialty fertilizers, and we are very excited with the opportunity it presents Evogene to apply its capabilities in a new, and very significant, market segment in agriculture," added Mr. Haviv. Eyal Ginzberg, CTO of ICL: "We are excited to embark on this cutting edge research with Evogene, a company well recognized for its high competency in genomic computational tools. ICL has a unique range of specialty fertilizers including controlled release fertilizers and solubles for fertigation and foliar application. Our products enhance the efficiency of plant nutrition, increase yield and improve crop quality. Our research aims to improve nutrient use efficiency with innovative technologies. We look forward to our collaboration with Evogene, which will give us access to novel crop enhancers to further enhance our product offering." -xxx- About Evogene Ltd.: Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. About ICL: ICL is a global manufacturer of products based on specialty minerals that fulfill humanity's essential needs primarily in three markets: agriculture, food and engineered materials. ICL is a public company whose shares are dual listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL). The company employs approximately 13,000 people worldwide, and its sales in 2015 totaled US$5.4 billion. For more information, visit the company's website at www.icl-group.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of the Companies may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond the Companies' control, including, without limitation, those risk factors contained in the Companies' reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Contact: Karen Mazor, Evogene Director, Public and Investor Relations E: IR@evogene.com T: 972 54 22 88 039 Gadi Ohana, Debby Communications E: gady@debby.co.il T: 972 3-5683000 14/02/2017 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-ICL-Innovation-Sign-Collaboration-for-Development-of-Crop-Enhancers Evogene Fourth Quarter and Full Year 2016 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Fourth-Quarter-and-Full-Year-2016-Earnings-Announcement-Schedule Rehovot, Israel - February 13, 2017 - Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the fourth quarter and full year 2016 on Monday, February 27, 2017. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-407-2553 toll free from the United States, or 972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or 972-3-925-5901 internationally. The replay will be accessible through March 1, 2017, and an archive of the webcast will be available on the Company's website through March 10, 2017. -xxx- About Evogene Ltd.: Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Contact: Karen Mazor, Director Investor Relations E: IR@evogene.com T: 972 54 228 8039 13/02/2017 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Fourth-Quarter-and-Full-Year-2016-Earnings-Announcement-Schedule Evogene to Transfer Stock Exchange Listing to Nasdaq http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Transfer-Stock-Exchange-Listing-to-Nasdaq Rehovot, Israel - December 19, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today that it will transfer its stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). Evogene's ordinary shares will continue to trade on the NYSE until the market close on December 29, 2016. The Company expects its ordinary shares will begin trading on Nasdaq on December 30, 2016, and its shares will continue to trade under the ticker symbol "EVGN". "Nasdaq is home to many of the world's most innovative companies," said Ofer Haviv, President and Chief Executive Officer of Evogene. "Evogene's biological expertise combined with our cutting-edge computational capabilities, positions us as a driving force behind the development of the next-generation of agriculture products, and we are proud to be part of a marketplace that nurtures young, growth oriented companies as we continue to deliver on our long-term vision." "We are excited to welcome Evogene to the Nasdaq family. Evogene is a market leader in the field of crop productivity improvement through biotechnology and one of the innovative companies from Israel which is striving to make this world a better place by using cutting edge technology. Nasdaq, home to the world's largest and most innovative companies, is proud to have over 80 Israeli companies listed, making it the country with the second largest number of companies trading on the Nasdaq after the U.S.," said Nelson Griggs, Executive Vice President, Global Listing Services at Nasdaq. "We look forward to working with and supporting Evogene as it grows and achieves new milestones." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Contact: Karen Mazor Director, Public and Investor Relations E: IR@evogene.com T: 972 54 22 88 039 20/12/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Transfer-Stock-Exchange-Listing-to-Nasdaq Evogene Reports Third Quarter 2016 Financial Results http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Third-Quarter-2016-Financial-Results Rehovot, Israel - November 21, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today its financial results for the third quarter and nine months ended September 30, 2016. Ofer Haviv, Evogene's President and CEO, stated: "We continue to be very pleased with the progress we are seeing in both our on-going collaborations with leading agriculture related companies world-wide, and our own internal programs. In this respect, we are particularly pleased to have recently announced positive results in our Ag-biologicals program, focused on bio-stimulants, for more than ten microbial strains that successfully completed the first year of testing and validation in corn for drought resistance. Further ahead, we will look to out-license advanced microbial strains to relevant partners for further development and commercialization, with the view to have a commercial product offering as early as five to six years from today." "In our seed traits area, where we have active programs for the development of both crop enhancement traits and crop protection traits, we continue to build upon the positive results we announced in several of our most significant programs. These activities include supporting the advancement of our most promising candidate genes further in Monsanto's product development pipeline, and further validation of several successful candidate toxins we identified as part of our insect control program," continued Mr. Haviv. "In addition, this past quarter we expanded our collaboration pipeline with the signing of an agreement with IMAmt, a leading Brazilian developer and marketer of cotton seeds, for the discovery and validation of novel genomic elements to support IMAmt's product development of insect-resistant cotton varieties." "Finally, we continue to successfully advance our program for the discovery of novel chemical compounds for herbicides. This past quarter, chemical compounds identified by Evogene have demonstrated herbicidal activity in plant bio-essay tests and were advanced to the next stage of optimization," concluded Mr. Haviv. Financial results for the period ended September 30, 2016: Cash position: As of September 30, 2016, Evogene had $93.1 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $3.9 million for the third quarter and $7.6 million for the nine months ended September 30, 2016. We expect our net annual cash usage for the current calendar year to be slightly below our previously disclosed range of $14 to $16 million. Revenues primarily consist of research and development payments, reflecting R&D cost reimbursement under certain of our collaboration agreements. The majority of these agreements also provide for development milestone payments and royalties or other forms of revenue sharing from successfully developed products, and therefore, longer term, the Company anticipates that its future revenues and profitability will largely reflect the receipt of such payments from its existing and future collaborations. Revenues for the third quarter of 2016 were $1.5 million compared to $3.3 million for the same period in 2015. Revenues for the nine months ended September 30, 2016 were $5.4 million, compared to $8.7 million for the same period in 2015. This decline reflects the net decrease in such research and development payments in accordance with the work plans under Evogene's various collaboration agreements. It includes changes in the scope and type of activities undertaken by the Company as part of its yield and stress collaboration with Monsanto, whereby resource intensive activities, such as novel gene discovery and validation, evolved to focus increasingly on optimization activities supporting Monsanto's ongoing development with respect to advancing Evogene discovered genes. Cost of revenues include research and development expenses related to the Company's on-going activities in support of collaboration agreements. Cost of revenues for the third quarter of 2016 were $1.4 million compared to $2.5 million for the same period in 2015. Cost of revenues for the nine months ended September 30, 2016, were $4.5 million, compared to $6.2 million, for the same period in 2015. The net decrease primarily related to the change in the scope and type of activities performed under Evogene's collaboration with Monsanto, as noted above. R&D expenses for the third quarter of 2016 were $3.9 million compared to $3.1 million for the same period in 2015. R&D expenses for the nine months ended September 30, 2016, were $11.7 million, compared to $10.3 million for the same period in 2015. This increase largely related to the expansion of activities, primarily focused on the development of computational platforms, as well as discovery and validation activities, in our key growth engines - insect control, ag-chemicals and ag-biologicals. Operating loss for the third quarter of 2016 was $5.2 million compared with $3.8 million for the third quarter of 2015. Operating loss for the nine months ended September 30, 2016, was $14.9 million compared with $12.6 million for the same period in 2015. The increase in operating loss was primarily due to the decrease in revenues discussed above, which were partially offset by the net decline in other expense categories. Net loss for the third quarter of 2016 was $5.1 million compared with a net loss of $3.4 million in the third quarter of 2015. Net loss for the nine months ended September 30, 2016, was $12.9 million compared with a net loss of $11.7 million for the same period in 2015. Conference call and webcast details: Evogene management will host a conference call today at 9:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0610. A replay of the conference call will be available beginning at approximately 1:00 pm Eastern time, 20:00 Israel time today, and will be accessible through November 23, 2016. US-based participants are invited to access the replay by dialing 1-888-254-7270, and participants from Israel and other countries are invited to access the replay at 972-3-925-5937. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. Financial Tables -xxx - About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 21/11/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Third-Quarter-2016-Financial-Results Evogene Announces Positive Field Trial Results in Ag-biologicals Program http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Positive-Field-Trial-Results-in-Ag-biologicals-Program- Rehovot, Israel - November 16, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today positive field trial results conducted in Israel from its Ag-biologicals program, which is currently focused on the development of Bio-stimulant products. In these tests, candidate microbial strains identified and predicted by Evogene for their ability to improve corn resistance to drought conditions, yielded positive efficacy and stability results in the first year of field testing. Ag-biologicals represent a growing approach for driving agriculture productivity, and are being increasingly adopted by farmers to supplement existing solutions of improved seed traits and protective chemicals. Initiated in 2015, Evogene's Ag-biologicals program is currently focused on developing microbial based solutions targeting yield improvement and environmental stress tolerance in key crops, such as corn, soy and wheat. These biologically derived agriculture solutions are based on microbial communities that reside on or within the plant's immediate microbial environment (also known as microbiome). "One of the key challenges facing the Ag-biologicals industry is developing products that demonstrate efficacy and stability across geographies, seasons and germplasms," said Ofer Haviv, CEO and President of Evogene. "Therefore, Evogene's broadly applicable predictive biology platform leverages multiple complex data sets and algorithms to enable the identification, among the huge microbial diversity affecting plants, of those microbial strains that are predicted not only to have the desired efficacy, but also to provide the critical stability required for broad commercial usage." "We are very encouraged by this significant progress within our Ag-biologicals program in less than two years; progress which could only have been achieved through the use of our computational predictive platform," continued Mr. Haviv. "During 2017, we intend to further strengthen our microbial candidate pipeline and in parallel, target additional Ag-biological market segments, such as bio-pesticides, where we can also leverage our already existing extensive predictive capabilities for disease and insect control." According to industry reports, the market for Ag-biological products for 2015 was estimated at approximately $4 billion, and is expected to grow at an annual rate of 12-15 percent. In view of this growing market potential, Ag-biologicals is seen as an attractive market opportunity for Evogene to apply its unique research and product development capabilities. The Company intends to out-license advanced product candidates to collaborators for further development and commercialization. For more details about the results, click here. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 16/11/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Positive-Field-Trial-Results-in-Ag-biologicals-Program- Evogene Third Quarter 2016 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Third-Quarter-2016-Earnings-Announcement-Schedule Rehovot, Israel - November 2, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third quarter of 2016 on Monday, November 21, 2016. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or 972-3-925-5937 internationally. The replay will be accessible through November 23, 2016, and an archive of the webcast will be available on the Company's website through December 2, 2016. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 02/11/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Third-Quarter-2016-Earnings-Announcement-Schedule Evogene and IMAmt Sign Collaboration for Genomic Promoter Discovery and Validation in Cotton http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-IMAmt-Sign-Collaboration-for-Genomic-Promoter-Discovery-and-Validation-in-Cotton Rehovot, Israel and Cuiabá/MT, Brazil - October 19, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading biotechnology company for the improvement of crop productivity, and Instituto Mato-grossense do Algodão (IMAmt), a leading developer and marketer of cotton seeds, announced today a collaboration for the discovery and validation of novel genomic promoters to support IMAmt's product development of insect-resistant cotton varieties. The multi-year collaboration agreement between the companies provides for R&D fees and royalty payments from any future products developed as a result of the collaboration, to be paid to Evogene. As part of the collaboration, Evogene will apply its biology-driven, predictive computational technology to identify novel genomic promoters. The two companies will then work jointly to validate the candidate promoters in cotton. The resulting validated promoters will support IMAmt's product development pipeline of cotton varieties based on Bt toxins, a family of bacterial genes toxic to insects, and featuring resistance to Boll Weevil, a beetle-like pest which feeds on cotton buds and flowers. Genomic promoters are segments of DNA that determine the expression patterns for genes. Such promoters, when used with appropriate genes, are an essential component of improving seed trait efficacy. "We are very excited to support IMAmt's product development efforts in the area of novel insect resistant varieties. This collaboration is indicative of a growing realization in our industry that the selection of the most appropriate promoter is a crucial component in the successful development of a seed trait," said Ofer Haviv, Evogene President and Chief Executive Officer. "Evogene's broadly applicable biology-driven computational platform provides a very unique solution to this need." "We have great expectations towards this partnership with Evogene and we are sure that it will be crucial for the success of our project of developing cotton GM plants resistant to boll weevil, key pest of this crop in South America" said Alvaro Salles, IMAmt Chief Executive Officer. The agreement expands Evogene's activity in the field of promoter discovery and follows the Company's recent initial results for successful promoter validation. About IMAmt: Instituto Mato-grossense do Algodão (IMAmt) is a crop research and extension company, owned by Mato Grosso Cotton Grower's Association (Ampa, Cuiabá/ Brazil). Created in 2007, IMAmt release cotton, soybean and other crop varieties for farmers of Brazilian's cerrados, with technologies for herbicides, pests, diseases and nematode resistance. For more informations, please visit www.imamt.com.br About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/10/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-IMAmt-Sign-Collaboration-for-Genomic-Promoter-Discovery-and-Validation-in-Cotton Evogene Announces Joint Microbial Diversity Activity with University of Missouri http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Joint-Microbial-Diversity-Activity-with-University-of-Missouri- Rehovot, Israel - September 13, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it has entered into an agreement with the University of Missouri to collect and sequence soil samples from several university field sites. The soil samples represent previously untapped sources for microbial diversity from one of the primary corn growing regions of the United States. Under the agreement, Evogene will utilize the results as an additional novel source of leads for its microbial data base supporting its Insect Control and Ag-biological product programs. Activities associated with the collecting and sampling of the soil will be led by Evogene's R&D site in St. Louis and will be performed in several different field sites situated across the state of Missouri. The unique set of research stations includes field sites with diverse range of insects, crops, and environments. "We are excited to collaborate with Evogene, a leading Israeli biotechnology company focusing on crop improvement," said Dr. Marc Linit, Senior Associate Dean for Research and Extension. "Collaboration with Evogene to discover novel soil-borne microbes will lead to the development of new bio-based insect control and other ag-based biological programs that will benefit farmers in Missouri and elsewhere." "As we continue to expand our activities in the US, we are very pleased to be joining forces with the University of Missouri in a unique project bringing together world class academic researchers in agricultural science with one of the industry's most advanced computational discovery groups," said Ofer Haviv, Evogene President and CEO. "Tapping into the diversity of University of Missouri's field sites introduces a new source of microbial leads for our already extensive database, allowing us to strengthen the potential novelty of our product offering in the area of insect control and ag-biologicals." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 13/09/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Joint-Microbial-Diversity-Activity-with-University-of-Missouri- Evogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Participation-at-the-18th-Annual-Rodman--Renshaw-Global-Investment-Conference-in-New-York-City-September-11-13th-2016- Rehovot, Israel - September 01, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. Ofer Haviv, Evogene President and Chief Executive Officer, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. Event: 18th Annual Rodman & Renshaw Global Investment Conference Date: Tuesday, September 13, 2016 Time: 11:15-11:40 AM (Eastern Time) Location: Holmes II (4th floor); Lotte New York Palace Hotel in New York City The presentation will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 01/09/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Announces-Participation-at-the-18th-Annual-Rodman--Renshaw-Global-Investment-Conference-in-New-York-City-September-11-13th-2016- Evogene Appoints a New Member to Board of Directors and a New Chief Operating Officer http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Appoints-a-New-Member-to-Board-of-Directors-and-a-New-Chief-Operating-Officer - Appointment of Ms. Sarit Firon adds substantial financial expertise to Board - - Mr. Yuval Ben-Galim to bring extensive operational and computational technology experience to Company management - Rehovot, Israel - August 11, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading biotechnology company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today the appointment of Ms. Sarit Firon to the Company's Board of Directors and the appointment of Mr. Yuval Ben-Galim as Chief Operating Officer, replacing Mr. Assaf Kacen. Ms. Sarit Firon is an experienced finance executive and currently serves on the Boards of MediWound, Datorama and is the Chairperson of myThings. She has nearly two decades of experience as CFO in numerous hi-tech companies. Ms. Firon holds a B.A. in Accounting and Economics from the Tel Aviv University. "On behalf of Evogene, I am pleased to welcome Sarit as a director to our Board," said Martin Gerstel, Chairman of the Board of Evogene. "As a financial expert in technology oriented companies and an experienced Board member, Sarit brings valuable expertise to complement the skills of our existing members and further support Evogene's evolvement. I enthusiastically look forward to working with her," concluded Mr. Gerstel. Mr. Yuval Ben-Galim will join the Company on September 15, 2016 and will replace Mr. Assaf Kacen who has been with the Company since July 2009. Mr. Ben-Galim brings with him extensive background in management of technological operations. In his last role he served as Chief Product Development at Como, a company specializing in consumer loyalty management through mobile apps. Prior to this, from 2011 to 2015, Mr. Ben-Galim served as COO at MyHeritage, responsible for the global operations of a world leading family history company. Previously held positions by Mr. Ben-Galim include various operation and software R&D experience. Mr. Ben-Galim holds an M.Sc. in Computer Science and a B.Sc. in Computer Science and Business Management from The Hebrew University of Jerusalem. "Yuval has an impressive record as a result driven leader. In his prior roles he has proven himself as a key executive responsible for leading technological operation and development efforts. His record demonstrates the skills and experience necessary to support the continued development of our unique technological infrastructure, which is at the core of our diverse activities," said Ofer Haviv, Evogene's President and CEO. "We welcome Yuval and look forward to his contribution to our senior management team." Mr. Haviv continued: "I would like to thank Assaf who is leaving Evogene after more than seven years to pursue Ph.D. studies at the Weizmann Institute of Science, for his significant contribution to the Company during a period of rapid progress and growth. Assaf led Evogene's Technological Platform and established a strong foundation that leaves us well-positioned for the future. I wish him great success in his Ph.D. academic studies." - xxx - About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 11/08/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Appoints-a-New-Member-to-Board-of-Directors-and-a-New-Chief-Operating-Officer Evogene Reports Second Quarter 2016 Financial Results http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Second-Quarter-2016-Financial-Results Rehovot, Israel - August 11, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading biotechnology company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today its financial results for the quarter and six months ended June 30, 2016. Ofer Haviv, Evogene's President and CEO, stated: "Just three years ago Evogene's research and development programs were almost entirely focused on one market segment of seed traits, and within this segment primarily at improving yield and a-biotic stress tolerance. Since then, we have grown to a company that has leveraged its unique technology platform to address multiple product opportunities in three different multi-billion-dollar markets - expanding our seed traits activities to include insect control, and entering the ag-chemicals and ag-biologicals market segments." "We are extremely pleased with the advancements and the encouraging initial results we are seeing this year in key programs within each of these three market segments, particularly in our newer areas of activity. Some recent results and on-going activities include: Positive results for a set of Evogene discovered genes demonstrating the potential to achieve yield enhancement in corn and soybean as previously reported. Genes are progressing into further testing under our collaboration with Monsanto; Microbial genes identified as part of our collaboration with Marrone Bio Innovations have demonstrated toxic activity against target insects and are now progressing into further characterization tests and validation in plants; Following positive results received in soybean model system in our nematode program, promising genes are now undergoing stable soybean transformation at our facilities in St. Louis and are expected to begin validation tests next year; Genes showing positive results for black sigatoka resistance are currently undergoing larger scale field trials in Central America; Positive initial results in our promotor discovery activity where we were able to validate that our predicted promotors led to the specific gene expression pattern; The discovery and successful validation in plants of the first set of novel plant targets for herbicides which have now been incorporated into our BASF collaboration, and the on-going design of chemical libraries to inhibit these targets utilizing a unique computational based methodology; Successful demonstration in lab and greenhouse of herbicidal activity for several Evogene chemical compounds, including selected compounds displaying activity against a panel of weeds, which have now progressed into additional characterization within our product development pipeline; And finally, positive performance in initial model plant and corn greenhouse testing of tens of bacterial strain candidates predicted to have potential for development of ag-biologicals, a portion of which are now undergoing corn field trials." Evogene management will be hosting a conference call today to discuss recent developments and achievements highlighting validation results achieved in several of its key product programs. Management remarks will be accompanied by a slide presentation, which will be available at www.evogene.com. Please see conference call and webcast details below for additional information. Mr. Haviv concluded: "Most importantly, these impressive results, and the relatively short time frame in which they were achieved, are further testaments to the power and accuracy of the predictive capabilities provided by our science based technology platform established over the past decade and continuing to be expanded and enhanced. This platform has been designed to be broadly applicable, and its success in doing so is now being demonstrated as we address very diverse market segments, each with its own discovery pathways, but all of which nestle on the core of our capabilities - bringing plant science and computational power together." Financial results for the period ended June 30, 2016: Cash position: As of June 30, 2016, Evogene had approximately $97 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $3.8 million for the six months ended June 30, 2016 and $1.9 million for the second quarter. Revenues are largely research and development payments, reflecting R&D cost reimbursement under certain of our collaboration agreements. The majority of these agreements also provide for development milestone payments and royalties or other forms of revenue sharing from successfully developed products, and therefore longer term, the Company anticipates that its future revenues and profitability will largely reflect the receipt of such payments from its existing and future collaborations. Revenues for the six months ended June 30, 2016 were $3.8 million, compared to $5.4 million for the same period in 2015. Revenues for the second quarter of 2016 were $1.8 million compared to $2.7 million for the same period in 2015. This decline reflects the net decrease in such research and development payments in accordance with the work plans being pursued under the Company's various collaboration agreements. It includes changes in the scope and type of activities undertaken by the Company as part of its yield and stress collaboration with Monsanto, where by resource intensive activities such as novel gene discovery and validation evolved to increasingly focus on optimization activities supporting Monsanto's ongoing development activities with respect to advancing Evogene discovered genes. Cost of revenues includes research and development expenses related to the Company's on-going activities in support of collaboration agreements. Cost of Revenues for the six months ended June 30, 2016 were $3.1 million, compared to $3.8 million, for the same period in 2015. Cost of revenues for the second quarter of 2016 were $1.6 million compared to$ 1.9 million for the same period in 2015. The net decrease primarily relates to the change in the scope and type of activities performed under the Company's collaboration with Monsanto, as noted above. Research and development expenses for the six months ended June 30, 2016 were $7.8 million, compared to $7.2 million for the same period in 2015. Research and development expenses for the second quarter of 2016 were $4.0 million compared to $3.7 million for the same period in 2015. This increase largely relates to expansion of activities, primarily focused on the development of computational platforms as well as discovery and validation activities in our key growth engines - insect control, ag-chemicals and ag-biologicals. Operating loss for the first half of 2016 was $9.8 million compared with $8.8 million for the same period in 2015, and $5.2 million for the second quarter of 2016 compared with $4.6 million for the second quarter of 2015. The increase in operating loss is mainly due to the decrease in revenues discussed above, which were partially offset by the net decline in other expense categories. Net loss for the first half of 2016 was $7.8 million compared with a net loss of $8.4 million for the same period in 2015. Net loss for second quarter of 2016 was $4.5 million compared with a net loss of $5 million in the second quarter of 2015. The decline in net loss is attributed to the increase in financing income, reflecting the company's strong cash position. Conference call and webcast details: Evogene management will host a conference call today at 09:30 am Eastern time, 16:30 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-866-860-9642, and participants from Israel and other countries are invited to access the call at 972-3-918-0644. The conference call will be accompanied by a presentation which will be referred to by management and will be filed with the SEC and made available on the Company's website prior to the beginning of the call. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through August 13, 2016. US-based participants are invited to access the replay by dialing 1-877-456-0009, and participants from Israel and other countries are invited to access the replay at 972-3-925-5936. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. Financial Tables -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 11/08/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Second-Quarter-2016-Financial-Results Evogene to Participate at Piper Jaffray Global Agriculture Symposium http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Participate-at-Piper-Jaffray-Global-Agriculture-Symposium Rehovot, Israel - August 1, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, announced today that Assaf Kacen, Chief Operating Officer, will participate at the Piper Jaffray Global Agriculture Symposium taking place in Minneapolis, Minnesota, August 2, 2016. Mr. Kacen will take part at the Gene Editing panel which will take place on Tuesday, August 2, at 2:00 pm. He will discuss the potential of genome editing to significantly impact traditional breeding pipelines, and the potential effect of the disruptive technology on the expansion of Evogene's business offering. Investors or potential partners attending the conference, who wish to meet with Mr. Kacen, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 01/08/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Participate-at-Piper-Jaffray-Global-Agriculture-Symposium Evogene Second Quarter 2016 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Second-Quarter-2016-Earnings-Announcement-Schedule Rehovot, Israel - July 25, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the second quarter of 2016 on Thursday, August 11, 2016. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:30 AM Eastern time, 16:30 Israel time. To access the conference call, please dial 1-866-860-9642 toll free from the United States, or 972-3-918-0644 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-877-456-0009 toll free from the United States, or 972-3-925-5936 internationally. The replay will be accessible through August 13, 2016, and an archive of the webcast will be available on the Company's website through August 22, 2016. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 25/07/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Second-Quarter-2016-Earnings-Announcement-Schedule Evogene to Present at Crops and Chemicals 2016 Conference http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-at-Crops-and-Chemicals-2016-Conference Rehovot, Israel - July 13, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading biotechnology company for the improvement of crop productivity, today announced that its Chief Scientific Officer, Dr. Eyal Emmanuel, will present initial results from the Company's Insect Control Novel Toxin Discovery Program at the Crops and Chemicals Conference taking place July 19 - 21, 2016 in Raleigh, North Carolina. Dr. Emmanuel's presentation is scheduled for July 20th at 11:30am in the Plant Biotechnology stream of the conference. At his presentation, Dr. Emmanuel will describe Evogene's unique approach for the discovery of microbial genes demonstrating insecticidal activity with novel 'mode of action' and will present preliminary results for certain selected genes. The genes for which preliminary results will be provided include genes discovered from cultured bacteria as part of Evogene's program with Marrone Bio Innovations Inc. (NASDAQ: MBII), as well as genes discovered from its proprietary, experiments incorporating metagenomics data. The candidate genes from both sources were discovered using the Company's in silico algorithmic approach. Validation of the insecticidal activity for such genes included diet-based assays against several key target insects, demonstrating strong support for the unique methodologies utilized in Evogene's Insect Control Program. Evogene's in silico approach for novel toxin discovery leverages two key proprietary technologies - comprehensive integrated databases, and a dedicated computational analysis platform (BiomeMinerTM). The integrated databases are enriched with microbial genes consisting of insecticidal activity from both cultured and uncultured bacteria (metagenomics), sourced from proprietary and public experiments. The BiomeMinerTM computational platform utilizes advanced algorithms and machine learning technologies, and has been designed to sift through many millions of genes and pinpoint the most promising candidates to yield potential novel insecticidal modes of action. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control; and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at info@evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 13/07/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-at-Crops-and-Chemicals-2016-Conference Evogene Reports Financial Results for the First Quarter of 2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Financial-Results-for-the-First-Quarter-of-2016- Rehovot, Israel - May 19, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the first quarter ended March 31, 2016. Ofer Haviv, Evogene's President and CEO, stated: "We continue to be very pleased with the progress we are seeing across our various business areas. This is based on initial results received for key product programs in our three market segments of focus: improved seed traits, innovative ag-chemicals and novel ag-biologicals." "Within our improved seed traits market segment, the first quarter was marked with a significant achievement in our multi-year collaboration with Monsanto, with several of the genes identified by Evogene under the collaboration demonstrating positive initial results in field trials. We are extremely encouraged with this progress, and believe it represents an important step forward towards achieving the desired plant traits pursuant to our recently disclosed "Trait-First" development methodology." "This quarter we also made headway in our seed traits program for insect control, specifically in our multi-year collaboration with Marrone, where we are aiming to develop seed traits displaying resistance to some of agriculture's most devastating insects. In this program, we were excited to report that in diet-based insect assays, several of the identified genes showed toxic activity against the target insects. Those genes will now be advanced for further validation at our R&D site in St. Louis, Missouri." "In our ag-chemical market segment, where we are currently focusing our efforts on developing herbicide solutions, we began 2016 with two very significant achievements. First, the discovery and successful in-planta validation of the first set of novel plant targets for herbicides, and second, the signing of a multi-year collaboration agreement with BASF." "In our ag-biologicals market segment, we recently completed several milestones in establishing the necessary infrastructure that will form the basis for our future product development pipeline in bio-stimulants. This includes the development of the microbial mining platform which performs prioritization of microbial strains and establishing a collection of over 10 thousand microbial strains. Our screening platforms for corn are now operational and we expect by the end of this year to complete the screening of over 500 candidate strains and the prioritization process for the most promising of these strains based on their efficacy and stability for yield improvement and abiotic stress tolerance for corn." "Lastly, as recently announced, our incorporation of genome editing technology into our discovery infrastructure opens up an entirely new spectrum of business application opportunities for Evogene, including the leveraging of the significant knowhow and assets we built over the years in seed trait improvement. This expansion of our biological scope is expected to significantly broaden the applicability of our discovery and development infrastructure as we look to applying this powerful technology to additional crops, traits, and geographies. The maturation of the technology, combined with potential favorable regulatory restrictions, could enable products based on genome editing to benefit from shorter times to market, lower development costs and higher probability for success." "We believe that our accelerating and very promising progress in multiple market areas, combined with our broadly applicable discovery and development infrastructure, key industry partnerships and financial strength, well position us to capitalize on the many significant opportunities existing in each of our different market segments of focus." Financial results for the quarter ended March 31, 2016: Cash Position: As of March 31, 2016, Evogene had approximately $98.8 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $1.9 million for the quarter. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its net cash usage for full year 2016 will be in the range of $14 to $16 million, as previously disclosed. Revenues include mainly periodic payments for research and development activities provided under certain of the Company's collaboration agreements, primarily with seed companies. Evogene anticipates that for the longer term, its primary sources of revenues will be future milestone and/or royalties and other revenue sharing amounts from current and future collaborations. Revenues for the first quarter ended March 31, 2016 were $2.0 million, compared to $2.7 million for the same period in 2015. The decrease relates to reduced levels of activity required for Evogene under certain collaboration agreements. Cost of Revenues includes research and development expenses related to the Company's on-going activities in support of collaboration agreements primarily with seed companies. Cost of Revenues for the first quarter ended March 31, 2016 were $1.5 million, compared to $1.8 million, for the same period in 2015. The decrease primarily relates to the reduced levels of activity under certain collaborations, as described above. Research and Development expenses for the first quarter of 2016 were $3.7 million, compared to $3.5 million for the same period in 2015. This increase largely relates to the expansion in our key growth segments - insect control, ag-chemicals and ag-biologicals. Operating Loss for the first quarter of 2016 was $4.6 million (including a non-cash expense of approximately %v.9 million for share-based compensation), compared to an operating loss of $4.1 million (including a non-cash expense of approximately %v.8 million for share-based compensation) for the same period in 2015. This increase is mainly attributable to the decrease in revenues, as described above. Financial Tables * * * Conference call and webcast details: Evogene management will host a conference call today at 09:00 Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through May 22, 2016. US-based participants are invited to access the replay by dialing 1-877-456-0009, and participants from Israel and other countries are invited to access the replay at 972-3-925-5904. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/05/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Financial-Results-for-the-First-Quarter-of-2016- Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-Marrone-Bio-Innovations-Disclose-Positive-Results-in-Insect-Control-Collaboration- Rehovot, Israel and Davis, California - May 16, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, and Marrone Bio Innovations Inc. (MBI), (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, announced today that they have successfully met an important milestone in their multi-year collaboration focused on discovery and validation of novel genes for insect control. In diet-based insect assays, certain proteins demonstrated control activity against several target pest insects, including fall armyworm, a devastating pest that causes annual damage of approximately $1 billion worldwide. Based on these results, selected bioactive proteins are now being advanced by the two companies to plant validation. The collaboration, initiated in July 2014, and supported by funding from the Binational Industrial Research and Development (BIRD) Foundation, aims to bring to market new insect control solutions - seed traits and bio-insecticides - through leveraging the expertise and distinct assets and capabilities of each party. Utilizing Evogene's proprietary computational platform BiomeMiner® and other predictive discovery capabilities, the two companies were able to pinpoint candidate proteins out of over tens of thousands of proteins identified from MBI's extensive and proprietary microbial collection. The proteins' bioactivity for pest control were then validated in diet-based insect assays by both companies, and a subset of the candidates showed positive insecticidal results. Ofer Haviv, President and CEO of Evogene stated, "We are very pleased with the advancement of the microbial insecticidal proteins in the pipeline. Teaming our capabilities for predictive bioactive protein discovery with MBI's valuable microbial libraries provides a clear win/win opportunity for both companies, and we look forward to successful development of future plant protection products. In addition, this positive advancement is another indication of Evogene's predictive capabilities in crop protection technology in general, and specifically in insect control solutions." Pam Marrone, CEO and Founder of Marrone Bio Innovations said "Increasing resistance of major insects to existing insect control products creates a growing need for novel products with new modes of action, and is the basis of our multi-year collaboration with Evogene. These promising results further demonstrate the synergy between our two companies. We are pleased to leverage our microbial assets into new areas." Based on the positive results announced today, the parties agreed to advance several novel insecticidal protein candidates, which have met the required test criteria, to model plant validation and to be followed by target crop validation. Successful candidates will then be further developed by Evogene, potentially in collaboration with a seed company, for insect control in crops such as corn, soybean and cotton, while MBI may commercialize the microbials as sprayable bio-insecticide products. The parties have agreed to share revenues from any products that may result from this collaboration. * * * About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. About Marrone Bio Innovations Smart. Natural. Solutions. Marrone Bio Innovations, Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have four products for agriculture on the market (Regalia®, Grandevo®, Venerate® and Majestene®). MBI also distributes Bio-tam 2.0® for Isagro USA in the western U.S. and MBI also markets Zequanox® for invasive mussels for water markets. We also have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com. Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertain-ties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI's or Evogene's views as of any subsequent date. Examples of such statements include statements regarding potential products or product candidates that may be identified and developed by MBI or Evogene, including the isolation, development, commercialization, market for, potential benefits of or revenues from any such product or product candidate, the results of any studies or validation tests on any product candidates, MBI's or Evogene's efforts with respect to other potential products, the ongoing strategic partnership between MBI and Evogene and funding by BIRD Foundation. Such forward-looking statements are based on information available to MBI and Evogene as of the date of this release and involve a number of risks and uncertainties, some beyond the either party's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including any difficulty in isolating, developing and commercializing any potential product or product candidate, marketing the potential product with either party's principal customers, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI's or Evogene's performance is contained in their respective filings with the SEC or other appropriate securities authorities. Neither MBI nor Evogene is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise. 16/05/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-and-Marrone-Bio-Innovations-Disclose-Positive-Results-in-Insect-Control-Collaboration- Evogene to Present the Potential of Integrating Novel Genome Editing Technology with its Core Capabilities for Improved Seed Traits at Plant Genomics Congress http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-the-Potential-of-Integrating-Novel-Genome-Editing-Technology-with-its-Core-Capabilities-for-Improved-Seed-Traits-at-Plant-Genomics-Congress Rehovot, Israel - May 3, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that it will present the potential of integrating genome editing revolutionary technology with the company's core capabilities and assets for improving seed traits, and its potential effect on the expansion of Evogene's business offering, in the upcoming 4th Plant Genomics Congress in London on May 9th. The congress will present cutting edge Ag-genomic technologies in various areas and will include world-leading participants from the industry and academia. Genome editing is gaining high traction in multiple areas of research and development in both pharma and agriculture as this molecular technological enabler allows the specific modification of essentially any nucleotide within a given genome, in a highly precise and targeted manner. By providing new venues for genomic manipulation within a crop of interest, genome editing brings significant opportunities for biotechnological crop trait improvement not available via previous technologies. This molecular technology may enable Evogene to leverage its core capabilities in both existing and new areas, and is expected to significantly broaden the applicability of the Company's discovery and development infrastructure with respect to additional crops, traits, and geographies. Two key requirements and significant challenges in the utilization of this powerful new genome-editing technology in ag-biology are the identification of the specific area in the crop genome to be modified and the discovery of the specific modifications to that area that are predicted to lead to the desired trait improvement. The complexity of the challenge lies in targeting and selecting specific nucleotides from the billions of nucleotides forming the crop's genome. Evogene's proprietary technological platform, developed for genomic discovery, is a natural fit to meet the challenge of 'where and what to edit'. This is performed by utilizing proprietary assets and capabilities in functional genomics across species, gained through years of Company investment, development and computational driven learning. Ofer Haviv, Evogene's President and CEO, stated: "Evogene's significant gene discovery capabilities for seed improvement have been leveraged to date mostly for transgenic applications. The maturation of the genome editing technology opens up an entirely new spectrum of business application opportunities for our technology. Combined with potentially "lighter" regulatory hurdles, products based on genome editing might benefit from shorter times to market, lower development costs and higher probability for success. We expect to position ourselves as a key player in the application of this new innovative technology for improving crop productivity, further expanding our Company's value proposition. " * * * About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology Company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 03/05/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-to-Present-the-Potential-of-Integrating-Novel-Genome-Editing-Technology-with-its-Core-Capabilities-for-Improved-Seed-Traits-at-Plant-Genomics-Congress Evogene’s First Quarter 2016 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2016/Evogenes-First-Quarter-2016-Earnings-Announcement-Schedule Rehovot, Israel - May 2, 2016- Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the first quarter 2016 on Thursday, May 19, 2016. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-877-456-0009 toll free from the United States, or 972-3-925-5904 internationally. The replay will be accessible through May 21, 2016, and an archive of the webcast will be available on the Company's website through May 29, 2016. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may","expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 02/05/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogenes-First-Quarter-2016-Earnings-Announcement-Schedule Evogene Files Annual Report for the Year Ended December 31, 2015 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Files-Annual-Report-for-the-Year-Ended-December-31-2015 Rehovot, Israel - April 25, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report, which contains the Company's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov/ as well as via the Company's investor relations website at http://investors.evogene.com/financial-reports/report-2015.aspx. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: ir@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 25/04/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Files-Annual-Report-for-the-Year-Ended-December-31-2015 Evogene Selected for Photosynthesis Research Consortium within European Horizon 2020 Program http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Selected-for-Photosynthesis-Research-Consortium-within-European-Horizon-2020-Program Rehovot, Israel - April 19, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food feed and biofuel industries, announced today that it is participating in a consortium for research in photosynthesis within the EU Horizon 2020 Program for Research and Innovation. Academic participants include the Max Planck Institute of Molecular Plant Physiology and the Institute of Terrestrial Microbiology, Weizmann Institute of Science, and the Imperial College of Science Technology and Medicine. The consortium's research program is focused on an innovative approach to modulate photosynthesis related pathways aiming to improve photosynthetic efficiency. Evogene, the only commercial entity in this consortium, will lead the efforts for discovery of regulatory elements required for pathway modulation and undertake in plant proof of concept validation, as well as potentially lead commercialization. The consortium will receive a grant of approximately 5 million Euros for the program in total, Evogene will receive 902,000 Euro from this amount for its participation in the consortium. Ofer Haviv, Evogene's President and CEO commented: "Evogene is very proud to be a key member of this prestigious consortium addressing a fundamental and critical aspect of ag-biology, further demonstrating the recognition of our expertise and ability to bring innovation to agriculture. This capability rests on our unique technology platform, combining proprietary scientific understanding and advanced computational technologies to utilize agriculture big-data. We are confident that our participation will both be of significant value to the research being undertaken by the consortium and enable Evogene to establish novel expertise in photosynthesis as a means of yield improvement, thus adding to our world leading scientific expertise in traits for enhancing crop productivity". Dr. Arren Bar-Even of the Max Planck Institute of Molecular Plant Physiology, the coordinator of the consortium added: "Feeding 10-15 billion people at the end of this century is a tremendously challenging task that will only be met by the implementation of drastic measures to increase agricultural productivity. We try to tackle this challenge by using state-of-the-art synthetic biology tools to design, evolve, and implement highly efficient carbon fixation routes. The project comprises an interdisciplinary effort that integrates diverse skills in computational biology, chemistry, biochemistry, microbiology and plant physiology". -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies like: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com. About Horizon 2020.: Horizon 2020 is the EU Framework Program for Research and Innovation. Horizon 2020 is the biggest EU Research and Innovation program with nearly €80 billion of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The FET Open program in which the Consortium participates is a program that supports the early-stages of the science and technology research and innovation around new ideas towards radically new future technologies. It also funds coordination and support actions for such high-risk forward looking research to prosper in Europe. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/04/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Selected-for-Photosynthesis-Research-Consortium-within-European-Horizon-2020-Program Evogene Reports Fourth Quarter and Full Year 2015 Financial Results http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-Results Rehovot, Israel - March 1, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the fourth quarter and year ended December 31, 2015. Ofer Haviv, Evogene's President and CEO, stated: "This past year and early 2016 has been a period of high achievement across multiple fronts for Evogene, as we both demonstrated important progress and key achievements in our initial market areas of activity, and successfully leveraged our proprietary discovery and development capabilities to address major new market segments in agriculture. These accomplishments included: Reporting positive results in our yield improvement collaboration with Monsanto utilizing novel 'Trait-First' methodology; The signing of a collaboration agreement for novel herbicide discovery and development with BASF; Opening a research and development facility in St. Louis, Missouri to support our crop protection efforts and U.S. experimental genomics activities; Successfully completing our first computational discovery of novel microbial genes for insect control; Discovering and validating novel plant targets predicted to represent new modes-of-action for development of herbicides; The signing of an advanced breeding collaboration with a leading multinational food company for improving key crop productivity underlying a major branded product line; and Disclosing incorporation of a new gene optimization program into our yield & environmental stress collaboration with Monsanto. This follows entry of more than 1,000 Evogene identified and validated candidate genes into Monsanto's product development pipeline." Mr. Haviv continued: "All of these accomplishments directly result from our long-term successful efforts to establish a broadly applicable, and unique, science based discovery and development infrastructure. This infrastructure, combining innovative computational capabilities - such as 'big-data' integration and analysis - is driven by our proprietary expertise in genomics, plant science, chemistry, micro-biology, and other knowledge bases relevant for the systematic development of 'next generation' products for improving crop productivity and economics." "We are proud to continue to report results further validating the predictive capabilities of our science based infrastructure", Mr. Haviv added. "Two recent examples are the positive results for our discovered genes in corn and soybean testing conducted by our partner Monsanto, and our discovery and successful validation in plants of the first set of novel herbicide targets. In parallel with these achievements, we are pleased to be increasingly recognized by world leading companies for our unique expertise and capabilities with which we can address key unmet needs in the agriculture world. Our recently announced collaboration agreement with BASF, the world's largest chemical company, in ag-chemicals is a recent demonstration of this acknowledgment." Mr. Haviv continued: "We believe Evogene is positioned today to rapidly take advantage of future opportunities in the agriculture world. This position relies primarily on our broadly applicable discovery infrastructure, as well as on three key strategic decisions we made during the past few years. The first decision involved the allocation of substantial resources to expand our fields of focus to include three new market segments: Insect Control, Ag-chemistry and Ag-biologicals. All three markets present substantial opportunities, with significant unmet needs, and where we believe our capabilities can provide the most advanced solutions. The second decision related to our new, and already successfully implemented, organizational structure which groups all of our line operations into two main hubs: Crop Enhancement and Crop Protection. Key, of course, to the success of this new organizational structure is our proven ability to attract and retain highly qualified professionals for our multi-disciplinary teams and management. The third decision related to our financial strength, mainly to our decision to raise funds in late 2013, ensuring that we will have the capital we need to pursue our objectives while still maintaining financial health, as demonstrated by over $100 million cash on our balance sheet at year end 2015." Mr. Haviv concluded: "In summary, we began 2016 with a strong sense of accomplishment and pride in what we have achieved to date and excitement regarding the future for our Company. With the continuous expansion of our unique R&D infrastructure to a broader activity base, we believe we now have the organization, the required financial resources, and the industry recognition to allow us to make important contributions in a large and increasing number of substantial agriculture based markets." Financial results for the fourth quarter and full year 2015 Cash Position: As of December 31, 2015, Evogene had $100.7 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $15.6 million for the year. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its net cash usage for full year 2016 will be in the range of $14 to $16 million. Research Revenues include mainly periodic payments for research and development activities provided under certain of the Company's collaboration agreements, primarily with seed companies. Evogene anticipates that for the longer term, its primary sources of revenues will be future milestone and/or royalties and other revenue sharing amounts from current and future collaborations. Revenues from research and development payments for the year ended December 31, 2015 were $11 million, compared to $14.2 million for the same period in 2014. Revenues from research and development payments for the fourth quarter of 2015 were $2.4 million, compared to $3.6 million for the same period in 2014. These decreases relate to reduced levels of activity required for Evogene under certain collaboration agreements, primarily relating to the previously disclosed amended work plans with Bayer and Syngenta. Cost of Revenues includes research and development expenses related to the Company's on-going activities in support of collaboration agreements primarily with seed companies. Cost of Revenues for the year ended December 31, 2015 was $8.3 million, compared to $9.7 million, for the same period in 2014. Cost of revenues for the fourth quarter of 2015 was $2 million, compared to $2.4 million, for the same period in 2014. These decreases primarily relate to the reduced levels of activity under certain collaborations, as described above. Research and Development expenses for the year ended December 31, 2015 were $14.4 million, compared to $14 million for the same period in 2014. This increase mainly derives from increases in non-cash share-based compensation expenses and self-funded R&D activities, offset in part by US dollar/Israeli Shekel exchange rate changes. Research and Development Expenses for the fourth quarter of 2015 were $4.1 million, compared to $4.3 million for the same period in 2014. Operating Loss for the year ended December 31, 2015 was $17.9 million (including a non-cash expense of approximately $4.4 million for amortization of share-based compensation), compared to an operating loss of $15.3 million (including a non-cash expense of approximately $3.2 million for amortization of share-based compensation) for the same period in 2014. Operating Loss for the fourth quarter of 2015 was $5.4 million (including a non-cash expense of approximately $1.1 million for amortization of share-based compensation), compared to an operating loss of $4.6 million (including a non-cash expense of approximately %v.7 million for amortization of share-based compensation) for the same period in 2014. This increase is mainly attributable to the decrease in research revenues and the increase in non-cash share-based compensation expenses, as described above. Financial tables XXX Conference call and webcast details: Evogene management will host a conference call today at 09:00 Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through March 3, 2016. US-based participants are invited to access the replay by dialing 1-888-326-9310, and participants from Israel and other countries are invited to access the replay at 972-3-925-5900. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 01/03/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-Results Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Discloses-Positive-Results-in-Yield-Improvement-Collaboration-with-Monsanto-Utilizing-Novel-Trait-First-Methodology- Rehovot, Israel - February 23rd, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries announced today positive results from the testing of a set of the Company's discovered genes in corn and soybeans conducted this past season by its key collaborator, Monsanto. These are the first results for genes discovered and tested pursuant to a 'Trait-First' methodology implemented in the frame of the parties' on-going, multi-year collaboration which focuses on yield enhancement and abiotic stress resistance. The new methodology, which leverages and utilizes knowledge unlocked through the collaboration, has enabled the two companies to identify and prioritize a series of key enabling traits that are expected to improve plants' overall performance leading to yield improvement, as well as the trait attributes required for achieving these key traits. The methodology implementation incorporates the synergistic application of Evogene's 'big data' integration, analysis and prediction capabilities, including gene identification and optimization for specific trait attributes and gene stacking for achieving the key enabling traits, together with Monsanto's industry leading development, validation and field trial network for testing both trait attributes and the key traits. The positive results reported today represent a key step towards achieving the targeted plant traits for yield improvement, and confirm Evogene's computational predictions for this set of novel genes with respect to the underlying trait attributes. Further testing of these genes will now be undertaken while the parties evaluate additional previously discovered genes from the collaboration as well as new ones. Tom Adams, VP Global Biotechnology at Monsanto stated: "Farmers throughout the world are increasingly focused on delivering better harvests to meet the demands of our planet. The ability to identify novel traits that can improve on-farm yields means that farmers can produce more on their existing farmland thus taking steps to preserve our natural habitats. Monsanto is pleased to collaborate with Evogene to continue our research to discover the specific plant improvements that can help drive on-farm yield". Ofer Haviv, Evogene's President and CEO added: "These recent results for Evogene discovered genes from Monsanto's corn and soybean programs support Evogene's unique prediction capabilities in discovering genes that influence plant trait attributes. We look forward to our continuing joint efforts with Monsanto as we leverage both parties' assets, capabilities and expertise in further promoting positive genes in the development processes and evaluating additional genes. We expect that the collaboration will lead to breakthrough yield-enhancing products for farmers world-wide." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 23/02/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogene-Discloses-Positive-Results-in-Yield-Improvement-Collaboration-with-Monsanto-Utilizing-Novel-Trait-First-Methodology- Evogenes Fourth Quarter with Full Year 2015 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2016/Evogenes-Fourth-Quarter-with-Full-Year-2015-Earnings-Announcement-Schedule Rehovot, Israel - February 9th, 2016- Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2015 on Tuesday, March 1st, 2016. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or 972-3-925-5900 internationally. The replay will be accessible through March 3rd, 2016, and an archive of the webcast will be available on the Company's website through March 11th, 2016. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 09/02/2016 http://www.evogene.com/News-Events/Press-Releases/2016/Evogenes-Fourth-Quarter-with-Full-Year-2015-Earnings-Announcement-Schedule Evogene Appoints Eyal Leibovitz as Chief Financial Officer http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Appoints-Eyal-Leibovitz-as-Chief-Financial-Officer Rehovot, Israel - December 22, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, today announced the appointment of Eyal Leibovitz as Chief Financial Officer. Mr. Leibovitz is joining the Company effective January 1, 2016 and will replace Sigal Fattal who has been with the Company since June 2012 and will remain until January 31, 2016 to ensure a smooth transition. Ms. Fattal will continue to support the Company after her departure and until April 2016. Mr. Leibovitz will report to Ofer Haviv, Evogene's President and Chief Executive Officer, and will have executive responsibility for all corporate functions of the company. Mr. Leibovitz brings with him an extensive background in senior management, finance, investor relations, M&A and business development in international companies headquartered in both Israel and the United States. In his last role he served as CFO and member of the executive committee of N-trig Ltd., an electronic inking company. Prior to this, from 2007 to 2011 Mr. Leibovitz served as the CFO of Kamada Ltd. (NASDAQ & TASE: KMDA). From 2002 to 2007 Mr. Leibovitz served as the International controller of Harmonic Inc. (NASDAQ:HLIT), headquartered in California and operating in the digital video space. Mr. Leibovitz holds a BBA degree from the City University of New York. "Eyal has an impressive track record as a CFO in both private and public companies. In his prior roles, Eyal has proven himself a key member of executive management teams with direct responsibility for finance, M&A and business development. This record clearly demonstrates the skills and experience necessary to help guide our Company's growth and continued diversification. In addition, a key objective for Eyal will be to increase the awareness in the US financial market of Evogene's unique capabilities in providing next generation products for the enhancement of agriculture and of our rapidly growing presence in multiple key market areas." said Ofer Haviv, Evogene's President and CEO. "We welcome Eyal and look forward to his contribution to our senior management team." Mr. Haviv continued:" I would like to thank Sigal Fattal who is leaving Evogene after more than 3.5 years for her significant contributions to the Company during a period of rapid change and growth. Among her many accomplishments, Sigal led Evogene's US IPO and built a strong financial and international corporate foundation that leaves us well-positioned for the future. I am confident that she will continue her record of success in her future endeavors. " -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 22/12/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Appoints-Eyal-Leibovitz-as-Chief-Financial-Officer BASF and Evogene Sign Collaboration Agreement for Novel Herbicide Discovery and Development http://www.evogene.com/News-Events/Press-Releases/2015/BASF-and-Evogene-Sign-Collaboration-Agreement-for-Novel-Herbicide-Discovery-and-Development Ludwigshafen, GERMANY and Rehovot, ISRAEL - Dec 8th, 2015 - BASF, the world's leading chemical company, and Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity, announced today the signing of a three-year collaboration for the discovery and development of novel herbicides. Under the terms of agreement, Evogene will utilize its biology-driven computational discovery approach to identify potential candidate chemicals for novel herbicides. BASF will use its proprietary advanced plant platform to screen the candidate chemicals in order to experimentally validate their biological effects on weeds. Successful candidates from this collaboration will be further developed by BASF BASF and Evogene bring key capabilities to the collaboration. With its first herbicide launched already in 1949, BASF currently offers one of the industry's strongest and most diverse weed control portfolios. The company's leading position is based on its continuing focus on innovation to drive its pipeline. Evogene is a market leader in bringing predictive biology to agricultural innovation by combining deep understandings of plant science with advanced computational tools for the analysis of big data. Building on these core capabilities, Evogene disclosed the discovery and successful validation of a set of plant targets in July of this year. These will be part of the collaboration. "Weed resistance is a pressing issue for many growers across the world. Thus, establishing such a partnership to help us identify and develop herbicides with novel modes of action is more needed than ever before. It is a great opportunity to combine Evogene's expertise in plant physiology and computational biology with BASF's strength in lead structure optimization and product development," said Jordi Tormo, Vice President Global Research Herbicides & Services, BASF Crop Protection. Ofer Haviv, President and CEO of Evogene stated: "We see a significant opportunity for our company to provide novel biology driven approaches for meeting key unmet commercial needs in the ag-chemical field. Therefore, we are extremely pleased and proud to have teamed with BASF in our initial efforts to identify promising candidates to serve as the basis for next generation herbicides. We are confident that the combined knowledge and experience of the companies will lead to development of breakthrough solutions for this critical need." The collaboration will be for a period of three years. Additional details of the agreement were not disclosed. About BASF's Crop Protection division With sales of more than €5.4 billion in 2014, BASF's Crop Protection division provides innovative solutions in crop protection, seed treatment and biological control as well as innovations to manage nutrients and plant stress. Its portfolio also includes products for turf and ornamental plants, pest control and public health. BASF Crop Protection is a leading innovator that partners with growers to protect and enhance crop yields, enabling them to produce high quality food more efficiently. By delivering new technologies and know-how, BASF Crop Protection supports growers to make a better life for themselves, their families and communities. Further information can be found on the web at www.agro.basf.com or on our social media channels. About BASF At BASF, we create chemistry - and have been doing so for 150 years. Our portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. As the world's leading chemical company, we combine economic success with environmental protection and social responsibility. Through science and innovation, we enable our customers in nearly every industry to meet the current and future needs of society. Our products and solutions contribute to conserving resources, ensuring nutrition and improving quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF had sales of over €74 billion in 2014 and around 113,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 08/12/2015 http://www.evogene.com/News-Events/Press-Releases/2015/BASF-and-Evogene-Sign-Collaboration-Agreement-for-Novel-Herbicide-Discovery-and-Development Evogene Officially Opens Research and Development Facility in St. Louis, Missouri http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Officially-Opens-Research-and-Development-Facility-in-St-Louis-Missouri Rehovot, Israel - November 19, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, will officially open its new Research and Development facility in St. Louis today with an event highlighting "Driving Innovation for Agriculture". The new facility is located at the Bio-Research and Development Growth (BRDG) Park, on the campus of The Donald Danforth Plant Science Center in St. Louis, Missouri, a world leading center for innovation in agriculture. In addition to Mr. Ofer Haviv, Evogene's President and CEO and Dr. James Presnail, the Site Head for Evogene, senior officials from Evogene and The Donald Danforth Plant Science Center will be participating in the opening celebration. Ofer Haviv, Evogene's President and CEO commented, "We are pleased to be officially opening today our first R&D site located in the U.S, and in particular on the Campus of the Danforth Plant Science Center in St. Louis. This important expansion brings us geographically much closer to both world leading companies and research centers in our industry and to key target markets for our Company. The site will initially be focused on our growing crop protection activities, primarily the Company's ongoing insect control product programs and collaborations for controlling Coleopteran, Lepidopteran and Hemipteran - key crop damaging insects - and we expect to expand its activities in the future to additional Evogene areas of focus, in both crop enhancement and crop protection." Within its crop protection area of activities, Evogene is a leader in the integration and analysis of vast amounts of microbial genomic data, in order to identify genes that can be specifically toxic to insects and fungi that lead to substantial crop damage and losses. In its initial activities, the new St. Louis facility will support these efforts, providing data generation experiments, functional screening and validation of discovered genes in biological systems, as well as establishing transformation and validation capabilities for biotechnology soybean. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/11/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Officially-Opens-Research-and-Development-Facility-in-St-Louis-Missouri Evogene Reports Third Quarter 2015 Financial Results http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Third-Quarter-2015-Financial-Results Rehovot, Israel - November 18, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the quarter and nine months ended September 30, 2015. Ofer Haviv, Evogene's President and CEO, stated: "For more than a decade we have focused on creating a unique discovery and validation infrastructure based on a deep understanding of plant science and our ability to create, integrate and analyze ag-related "big data". Our purpose in doing so was to create a broadly applicable capability for the development of improved input products for agriculture, such as: seeds, ag chemicals and ag biologicals, offering substantial measurable benefits to farmers. I believe that our ongoing success in this long-term effort is clearly demonstrated by both the impressive number of leading agriculture companies that entered into collaborations with us in our initial area of focus - yield and abiotic stress - and by the advancements we are now achieving as we enter additional major ag-market segments, such as ag-chemicals and insect control". Mr. Haviv continued: "It is well recognized that the worldwide need for food, feed & fuel will be continuing, and most likely, will increase in the future. Therefore, it is expected that the demand for the input products required for their production will also be substantial. In addition, past industry experience has shown that with respect to input products for agriculture, a product providing measurable new benefits can dominate a major market." "In order to fully utilize our unique infrastructure and capabilities as we leverage its application into a growing number of areas, we are now making certain organizational changes. The key to this re-organization is to group all of our operations into two operating hubs: Crop Enhancement - which aims to improve yield and tolerance to a-biotic stress, such as drought, and Crop Protection - covering crop resistance to various biotic organisms, such as insects, fungi and weeds. Each of these two operating hubs has the benefit of our existing expertise and assets gained through our long experience in the field, including an experienced multidisciplinary professional team, designated databases, proprietary data generation and validation capabilities, and an inventory of specific algorithms and data analysis tools." Mr. Haviv concluded, "Considering the global ag-opportunities that we see for the Company, our existing and expanding leading capabilities and the major market needs they address, along with the benefit of a strong balance sheet, we believe Evogene is well positioned to play an important role in providing new improved products in each of the market segments that we are addressing and we enthusiastically look forward to doing so, both directly and under milestone and royalty bearing agreements." Program highlights for the quarter: Crop Enhancement (former yield and abiotic stress division and ag biologicals) Activities in accordance to the work plan across all 18 seed trait product programs for yield and abiotic stress tolerance primarily with leading seed companies worldwide. Through the joint research with Monsanto the Company has been able to identify a series of key enabling traits, which the Company believes will improve overall performance in the collaboration crops, leading to increased yield. Initiated discovery activities in the area of ag biologicals for yield improvement with current focus on bio-stimulants. Crop Protection (former biotic stress division and ag chemicals division) In the Company's insect resistance trait program, novel toxins discovered by Evogene earlier this year are now undergoing validation against Coleoptera and Lepidoptera insects. In the Company's collaboration with Monsanto, the Company recently delivered the first batch of novel genes predicted to improve resistance to stalk rot (Fusarium) in corn. A first set of Evogene discovered novel targets for herbicides has advanced to the next stage of identifying chemical molecules designed to inhibit the activity of such targets. Evofuel Ltd (a wholly owned development stage company) Field trials in 2015 demonstrated the ability to produce castor as a row crop, and jointly with CNH industrial, the ability to mechanically harvest the crop. Decision by SLC and Evofuel to further evaluate castor on an experimental scale, therefore not moving to commercial production in 2016. Ongoing activities with existing partners, including SLC and Insolo, and other partners in Brazil and other countries in Latin America to prepare for initial commercialization. Financial results for the period ended September 30, 2015: Cash Position: As of September 30, 2015, Evogene had $106.4 million in cash, short-term bank deposits and marketable securities, representing a net cash usage of $9.9 million for the nine months ended September 30, 2015. Research Revenues include mainly periodic payments for research and development activities, provided under certain of the Company's collaboration agreements primarily with seed companies. Revenues from research and development payments for the nine months ended September 30, 2015 were $8.5 million, compared to $10.6 million for the same period in 2014. The decrease was primarily related to the previously announced amendment to the collaboration work plan with Bayer. Revenues from research and development payments for the third quarter of 2015 were $3.3 million, compared to $3.1 million for the same period in 2014. Evogene anticipates that for the longer term, its primary sources of revenues will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. Research revenues which reflect R&D related cost reimbursement under certain of Evogene's collaboration agreements, were in the past a meaningful contributor to cash flow. Currently, in view of the Company's financial strength, Evogene considers, on a case by case basis, self-financing certain activities under its collaborations. Although possibly resulting in less short term research revenues than would otherwise be the case, the Company's goal in negotiating the terms for collaborations is to maximize long-term revenues, consistent with maintaining its financial strength. Cost of Revenues includes research and development expenses related to the support of the Company's on-going activities under collaboration agreements primarily with seed companies, which provide for future milestone and/or royalty revenues. Cost of Revenues for the nine months ended September 30, 2015 was $6.2 million, compared to $7.3 million, for the same period in 2014. The decrease was primarily related to the previously announced amendment to the collaboration work plan with Bayer. Cost of revenues for the third quarter of 2015 was $2.5 million, compared to $2.3 million, for the same period in 2014. Research and Development Expenses for the nine months ended September 30, 2015 were $10.3 million, compared to $9.8 million for the same period in 2014. This increase derives from an increase in non-cash share-based compensation expenses. Research and Development Expenses for the third quarter of 2015 were $3.1 million, compared to $3.7 million for the same period in 2014. This decrease mainly relates to (1) the increase in the exchange rate of the US dollar against the Israeli Shekel, creating a decrease in the company expenses in terms of USD (2) a decrease in overhead expenses related to those R&D expenses. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as cost of revenues. Operating Loss for the nine months ended September 30, 2015 was $12.6 million (including a non-cash expense of approximately $3.3 million for amortization of share-based compensation), compared to an operating loss of $10.7 million (including a non-cash expense of approximately $2.5 million for amortization of share-based compensation) for the same period in 2014. This increase is mainly attributable to the increase in non-cash share-based compensation expenses and the decrease in revenues from research and development payments as described above. Operating Loss for the third quarter of 2015 was $3.8 million (including a non-cash expense of approximately $1.1 million for amortization of share-based compensation), compared to an operating loss of $4.3 million (including a non-cash expense of approximately %v.8 million for amortization of share-based compensation) for the same period in 2014. This decrease is mainly related to the decrease in R&D expenses as noted above. Conference call and webcast details: Evogene management will host a conference call today at 09:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through November 20, 2015. US-based participants are invited to access the replay by dialing 1-888-326-9310, and participants from Israel and other countries are invited to access the replay at 972-3-925-5901. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Financial Tables Contact: Sigal Fattal, Evogene Chief Financial Officer sigal.fattal@evogene.com 18/11/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Third-Quarter-2015-Financial-Results Evogene’s Third Quarter 2015 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Third-Quarter-2015-Earnings-Announcement-Schedule Rehovot, Israel - October 28, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the third quarter ended September 30, 2015 on Wednesday, November 18, 2015. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or 972-3-925-5901 internationally. The replay will be accessible through November 21, 2015, and an archive of the webcast will be available on the Company's website through November 28, 2015. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 28/10/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Third-Quarter-2015-Earnings-Announcement-Schedule Evogene to Present at Credit Suisse Annual Basic Materials Conference http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-Credit-Suisse-Annual-Basic-Materials-Conference Rehovot, Israel - September 16, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today that Ofer Haviv, President and CEO, will present at the Credit Suisse Annual Basic Materials Conference taking place in New York, September 16 and 17, 2015. Mr. Haviv's presentation will review Evogene's computational discovery platform, current product pipeline and areas of activities, and will take place on Thursday, September 17 at 11:30 am. Investors or partners attending the conference, who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 16/09/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-Credit-Suisse-Annual-Basic-Materials-Conference Evogene to Establish Validation Capabilities for Soybean Cyst Nematodes http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Establish-Validation-Capabilities-for-Soybean-Cyst-Nematodes Rehovot, Israel - August 17, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today that it intends to establish transformational and validation capabilities for biotechnology soybean. Activities will initially focus on soybean cyst nematode resistance with certain knowhow to be obtained from Syngenta pursuant to a recently signed amendment to the collaboration agreement targeting soybean cyst nematodes initially signed by the two companies in 2009, and extended in 2013. To date, under Evogene's multiple collaboration agreements with leading seed companies worldwide, Evogene has utilized its unique predictive discovery infrastructure and model plant validation systems, to undertake all of the first stage discovery responsibilities. The resulting candidate genes are then provided to its partners for transformation and validation in the target crop (such as soybean and corn), allowing further development under milestone and royalty bearing licenses from Evogene. Under the amendment, validation activities for the candidate genes, which have already been discovered by Evogene under the nematode collaboration, will now be undertaken by Evogene, at its expense and under Syngenta's guidance, with enhanced commercial terms for Evogene. Moving into the area of gene transformation and validation in soybean represents an important capability for Evogene, in addition to its existing discovery capabilities, with respect to both its internal research efforts and future collaboration arrangements. Ofer Haviv, Evogene's President and CEO commented: "Since the existing candidate genes already discovered by us in this collaboration have demonstrated positive indications for resistance to soybean cyst nematode in early testing, we are very enthusiastic about moving forward under these revised conditions." "In addition, having soybean transformation capabilities in house is expected to enable Evogene to take on further activities in the product development value chain for this key crop and provide the potential to enter into later stage collaborations," added Mr. Haviv. Michiel van Lookeren Campagne, Syngenta's Head of Biology Research, noted: "After more than five years of a fruitful partnership with Evogene in the soybean cyst nematode space, we are thrilled to push this collaboration to the next level and help Evogene deploy new capabilities that will positively impact the outcome of our program." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 17/08/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Establish-Validation-Capabilities-for-Soybean-Cyst-Nematodes Evogene to Present at Jefferies 2015 Industrials Conference http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-Jefferies-2015-Industrials-Conference Rehovot, Israel - August 6, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today that Ofer Haviv, Evogene's President and CEO, will present at the Jefferies 2015 Industrials Conference taking place in New York City, August 10-13, 2015. Mr. Haviv's presentation will review Evogene's technology platform, current product pipeline and areas of activity, and will take place on Monday, August 10. Investors attending the conference, who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 06/08/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-Jefferies-2015-Industrials-Conference Evogene Reports Second Quarter 2015 Financial Results http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Second-Quarter-2015-Financial-Results Rehovot, Israel - August 5, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today its financial results for the quarter and six months ended June 30, 2015. Ofer Haviv, Evogene's President and CEO, stated: "These past few weeks have been extremely rewarding from the standpoint of Evogene's on-going corporate growth and development. As we indicated at the time of our US IPO in late 2013, Evogene intended to allocate a large portion of the IPO proceeds towards new opportunities with substantial growth potential and a real need for innovation to drive the next generation of product development. This strategic undertaking, and the investment we made over the past year and a half in doing so, was well demonstrated by two milestone achievements that we recently disclosed." "First, in our herbicide program, last month we announced the successful discovery and validation in plants of the first set of potential targets. These novel targets are a significant achievement for Evogene's herbicide program, particularly since they are predicted to represent potential new 'mode of action', or manner, to kill weeds, and thus may provide the basis to the development of future weed-killing products." "Second, we recently disclosed the successful completion of our first computational round of microbial genes in our insect control program, which was only initiated mid last year. This is a remarkable achievement considering that in a relatively short period of time we were able to leverage our knowhow and technology to tackle a new and commercially attractive market segment with significant barriers to innovation. This first set of promising genes provides us with strong confidence in the approach we are pursuing for the discovery of microbial genes, and more importantly in their likelihood to eventually yield a commercial product." "In addition to the importance of these achievements for the programs themselves, they again demonstrate the power and broad applicability of our computational based predictive approach in the development of next-generation agriculture based products." Mr. Haviv concluded, "In summary, when looking across the various areas of the business, we are extremely excited with the initial progress we have made in advancing our newest areas of focus - insect control and novel herbicides - to the next stages of product development, and pleased with our continued efforts in narrowing the gap to successful product introduction in our more established market areas." Financial results for the period ended June 30, 2015: Cash Position: As of June 30, 2015, Evogene had $110 million in cash, short term bank deposits and marketable securities, representing a net cash usage of $6.3 million for the six months ended June 30, 2015. Research Revenues include mainly periodic payments for research and development activities provided under certain of the Company's collaboration agreements with seed companies. Revenues from research and development payments for the six months ended June 30, 2015 were $5.3 million, compared to $7.5 million for the same period in 2014. Revenues from research and development payments for the second quarter of 2015 were $2.6 million, compared to $3.8 million for the same period in 2014. The decline was primarily related to the previously announced amendment to the Company's Bayer collaboration work plan. Evogene anticipates that longer term, its primary sources of revenues will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. In that regard, research revenues, which reflect R&D related cost reimbursement under certain of Evogene's collaboration agreements, were in the past a meaningful contributor to cash flow. Today, in consideration of the Company's strong cash balances, research revenues do not constitute a significant or essential part of the Company's cash flow. Looking forward, Evogene intends to consider, on a case by case basis, self-financing certain activities under future collaborations. Although possibly resulting in less short term R&D revenues than would otherwise be the case, the Company's goal in negotiating the terms for future collaborations will be to maximize long term revenues, consistent with maintaining its financial strength. Cost of Revenues largely includes research and development expenses related to the support of the Company's on-going activities under collaboration agreements with seed companies, which provide for future milestone and/or royalty revenues. Cost of revenues for the six months ended June 30, 2015 was $3.8 million, compared to $5.0 million, for the same period in 2014. Cost of revenues for the second quarter of 2015 was $1.9 million, compared to $2.4 million, for the same period in 2014. Research and Development Expenses for the six months ended June 30, 2015 were $7.2 million, compared to $6.0 million for the same period in 2014. This increase largely relates to expansion of self-funded activities, primarily focused on the development of new computational genomics platforms and validation technologies, mainly in our key growth engines - insect resistance and ag-chemicals. The increase also derives from an increase in non-cash share-based compensation expenses. Research and Development Expenses for the second quarter of 2015 were $3.7 million, compared to $3.4 million for the same period in 2014. This increase mainly relates to increase in non-cash share-based compensation expenses. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Operating Loss for the six months ended June 30, 2015 was $8.8 million (including a non-cash expense of approximately $2.2 million for amortization of share-based compensation), compared to an operating loss of $6.4 million (including a non-cash expense of approximately $1.7 million for amortization of share-based compensation) for the same period in 2014. Operating Loss for the second quarter of 2015 was $4.6 million (including a non-cash expense of approximately $1.4 million for amortization of share-based compensation), compared to an operating loss of $3.7 million (including a non-cash expense of approximately %v.9 million for amortization of share-based compensation) for the same period in 2014. This increase is mainly attributable to the increase in self-funded research and development expenses, the increase in non-cash share-based compensation expenses and the decrease in revenues from research and development payments as described above. Conference call and webcast details: Evogene management will host a conference call today at 09:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through August 7, 2015. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5904. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Financial Tables 05/08/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Second-Quarter-2015-Financial-Results Evogene Announces Successful Completion of First Computational Discovery of Novel Microbial Genes for Insect Control http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Announces-Successful-Completion-of-First-Computational-Discovery-of-Novel-Microbial-Genes-for-Insect-Control Rehovot, Israel - August 4, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today a key milestone in its insect control program with the successful completion of the first computational discovery round for microbial genes with insecticidal properties. The discovery round utilized a unique computational technology infrastructure consisting of a proprietary microbial-based database and a dedicated analysis platform, BiomeMinerTM. The candidate genes will be validated against target insects at the Company's dedicated R&D site located in St. Louis, Missouri. Validation is expected to be completed next year. The first computational discovery round using BiomeMinerTM yielded a set of novel candidate genes with insecticidal properties to be validated against Coleoptera and Lepidoptera insects. These families of insects include some of the most devastating insects to crop yields such as corn rootworm and corn earworm. In addition to these novel candidate genes, the platform also identified previously known genes that are already recognized for their insecticidal properties, providing a proof of concept for the predictive power of Evogene's discovery platform. Ofer Haviv, President and CEO of Evogene stated: "This milestone in Evogene's insect control program is an important achievement. Within a very short period of time we were able to leverage our knowhow and technology in plant science to tackle the field of microbial traits, a new field for us with significant barriers to innovation. By formulating unique approaches to data generation and computational analysis, we are paving the path for the future development of new insect control products. The validation of these candidate genes, which is the next significant milestone in the program, will further advance us on this path." The current market for insect control traits based on microbial genes is estimated at approximately $4.5 billion annually. When inserted into a target crop, these genes and their insecticidal traits provide protection for the plant from certain harmful insects. Today, most of these products are based on microbial genes derived from one type of bacteria, named Bacillus thuringiensis (Bt), to which insects have grown resistant over the years. The next generation of insect control products that will address this growing resistance will most probably be based on the discovery of microbial genes not derived from the Bt bacteria. With the microbial gene pool constituting hundreds of millions of potential genes, the challenge of finding novel microbial genes that can form the basis of future insect control products, depends on both compiling the huge amount of relevant data into one integrated database and successfully analyzing this huge diversity. Evogene has utilized its core competencies to meet this challenge with the development of a proprietary microbial-based database and BiomeMinerTM, a data analysis platform. The database, currently containing tens of millions of microbial genes, is capable of integrating data from diverse microbial sources including publicly available data and data collections from proprietary experimental samples enriched for insecticidal activity. A unique feature of the database is the integration capabilities of vast amounts of highly sparse and complex 'metagenomics' data. To process this huge microbial gene pool within the database, the BiomeMinerTM analysis platform utilizes advanced machine learning algorithms to rapidly identify and prioritize genes with insecticidal properties. The platform sifts through the vast microbial gene pool in the database and elects a limited number of genes with the potential for insecticidal properties. xxx About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 04/08/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Announces-Successful-Completion-of-First-Computational-Discovery-of-Novel-Microbial-Genes-for-Insect-Control Evogene to Participate at Piper Jaffray Technology Enabled Industrials Symposium http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Participate-at-Piper-Jaffray-Technology-Enabled-Industrials-Symposium- Rehovot, Israel - August 3, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today that Assaf Oron, Executive Vice President for Strategy and Business Development, will participate at the Piper Jaffray Technology-Enabled Industrials Symposium taking place in Minneapolis, Minnesota, August 4 and 5, 2015. Mr. Oron will take part at the conference Ag Biotech and the Future of Crop Science panel which will take place on Wednesday, August 5, at 11:00 am. Investors or potential partners attending the conference, who wish to meet with Mr. Oron, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 03/08/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Participate-at-Piper-Jaffray-Technology-Enabled-Industrials-Symposium- Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Announces-Discovery-and-Validation-of-Novel-Plant-Targets-for-Herbicides- Rehovot, Israel - July 29, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today the discovery and successful validation in plants of the first set of novel plant targets, representing a key milestone in its product program for new chemical herbicides. Targets for herbicides are vital plant macro-molecules taking part in essential biological processes in weeds ('modes of action'). The Evogene discovered targets will now be the subject of a unique methodology for the discovery of chemical molecules that can inhibit their functionality, resulting in weed death. These chemical molecules would then serve as the basis for the development of the active ingredients in commercial herbicide products. The milestone follows an earlier announcement this year on the completion of a dedicated start-to-end discovery infrastructure for the herbicide program. Herbicides ("weed killers"), currently a market of approximately $26 billion, are chemicals that are toxic to plants and are applied to eradicate unwanted weeds. Over the past two decades, weed resistance to existing chemical solutions is soaring, mainly due to the over-use of these chemicals that act on a very limited number of known 'modes of action' (MoA). A key avenue for alleviating this challenge would be the discovery of new targets associated with new MoA to serve as the basis for the next generation of herbicide solutions. Evogene's newly discovered and successfully validated targets are predicted to provide this potential. Ofer Haviv, President and CEO of Evogene stated, "The discovery and successful validation in plants of these novel targets is a significant achievement for Evogene's herbicide program, particularly since they are predicted to represent potential new 'modes of action'. In addition, this achievement provides further evidence that our computational based predictive approach for the development of agriculture based products has the potential to be a game-changer in shaping the future landscape of our industry." Utilizing Evogene's proprietary target identification platform PoinTarTM, the newly discovered and validated targets have been prioritized based on their predicted role in essential biological processes in plants, their ability to interact with chemical molecules, and other considerations relating to desired product attributes. The next major milestone in the program will utilize PointHitTM for identification of chemical molecules that are designed to inhibit the activity of the discovered targets. Once discovered and validated on a wide range of weeds and crops, these chemical molecules could then serve as the active ingredients for the development of next generation herbicide products, a major unmet market need in worldwide agriculture. xxx About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 29/07/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Announces-Discovery-and-Validation-of-Novel-Plant-Targets-for-Herbicides- Evogene’s Second Quarter 2015 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Second-Quarter-2015-Earnings-Announcement-Schedule Rehovot, Israel - July 15, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the second quarter 2015 on Wednesday, August 5, 2015. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or 972-3-925-5904 internationally. The replay will be accessible through August 7, 2015, and an archive of the webcast will be available on the Company's website through August 15, 2015. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 15/07/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Second-Quarter-2015-Earnings-Announcement-Schedule Evogene to Present at LD Micro Invitational http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-LD-Micro-Invitational- Rehovot, Israel - May 28, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that Ofer Haviv, Evogene's President and CEO will make a presentation at the LD Micro Invitational Conference in Los Angeles, CA on Tuesday, June 2nd, 2015. Mr. Haviv's presentation will review Evogene's technology platform for gene-based discovery, current product pipeline and areas of activities. Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at investors@evogene.com xxx About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 28/05/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Present-at-LD-Micro-Invitational- Evogene Reports First Quarter 2015 Financial Results http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-First-Quarter-2015-Financial-Results Rehovot, Israel - May 19, 2015 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today its financial results for the quarter ended March 31, 2015. Ofer Haviv, Evogene's President and CEO, stated: "This past quarter, we were very pleased with our continuing progress in each of our four market oriented divisions. We saw advances in development across our individual product programs and increased recognition by the industry of our broad discovery capabilities, as demonstrated by our recent announcements regarding the incorporation of our gene optimization program into our collaboration with Monsanto following the entry of over 1,000 Evogene candidate genes into their product development pipeline, and the signing of our first collaboration with a leading multinational food company." Mr. Haviv continued, "Looking at the worldwide agriculture market, demand for key crops continues to increase steadily to new record levels. For example, corn consumption during the past five years increased by 25%, and is expected to reach record levels this year. In view of the combination of continuing world-wide population growth and changing food habits, these increases in demand are certain to continue. Furthermore, due to on-going changes such as increasing resistance of insects and weeds to current pesticides and herbicides, along with negative trends in arable land and environmental pressures, it is reasonable to project that without significant technological advances, just sustaining today's levels of production will be a major challenge, let alone meeting the continuing increases in demand." Mr. Haviv concluded, "We are confident that Evogene is uniquely qualified to address this critical need for technological advances in agriculture. For the past 10 years we have been establishing and enhancing a broadly applicable discovery platform that combines deeper understandings of plant biology with industry leading computational based 'big data' integration, analysis and prediction technologies. And this unique capability, now being applied by us to address the key needs in four major market segments, is being recognized by an increasing number of collaborations with leading seed and other ag-bio based companies world-wide." Financial results for the quarter ended March 31, 2015: Cash Position: As of March 31, 2015, Evogene had $113.2 million in cash, short term bank deposits and marketable securities, representing a net cash usage for the quarter of $3.1 million. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its net cash usage for full year 2015 will be in the range of $16 to $18 million. Research Revenues include mainly periodic payments for research and development activities provided under certain of the Company's collaboration agreements with seed companies. Revenues from research and development payments for the first quarter of 2015 were $2.7 million, compared to $3.8 million for the first quarter of 2014. The decline was primarily related to the previously announced amendment to the Company's Bayer collaboration work plan. Evogene anticipates that longer term, its primary sources of revenues will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. In that regard, research revenues, which reflect R&D related cost reimbursement under certain of Evogene's collaboration agreements, were in the past a meaningful contributor to cash flow. Looking to the future, Evogene intends to consider, on a case by case basis, self-financing or jointly financing with potential partners, certain additional activities under future collaborations, particularly with respect to the Company's newer growth areas. Although possibly resulting in less short term R&D revenues than would otherwise be the case, the Company's goal in negotiating the terms for future collaborations will be to maximize long term revenues, consistent with maintaining its financial strength. Cost of Revenues largely includes research and development expenses related to the support of the Company's on-going activities under collaboration agreements with seed companies, most of which provide for future milestone and royalty revenues. Cost of revenues for the first quarter of 2015 was $1.8 million, compared to $2.6 million, for the same period in 2014. Research and Development Expenses for the first quarter of 2015 were $3.5 million, compared to $2.7 million for the same period in 2014. The increase in these expenses largely relates to expansion of self-funded activities, primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, mainly in our key growth engines - insect resistance, ag-chemicals and Evofuel. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Operating Loss for the first quarter of 2015 was $4.1 million, compared to an operating loss of $2.6 million for the same period in 2014. This increase is mainly attributable to the decrease in revenues from research and development payments, as well as the increase in self-funded research and development expenses, and certain other operating expenses. Conference call and webcast details: Evogene management will host a conference call today at 09:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through May 21, 2015. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5901. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/05/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-First-Quarter-2015-Financial-Results Evogene Files Annual Report for the Year Ended December 31, 2014 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Files-Annual-Report-for-the-Year-Ended-December-31-2014 Rehovot, Israel - April 30, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report, which contains the Company's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov/as well as via the Company's investor relations website at http://investors.evogene.com/financial-reports/report-2014.aspx. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: karen.mazor@evogene.com. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions 30/04/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Files-Annual-Report-for-the-Year-Ended-December-31-2014 Evogene’s First Quarter 2015 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-First-Quarter-2015-Earnings-Announcement-Schedule Rehovot, Israel - April 28, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the first quarter 2015 on Tuesday, May 19, 2015. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or 972-3-925-5901 internationally. The replay will be accessible through May 21, 2015, and an archive of the webcast will be available on the Company's website through May 29, 2015. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 28/04/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-First-Quarter-2015-Earnings-Announcement-Schedule Evogene CEO Ofer Haviv and Marrone Bio Innovations CEO Pam Marrone to Participate in 'Profiling Tomorrow's Ag Solutions' Panel Discussion at AgriVest 2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-CEO-Ofer-Haviv-and-Marrone-Bio-Innovations-CEO-Pam-Marrone-to-Participate-in-Profiling-Tomorrows-Ag-Solutions-Panel-Discussion-at-AgriVest-2015 Rehovot, Israel and Davis, California - April 27, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, and Marrone Bio Innovations, Inc. (MBI), (NASDAQ: MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced their respective Chief Executive Officers, Ofer Haviv and Pam Marrone, will participate in the 'Profiling Tomorrow's Ag Solutions' panel discussion at AgriVest 2015, the Israeli Agritech Investment Event. The panel discussion will take place on April 27th at 11:30 AM Israel Time in Wix Auditorium at the Weizmann Institute of Science, in Rehovot, Israel. The panel will be moderated by Eyal Lipetz-Eliassi, Israel Country Manager & Innovation-Based Growth Leader, DuPont. Additional panel members include Sam Fiorello, COO, Danforth Plant Science Center & President, Bio-Research & Development Growth Park; Barry J. Schindler, Co-Chair Global Patent Prosecution Group, GreenbergTraurig; and Alexander Wiegelmann, VP M&A/Head of Transactions, KWS SAAT AG. Marrone will provide perspective on the role of bio-based pesticides in helping growers strengthen their integrated pest management programs, improve plant health, boost yields and increase profitability. As part of the panel discussion, Evogene will provide insight on its strategic collaborations with some of the world's leading agricultural companies, particularly in the area of improved seed traits development, as well as its more recent research and development efforts for novel crop protection solutions. The two companies will also provide an update on their previously announced multiyear collaborative agreement targeting the joint discovery of novel modes of biological action for insect control, followed by the development and commercialization of new insect control products by each of the companies. "The unique partnership with MBI has brought together two very unique capabilities in our industry today - MBI's expertise in microbial-based solutions for pest control and plant health, and Evogene's computational gene discovery capabilities," said Ofer Haviv, President and CEO of Evogene. "Only a few months into the collaborative work plan, we have already completed the selection process, with the first set of candidate microbes showing high efficacy in testing. These microbial candidates will form the key targets for the upcoming gene discovery round which will be conducted utilizing Evogene's proprietary computational platforms." "This is an exciting time for agtech as there is an explosion of innovation all along the food chain from farm to fork," said Pam Marrone, CEO of Marrone Bio Innovations. "Collaboration is critical to driving innovation and we are very pleased with the results of our partnership with Evogene. We are making good progress towards developing novel modes of action for insect control as our collaboration is enabling us to leverage our discovery and development strategy to explore an even wider range of microbes with novel insecticidal genes." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. About Marrone Bio Innovations Marrone Bio Innovations, Inc. (NASDAQ: MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com. Forward Looking Statements Portions of this press release may constitute "forward-looking statements," and assumptions underlying such forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any such forward-looking statements are made within the "safe-harbor" protections of the PSLRA, should not be relied upon as representing our views as of any subsequent date, and we are under no obligation to, and expressly disclaims any responsibility to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements in this filing include those regarding implementing our business strategy, expectations regarding our sales team and driving sales of our products. Such forward-looking statements are based on information available to us as of the date of this release and involve a number of risks and uncertainties, some beyond our control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Such risks include adverse weather conditions and seasonality that may affect sales, failure of customers to adopt our products, the high level of competition in the market for pest management products, inability to maintain and further establish successful relationships with third-party distributors, the failure of our third-party distributors to sell to end users and uncertainty surrounding our compliance with our financial reporting obligations. Additional information that could lead to material changes in our performance is contained in our filings with the Securities and Exchange Commission 27/04/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-CEO-Ofer-Haviv-and-Marrone-Bio-Innovations-CEO-Pam-Marrone-to-Participate-in-Profiling-Tomorrows-Ag-Solutions-Panel-Discussion-at-AgriVest-2015 Evogene Discloses First Collaboration with Leading Multinational Food Company for Improving Crop Productivity http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Discloses-First-Collaboration-with-Leading-Multinational-Food-Company-for-Improving-Crop-Productivity Rehovot, Israel - March 18, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, disclosed today its first collaboration agreement with a multinational food company. The focus of the multi-year collaboration is to improve productivity of a key crop underlying one of the consumer company's leading branded product lines through advanced breeding methods. "As the consumer market becomes increasingly competitive, the industry is displaying increased interest and involvement in assuring the long-term quality, availability and sustainability of the agricultural feedstocks required for its branded products," said Ofer Haviv, Evogene's President and CEO. "This collaboration allows us to venture into this previously untapped segment of consumer goods, where Evogene's unique capabilities in improving the performance and productivity of underlying crops, can help meet the growing needs of food companies for more sustainable and higher quality feedstock supply." The agreement leverages Evogene's decade-long experience, data base and knowhow for yield improvement and advanced breeding methods. Under the agreement, Evogene will utilize its proprietary computational and plant validation platforms to develop improved pre-breeding varieties of the target crop. Proof of concept validation activities will be conducted in both model plants and the target crop, which represents a new addition to Evogene's growing crop improvement portfolio. The three year collaboration, signed late last year, entitles Evogene to research and development fees and success based payments. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 18/03/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Discloses-First-Collaboration-with-Leading-Multinational-Food-Company-for-Improving-Crop-Productivity Evogene Reports Fourth Quarter and Full Year 2014 Financial Results http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results Rehovot, Israel - February 26, 2015 - Evogene Ltd. (NYSE;TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today its financial results for the fourth quarter and year ended December 31, 2014. Ofer Haviv, Evogene's President and CEO, stated: "This past year was a year of significant progress and achievements as we continue to establish Evogene as a recognized innovation engine for novel product candidates in multiple agriculture based industries." "In the area of yield and abiotic stress, the most mature of our four current areas of activity, we have expanded our capabilities to include new computational systems designed to optimize desired trait efficacy and accelerate product development efforts for the genes we discover, as demonstrated in the incorporation of these new capabilities into our collaboration with Monsanto." "In the area of biotic stress, during 2014 we announced our entry into the field of insect resistance with an initial projected investment of $10 million in support of our activities in this significant market area. As a first step, we enhanced our computational discovery capabilities and expanded our supporting infrastructure with dedicated R&D facilities in Israel, accompanied by a larger US-based facility to be operational by end 2015." "In ag-chemicals, our most recent and rapidly growing area, we believe that our unique approach of biology driven chemical discovery can be a game changer in this enormous segment of the agriculture industry. Our initial application in ag-chemicals will be novel herbicide solutions, and earlier this week we announced the completion of our 'start-to-end' computational platform addressing this activity." "Lastly, our wholly owned subsidiary, Evofuel, continues to make progress towards the goal of commercialization of its proprietary castor seeds in 2016, with key achievements in strengthening its agronomic offering and commercial reach in Brazil." Mr. Haviv concluded: "We are very proud of these continuing achievements in these critical agriculture based areas, which not only offer substantial potential value for the industry and for our shareholders, but more importantly, continue to demonstrate the power and unique discovery capability we have created at Evogene." Financial results for the fourth quarter and year end 2014: Total Revenues include (i) research and development payments, including up-front payments, and (ii) share purchase related revenues. Evogene anticipates that longer term, its primary sources of revenues and profits will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. (i) Revenues from research and development payments include periodic payments for research and development services generated under the Company's collaboration agreements with seed companies, as well as up-front payments received under the Company's agreements with collaborators, which are recognized as revenues over the duration of the relevant agreement. R&D revenues for 2014 were $14.2 million, compared to $15 million for 2013. Revenues for the fourth quarter of 2014 were $3.6 million, compared to $4.2 million for the same period in 2013. The decline in full year revenues was primarily related to the amendment to the Company's Bayer collaboration work plan, whereby $1.7 million of research payments will be recognized as revenues in 2015 and onwards. This decline was offset in part by an increase in revenues associated with a new collaboration and the expansion of activities in certain existing collaborations, including the Company's agreements with Monsanto and Syngenta, which were extended and expanded in late 2013. (ii) Share purchase related revenues result from the required accounting treatment for the past acquisitions of Evogene ordinary shares by Monsanto and Bayer, as well as the put option agreement that the Company entered into with Monsanto, all in conjunction with the research and development collaboration agreements signed with these partners. Share purchase related revenues for 2014 were $313 thousand, compared to $2.6 million in 2013. The decline in share purchase related revenues reflects accounting treatment of certain past transactions involving Evogene ordinary shares with Monsanto and Bayer and does not reflect any current cash flow. In the fourth quarter of 2014, the Company recorded $73 thousand of share purchase related revenues, compared with $167 thousand for the fourth quarter of 2013. Cost of revenues largely consists of research and development expenses related to the support of the Company's ongoing activities under collaboration agreements with seed companies, all of which provide for future milestone and royalty revenues. Cost of Revenues for 2014 was $9.7 million, compared to $10.1 million for the same period in 2013. Cost of Revenues for the fourth quarter of 2014 was $2.4 million, compared to $2.8 million for the same period in 2013. Research and Development Expenses for 2014 were $14 million, compared to $11.1 million for the same period in 2013. Research and development expenses for the fourth quarter of 2014 were $4.3 million, compared to $3.5 million for the same period in 2013. The increase in these expenses largely relates to expansion of self-funded activities, primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, mainly in our key growth engines - insect resistance, ag-chemicals and Evofuel. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Business Development Expenses for 2014 were $1.9 million, compared to $1.5 million for the same period in 2013. This increase reflects costs associated with the Company's decision to establish dedicated Business Development capabilities within each of its four operating divisions, as well as costs associated with ongoing efforts to introduce the Company's business proposition to prospective partners in new and existing areas. Business Development expenses for the fourth quarter of 2014 were $508 thousand, compared to $611 thousand for the same period in 2013. General and Administrative Expenses for 2014 were $4.2 million (including a non-cash expense of $1.3 million for amortization of share-based compensation), compared to $3.6 million (including a non-cash expense of $936 thousand for amortization of share-based compensation) for the same period in 2013. In addition to the non-cash share-based compensation, this increase relates to continued growth in the Company's operations and costs associated with being a publicly traded entity in the US. General and Administrative expenses for the fourth quarter of 2014 were $1.1 million (including a non-cash expense of $224 thousand for amortization of share-based compensation), compared to $1.5 million (including a non-cash expense of $433 thousand for amortization of share-based compensation) for the same period in 2013. The decrease relates to one-time costs recorded in the fourth quarter of 2013, associated with the equity offering in the US and listing on the New York Stock Exchange, completed during November 2013. Operating Loss for 2014 was $15.3 million (including a non-cash expense of approximately $3.2 million for amortization of share-based compensation), compared to an operating loss of $8.7 million (including a non-cash expense of approximately $2.7 million for amortization of share-based compensation) for the same period in 2013. This increase is mainly attributable to the decrease in non-cash share purchase related revenues, as well as the increase in self-funded research and development expenses, among other operating expenses, and non-cash share-based compensation expenses, as described above. Operating loss for the fourth quarter of 2014 was $4.6 million (including a non-cash expense of $693 thousand for amortization of share-based compensation), compared to an operating loss of $4 million (including a non-cash expense of $1.1 million for amortization of share-based compensation) for the same period in 2013. Cash Position: As of December 31, 2014, Evogene had $116.3 million in cash, short term bank deposits and marketable securities, compared to $126.9 million as of December 31, 2013. Key achievements to date: -Introduces biology-driven ag-chemical discovery platform -Expands castor activity in Brazil with Insolo -Announces plans to establish R&D Facility in the United States -Incorporates new gene optimization program into its collaboration with Monsanto -Extends collaboration with CNH for development of mechanized harvesting solution for castor -Expands crop protection activities with dedicated R&D facilities in Israel -Collaborates with Embrapa on advancing castor cultivation in Brazil -Amends Bayer wheat agreement to focus on discovery of genomic promoters -Enters multi-year collaboration agreement with Marrone Bio Innovations -Enters field of Insect Resistance -Announces plans for commercial production of castor bean in Brazil with SLC -Launches PlaNet version 2.0 with enhanced gene stacking capabilities -Launches PoinTar target discovery platform for novel herbicides Conference call and webcast details: Evogene management will host a conference call today at 09:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at (972) 3-918-0609. A replay of the conference call will be available beginning at approximately 12:00 Eastern time, 19:00 Israel time today, and will be accessible through February 28, 2015. US-based participants are invited to access the replay by dialing 1-888-326-9310, and participants from Israel and other countries are invited to access the replay at (972) 3-925-5901. A replay of the call may also be accessed as a webcast via Evogene's website at http://investors.evogene.com and will be available for a period of ten days. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 26/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results Evogene Introduces Biology Driven Ag-Chemical Discovery Platform http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Introduces-Biology-Driven-Ag-Chemical-Discovery-Platform Rehovot, Israel - February 24, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today the introduction of its biology-driven platform for the discovery of novel ag-chemicals, with the initial application focused on novel herbicides. The ag-chemical discovery platform includes a new chemical-discovery computational platform, PointHit, and follows the announcement last year of Evogene's target-discovery computational platform, PoinTar. Together, these two platforms, along with a uniquely designed chemical database also being announced today, provide a start-to-end discovery infrastructure for Evogene's rapidly growing ag-chemical program. Addressing the need for weed control solutions, currently a worldwide market of over $20 billion, Evogene's herbicide discovery program offers a unique approach of integrating predictive biology and chemistry. Last year, the Company launched its PoinTar target-discovery platform, aimed at identifying key plant macro-molecules responsible for essential biological processes in weeds. The new chemical-discovery platform PointHit will utilize the chemical database and the targets identified by PoinTar to discover chemical molecules that inhibit the target within the weed, resulting in weed death. The combination of these computational technologies, form a start-to-end unique discovery infrastructure leveraging biological rationale to drive predictions for novel chemical herbicide candidates with new 'modes of action'. Ofer Haviv, President and CEO of Evogene stated: "Evogene looks to provide a powerful new discovery approach to one of agriculture's most critical challenges and largest commercial opportunities. The completion of our chemical database and biology-driven discovery platforms represent a significant building block in our herbicide discovery program. Having put in place the necessary start-to-end infrastructure, with both biological and chemical discovery components in place, we now have the basis to explore 'go to market' strategies and potential collaborations, as well as leverage our infrastructure to address future opportunities in related ag-chemical fields, such as insecticides and fungicides." The new start-to-end computational infrastructure leverages Evogene's expertise and capabilities in 'big data' integration and analysis developed through its expertise in plant genomics. A key component of this infrastructure is Evogene's new chemical database, currently encompassing over 70 million chemicals, derived from a variety of available sources, including synthetic and natural chemistry. A unique property of the database is its ability to provide computational prediction of the chemical's plant activity, namely the chemical's ability to penetrate the plant and allow the necessary herbicidal effect. The PointHit chemical-discovery platform, mines the huge database in a high throughput manner to identify candidate chemicals predicted to serve as potential herbicide 'hits' with a new 'mode of action'. The platform uses multiple biologically-driven strategies to pinpoint potentially relevant chemistry. In later stages in the program, predicted candidate chemicals will be screened on plants to examine their activity, with the results fed back to the systems to allow a learning process to improve future predictions. Weeds lead to crop losses estimated at the range of $100 billion annually. The need for new herbicide solutions arises from the substantial and growing resistance of weeds and other invasive plants to existing chemical solutions since no new herbicide 'mode of action' has been introduced in over 20 years (a 'mode of action' relates to the manner in which a chemical affects the plant's molecular processes, resulting in weed death). -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 24/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-Introduces-Biology-Driven-Ag-Chemical-Discovery-Platform Evofuel Expands Castor Activity in Brazil with Insolo http://www.evogene.com/News-Events/Press-Releases/2015/Evofuel-Expands-Castor-Activity-in-Brazil-with-Insolo- Rehovot, Israel - February 17, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today the signing of a collaboration agreement between its wholly-owned subsidiary Evofuel Ltd. and Insolo Agroindustrial S.A., for the selection and optimization of Evofuel's proprietary castor bean varieties in Insolo farms located in Piaui state in northeast Brazil. The two-year collaboration between the two companies will examine the suitability and adaptability of growing Evofuel's castor varieties as a second crop solution for Insolo farms located in one of the fastest developing agricultural regions in Brazil - the Cerrado. In the framework of the collaboration, the two companies will jointly evaluate the economic and agronomic benefits of growing Evofuel's castor seed varieties in this area, selecting the best performing varieties, and developing the agronomic know-how to integrate castor into Insolo's production system. Assaf Oron, General Manager of Evofuel, stated: "We are very excited to add Insolo as a partner in Brazil. The collaboration is a further step in Evofuel's expansion plans in Brazil as we near our commercial targets for 2016. Insolo is a pioneer in the development of agriculture in Piaui and the Cerrado region, Brazil's agricultural 'new frontier', and we are proud to have their support as we look to address a key need in the region for second crop solutions." Evofuel focuses on the development of castor bean seeds for industrial use and production of oil feedstock suitable for the growing biofuel market. Utilizing the unique characteristics of castor's high oil content and ability to withstand relatively harsh conditions, Evofuel is focused on growing castor as a second crop solution, particularly in semi-arid regions such as northeast Brazil. Evofuel recently announced its on-going collaboration with Case New Holland (CNH) for the development of a customized combine solution for large-scale harvesting of castor, and collaboration with Embrapa for research of castor disease control practices. -xxx- About Evofuel Ltd.: Evofuel is engaged in the development and commercialization of high yielding castor seeds as a cost-competitive, sustainable, and second-generation feedstock for the growing biofuel market and various industrial uses. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process, Evofuel applies advanced breeding methods utilizing cutting-edge plant genomics capabilities together with agro-technique expertise to enable efficient and sustainable large-scale production of castor. Initially established in 2007 as a division within Evogene Ltd. (TASE: EVGN), Evofuel was spun out as a wholly owned subsidiary in 2012. For additional information, please visit Evofuel's website at: www.evo-fuel.com About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions 17/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evofuel-Expands-Castor-Activity-in-Brazil-with-Insolo- Evogene to Establish Research and Development Facility in the United States http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Establish-Research-and-Development-Facility-in-the-United-States REHOVOT, Israel - February 9, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, today announced it has signed a Letter of Intent with plans to establish a research and development facility in the Bio-Research and Development Growth (BRDG) Park, developed by Wexford Science & Technology, a BioMed Realty Company, on the campus of the Donald Danforth Plant Science Center in St. Louis, Missouri. The establishment of the facility is a key component of the Company's previously disclosed entry into the field of advanced solutions for insect control. Evogene previously projected an expenditure of approximately $10 million in order to broaden its existing predictive discovery and validation capabilities into this substantial field. The facility will be headed by Dr. James Presnail, Ph.D. who was appointed to lead the Company's insect control research and development activities at the new facility. Dr. Presnail previously held senior management positions at DuPont Pioneer and brings to Evogene two decades of in-depth knowledge and experience in the planning, execution and management of insecticidal gene discovery and efficacy testing. The approximately 6,000 square foot facility will feature state-of-the-art laboratories and insect rearing rooms and is projected to be fully operational by the end of 2015. It will support Evogene's growing insect control activities, initially focusing on the Company's on-going product programs for corn rootworm and soybean aphids. The planned facility will incorporate both field specific modifications of the Company's existing gene testing and validation infrastructure and new capabilities for targeting these and other high impact pests. In addition, the facility will help facilitate the Company's field-based data generation activities in the United States. In support of its selection of St. Louis for its R&D facility, Evogene has been offered a strategic economic incentive package from the Missouri Department of Economic Development. Ofer Haviv, Evogene President and CEO stated: "The establishment of this new facility and the addition of Jim to our team will clearly take Evogene to a new level in the important area of insect control, a level which we hope will soon be similar to the leadership position we have already established in the area of yield and stress tolerance. In the short term, we are confident that this substantial strengthening of our assets and business propositions in insect control will now allow us to rapidly expand and accelerate our activities in this area, both on our own and through additional collaborations. In doing so, we are very pleased to expand our R&D operations to St. Louis, and to have the benefit of Jim's extensive knowledge and management experience in insecticidal gene discovery and development." Mr. Haviv concluded: "Our choice to locate at BRDG Park on the Danforth Center campus, a world leader in plant science research, is one we are very proud of as we join this innovative community. Being a company that is committed to the improvement of crop productivity, we share the Danforth Center's belief that plants hold the key to discoveries and products that will enrich and restore both the environment and the lives of people around the globe." -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions 09/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-to-Establish-Research-and-Development-Facility-in-the-United-States Evogene’s Fourth Quarter and Full Year 2014 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Fourth-Quarter-and-Full-Year-2014-Earnings-Announcement-Schedule Rehovot, Israel - February 5, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the fourth quarter and full year 2014 on Thursday, February 26, 2015. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or 972-3-925-5901 internationally. The replay will be accessible through February 28, 2015, and an archive of the webcast will be available on the Company's website through March 8, 2015. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions 05/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Fourth-Quarter-and-Full-Year-2014-Earnings-Announcement-Schedule Evogene New Gene Optimization Program Being Incorporated into Yield & Environmental Stress Collaboration with Monsanto http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-New-Gene-Optimization-Program-Being-Incorporated-into-Yield--Environmental-Stress-Collaboration-with-Monsanto- REHOVOT, ISRAEL - February 4, 2015 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that its recently developed comprehensive gene optimization program is being incorporated into its multi-year collaboration with Monsanto Company. The addition of these new capabilities, which have been designed to optimize desired trait efficacy and potentially accelerate product development, follows the successful identification and validation by Evogene of more than one thousand genes that have entered Monsanto's product development pipeline. The collaboration, which was initiated in 2008 and extended in 2013, is focused on transgenic approaches for improved yield and enhanced stress tolerance in corn, soybean, cotton and canola. Genes that have been identified under the collaboration represent an important component of Monsanto's yield and environmental stress research and development program. Tom Adams, Global Biotechnology Lead at Monsanto stated: "We continue to be very pleased with our long-term collaboration with Evogene, as we look to bring to market new products that help farmers increase their productivity. As a valuable complement to Evogene's proven gene discovery capabilities, we have recently also been very impressed with Evogene's comprehensive gene optimization platform, which has the potential to accelerate our product development efforts. This has led us to devote a substantial portion of our remaining joint efforts under our current collaboration to applying these innovative technologies." Ofer Haviv, Evogene President and CEO stated: "Our collaboration with Monsanto is a substantial and important component of our company's trait research and discovery activities. During the past six years, both teams have built a very strong and integrated relationship through the consistent sharing of knowhow and learnings, and the relationship continues to grow and evolve as we work together to bring yield and stress products to market. A key and increasing focus of our current efforts is to utilize more recently developed Evogene tools and systems in a comprehensive program for gene optimization, particularly with respect to gene combinations and trait stability. We are confident that our competitive advantages in these areas will have a significant impact on the probability of success for achieving novel end- products with substantial value to farmers." Evogene's gene optimization platform includes, among other components, advanced computational tools for defining the optimal expression pattern for a candidate gene, for assessing the ability of the gene to perform consistently across different varieties of the target crop, and for identifying novel gene combinations that improve crop performance. -xxx- About Evogene Ltd.: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 04/02/2015 http://www.evogene.com/News-Events/Press-Releases/2015/Evogene-New-Gene-Optimization-Program-Being-Incorporated-into-Yield--Environmental-Stress-Collaboration-with-Monsanto- CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanized Harvesting Solution for Castor Beans http://www.evogene.com/News-Events/Press-Releases/2014/CNH-Industrial-and-Evogene-Subsidiary-Announce-Ongoing-Collaboration-for-the-Development-of-a-Mechanized-Harvesting-Solution-for-Castor-Beans Rehovot, Israel - December 15, 2014 - Evogene Ltd. (NYSE, TASE: EVGN) and CNH Industrial Latin America Ltda., a subsidiary of CNH Industrial N.V. (NYSE, MI: CNHI), announce today the ongoing cooperation between CNH Industrial and Evofuel Ltd., Evogene's wholly-owned subsidiary. This cooperation involves the development of an efficient, easy-to-adopt combine solution for the large-scale harvesting of Evofuel castor bean varieties in Latin America. The collaboration between CNH Industrial and Evofuel was initiated in 2012 and has recently been extended for an additional year. Currently in its prototype phase, the final product, when released, will come to market under the Case IH brand. Case IH is a brand of CNH Industrial which globally produces agricultural machinery including tractors, combine harvesters, sugar cane, coffee and cotton harvesters, planters and sprayers. The availability of a combine for castor bean harvesting is a key factor for the large-scale adoption of castor as a sustainable and economically viable crop. The collaboration between the two companies is set to introduce a customised solution based on adaptations to CNH Industrial's brands' existing grain combine harvesters, including one pass reaping and threshing. The prototype combine is custom-designed to harvest Evofuel proprietary dwarf castor varieties that are uniquely suitable for mechanized harvest. "The market opportunity of castor beans as a sustainable and economically viable feedstock alternative for the growing biofuel market is substantial, and addresses one of the world's most significant challenges of fuel dependency. Currently however, the available seed varieties and the requirement to harvest castor beans by hand have been major roadblocks to the large-scale adoption of castor beans as a sustainable and economically viable crop for this purpose," said Corrado Mida, Business Development Director of CNH Industrial Latin America. "Through our joint work with CNH Industrial, we are addressing the significant hurdles in this field, showcasing the company's innovative approach to farming equipment and the advanced breeding capabilities of Evofuel to develop a proprietary castor seed variety designed to meet the requirements for large scale, mechanized commercialization," commented Assaf Oron, General Manager of Evofuel. Recently over 200 acres of pre-commercial testing fields of Evofuel proprietary castor varieties were harvested in northeast Brazil using a prototype of CNH's custom-made combine solution. These pre-commercial activities also included validation by BioOleo, a leading crusher in Brazil, confirming that the grain harvested meets customer requirements for the down-stream industrial process. The collaboration is set to support additional pre-commercial harvesting activities planned to take place in Brazil in 2015 as Evofuel progresses towards commercial availability of its proprietary castor bean varieties, expected to take place during 2016. -xxx- About CNH Industrial: CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com About Evofuel Ltd.: Evofuel is engaged in the development and commercialization of high yielding castor seeds as a cost-competitive, sustainable, and second-generation feedstock for the growing biofuel market. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process, Evofuel applies advanced breeding methods utilizing cutting-edge plant genomics capabilities together with agro-technique expertise to enable efficient and sustainable large-scale production of castor. Initially established in 2007 as a division within Evogene Ltd. (TASE: EVGN), Evofuel was spun out as a wholly owned subsidiary in 2012. For additional information, please visit Evofuel's website at: www.evo-fuel.com About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 15/12/2014 http://www.evogene.com/News-Events/Press-Releases/2014/CNH-Industrial-and-Evogene-Subsidiary-Announce-Ongoing-Collaboration-for-the-Development-of-a-Mechanized-Harvesting-Solution-for-Castor-Beans Evogene Reports Third Quarter 2014 Financial Results http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Third-Quarter-2014-Financial-Results Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today its financial results for the quarter and nine months ended September 30, 2014. Ofer Haviv, Evogene's President and CEO, stated: "During the approximately one year period following our initial public offering in the U.S., we have been pleased to report accelerating progress in both enhancing our leadership position as a premier provider of seed traits to the agriculture industry, and in making significant progress across our other areas of focus." "Our ability to successfully pursue these multiple strategic objectives in parallel, is the result of our more than decade-long, and continuing, investment in building one of the best knowledge-based, discovery platforms available in the agriculture industry today. The value of this unique infrastructure can be demonstrated in part by the hundreds of candidate genes, mainly for improved yield and abiotic stress resistance, provided to date under multiple milestone and royalty bearing collaboration agreements with a majority of the world's leading seed companies." "As our initial area of focus, seed traits represents our most mature area of operation, with our main goals currently being phase advancement and increasing the probability of success for achieving end-products. For this purpose, we continue to invest substantial efforts in building more robust and tailored computational and validation tools to further support the efficacy of Evogene genes currently undergoing field trial validation in our partners' pipelines." "We also continue to expand our product portfolio and technology in this area by targeting new traits and new crops, mainly in the field of biotic stresses. Earlier this year we disclosed our entry into the field of insect resistance and control. I am extremely proud that with the advantage of our existing infrastructure, we were able to successfully initiate a robust product program in such a short period of time, and I am very excited about the prospects for future collaborations in this area, which we consider one of Evogene's key growth engines." "A portion of the IPO proceeds was targeted towards the area of ag-chemicals, in particular to our ongoing activities in establishing a very innovative herbicide discovery program. This past year these activities included expanding our computational capabilities to support chemical discovery and building dedicated labs and plant validation systems in support of these growing activities. We are now evaluating the appropriate time to begin collaborative activities with one or more major companies in the field, and have been pleased with the interest shown during some initial discussions we have had." "The financial security provided by the capital raised in our IPO also allowed us to accelerate the product development and pre-commercialization progress of Evofuel's castor bean varieties, and we are pleased that we are now on track for initial commercial seed sales to begin in 2016. This year, in our pre-commercial field testing, we harvested over 200 acres of our castor varieties. This is a fantastic achievement, one which I am very proud of and is not a trivial accomplishment. The success of Evofuel will mean the introduction of a completely new modern crop into world agriculture for both industrial uses and with the potential for addressing one of the world's most significant challenges of fuel dependency," concluded Mr. Haviv. Financial results for the period ended September 30, 2014: Total Revenues include (i) research and development payments, including up-front payments, and (ii) share purchase related revenues. Evogene anticipates that longer term, its primary sources of revenues and profits will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. (i) Revenues from research and development payments include periodic payments for research and development services generated under the Company's collaboration agreements with seed companies, as well as up-front payments received under the Company's agreements with collaborators, which are recognized as revenues over the duration of the relevant agreement. R&D revenues for the nine months ended September 30, 2014 were $10.6 million, compared to $10.8 million for the same period in 2013. Revenues for the third quarter of 2014 were $3.1 million, compared to $3.5 million for the same period in 2013. The decline in revenues in the third quarter of 2014 was primarily related to the amendment to the Company's Bayer collaboration work plan, whereby $750 thousand of research payments due in 2014 were accounted for as deferred revenues and will be recognized as revenues in 2015 and onwards. This decline was offset in part by an increase in revenues associated with the expansion of activities in certain other collaborations, including the Company's agreements with Monsanto and Syngenta, which were extended and expanded in late 2013. (ii) Share purchase related revenues result from the required accounting treatment for the past acquisitions of Evogene ordinary shares by Monsanto and Bayer, as well as the put option agreement that the Company entered into with Monsanto, all in conjunction with the research and development collaboration agreements signed with these partners. Share purchase related revenues for the nine months ended September 30, 2014 were $240 thousand, compared to $2.4 million for the same period in 2013. In the third quarter of 2014, the Company recorded $75 thousand of share purchase related revenues, compared with $767 thousand for the third quarter of 2013. The decline in share purchase related revenues reflects accounting treatment of certain past transactions involving Evogene ordinary shares with Monsanto and Bayer and does not reflect any current cash flow. Cost of Revenues largely consists of research and development expenses related to the support of the Company's ongoing activities under collaboration agreements with seed companies, all of which provide for future milestone and royalty revenues. Cost of Revenues for the nine months ended September 30, 2014 was $7.3 million, compared to $7.3 million for the same period in 2013. Cost of Revenues for the third quarter of 2014 was $2.3 million, compared to $2.6 million for the same period in 2013. Research and Development Expenses for the nine months ended September 30, 2014 were $9.8 million, compared to $7.6 million for the same period in 2013. Research and development expenses for the third quarter of 2014 were $3.7 million, compared to $3.0 million for the same period in 2013. The increase in these expenses largely relates to expansion of self-funded activities, primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, such as in the areas of fungi, insect and weed control. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Business Development Expenses for the nine months ended September 30, 2014 were $1.3 million, compared to $906 thousand for the same period in 2013. Business Development expenses for the third quarter of 2014 were $407 thousand, compared to $374 thousand for the same period in 2013. This increase reflects costs associated with the Company's decision to establish dedicated Business Development capabilities within each of its four operating divisions, as well as costs associated with ongoing efforts to introduce the Company's business proposition to prospective partners in new and existing areas. General and Administrative Expenses for the nine months ended September 30, 2014 were $3.1 million (including a non-cash expense of $1.1 million for amortization of share-based compensation), compared to $2.0 million (including a non-cash expense of $503 thousand for amortization of share-based compensation) for the same period in 2013. General and Administrative expenses for the third quarter of 2014 were $984 thousand (including a non-cash expense of $294 thousand for amortization of share-based compensation), compared to $833 thousand (including a non-cash expense of $315 thousand for amortization of share-based compensation) for the same period in 2013. In addition to the non-cash share-based compensation, this increase relates to continued growth in the Company's operations and costs associated with being a publicly traded entity in the US. Operating Loss for the nine months ended September 30, 2014 was $10.7 million (including a non-cash expense of approximately $2.6 million for amortization of share-based compensation), compared to an operating loss of $4.7 million (including a non-cash expense of approximately $1.6 million for amortization of share-based compensation) for the same period in 2013. Operating loss for the third quarter of 2014 was $4.3 million (including a non-cash expense of $788 thousand for amortization of share-based compensation), compared to an operating loss of $2.5 million (including a non-cash expense of $1.0 million for amortization of share-based compensation) for the same period in 2013. This increase is mainly attributable to the increase in self-funded research and development expenses, among other operating expenses and non-cash share-based compensation expenses, as described above. Cash Position: As of September 30, 2014, Evogene had $118.8 million in cash, short and long term bank deposits and marketable securities. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company reiterates its guidance that its cash burn for calendar 2014 will be in the range of the previously estimated $15 to $18 million. Conference call and webcast details: Evogene management will host a conference call today at 09:30 am Eastern time, 16:30 Israel time to discuss the above-described results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0610. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through November 12, 2014. US-based participants are invited to access the replay by dialing 1-888-326-9310, and participants from Israel and other countries are invited to access the replay at 972-3-925-5901. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 10/11/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Third-Quarter-2014-Financial-Results Evogene Announces Expansion of Crop Protection Activities http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Expansion-of-Crop-Protection-Activities- Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, today announced the expansion of its crop protection activities with the completion of dedicated facilities to support research and development activities for the Company's product programs focusing on fungi, insect and weed control. The field of crop protection is a major focus of growth and expansion for Evogene where it looks to develop novel seed traits as well as seed external solutions for these areas. Over the past year, Evogene significantly increased its activities in the area of crop protection. In late 2013, as part of its multi-year collaboration with Monsanto, the company announced a new product program targeting Stalk Rot disease caused by various fungi species. In April of this year, Evogene disclosed its entry into the area of plant insect resistance and control with initial activities focusing on developing seed traits displaying resistance to two key insects, corn rootworm and soybean aphids. With respect to weed control, the company recently announced that it anticipates completing during 2015 a start-to-end molecular discover platform for the development of chemical herbicides based on novel "modes of action". The newly completed facilities support these new and increased areas of activity, and are part of Evogene's previously disclosed expectation to invest approximately $10 million over the next few years to expand its existing knowledge base, computational platforms, and testing and validation capabilities. "This expansion demonstrates our strategic commitment to strengthening our internal R&D capabilities in key areas within the crop protection field where there is a dire need for new solutions," commented Ofer Haviv, Evogene President and CEO. "Our substantially expanded capabilities in this area, including these new dedicated facilities, will provide Evogene with significantly greater in-house capacity for discovery, testing and evaluation of promising genes and chemical compounds. More importantly, we anticipate that leveraging our unique underlying discovery capabilities with this enhanced and expanded infrastructure will lead to important new product opportunities for fungi, insect and weed control." About the new facilities: The new research facilities, located in the vicinity of the Company's headquarters in Rehovot, Israel, will feature three separate state-of-the-art laboratories and will join Evogene's existing 380,000 square-feet of research and development facilities in Israel, which today include dedicated tissue culture and molecular laboratories, 36 greenhouses for gene validation and propagation in model plants, and testing fields. The new facilities will be staffed by research experts in the fields of plant science, entomology, microbiology and chemistry. The overall crop protection research and development activities will be led by Dr. Eyal Emmanuel, who was recently appointed as Executive Vice President R&D Crop Protection. The highly equipped laboratory space will enable advanced screening and validation for both biology and chemistry research. The facilities will also host additional server rooms to support the company's recent expansion of its computing grid to over 1,000 CPU's. The expanded backbone capability adds over 30% more bandwidth to Evogene's already substantial computing power. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com and www.evo-fuel.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 29/10/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Expansion-of-Crop-Protection-Activities- Evogene’s Third Quarter 2014 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Third-Quarter-2014-Earnings-Announcement-Schedule Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the third quarter of 2014 on Monday, November 10, 2014. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:30 AM Eastern time, 16:30 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or 972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or 972-3-925-5901 internationally. The replay will be accessible through November 12, 2014, and an archive of the webcast will be available on the Company's website through November 20, 2014. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit: www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 22/10/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Third-Quarter-2014-Earnings-Announcement-Schedule Evogene Subsidiary and Embrapa to Cooperate on Advancing Castor Cultivation in Brazil http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Subsidiary-and-Embrapa-to-Cooperate-on-Advancing-Castor-Cultivation-in-Brazil- The Brazilian Agricultural Research Corporation (Embrapa), Brazil's leading agricultural research institution, and Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed, and biofuel industries, announced today the signing of a joint research agreement between Embrapa and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the advancement of castor cultivation in Brazil. The cooperation will primarily focus on technologies for controlling castor-specific diseases as well as practices for castor cultivation in rotation with soybean. The global market for castor oil has tightened over the past few years with industrial demand, in Brazil and internationally, exceeding availability and production. Presently, castor is cultivated on approximately 100,000 hectares (approximately 250,000 acres) in Brazil, an area that can substantially increase with the introduction of advanced varieties and new-modern cultivation practices, as being addressed by Evofuel in the past years. The agreement is set to bring Embrapa's substantial experience in research and development of castor together with Evofuel's proprietary castor varieties, which are adapted to mechanized harvest and modern agricultural protocols, to offer Brazilian growers a full-scale solution for an economically viable, sustainable, and large-scale cultivation of castor. Cultivation of castor in rotation with soybean (second crop or 'safrinha' crop) consists of planting Evofuel's advanced castor varieties after harvesting the soybean crop. The target area for this rotation system is in the region of MATOPIBA (States of Maranhão, Tocantins, PiauÍ, and Bahia) in the northeast and central regions of Brazil, where approximately five million hectares (over 12 million acres) are estimated to be suitable for castor cultivation. "Embrapa has been working for three decades on castor research and development in Brazil, achieving remarkable progress in many areas, including fertilization, weed and disease management, added value to by-products, and genetic resources," said Liv Severino, Chief of Research and Development of Embrapa Cotton. "The joint work with Evofuel will promote synergy between the two partners and will consolidate our commitment to turn castor into a highly viable crop for Brazil's expanding agriculture." Commenting on the agreement, Assaf Oron, General Manager of Evofuel, said: "We are very pleased to join forces with Embrapa, which has a tremendous track record in developing research-based technology solutions for Brazilian agriculture. A key to the large-scale adoption of castor is the ability to cope with various stresses, such as diseases and weeds. We see in Embrapa's extensive local knowledge and dedicated researchers a great asset that complements our proprietary know-how and expertise, and will assist us in optimizing and accelerating our solution for castor growers." The collaboration with Embrapa follows three years of successful field trials of Evofuel's castor varieties in Brazil. The trials demonstrated the suitability and economic benefits of growing Evofuel's proprietary castor varieties as a second crop with soybean for production of oil feedstock for biofuels and other industrial uses. In March this year, Evofuel announced an agreement for the commercial production of castor in 2016 with SLC Agricola, one of Brazil's largest landowners and agriculture businesses. -xxx- About Embrapa Since its inception in 1973, Embrapa has generated and recommended more than nine thousand technologies for Brazilian agriculture, reduced production costs, helped Brazil to improve food security whilst, conserving natural resources and the environment, and diminished external dependence on technologies, basic products, and genetic materials. Please visit Embrapa's website for additional information: www.embrapa.br About Evofuel Ltd. Evofuel is engaged in the development and commercialization of high yielding castor seeds as a cost-competitive, sustainable, and second-generation feedstock for the growing biofuel market. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process, Evofuel applies advanced breeding methods utilizing cutting-edge plant genomics capabilities together with agro-technique expertise to enable efficient and sustainable large-scale production of castor. Initially established in 2007 as a division within Evogene Ltd. (TASE: EVGN), Evofuel was spun out as a wholly owned subsidiary in 2012. For additional information, please visit Evofuel's website at: www.evo-fuel.com About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity, and economics for the food, feed, and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and abiotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops such as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit: www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 20/10/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Subsidiary-and-Embrapa-to-Cooperate-on-Advancing-Castor-Cultivation-in-Brazil- Evogene Reports Second Quarter 2014 Financial Results http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Second-Quarter-2014-Financial-Results Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the quarter and six months ended June 30, 2014. Commenting on the results, Ofer Haviv, Evogene's President and CEO, stated: "Evogene continues to successfully extend the application of its powerful discovery and validation capabilities. Less than a year following its US IPO, the company is actively addressing major needs in four very substantial markets, and is doing so by applying its broadly applicable technology platform to provide unique discovery and development capabilities in each of those areas." "The first of these four areas addresses the critical need to enhance agricultural yields by improving seed traits for the major food and feed crops, which includes providing enhanced resistance to a-biotic stress conditions, such as drought. In this very important area, which was the initial area of market focus for our company, significant emphasis is being given to furthering our product programs in corn and soybean, where we see the highest probability of initial product advancement." Mr. Haviv continued, "Our second area of activity addresses improving seed traits to biotic stress conditions, such as those caused by plant diseases and insects. We recently announced our entry to the field of insect resistance, which is the largest segment within this market area. We see insect resistance as an important opportunity for our growth and new product programs over the next few years, and therefore a key activity this past quarter was establishing the necessary infrastructure to support multiple programs in this area. In addition, we were pleased to recently announce our collaboration with US-based Marrone Bio Innovations, a leading provider of bio-based pest management and plant health products. This collaboration is truly synergistic and opportunity expanding for both companies, and contributes a significant asset and accelerator to our insect resistance activities. This recent addition increases the total number of product programs we are managing within our biotic division from four at the beginning of the year to eight today." Mr. Haviv continued, "We are also very pleased with our initial efforts in our newest area of activity - ag-chemicals, where we have doubled our staffing and are building dedicated labs and plant validation systems in support of the division's growing activities. Our short term expectations for this activity are that during 2015 we will have in place a start-to-end molecular discovery process for this area, including novel target discovery, identification of molecular hits, and molecular validation." Mr. Haviv concluded, "Our seed activity, being pursued by our wholly owned subsidiary, Evofuel, remains on track to achieve initial castor grain sales in 2016. We recently harvested over 200 acres of our unique castor varieties in Brazil and the analysis of the yield and harvest results of these pre-commercial fields will provide us with the necessary indications of how well we are tracking towards commercial viability." Financial results for the period ended June 30, 2014: Total Revenues include (i) research and development payments, including up-front payments, and (ii) share purchase related revenues. Evogene anticipates that longer term, its primary sources of revenues and profits will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. (i) Revenues from research and development payments for the six months ended June 30, 2014 were $7.5 million, compared to $7.3 million for the same period in 2013. Revenues for second quarter of 2014 were $3.7 million, compared to $3.5 million for the same period in 2013. These revenues include periodic payments for research and development services generated under the Company's various collaboration agreements with seed companies, as well as up-front payments made under the Company's agreements with collaborators, which are recognized as revenues over the duration of the relevant agreement. (ii) Share purchase related revenues result from the required accounting treatment for the past acquisitions of Evogene ordinary shares by Monsanto and Bayer, as well as the put option agreement entered into with Monsanto, all in conjunction with the research and development collaboration agreements signed with these partners. Share purchase related revenues for the six months ended June 30, 2014 were $165 thousand, compared to $1.6 million for the same period in 2013. The second quarter of 2014 includes $83 thousand respectively of share purchase related revenues, compared with $810 thousand for the second quarter of 2013. Cost of Revenues largely consists of research and development expenses related to the support of the Company's on-going activities under collaboration agreements with seed companies, all of which provide for future milestone and royalty revenues. Cost of Revenues for the six months ended June 30, 2014 was $5.0 million (including a non-cash expense of $386 thousand for amortization of share-based compensation), compared to $4.7 million (including a non-cash expense of $159 thousand for amortization of share-based compensation) for the same period in 2013. Cost of Revenues during the second quarter of 2014 was $2.4 million (including a non-cash expense of $205 thousand for amortization of share-based compensation), compared to $2.5 million (including a non-cash expense of $66 thousand for amortization of share-based compensation) for the same period in 2013. Research and Development Expenses, net for the six months ended June 30, 2014, were $6.0 million (including a non-cash expense of $417 thousand for amortization of share-based compensation), compared to $4.7 million (including a non-cash expense of $159 thousand for amortization of share-based compensation) for the same period in 2013. Research and development expenses, net for the second quarter of 2014 were $3.3 million (including a non-cash expense of $221 thousand for amortization of share-based compensation), compared to $2.5 million (including a non-cash expense of $67 thousand for amortization of share-based compensation) for the same period in 2013. These expenses largely relate to self-funded activities primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, such as the areas of Biotic Stress and Ag-chemicals. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations which are accounted for as cost of revenues. Business Development Expenses for the six months ended June 30, 2014, were $936 thousand (including a non-cash expense of $186 thousand for amortization of share-based compensation), compared to $532 thousand (including a non-cash expense of $70 thousand for amortization of share-based compensation) for the same period in 2013. Business Development expenses for the second quarter of 2014 were $562 thousand (including a non-cash expense of $86 thousand for amortization of share-based compensation), compared to $305 thousand (including a non-cash expense of $30 thousand for amortization of share-based compensation) for the same period in 2013. This increase reflects costs associated with the Company's decision to establish dedicated Business Development capabilities within each of its four operating divisions. General and Administrative Expenses for the six months ended June 30, 2014, were $2.1 million (including a non-cash expense of $760 thousand for amortization of share-based compensation), compared to $1.2 million (including a non-cash expense of $186 thousand for amortization of share-based compensation) for the same period in 2013. General and Administrative expenses for the second quarter of 2014 were $1.2 million (including a non-cash expense of $411 thousand for amortization of share-based compensation), compared to $642 thousand (including a non-cash expense of $87 thousand for amortization of share-based compensation) for the same period in 2013. In addition to the non-cash share-based compensation, this increase relates to continued growth in the Company's operations and costs associated with being a publicly traded entity in the US. Operating Loss for the six months ended June 30, 2014 was $6.4 million, compared to an operating loss of $2.1 million for the same period in 2013. Operating loss for the second quarter of 2014 was $3.8 million, compared to an operating loss of $1.5 million for the same period in 2013. This increase is mainly attributable to the increase in self-funded research and development expenses, among other operating expenses and non cash expenses, as described above. Cash Position: As of June 30, 2014, Evogene had $121.3 million in cash, short and long term bank deposits and marketable securities. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its cash burn for calendar 2014 will be in the range of the previously estimated $15 to $18 million. Conference call and webcast details: Evogene management will host a conference call today at 09:30 am Eastern time, 16:30 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-281-1167, and participants from Israel and other countries are invited to access the call at 972-3-918-0644. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through August 22, 2014. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5921. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 20/08/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Second-Quarter-2014-Financial-Results Evogene to Present at Credit Suisse 2014 Basic Materials Conference http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Credit-Suisse-2014-Basic-Materials-Conference Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that Mr. Ofer Haviv, Evogene's President and CEO, will present at the Credit Suisse 2014 Basic Materials Conference taking place at the Credit Suisse Auditorium, located at One Madison Avenue in New York City, September 16-18, 2014. The presentation will take place on Thursday, September 18, at 11:45 am. Investors or companies attending the conference, who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/08/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Credit-Suisse-2014-Basic-Materials-Conference Evogene to Present at Jefferies 2014 Global Industrials Conference http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Jefferies-2014-Global-Industrials-Conference Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that Assaf Kacen, Evogene's Executive Vice President Technology Platform, will present at the Jefferies 2014 Global Industrials Conference taking place at the Grand Hyatt, New York City, August 11-14, 2014. Mr. Kacen's presentation will review Evogene's technology platform for gene-based discovery, current product pipeline and areas of activity. The presentation will be part of Jefferies' Emerging Technologies and Industrials Biotech day, and will take place on Monday, August 11, at 10:30 am. Investors or potential partners attending the conference, who wish to meet with Mr. Kacen, may contact Evogene's Investor Relations team at investors@evogene.com. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 04/08/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Jefferies-2014-Global-Industrials-Conference Evogene’s Second Quarter 2014 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Second-Quarter-2014-Earnings-Announcement-Schedule Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that it will release its financial results for the second quarter of 2014 on Wednesday, August 20, 2014. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:30 AM Eastern time, 16:30 Israel time. To access the conference call, please dial 1-888-281-1167 toll free from the United States, or 972-3-918-0644 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or 972-3-925-5921 internationally. The replay will be accessible through August 22, 2014, and an archive of the webcast will be available on the Company's website through August 30, 2014. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit: www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 30/07/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Second-Quarter-2014-Earnings-Announcement-Schedule Evogene Announces Amendment to Bayer Wheat Agreement to Focus on Discovery of Novel Genomic Promoters http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Amendment-to-Bayer-Wheat-Agreement-to-Focus-on-Discovery-of-Novel-Genomic-Promoters Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced an amendment to the remaining work plan under its collaboration with Bayer CropScience LP (Bayer) for improved wheat. Pursuant to the amended work plan, Evogene will shift from discovery of additional genes and SNP's to discovery of novel genomic promoters. Genomic promoters are segments of DNA that when used with appropriate genes are an essential component of improving seed trait efficacy by determining the expression pattern for the genes in the plants. This pattern includes not only the level of expression of the gene, but also many other key related factors such as the timing or location of the expression. The original collaboration agreement between Bayer and Evogene was signed in December 2010 focusing on the discovery of novel genes for the improvement of wheat yield, nitrogen use efficiency, and abiotic stress tolerance. Under the collaboration to date, Evogene has utilized its ATHLETETM computational discovery capabilities to discover and provide Bayer with a large number of candidate genes for potential continued development in Bayer's wheat pipeline and commercialization under previously agreed milestone payments and royalty bearing licenses from Evogene. Under the amended agreement, Evogene will continue in close teamwork with Bayer to utilize its ATHLETETM discovery platform but will shift the focus from the discovery of additional genes and SNP's to identifying novel genomic promoters. "The amendment reflects a growing realization in the industry that the efficacy of a seed trait depends not only on the presence of the gene of interest, but on its optimization with other factors including how the gene is expressed in the plant. As such, selecting the most appropriate promoters that control the expression of the gene of interest is crucial to the successful development of the desired trait in the plant," said Ofer Haviv, Evogene President and CEO. "As part of the amended work plan, Evogene is looking to identify tens of promoters that will enhance the probability of success of genes in Bayer's wheat pipeline." For additional information, please see Evogene's 6K filing with the US Securities and Exchange Commission. -xxx- About Evogene Ltd Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit: www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 24/07/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Amendment-to-Bayer-Wheat-Agreement-to-Focus-on-Discovery-of-Novel-Genomic-Promoters Evogene and Marrone Bio Innovations Sign Multi-Year Collaborative Agreement http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-and-Marrone-Bio-Innovations-Sign-Multi-Year-Collaborative-Agreement Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, and Marrone Bio Innovations Inc. (MBI), (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, announced today the signing of a multiyear collaborative agreement targeting the joint discovery of novel modes of biological action for insect control, followed by the development and commercialization of new insect control products by each of the companies. The partnership will leverage the expertise and distinct assets and capabilities of each company in its respective field, namely MBI's expertise in microbial-based solutions for pest control and plant health, and Evogene's computational gene discovery capabilities. Integrating these industry leading discovery capabilities, the companies will utilize the collaboration's joint assets to separately develop and commercialize products. Specifically, Evogene will develop biotechnology insect resistance seeds, while MBI will develop biologically-based insecticides. The parties have agreed on revenue sharing from all insect control products developed through the collaboration. The target insects for the collaboration will be Lygus Hesperus, a sucking insect also known as the Western tarnished plant bug; and Spodoptera exigua, a chewing insect commonly known as Beet Armyworm, each of which currently causes significant damage to a variety of major crops. The world-wide damage to crop production due to insects, currently estimated at 20% of global yield, is expected to become an even greater problem in coming years. Among the trends underlying this concern is the fact that the most prominent bio-insecticides and all biotechnology insect resistant seeds solutions available today consist of 'modes-of-action' derived from a single microbial species (Bacillus thuringiensis, or Bt). These Bt-based solutions are not able to effectively control all types of insects damaging agriculture crops. And for those insects where Bt has been effective, the development of resistance is increasing. In light of this need, the parties will leverage their combined discovery capabilities to identify new 'modes-of-action' for insect control, focusing on other microbial species. Ofer Haviv, President and CEO of Evogene states, "This very unique collaboration being announced today brings together industry leading and synergistic discovery capabilities to address a major unmet need in agriculture biotechnology. We expect our joint efforts will result in significant product opportunities for both Evogene and MBI, and we are very pleased to join forces with a company that is an industry leader in its areas of interest. This collaboration demonstrates how Evogene's established capabilities can be leveraged into new fields and new product types, such as ag-biologicals, while in parallel, broadening the product portfolio in our existing fields by adding two new product programs to our recently launched activity in insect resistance seed traits." Pam Marrone, CEO of MBI comments, "The industry has long recognized the need for novel modes of action for insect control because of growing insect resistance to existing classes of chemistry. MBI's focus on this need has resulted in two novel mode of action insecticides based on microbial technology: GrandevoÒ, based on Chromobacterium substugae, and our newest product, Venerateä, based on a novel heat-killed Burkholderia spp. strain A396). Both products control a broad spectrum of chewing and sucking insects and mites, without harm to beneficials and pollinators. This exciting collaboration with Evogene will enable us to leverage our discovery and development strategy to explore an even wider range of microbes with novel insecticidal genes." The companies were recently notified by the Binational Industrial Research and Development Foundation (BIRD), a foundation that supports and encourages cooperation between Israeli and US companies in various areas of technology, that the collaboration was evaluated by BIRD and has been selected for partial funding. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com About Marrone Bio Innovations Marrone Bio Innovations, Inc. (NASDAQ: MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com. About the BIRD Foundation The BIRD (Binational Industrial Research and Development) Foundation works to encourage cooperation between Israeli and American companies in various areas of technology, and provides free assistance in locating strategic partners from both countries for developing joint products. The BIRD Foundation supports projects without receiving any rights in the participating companies or in the project itself. The financial assistance is repaid as royalties from sales. The Foundation provides support of up to 50% of a project's budget, beginning with R&D and ending with the initial stages of sales and marketing. The Foundation shares the risk and does not demand that the investment be repaid if the project fails to reach the sales stage. The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements involve risks, uncertainties and assumptions. For example, statements of expected synergies, earnings accretion and growth, timing of the transaction, market growth estimates, estimates of served available markets, industry leadership, customer solutions, profitability, distribution channels, revenue, management and organizational structure are all forward-looking statements. Please see the risks that are described from time to time in Marrone Bio Innovations' and Evogene's Securities and Exchange Commission reports (including but not limited to Marrone Bio Innovations' Form 10-K for the year ended December 31, 2013 and Evogene's annual report on Form 20-F for the year ended December 31, 2013, and subsequently filed reports). If any of these risks or uncertainties materializes or any of these assumptions proves incorrect Marrone Bio Innovations' or Evogene's results could differ materially from expectations in these statements. Marrone Bio Innovations or Evogene assume no obligation and do not intend to update these forward-looking statements. 22/07/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-and-Marrone-Bio-Innovations-Sign-Multi-Year-Collaborative-Agreement Evogene Reports First Quarter 2014 Financial Results http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-First-Quarter-2014-Financial-Results Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the quarter ended March 31, 2014. Commenting on the results, Ofer Haviv, Evogene's President and CEO, stated: "The uniqueness of our company rests on the broadly applicable proprietary discovery and validation infrastructure that has provided - and continues to provide - the basis for each of our four product divisions. This integrated infrastructure was specifically designed to be both scalable and flexible in order to allow continuing integration of additional types of data and new computational capabilities as they are developed or become available. We believe that both our short and long term success will in large part be determined by our ability to utilize these powerful proprietary capabilities to meet key unmet needs in the food, feed, and fuel industries." Mr. Haviv continued, "This flexibility is being demonstrated as we now generate innovative solutions to an increasingly broad range of crops, traits and different end-products. More specifically, our announcement last week disclosing our entry into the field of insect resistance provides an excellent example of how our past investment in building this carefully designed discovery infrastructure is allowing us to advance rapidly and at relatively low costs, not only in our current areas of interest, but in new areas as well." Mr. Haviv added, "Also of note this past quarter is the agreement signed between our subsidiary Evofuel and SLC Agricola, our long term partner and one of Brazil's largest agriculture businesses. The agreement sets the stage for the expected commercial introduction of our proprietary castor seed varieties in Brazil in 2016." Financial results for the quarter ended March 31, 2014: Total Revenues include (i) research and development payments, including up-front payments, and (ii) share purchase related revenues. (i) Revenues from research and development payments for the first quarter of 2014 were $3.8 million, compared to the same amount for the first quarter of 2013. These revenues include periodic payments for research and development services generated under the Company's various collaboration agreements with seed companies, as well as up-front payments made under the Company's agreements with collaborators, which are recognized as revenues over the duration of the relevant agreement. (ii) The first quarter of 2013 and full year 2013 include $811 thousand and $2.6 million respectively of share purchase related revenues, compared with $82 thousand for the first quarter of 2014. This decline is a result of the required accounting treatment of share purchase agreements entered into with Monsanto and Bayer, as well as the put option agreement entered into with Monsanto, in conjunction with the research and development collaboration agreements signed with these partners. Cost of Revenues largely includes research and development expenses related to the support of the Company's on-going activities under collaboration agreements with seed companies, all of which provide for future milestone and royalty revenues. Cost of revenues for the first quarter of 2014 was $2.6 million (including a non-cash expense of $181 thousand for amortization of share-based compensation), compared to $2.2 million (including a non-cash expense of $93 thousand for amortization of share-based compensation), for the same period in 2013. Research and Development Expenses for the first quarter of 2014 were $2.7 million (including a non-cash expense of $196 thousand for amortization of share-based compensation), representing an increase of approximately 22% compared to $2.2 million (including a non-cash expense of $92 thousand for amortization of share-based compensation), for the same period in 2013. These expenses largely relate to self-funded activities primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, such as the areas of Biotic Stress and Ag-chemicals. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations which are accounted for as cost of revenues. Business Development Expenses for the first quarter of 2014 were $374 thousand (including a non-cash expense of $100 thousand for amortization of share-based compensation) compared to $227 thousand (including a non-cash expense of $40 thousand for amortization of share-based compensation), for the same period in 2013. This increase reflects costs associated with the Company's decision to establish dedicated Business Development capabilities within each of its four operating divisions. General and Administrative Expenses for the first quarter of 2014 were $888 thousand (including a non-cash expense of $349 thousand for amortization of share-based compensation), compared to $555 thousand (including a non-cash expense of $99 thousand for amortization of share-based compensation), for the same period in 2013. In addition to the non-cash share-based compensation, this increase relates to continued growth in the Company's operations and costs associated with being a publicly traded entity in the US. Operating Loss for the first quarter of 2014 was $2.6 million, compared to an operating loss of $0.6 million for the same period in 2013. This increase is mainly attributable to the increase in self-funded research and development expenses, as described above. Cash Position: As of March 31, 2014, Evogene had $123.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Assuming regular course of business and no new revenue sources, such as additional collaborations, the Company estimates that its cash burn for calendar 2014 will be in the range of $15 to $18 million. Conference call and webcast details: Evogene management will host a conference call today at 09:30 am Eastern time, 16:30 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through May 9, 2014. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5904. A replay of the call may also be accessed as a webcast via Evogene's website at www.evogene.com and will be available for a period of ten days. -xxx- About Evogene Ltd: Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 07/05/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-First-Quarter-2014-Financial-Results Evogene Enters the Field of Insect Resistance http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Enters-the-Field-of-Insect-Resistance- Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, disclosed today its entry into the field of plant insect resistance and control. The Company's initial activities in this important field are focusing on developing seed traits displaying resistance to two key insects, corn rootworm and soybean aphids. The world-wide damage to crop production due to insects, currently estimated at 20% of global yield, is expected to become an even greater problem in coming years. Among the trends underlying this concern are the growing resistance of insects to currently available insect control products, primarily biotechnology seeds and ag-chemicals, and ongoing regulatory pressures to reduce the widespread use of chemical-based products. Evogene's insect resistance activities, which are being undertaken within the Company's Biotic Stress division, are focused on an innovative approach to the discovery of microbial genes responsible for insecticidal activity. This approach leverages Evogene's unique infrastructure of computational capabilities and plant genomic knowhow, primarily through the incorporation of huge amounts of microbial genomic data. Such data is only now becoming available due to recent advancements in microbial data generation technologies. Previously, it had been limited to data based on cultured bacteria representing only a small fraction of the potential bacterial sources that can now be addressed. Obtaining useful information from this newly available microbial "big-data", presents a major computational challenge requiring the type of broadly applicable and flexible genomic data integration and analysis infrastructure that has been created at Evogene during the past decade. With this underlying infrastructure now in place, Evogene estimates that approximately $10 million of investment will be required over the next few years to expand its existing knowledge base, computational capabilities, testing and validation capabilities to support this new field of activity. Ofer Haviv, Evogene's President and CEO stated, "Evogene's expansion into this new area of insect resistance, which represents one of the largest markets in the agriculture industry, further demonstrates both the broad applicability of our existing computational discovery infrastructure and its ability to incorporate new technologies, such as in this case with respect to microbial "big-data" generation. We are extremely pleased to disclose today this next natural addition to our commercial areas of focus as we continue to leverage our unique discovery assets in addressing multiple key agriculture needs and opportunities." Mr. Haviv continued, "The first insects to be targeted in this important new field of activity, corn rootworm and soybean aphids, are two of the industry's most devastating and challenging insects. For example, the impact of soybean aphids on yield has been estimated to reach as high as 50% in some of the prime soybean growing areas in the United States. Today, the main approach to tackle aphids is applying chemical insecticides, though their effect is limited as aphids begin developing resistance to such chemicals. A similar problem with growing resistance to available products is being seen with respect to corn rootworm as well as many other pests. Evogene, utilizing its predictive discovery infrastructure, is seeking to identify new gene-based 'modes-of-action' to mitigate the increasing resistance of these two and other insects to existing solutions." -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 29/04/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Enters-the-Field-of-Insect-Resistance- Evogene to Participate at Global AgInvesting 2014 Conference http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Participate-at-Global-AgInvesting-2014-Conference Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that Assaf Oron, Evogene's Executive Vice President Strategy and Business Development, will participate at the AgTech Investment Summit taking place at the Waldorf Astoria Hotel, New York City on Thursday, May 1st, 2014. Mr. Oron will take part at the 'Inputs: Seeds, Crop Protection, Plant Nutrition' panel taking place at 11:00 am. The panel will host key industry leaders to discuss advancement and drivers behind the global seed and crop protection industries. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 28/04/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Participate-at-Global-AgInvesting-2014-Conference Evogene’s First Quarter 2014 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-First-Quarter-2014-Earnings-Announcement-Schedule Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that it will release its financial results for the first quarter of 2014 on Wednesday, May 7, 2014. On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:30 AM Eastern time, 16:30 Israel time. To access the conference call, please dial 1-888-668-9141 toll-free from the United States, or 972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or 972-3-925-5904 internationally. The replay will be accessible through May 9, 2014, and an archive of the webcast will be available on the Company's website through May 17, 2014. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 17/04/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-First-Quarter-2014-Earnings-Announcement-Schedule Evogene Announces Filing of 2013 Annual Report http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Filing-of-2013-Annual-Report Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced that it has filed its annual report containing audited consolidated financial statements for the year ended December 31, 2013 with the United States Securities and Exchange Commission, on Form 20-F. The annual report is available in here. Shareholders may receive a printed copy of the annual report free of charge upon request to the Company Media Contact: Ms. Karen Mazor. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has early stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 08/04/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Announces-Filing-of-2013-Annual-Report Evogene Subsidiary and SLC Agricola Sign Collaboration Agreement for Commercial Production of Castor Bean in Brazil http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Subsidiary-and-SLC-Agricola-Sign-Collaboration-Agreement-for-Commercial-Production-of-Castor-Bean-in-Brazil- Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, and SLC Agricola S.A. (Bovespa: SLCE3; ADR's: SLCJY; Bloomberg: SLCE3:BZ; Reuters: SLCE3.SA), one of Brazil's largest landowners and agriculture businesses, announced today the signing of a collaboration agreement between SLC and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the commercial production of Evofuel developed castor bean varieties in Brazil, expected to take place during 2016. Evofuel focuses on the development of high yielding castor bean seeds as a second-generation feedstock for the growing biofuel and other industrial markets. Under the terms of the agreement, Evofuel will provide SLC with seeds of its proprietary castor bean varieties and SLC will be responsible for growing the crop on its farms in northeast Brazil. The resulting castor bean grain will be sold to local oil producers to address the industry need for castor oil. The agreement provides for the allocation between SLC and Evofuel of revenues from sales of castor bean grain. Commercial sales of castor bean grain under the agreement are expected to take place during 2016, prior to which the two companies will cooperate on scale up and pre-commercial activities for grain production, as well as development of best practices for agronomic management of castor bean in SLC's commercial production units. AurÉlio Pavinato, CEO of SLC AgrÍcola stated, "The successful implementation and adoption of castor bean as a second crop solution opens up new opportunities for crop rotation in areas, such as northeast region of Brazil, allowing SLC the potential to diversify our crops and improve the resulting farm economics. In addition, having a commercially viable solution for large scale production of castor bean provides SLC with the opportunity to tap into the castor oil market, providing local crushers with a more consistent supply of grain for this high-priced and multi-use oil." Assaf Oron, General Manager of Evofuel stated, "This agreement is a significant step forward in our three year relationship with SLC, and furthermore importantly represents for Evofuel our first commercial arrangement for sale of Evofuel developed seed from our overall castor bean enhancement development efforts." Ofer Haviv, CEO and President of Evogene added, "We are proud that SLC, with its high-end agricultural production expertise, has chosen to adopt Evofuel's castor bean seed on a commercial scale, and we believe this relationship provides a strong basis for the market development of castor bean as a sustainable and economically viable feedstock solution for the immediate market of lubricants and biopolymers, and as production capacity increases, for addressing the broader biofuel market." The recently signed collaboration agreement follows three years of successful field trials. These trials demonstrated the suitability and economic benefits of growing Evofuel developed castor bean varieties during the drier season on a rotation basis with soybean for production of oil feedstock for biofuels and other industrial uses. -xxx- About SLC Agricola SA. SLC Agricola is one of the largest land owners and agricultural producers in Brazil, being also the first in its sector (grains and cotton) to list its shares in a stock exchange. It focuses on the production of cotton, soybean and corn, and also on the acquisition and development of farmland in the country for future sale. The company currently operates 16 production units, in six different states, totaling 340 thousand hectares of planted area at the 2013/14 crop year. The company's business model is based on a large-scale, modern production system, with standardized production units, thoroughly up-to-date technology and rigorous cost controls, underpinned by social and environmental responsibility. About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has early stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com About Evofuel Ltd. Evofuel is engaged in the development and commercialization of high yielding castor bean seeds as a cost competitive, sustainable, second-generation feedstock for the growing biofuel market. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process, Evofuel applies advanced breeding methods utilizing cutting-edge plant genomics capabilities together with agro-technique expertise to enable efficient and sustainable large scale production of castor bean. Initially established in 2007 as a division within Evogene, Evofuel was spun out as a wholly owned subsidiary in 2012. For more information, please visit www.evo-fuel.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 25/03/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Subsidiary-and-SLC-Agricola-Sign-Collaboration-Agreement-for-Commercial-Production-of-Castor-Bean-in-Brazil- Evogene Reports Fourth Quarter and Year-End 2013 Financial Results http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Fourth-Quarter-and-Year-End-2013-Financial-Results Key highlights: Extension and expansion of key collaboration agreements with Monsanto, Syngenta and DuPont-Pioneer Launch of new computational technologies, including Gene2ProductTM and upgrade of 'PlaNet' gene stacking prediction platform Inauguration of ag-chemical activities with the launch of 'PoinTar' target discovery platform for novel herbicides Rehovot, Israel - March 19, 2014 - Evogene Ltd. (NYSE;TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the fourth quarter and year ended December 31, 2013. Commenting on the results, Ofer Haviv, Evogene's President and CEO, stated: "This past year has been extremely positive for Evogene, as we continued to build and expand our business, with significant achievements in each of our four product-focused operating areas and important enhancements to our unique discovery and development infrastructure. In addition, we significantly added to our financial strength with the completion of an initial public offering in the United States and listing on the New York Stock Exchange, raising gross proceeds of approximately $85 million." "In our most mature area of activity, Yield and Abiotic Stress, we were pleased to announce the extension and expansion of the scope and depth of our collaboration with Monsanto. The extension to 2016 is the second expansion of the original agreement and also includes a new five year program in our second area of activity, Biotic Stress. The new program is for the identification of genes providing resistance to Stalk Rot disease in corn. In addition, the two previously existing collaborations in Biotic Stress with Syngenta and DuPont-Pioneer were also both expanded this past year. We see this area as a substantial source for growth and therefore a portion of the proceeds from the recent offering in the US has been allocated for self-funding certain key infrastructure additions to support our activities in this area." "As for our Ag-chemicals operations, the newest of our four operating areas, which is currently focused on novel herbicides and crop enhancers, our competitive advantage arises from the potential ability of our predictive discovery platform to identify novel 'modes of action'. During the past year, we continued to enhance our capabilities and assets directed to this area and introduced a designated target discovery platform, 'PoinTar', as the first key milestone of the program. We expect this field to be a significant part of our company's operations in the future, and have also ear-marked a portion of the proceeds from the recent offering in the US to support our objectives." "Our wholly owned subsidiary, Evofuel, continues to make progress towards its goal of developing and supplying castor seeds as a sustainable and cost-effective feedstock for biopolymer and biofuel. Based on encouraging results from three years of field trials in Brazil, we expect to initiate commercialization of our proprietary castor seeds in 2016." "Looking forward, we are confident that our broadly applicable and continuously expanding technology infrastructure provides us with the foundation for substantial future growth in all of our current areas of focus," concluded Mr. Haviv. Revenues for 2013 were approximately $17.6 million, compared to revenues of $17.1 million for 2012. Revenues for the fourth quarter of 2013 were $4.4 million, compared with $4.8 million for the same period in 2012. At present, revenues consist primarily of research and development payments generated under the company's various Yield and A-biotic related collaboration agreements with seed companies. Cost of revenues primarily consists of research and development costs incurred in support of our ongoing collaborations. Cost of revenues for 2013 was $10.1 million, compared with $9.6 million in 2012. Cost of revenues for the fourth quarter of 2013 was $2.8 million, compared with $2.6 million for the same period in 2012. This increase in cost of revenues reflects growth in the activities and associate expenses within work programs supporting the collaborations. Research and development expenses for 2013 were $11.1 million, representing an increase of approximately 53% compared with $7.3 million in 2012. Research and development expenses for the fourth quarter of 2013 were $3.5 million, compared with $2.1 million for the same period in 2012. These expenses largely relate to self-funded activities primarily focused on the development of new computational genomics and validation technologies in support of both existing and new activities, such as the areas of Biotic Stress and Ag-chemicals. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations which are accounted for as Cost of Revenues. General and administrative expenses for 2013 were $3.6 million (including a non-cash expense of $936 thousand for amortization of share-based compensation), compared with $2.2 million in 2012 (including a non-cash expense of $248 thousand for amortization of share-based compensation). General and administrative expenses for the fourth quarter of 2013 were $1.5 million (including a non-cash expense of $433 thousand for amortization of share-based compensation), compared with $0.7 million for the same period in 2012 (including a non-cash expense of $59 thousand for amortization of share-based compensation). These increases primarily relate to non-cash share based compensation as stipulated above, as well as one-time costs associated with the recently completed equity offering in the US and listing on the New York Stock Exchange and the general growth in the Company's activities. Operating loss for 2013 was $8.7 million (including a non-cash expense of $2.7 million for amortization of share-based compensation), compared to an operating loss of $3.1 million in 2012 (including a non-cash expense of $1.1 million for amortization of share-based compensation). Operating loss for the fourth quarter of 2013 was $4.0 million (including a non-cash expense of $1.2 million for amortization of share-based compensation), compared to an operating loss of $0.9 million for the same period in 2012 (including a non-cash expense of $247 thousand for amortization of share-based compensation). The increase for 2013 compared to 2012 primarily relates to growth in research and development expenses and general and administrative expenses, each as described above and an increase in non-cash share based compensation. Total comprehensive loss for 2013 was $8.9 million (including a non-cash expense of $2.7 million for amortization of share-based compensation), compared to a total comprehensive loss of $2.5 million in 2012 (including a non-cash expense of $1.1 million for amortization of share-based compensation). Total comprehensive loss for the fourth quarter of 2013 was $4.2 million (including a non-cash expense of $1.2 million for amortization of share-based compensation), compared to a total comprehensive loss of $0.8 million for the same period in 2012 (including a non-cash expense of $247 thousand for amortization of share-based compensation). Cash position: As of December 31, 2013, Evogene had approximately $127 million in cash, cash equivalents and marketable securities, compared to approximately $55 million as of December 31, 2012, largely reflecting the net proceeds of approximately $77 million from the recently completed equity offering in the US. Key achievements to date: Launch of PlaNet version 2.0 with enhanced gene stacking capabilities Launch of PoinTar target discovery platform for novel herbicides Extension and expansion of Collaboration with Monsanto Expansion of soybean rust resistance collaboration with DuPont-Pioneer Extension of soybean Nematode resistance collaboration with Syngenta Completion by Evofuel of three years of successful field trials for improved castor seeds in Brazil Successful field trial results for Black Sigatoka resistance in bananas Collaboration with Chinese Biotechnology Company DBN on improving key rice traits Launch of model plant validation system for monocot plants Launch of Gene2ProductTM computational ag-bio platform Conference call and webcast details: Evogene management will host a conference call today at 10:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-866-860-9642, and participants from Israel and other countries are invited to access the call at (972) 3-918-0685. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 19:00 Israel time today, and will be accessible through March 21, 2014. US-based participants are invited to access the replay by dialing 1-888-254-7270, and participants from Israel and other countries are invited to access the replay at (972) 3-925-5929. A replay of the call may also be accessed as a webcast via Evogene's website at http://investors.evogene.com and will be available for a period of ten days. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/03/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Reports-Fourth-Quarter-and-Year-End-2013-Financial-Results Evogene Enhances Predictive Gene Stacking Capabilities http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Enhances-Predictive-Gene-Stacking-Capabilities Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in improving crop productivity for the food, feed and biofuel industries, announced today enhanced capabilities for gene stacking prediction with the introduction of PlaNet (Plant Networks) version 2.0 computational platform. The upgraded version includes more than doubling of the platform's interaction data sources and types, and improved algorithms for data analysis. Gene stacking prediction refers to the combination of multiple genes to improve a particular trait, or several traits, in order to enhance the productivity of seed products, either via biotechnology or advanced breeding applications. Gene stacking is increasingly seen by the agriculture industry as essential for enhancing the efficacy of complex traits such as yield improvement. PlaNet is part of Evogene's Gene2ProductTM multi-platform solution designed to improve trait efficacy by high throughput optimization of a candidate gene's functionality in target crops. More specifically, PlaNet is designed to predict the most promising genes to combine with the selected candidate gene to improve a desired trait. The platform applies advanced algorithms on multiple interaction data layers derived from various data sources and types. Evogene capabilities in the field of gene stacking utilize the company's proprietary database which today incorporates and integrates more than five years of tailored-generated data for the development of optimal multi-gene prediction models. PlaNet version 2.0 substantially improves gene stacking prediction capabilities by enhancing the quality and scope of the platform's interaction data and the accuracy of its analysis tools. This is accomplished through more than doubling of the platform's data sources and types, incorporating new and improved algorithms for data mining, and significant advancements to the platform's statistical analysis capabilities. Through the utilization of scoring and subsequent ranking of hundreds of millions of possible gene combinations, the platform is able to prioritize the selected combinations according to their predicted ability to improve the efficacy of a given gene. "PlaNet forms an integral part of our proposition to our partners and is currently being adopted across our main product programs," said Ofer Haviv, President and CEO of Evogene. "Furthermore, Evogene is already in advance stages of development of the next generation of our gene stacking capabilities with a mining platform that will allow us to evaluate and prioritize multi-gene combinations at the initiation of the gene selection process." -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 06/03/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Enhances-Predictive-Gene-Stacking-Capabilities Evogene’s Fourth Quarter and Full Year 2013 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Fourth-Quarter-and-Full-Year-2013-Earnings-Announcement-Schedule Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that it will release its fourth quarter and full year 2013 financial results on Wednesday, March 19, 2014. On the day of the announcement, the company's management will host a conference call to discuss the results at 10:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-866-860-9642 toll-free from the United States, or 972-3-918-0685 internationally. A listening-in option of the call will also be available via live webcast through the investor relations section of Evogene's website at http://investors.evogene.com. A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or 972-3-925-5929 internationally. The replay will be accessible through March 21, 2014, and an archive of the webcast will be available on the Company's website at the above link through March 29, 2014. -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 27/02/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogenes-Fourth-Quarter-and-Full-Year-2013-Earnings-Announcement-Schedule Evogene Launches Target Discovery Platform for Novel Herbicides http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Launches-Target-Discovery-Platform-for-Novel-Herbicides- Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today a key milestone in its discovery program for novel chemical herbicides with the launch of PoinTar, a computationally based target discovery platform for novel herbicides. Targets are key molecules, responsible for essential biological processes in weeds, which have the potential to be chemically inhibited to cause weed death. Crop losses from weeds are estimated to reach more than $100 billion annually and chemical herbicides, with a worldwide market currently estimated at $20 billion, are the dominant approach for weed control. The need for new herbicide solutions arises from the substantial and growing resistance of weeds and other invasive plants to existing chemical solutions since no new herbicide mode of action has been introduced in over 20 years. Evogene's herbicide discovery program, initiated in 2012 within the Company's ag-chemical operations, is addressing this unmet need for new herbicide modes of action through the development of computationally-based platforms integrating predictive biology and chemistry. The launch of the PoinTar platform is the first key milestone in the program. An important feature of the new platform, in addition to the predictive discovery of potential targets, is the ability to prioritize the resulting predictions for proteins on the basis of structural information such as 'drugability', that is the ability of the predicted target to interact with a chemical molecule. In addition, PoinTar is able to identify non-coding RNAs as potential targets, adding a substantial new class of overlooked molecules to the discovery process. The combination of these two computationally based features is anticipated to provide a unique and effective target discovery capability. The remaining key development milestone for the establishment of Evogene's herbicide discovery capability is the completion of a second, complementary platform for the discovery of chemical molecules that are designed to inhibit the activity of targets discovered using the PoinTar platform. These chemical molecules will then serve as the active ingredients for the final herbicide product. "Our on-going herbicide discovery program rests on our two core infrastructure assets - our extensive and proprietary computational capabilities for data integration and analysis, and our deep predictive understanding of how plants work at the genomic level," said Ofer Haviv, Evogene's President and CEO. "Through the use of these underlying capabilities, this program combines relevant aspects of biology and chemistry into one integrated and complete solution designed to provide a powerful new discovery approach to one of agriculture's most critical challenges and largest commercial opportunities." -xxx- About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 11/02/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-Launches-Target-Discovery-Platform-for-Novel-Herbicides- Evogene to Present at 'Plant and Animal Genome XXII' International Conference http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Plant-and-Animal-Genome-XXII-International-Conference Evogene (NYSE, TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced it will present key advances in OMIC-based trait discovery at this year's Plant and Animal Genome (PAG) XXII international conference, taking place January 11-15, 2014. PAG is one of the world's largest ag-genomics conferences, attended by over 3,000 genetic scientists and researchers from around the world. The term OMICs refers to the collection, processing and integrated analysis of various biological data layers, including genomic, proteomic and metabolomic "big data", in order to understand broad molecular processes. During the past few years, as enormous amounts of such data have become widely available to ag-bio researchers, the ability to analyze and integrate the data has become a major challenge and bottleneck for the industry. To address this challenge, Evogene has developed a proprietary, multi-dimensional computational infrastructure for identifying plant genes that have the potential to improve the performance and productivity of crops through the use of OMICs metadata. Evogene's workshop, Trait Improvement Driven by OMICs Discovery, will take place Tuesday, January 14, from 4:00 pm - 6:10 pm at the San Diego room. At the workshop, Evogene scientists and invited experts will discuss key advances in OMICs based discovery, specifically in the fields of metabolomics and long non-coding RNA, offering new horizons for OMICs based trait improvement. The workshop will also present key aspects of Evogene's proprietary computational infrastructure, focusing on the Company's ATHLETETM gene discovery platform and PlaNet gene stacking prediction solution. In additions to the workshop, Evogene will be conducting on-site meetings at PAG XXII. To arrange for a meeting, please contact: pag2014@evogene.com About Evogene Ltd. Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 08/01/2014 http://www.evogene.com/News-Events/Press-Releases/2014/Evogene-to-Present-at-Plant-and-Animal-Genome-XXII-International-Conference Evogene Announces Closing of its Initial Public Offering in the United States and Full-Exercise of Over-Allotment Option http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Closing-of-its-Initial-Public-Offering-in-the-United-States-and-Full-Exercise-of-Over-Allotment-Option Evogene Ltd. (NYSE, TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today the closing of its previously announced initial public offering in the United States of 5,750,000 ordinary shares at the price to the public of $14.75 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional ordinary shares. All of the shares in the offering were offered by Evogene. The shares began trading on the New York Stock Exchange on November 21, 2013 under the symbol "EVGN". Evogene received gross proceeds from the offering of approximately $84.8 million, before underwriting discounts and commissions and other estimated offering expenses. Credit Suisse Securities and Deutsche Bank Securities acted as joint book-running managers for the offering, and Oppenheimer & Co. and Piper Jaffray & Co. acted as co-managers. This offering is being made solely by means of a prospectus, copies of which may be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY, 10010, telephone: 1 (800) 221-1037, e-mail: newyork.prospectus@credit-suisse.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, telephone: 1 (800) 503-4611, email: prospectus.CPDG@db.com. A registration statement relating to the initial public offering has been filed with and declared effective by the United States Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. -xxx- About Evogene Ltd. Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. Evogene's headquarters are located in Rehovot, Israel and the Company is listed for trading on the New York Stock Exchange (NYSE: EVGN) and on the Tel Aviv Stock Exchange (TASE: EVGN). 26/11/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Closing-of-its-Initial-Public-Offering-in-the-United-States-and-Full-Exercise-of-Over-Allotment-Option Evogene Prices Its Initial Public Offering in the United States http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Prices-Its-Initial-Public-Offering-in-the-United-States Evogene Ltd. (TASE: EVGN) today announced the pricing of its initial public offering in the U.S. of 5 million ordinary shares at a price of US$14.75 per share. In connection with the offering, Evogene has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same price per share. As part of the offering, one of the company's shareholders, Monsanto Company, has agreed to purchase 813,560 ordinary shares at the initial public offering price, amounting to approximately US$12 million. The shares are expected to begin trading on the New York Stock Exchange under the symbol "EVGN" on November 21, 2013. The offering is expected to close on November 26, 2013. Credit Suisse Securities and Deutsche Bank Securities are acting as joint book-running managers for the offering, and Oppenheimer & Co. and Piper Jaffray & Co. are acting as co-managers. This offering is being made solely by means of a prospectus, copies of which may be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY, 10010, telephone: 1 (800) 221-1037, e-mail: newyork.prospectus@credit-suisse.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, telephone: 1 (800) 503-4611, email: prospectus.CPDG@db.com. A registration statement relating to the initial public offering has been filed with and declared effective by the United States Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. -xxx- About Evogene Ltd. Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. Evogene's headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). 21/11/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Prices-Its-Initial-Public-Offering-in-the-United-States Monsanto and Evogene Extend and Expand Collaboration for Crop Improvement http://www.evogene.com/News-Events/Press-Releases/2013/Monsanto-and-Evogene-Extend-and-Expand-Collaboration-for-Crop-Improvement Monsanto Company and Evogene Ltd. (TASE: EVGN) announced today the extension and expansion of their research and development collaboration. The collaboration, initially signed in 2008 and later extended in 2011, has focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola. The newly signed agreement extends these existing programs through to August 2016, and adds a new five year program for the identification of genes providing resistance to Stalk Rot disease in corn, caused by multiple Fusarium species. Fusarium is a family of fungi that causes significant yield loss across the world's major crops. "We are extremely pleased with Monsanto's decision to again extend our excellent broad collaboration in the areas of yield and abiotic stress tolerance with respect to the four major field crops," said Ofer Haviv, Evogene's President and CEO. "The addition of a new discovery program focused on Fusarium resistance is another indication of Evogene's growing commitment and activities targeted at biotic stress related conditions, and the broad applicability of our unique technology platform." "Agricultural innovation will be key to helping meet growing global demand," added David Fischhoff, Monsanto Technology Strategy Development Lead. "Through the combination of Evogene's gene discovery technologies with our company's trait development expertise, this collaboration is focused on developing new tools that help farmers drive yields even further." Terms of the revised collaboration agreement include: Evogene will provide Monsanto with candidate genes that are predicted to improve yield, fertilizer utilization and plant resistance to environmental stress. Monsanto will receive exclusive license rights to develop and commercialize the candidate genes as part of Monsanto's trait pipelines for corn, soybean, canola, and cotton. Evogene will also provide Monsanto with candidate genes predicted to provide resistance to Stalk Rot disease caused by multiple Fusarium species. Monsanto will receive exclusive license rights to develop and commercialize the candidate genes as part of Monsanto's trait pipeline for corn. For all collaboration programs, Evogene will utilize its ATHLETETM computational technology for gene discovery, and its Gene2ProductTM platform for optimizing trait efficacy and accelerating the product development process. Evogene will be entitled to receive both milestone payments and royalty payments for all successful candidate genes emerging from the collaboration that are developed and commercialized by Monsanto. Evogene will also receive additional research and development payments to support the increased activities. The prior agreement included a put option giving Evogene the right, under defined conditions, to sell one million Evogene shares to Monsanto at $12 per share. The prior put option has been cancelled in exchange for an increase in all future milestone payments and royalty rates with respect to genes licensed by Evogene to Monsanto. The prior put option has been replaced with a new $12 million put option under which shares will be sold at market value at time of exercise (subject to set minimum and maximum prices). -xxx- About Evogene Ltd. Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com About Monsanto Company Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter® at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows at www.monsantoblog.com, or subscribe to our News Release RSS Feed. As it applies to Evogene Ltd., this press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. As it applies to Monsanto Company, this press release contains "forward-looking statements", such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits and the previously-announced SEC investigation; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent Form 10-K Report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results. 28/10/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Monsanto-and-Evogene-Extend-and-Expand-Collaboration-for-Crop-Improvement Evogene Reports Third Quarter 2013 Financial Results http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Third-Quarter-2013-Financial-Results Evogene Ltd. (TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced its financial results for the third quarter and nine months ended September 30, 2013. Ofer Haviv, Evogene's President and CEO, stated: "Last year, in view of the broad applicability of the unique technological capabilities and infrastructure that we have established over the past decade, we reorganized our company into four operating divisions, each focused on leveraging these assets to create improved products in a different and substantial market area." "In our most mature division, Yield and Abiotic Stress, we currently have seventeen product programs with many of the leading seed companies in the world, including our multiyear collaborations with Monsanto Company in corn, soybean, cotton and canola, and with Bayer CropScience for wheat." "We continue to broaden our activities in our division focused on Biotic Stress. We recently expanded our Asian Soybean Rust collaboration with Pioneer DuPont, and, following promising results for Evogene-supplied candidate genes, we also extended our collaboration with Syngenta in the field of Soybean Nematode. We were also pleased to announce positive field trial results in our collaboration with RAHAN, targeting Black Sigatoka disease in bananas." "In our Ag-Chemicals division, the newest of our four operating divisions, our current focus is on new 'modes of action' for herbicides and novel crop enhancers. During the past quarter we continued to extend certain of our existing capabilities to meet these new pursuits and to add the required chemical-specific capabilities and infrastructure." "Our wholly owned subsidiary, Evofuel, continues to progress towards its goal of developing and supplying castor seeds as a cost-competitive biofuel feedstock. During the past quarter, we were pleased to announce the completion of three years of field trials in Brazil and, based on encouraging results, our expectation to initiate commercialization of our proprietary castor seeds in 2016." "Everything that we are able to accomplish in our four operating divisions rests on our unique technology platforms and highly skilled professional staff. As such, in addition to our program-directed activities in each division, we continue to make increasing investments to enhance and extend our core technologies and capabilities. These efforts have been primarily related to our computational technologies and plant validation platforms, including the broadening of our field-trial capabilities and greenhouse facilities," concluded Mr. Haviv. Revenues for the first nine months ended September 30, 2013 were $13.2 million, compared to $12.3 million for the same period in 2012. Revenues for the third quarter of 2013 were $4.2 million, compared to $4.0 million reported for the same period in 2012. Revenues for the first nine months and the third quarter of 2013 consist primarily of research and development payments under the Company's various collaboration agreements. Cost of revenues consists of expenses incurred in support of our ongoing collaborations that provide, in addition to current revenues stemming from research and development fees, the potential for future milestone and royalty revenues. Cost of revenues for the first nine months ended September 30, 2013 was $7.3 million, compared to $6.9 million for the same period in 2012. Cost of Revenues for the third quarter of 2013 was $2.6 million, compared to $2.4 million for the same period in 2012. This increase in costs primarily relates to the expansion in the Company's scope of activities in order to meet the obligations of its various contractual agreements. Research and development expenses for the first nine months ended September 30, 2013, which do not include expenses incurred in support of ongoing collaborations which, as stated above, are accounted for as cost of revenues, were $7.6 million, compared to $5.2 million for the same period in 2012. Research and development expenses for the third quarter of 2013 were $3.0 million, compared to $1.9 million for the same period in 2012. The increases for 2013 compared to 2012 primarily relate to the significant increase in activities devoted to strengthening the infrastructure and expanding the product offerings across Evogene's four operating divisions, including the establishment of dedicated computational platforms and related increases in professional staff. General and administrative expenses for the first nine months ended September 30, 2013 were $2.1 million (including a non-cash expense of $503 thousand for amortization of share-based compensation), compared to $1.5 million for the same period in 2012 (including a non-cash expense of $221 thousand for amortization of share based-compensation). General and administrative expenses for the third quarter of 2013 were $863 thousand (including a non-cash expense of $315 thousand for amortization of share-based compensation), compared to $470 thousand for the same period in 2012 (including a non-cash expense of $49 thousand for amortization of share-based compensation). The increases for 2013 compared to 2012 primarily relate to the increase in non-cash expense for amortization of share-based compensation, as well as an increase in other expenses to support the growth of the ongoing activities of the Company. Loss from ordinary operations for the first nine months ended September 30, 2013 was $4.7 million (including a non-cash expense of $1.6 million for amortization of share-based compensation), compared to loss from ordinary operations of $2.2 million for the same period in 2012 (including a non-cash expense of approximately $925 thousand for share-based compensation). Loss from ordinary operations for the third quarter of 2013 was $2.5 million (including a non-cash expense of approximately $1 million for share-based compensation), compared to loss from ordinary operations of $1.1 million for the same period in 2012 (including a non-cash expense of approximately $352 thousand for share-based compensation). This increase in loss from ordinary operations primarily relates to the increase in research and development expenses and an increase in non-cash expenses for share-based compensation as described above. Total comprehensive loss for the first nine months ended September 30, 2013 was $4.7 million (including a non-cash expense of $1.6 million for amortization of share-based compensation), compared to a total comprehensive loss of $1.8 million for the same period in 2012 (including a non-cash expense of approximately $925 thousand for share-based compensation). Total comprehensive loss for the third quarter of 2013 was $2.3 million (including a non-cash expense of approximately $1.0 million for share-based compensation), compared to a total comprehensive loss of $1.0 million for the same period in 2012 (including a non-cash expense of approximately $352 thousand for share-based compensation). As of September 30, 2013, Evogene had approximately $48.3 million in cash, cash equivalents and marketable securities compared to approximately $55.1 million as at December 31, 2012. - xxx - About Evogene Evogene is a plant genomics company utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops such as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 24/10/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Third-Quarter-2013-Financial-Results Evogene and DuPont Pioneer Expand Collaboration For Soybean Rust Resistance http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-and-DuPont-Pioneer-Expand-Collaboration-For-Soybean-Rust-Resistance Evogene Ltd. (TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced the extension and expansion of its multi-year research collaboration with DuPont Pioneer, the seed business of DuPont (NYSE:DD), for developing soybean varieties displaying resistance to Asian Soybean Rust (ASR). Soybean is one of the most important commercial crops around the world, supplying protein for human and animal consumption, as well as feedstock for oil production. ASR is a major disease that affects the crop, mostly in the prime soybean growing regions of North and South America. As part of the original collaboration, signed in 2011, Evogene and Pioneer established a joint research program aimed at identifying and validating novel genes portraying the highest probability for in-plant resistance to ASR. Under the program, novel genes identified by Evogene will be evaluated and validated by Pioneer in their soybean research lines as possible leads for further development and commercialization. Under the one-year extension announced today, the parties will add Evogene's Gene2ProductTM computational platform to the gene discovery program. The platform, which offers gene optimization by utilizing advanced gene stacking (i.e. combining of multiple genes) and regulation prediction, is designed to improve the efficacy and probability of success of the resulting novel seed products. Ofer Haviv, President and CEO, Evogene stated: "Our Gene2ProductTM platform is a key component of our predictive capabilities aimed at utilizing improved gene efficacy to reduce development timeframes and promote the probability of success of end-products. Under the joint DuPont Pioneer/Evogene ASR program to date, significant progress has been made and an excellent collaborative relationship established. Therefore we are very pleased that Pioneer has chosen to expand and accelerate our efforts by incorporating this recently developed Evogene platform." "Asian soybean rust remains a challenge for growers," said Gusui Wu, Senior Research Director, DuPont Pioneer. "We value our collaboration with Evogene and their technology strengths to help deliver effective resistance to this devastating disease to our customers." The original collaboration program included partial funding by the BIRD Foundation, a bi-national foundation which supports and encourages cooperation between Israeli and American companies in various areas of technology. Evogene's current gene discovery activity in the field of biotic stresses (stresses caused by pests such as fungi and insects), is one of the Company's four product divisions. Commenting on the potential of the biotic market, Mr. Haviv added: "I believe the field of acute biotic stresses holds a significant opportunity for Evogene. This opportunity will be derived from expanding our existing programs, as well as focusing on new biotic stresses that are not currently part of our discovery portfolio." -xxx- About Evogene Evogene is a plant genomics company utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 15/10/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-and-DuPont-Pioneer-Expand-Collaboration-For-Soybean-Rust-Resistance Evogene Strengthens Scientific and Corporate Management Teams http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Strengthens-Scientific-and-Corporate-Management-Teams Evogene (TASE: EVGN) ), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced the expansion of its scientific and corporate teams with the recruitment of key plant genomics Ph.D. holders, as well as senior management positions in its legal and corporate communications departments. "Evogene is fortunate to be located at the heart of one of the world's leading talent pools in the field of plant genomics. Based in Israel, we are able to attract candidates that are leaders in their respective fields, having attended some of the world's most renowned academic institutions in the area of genomic and computational research," said Ofer Haviv, President and CEO of Evogene. "With over 75% of our staff dedicated to R&D and 25% holding Ph.D.'s we have managed to build an expert team that is unique in our industry and serves as an attractive proposition to world leading agriculture companies looking for unmatched knowhow and innovation in gene discovery." "As Evogene continues to grow and expand its activities, enhancing our corporate capabilities will continue to be an important aspect of maintaining the right building blocks to support the Company's advancements both on a scientific and business levels," concluded Mr. Haviv. The additions to the Company's scientific teams reflect Evogene's industry strong hold in the leading areas of plant genomics including trait research, plant tissue culture and transformation, computational biology and genomics. Key additions to the team include: Micha Brog, Ph.D. - Trait Researcher Dr. Brog holds a Ph.D. in plant genetics and breeding and a B.Sc. in plant sciences from the Robert H. Smith Faculty of Agriculture of the Hebrew University of Jerusalem. His studies focused on mapping and characterizing of quantitative trait loci and comparison of their conservation between tomato species. Yifat Ofir-Birin, Ph.D. - Trait Researcher Dr. Ofir-Birin holds a Ph.D. from the Department of molecular biology and biochemistry from the Faculty of Medicine of the Hebrew University. Her studies focused on structural and functional characterization of novel Ap4A-LysRS signaling pathway in mast cells. Dror Hilman, Ph.D. - Trait researcher Prior to joining Evogene, Dr. Hilman served as a post-doctoral researcher in the Volcani agricultural center, focusing on ripening in bananas. Dr. Hilman holds a Ph.D. from the Department of Cellular and Developmental Biology in the Hebrew University of Jerusalem where his published and awarded work focused developmental biology and bioinformatics relating to pathways evolution. Dan Reshef, Ph.D. - Computational Biologist Dr. Reshef holds a Ph.D. from the Faculty of Medicine of the Hebrew University of Jerusalem where his work focused on computational structural analysis of the cohesin-dockerin interaction as well as on the analysis of conservation of protein domain repeats. Idit Buch, Ph.D. - Senior Computational Genomics Algorithm Developer Dr. Buch has over ten years of computational R&D experience in leading Israeli biotechnology and hi-tech companies. Prior to joining Evogene, Dr. Buch served as senior bioinformatician at Rosetta Green Ltd. focusing on computational discovery of novel RNAi in plants. She completed her Ph.D. from the Tel-Aviv University in 2010, acquiring deep knowledge in computational simulations of biological processes and structural bioinformatics. Arie Cohen, Ph.D. - AgChem Discovery Scientist Dr. Cohen holds a Ph.D. from the Hebrew University of Jerusalem. He is a highly experienced quantum theoretical chemist with a theoretical and experimental background in protein/enzyme/biosensor design and a theoretical background in drug design. His well published work includes 14 publications and over 280 citations to these publications. Mr. Shay Gusin - Head of Information Management Systems (IMS) Mr. Gusin brings over 10 years of experience in IT and software development to his role. Prior to joining Evogene, he served as Professional Services Manager of Service Oriented Architecture and Business Intelligence units at One1 Ltd., a leading Israeli IT company. Prior to that, Mr. Gusin served as an officer in the Israeli Defense Forces, where he held various managerial roles including Project Manager and Software Development Manager for the IDF's elite intelligence unit and as Chief Information Officer for one of the military's key divisions. Mr. Gusin holds a B.Sc. in Software Engineering from Tel Aviv Academic College of Engineering. Att. Inbal Israeli Gaffa - Legal Advisor Prior to joining Evogene, Att. Israeli Gaffa worked at Odis Filtering Ltd., Water Treatment Plants Company as legal advisor and international marketing associate. Previously, she worked at Reches, Rosenseft & Norkin Law Firm and interned at Shibolet and Co. specializing in commercial law, supporting a range of start-up and public companies. Att. Israeli Gaffa holds a joint degree in Law (LLB) and Business Administration degrees (Cum Lauda) from the Interdisciplinary Center in Herzliya. She was part of the "Zell Entrepreneurship Program" for outstanding students, and co-founded Green Life CafÉ Ltd., which develops and manufactures premium alternative coffee drinks. Karen Mazor - Director of Public and Investor Relations Ms. Mazor joined Evogene in April as Director of Public and Investor Relations, overseeing the company's communication and brand equity with key stakeholder groups. Prior to joining Evogene, Ms. Mazor served as Director of Corporate Communications for Gilat Satellite Networks and as Director of Public Relations for ECI Telecom. Previously, she served at various communication roles for Hutchison Telecoms Australia and as Director of Investor Relations for Partner Communications. Ms. Mazor holds a B.A. in Communications and Business Administration from York University and an MBA from Manchester University. About Evogene Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without imitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 07/10/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Strengthens-Scientific-and-Corporate-Management-Teams Evogene Files Registration Statement for Proposed Initial Public Offering in the United States http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Files-Registration-Statement-for-Proposed-Initial-Public-Offering-in-the-United-States Rehovot, Israel, September 24, 2013 - Evogene Ltd. (TASE: EVGN) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares in the United States. The size of the offering has not yet been finalized. Evogene has applied to have its ordinary shares listed on the New York Stock Exchange under the ticker symbol "EVGN." Credit Suisse Securities and Deutsche Bank Securities are the joint book-running managers for the proposed offering, and Oppenheimer & Co. and Piper Jaffray & Co. are the co-managers. A copy of the preliminary prospectus related to the offering may be obtained when available from either: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY, 10010; or by phone at (800) 221-1037; or by e-mail at: newyork.prospectus@credit-suisse.com Deutsche Bank Securities, Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836; or by phone at 1-800-503-4611; or by email at: prospectus.CPDG@db.com A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission (SEC) but has not yet become effective. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. -xxx- About Evogene Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene.com. This press release may contain "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 24/09/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Files-Registration-Statement-for-Proposed-Initial-Public-Offering-in-the-United-States Syngenta and Evogene Extend Soybean Nematode Resistance Collaboration http://www.evogene.com/News-Events/Press-Releases/2013/Syngenta-and-Evogene-Extend-Soybean-Nematode-Resistance-Collaboration REHOVOT, ISRAEL, September 23, 2013 - Evogene Ltd. (TASE: EVGN), a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced a three year extension of its research collaboration with Syngenta Biotechnology, Inc. The collaboration was established in mid-2009 to identify plant genes providing resistance to Soybean Cyst Nematode. Plant parasite nematode is one of the most devastating and yield reducing pests affecting agriculture today, accounting for almost $100 billion in crop damages annually. The soil borne parasite is widely prevalent in soybean, attacking the roots of developing soybean plants and resulting in yield losses of between 30 and 50 percent in heavily infected fields. The impact to U.S. soybean growers alone has been estimated to reach $1.3 billion annually. The three year collaboration extension follows successful results obtained by Syngenta for candidate genes provided by Evogene as part of the original collaboration. Candidate genes have demonstrated reduced nematode infection and have advanced to further testing in Syngenta's soybean pipeline for potential development and future commercialization of improved soybean seeds. "Nematodes are one of the most underdiagnosed plant diseases dearly in need of new technological solutions," said Michiel van Lookeren Campagne, Head of Biotechnology for Syngenta. "We believe that through our collaboration with Evogene, we will be able to bring new offers for nematode control to growers more quickly." Under the extended collaboration, Evogene will utilize broader discovery strategies to provide Syngenta with additional candidate genes acting under new modes of action to achieve nematode resistance. Furthermore, Evogene will utilize its proprietary PlaNet technology, part of Evogene's integrated Gene2ProductTM platform, to predict the most promising candidate genes for stacking (i.e. combining of multiple genes) in order to further improve product efficacy. "We are very pleased by both the results achieved to date with respect to soybean cyst nematode resistance and our continuing and expanding relationship with Syngenta, and are confident that the combination of our discovery capabilities and Syngenta's development expertise will result in novel paths to address this devastating pest," said Ofer Haviv, President and CEO of Evogene. "The agreement extension is an important addition to our growing activities in addressing biotic stress conditions, such as nematodes and other plant parasites, where Evogene has built significant capabilities for identifying novel genes to combat the variety of acute biotic stresses affecting the world's key crops." Under both the original agreement and the extension, Evogene is entitled to receive research payments, success-based milestone payments and future royalty payments based on the sale of resulting products by Syngenta -xxx- Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. Evogene's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 23/09/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Syngenta-and-Evogene-Extend-Soybean-Nematode-Resistance-Collaboration Evogene Subsidiary Completes Three Years of Successful Field Trials for Improved Castor Seeds http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Subsidiary-Completes-Three-Years-of-Successful-Field-Trials-for-Improved-Castor-Seeds- Evogene Ltd. (TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced that its wholly owned subsidiary, Evofuel Ltd., has completed three years of successful field trials in Brazil for the development of castor bean as an alternative feedstock for production of biodiesel and other industrial uses. The field trials, which were conducted in cooperation with SLC AgrÍcola S.A., one of Brazil's largest landowners and leading agriculture businesses, demonstrated strong yield performance of Evofuel's proprietary castor seed varieties under rain-fed conditions in northeast Brazil, and supported the use of castor seed as a competitive biodiesel feedstock. Moreover, Evofuel's castor seed varieties have the potential of being highly attractive to the traditional industries currently using castor oil, such as the lubricant and biopolymer industries, which today face the challenge of castor oil price instability. Based on three consecutive years of successful yield results, Evofuel expects to initiate commercialization of its proprietary castor seeds in 2016, following advanced product development and pre-commercial trials which are targeted to begin next year. The collaboration with SLC is aimed at developing castor as a rotation crop with soybean, with the sowing of the castor seeds taking place after the harvesting of the soybean. Being grown during a period in which rainfall levels are typically not sufficient to cultivate other crops, castor production under this model does not compete with the production of staple crops, and provides farmers with a high value crop offering and additional revenue source. "We are excited to complete our proof of concept stage demonstrating three years of strong yield performance. These results are especially encouraging seeing as the past two years were relatively dry, with approximately 50% of the average rainfall," said Assaf Oron, General Manager of Evofuel. "Despite these challenging conditions, we were able to achieve the required yield performance, positioning our castor varieties as an attractive and scalable crop, especially for rotation in areas where the soybean counter season leaves local farmers with limited cultivation options." "Castor is a high value crop that we believe has the potential to diversify our crop portfolio and crop rotation systems, especially in the Cerrado region in Brazil, the county's agriculture frontier," said AurÉlio Pavinato, CEO of SLC AgrÍcola. SLC AgrÍcola operates over 280,000 hectares of soybean, corn and cotton across Brazil. Evofuel estimates that under the soybean rotation model, and leveraging SLC's footprint, the potential land area in Brazil for economically viable commercial production of castor seeds is over five million hectares. -xxx- About Evofuel Ltd. Evofuel is engaged in the development and commercialization of high yielding castor bean seeds as a cost competitive, sustainable, second-generation feedstock for the growing biofuel market. It has built its castor genetic assets based on a broad collection of over 300 castor lines from over 40 different geographic and climatic regions. As part of its development process, Evofuel applies advanced breeding methods utilizing cutting-edge plant genomics capabilities together with agro-technique expertise to enable efficient and sustainable large scale production of castor bean. Initially established in 2007 as a division within Evogene Ltd. (TASE: EVGN), Evofuel was spun out as a wholly owned subsidiary in 2012. For additional information, please visit Evofuel's website at: www.evo-fuel.com About Evogene Ltd. Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans","believes", "scheduled","estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 16/09/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Subsidiary-Completes-Three-Years-of-Successful-Field-Trials-for-Improved-Castor-Seeds- Evogene Reports Second Quarter and First Half 2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Second-Quarter-and-First-Half-2013 Evogene Ltd. (TASE: EVGN), a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the second quarter and half year ended June 30, 2013. Ofer Haviv, Evogene's President and CEO, stated: "The second quarter of this year saw significant progress and achievements as we further broadened our unique discovery and validation capabilities supporting our four market focused operating divisions, and continued to successfully meet objectives for both our partnered and Evogene sponsored product programs." Mr. Haviv continued, "During the first half of 2013, and in particular the second quarter, we significantly increased our activities devoted to strengthening the infrastructure and expanding product offerings in our two newest operating divisions, Evofuel and Ag-chemicals. Evofuel, whose mission is the development of second generation feedstock for biodiesel, is in the process of completing the third year of field trials for our advanced castor varieties in northeast Brazil. We remain on track in our efforts to introduce a commercially viable alternative feedstock for biodiesel based on castor seeds in Brazil and Argentina." "With respect to Ag-chemicals, which is the focus of our newest operating division, we believe our computational biology capabilities and plant genomic knowledge provide us with a unique opportunity to address the growing need for new and innovative products that can overcome the growing resistance of weeds and other pests to available chemical solutions. During the past quarter, in preliminary discussions with several leading companies in this field, we received initial confirmation that others share our belief." "In our two operating divisions targeted at improving seed traits, one focused on yield and abiotic stress tolerance and the other on biotic stress tolerance, we continue to successfully meet the discovery and product candidate objectives under our existing collaborations with leading seed companies and evaluate new collaborations. During the past quarter, we announced the signing of a yield and abiotic stress tolerance focused collaboration for rice with DBN, a leading Chinese biotechnology company. In the area of biotic stress, we were pleased to recently announce successful field trial results in our program with Rahan Meristem to develop banana varieties expressing tolerance to Black Sigatoka disease. In addition to the potential value of this specific achievement, these results, although initial, provide a strong validation of the applicability of our predictive computational biology and gene discovery capabilities to biotic stress conditions, in addition to yield and abiotic stress conditions." "Looking forward, it is our belief that the increased use of high-end agriculture technologies to provide improved seeds and new ag-chemical solutions will be an absolute requirement in order to address the growing worldwide needs for food, feed and fuel. Therefore, with the constantly increasing recognition by leading agriculture companies worldwide of Evogene as a unique and attractive solution provider, we are very optimistic regarding the future for our company," concluded Mr. Haviv. Revenues for the first six months ended June 30, 2013 were $8.9 million, compared to $8.3 million for the same period in 2012. Revenues for the second quarter of 2013 were $4.3 million, compared to $4.1 million reported for the same period in 2012. Revenues for the first half and the second quarter of 2013 consist primarily of research and development fees under the company's various collaboration agreements with seed companies. Cost of Revenues consists of expenses incurred in support of our on-going collaborations with seed companies which provide, in addition to current revenues related to research and development fees, the potential for future milestone and royalty revenues. Cost of Revenues for the first six months ended June 30, 2013 was $4.7 million, compared to $4.5 million for the same period in 2012. Cost of Revenues during the second quarter of 2013 was $2.5 million, compared to $2.4 million reported for the same period in 2012. Research & Development expenses for the first six months ended June 30, 2013, which do not include expenses incurred in support of on-going collaborations, were $4.7 million, compared to $3.3 million for the same period in 2012. Research and development expenses for the second quarter of 2013 were $2.5 million, compared to $1.9 million reported for the same period in 2012. The increases for 2013 compared to 2012 primarily relate to significantly increased activities devoted to strengthening the infrastructure and expanding product offerings in Evogene's two newest operating divisions, Evofuel and Ag-chemicals, including establishment of dedicated computational platforms and related headcount. These increases for 2013 also relate to broadening the company's competencies in the area of biotic discovery. Loss from ordinary operations for the first six months of 2013 was $2.1 million, compared to loss from ordinary operations of $1.1 million in the same period in 2012. Loss from ordinary operations for the second quarter of 2013 was $1.6 million, compared to loss from ordinary operations of $1.0 million in the same period in 2012. The increase in loss from ordinary operations is mainly due to the increase in R&D expenses, as described above Total comprehensive loss for the first six months ended June 30, 2013, was $2.4 million, compared to a total comprehensive loss of $0.7 million for the same period in 2012. Comprehensive loss for the second quarter of 2013 was $1.9 million, compared to a comprehensive loss of $1.2 million for the same period in 2012. The increase of comprehensive loss is mainly due to the increase in loss from ordinary operations, as described above, and an increase in financial expenses, mainly due to a decrease in market value of marketable securities the Company holds. As of June 30, 2013, Evogene had $50.5 million in cash, cash equivalents and short term marketable securities, compared to $55.1 million as of December 31, 2012. - XXX - About Evogene Evogene is a plant genomics company utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops such as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 19/08/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Second-Quarter-and-First-Half-2013 Evogene and Rahan Announce Successful Field Trial Results For Black Sigatoka Resistance in Bananas http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-and-Rahan-Announce-Successful-Field-Trial-Results-For-Black-Sigatoka-Resistance-in-Bananas- Evogene Ltd. (TASE: EVGN), a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, and Rahan Meristem (1998) Ltd. (Rahan), a leading fruit biotechnology and breeding company, announced today successful field trial results in their joint program to develop banana varieties expressing tolerance to Black Sigatoka (also known as Black Leaf Streak Disease), the most damaging disease threatening commercial banana plantations. The joint collaboration focuses on the discovery and validation of genes with the potential to demonstrate resistance for Black Sigatoka. As part of the field trials which were conducted by Rahan, banana crops consisting genes discovered by Evogene, demonstrated a lower infection rate than banana crops which did not contain the selected genes. "With banana constituting the world's fourth most valuable food staple, Black Sigatoka is particularly devastating, affecting over 50% of this $2.5 billion crop," explained Ron Dinar, CEO of Rahan. "The disease has the capacity to reduce yields by 35-50%, causing tremendous impact to growers in major producing countries of Central America, the Caribbean Islands, Africa and the Far East." Current methods to control Black Sigatoka include fungicide applications, the annual cost of which is estimated at 30% of a typical grower's total production cost and adding an estimated 15-20% to the final retail price of bananas. In addition to this substantial cost, the high frequency of applications has shown significant adverse environmental and health effects. "Although initial, the field trial results from our joint work with Evogene are very encouraging and have the potential to combat one of the world's most devastating crop diseases," added Mr. Dinar. Ofer Haviv, Evogene's President and CEO added: "Our joint work with Rahan is one of our first collaborations in the biotic field. We are very pleased with these results which reinforce our confidence in the applicability of our unique discovery capabilities with respect to plant diseases and other biotic threats." "We enthusiastically look forward to continuing and expanding our collaboration with Rahan as we move forward in pursuing our joint objective of providing a more effective, healthier and economically viable alternative to the application of fungicides in banana cultivation," concluded Mr. Haviv. The joint program focuses on the discovery and validation of genes identified by Evogene's ATHLETETM computational technology. Transformation to banana plants and further validation in heavily infected areas is then conducted by Rahan. -xxx- About Rahan Meristem (1998) Ltd. Rahan is a plant biotechnology and propagation company specializing in tissue culture, molecular genetics and breeding. Established in 1974, Rahan is currently the world's largest producer of banana plantlet by tissue culture. Rahan's selected clones are currently in demand in all tropical regions where desert banana fruit are produced for the export markets. The selection lines "Gal" , "Jaffa", FF17 and Adi have gained a demand in tropical and subtropical regions of Latin America, Middle East, Africa, and the Far East. About Evogene Evogene is a leading plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 06/08/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-and-Rahan-Announce-Successful-Field-Trial-Results-For-Black-Sigatoka-Resistance-in-Bananas- Evogene Appoints Two New Members to Board of Directors http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Appoints-Two-New-Members-to-Board-of-Directors- Evogene Ltd., a world leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, announced the appointment of Akiva Mozes and Ziv Kop to the Company's Board of Directors. Akiva Mozes is the Chairmen of Bazan Group's Oil Refinery, and member of the Board of Directors of Strauss Group. Previously, Mr. Mozes served as President and Chief Executive Officer of Israel Chemicals, one of the world's leading manufacturers of fertilizer and specialty chemicals, retiring from this position last year. Ziv Kop is the founder and CEO of Go Capital, a newly formed Private Equity fund. Prior to founding Go Capital, and since its inception in 2003, Mr. Kop was the Managing Partner at Glenrock Israel, a private equity investment firm where he managed a portfolio of growth companies and served on the board of more than ten private and public companies. Previously, Mr. Kop served as Chief Executive Officer of POC Management Consulting, a leading Israeli consultancy in the field of strategic planning. "On behalf of Evogene, I am pleased to welcome Akiva Mozes and Ziv Kop as directors to our board," said Martin Gerstel, Chairman of the Board of Evogene. "As experts and leaders in their respective fields they bring valuable and very relevant expertise to complement the skills of our existing members, and further support Evogene's continuing rapid growth." "In addition to his outstanding general management skills, Akiva Mozes' specific expertise, gained during decades of leadership at the forefront of the world's fertilizer and chemical industry, represents an important and timely asset as we look to extend our activities in the ag-chemical field," added Mr. Gerstel. "Likewise, adding Ziv Kop's extensive experience in strategic planning and guidance of a large number of growth companies, is expected to be of significant value as we continue to evaluate the extension of our unique and growing capabilities to new areas of activities." "I enthusiastically look forward to working with them both," concluded Mr. Gerstel. Mr. Mozes' other prior Chairman of the Board positions include Dead Sea Works Ltd, Rotem Amfert Negev Ltd, and Bromine Compounds Ltd. He holds several public advisory positions and received a number of leading industry and business awards. Mr. Mozes holds a BA in Economics and Political Science and an MBA, both from the Hebrew University of Jerusalem. Mr. Kop is a graduate of both Tel Aviv University Law School and Business School, and INSEAD's Young Managers Program. Additional information regarding Evogene's Board of Directors can be accessed here. - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and seed development. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Israel, with field operations in South America. For additional information, please visit Evogene's website at www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 22/07/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Appoints-Two-New-Members-to-Board-of-Directors- Evogene Hosts President of the State of Israel, Mr. Shimon Peres http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Hosts-President-of-the-State-of-Israel-Mr-Shimon-Peres Evogene Ltd. (TASE: EVGN), a world leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced it hosted the President of the State of Israel, Mr. Shimon Peres, at its greenhouse facilities, located in Na'an. The President, who was recently awarded for his contribution to the promotion of the biotechnology sector in Israel, chose to visit Evogene in order to learn more about the company's activity with leading international seed companies to improve yield and resistance traits in agriculture crops. During his visit, the President met with Evogene's management and was presented with an overview of the company's research and development capabilities. As part of his visit, the President conducted an on-site validation trial for yield improvement in model plants. "Thanks to the development and innovation that is at the heart of Israeli agriculture, we have become a global leader in this field - a center for high-technology agriculture. As such, Israel can be the source for those technologies that will eventually help find a solution to world hunger," stated the President of the State of Israel, Mr. Shimon Peres. "The world today is faced with the challenge of providing more food with fewer resources, mostly as a result of the rapid growth in human population and ongoing changes in nutritional habits of developing countries. In the last decade alone, the global demand for major crops such as corn, soybean, wheat and rice increased by more than 20%, and is expected to continue to grow by over 10% in the next five years," said Ofer Haviv, President and CEO of Evogene. "As a global leader in developing improved plant traits for a variety of crops, Evogene is working towards improving key traits such as yield and biotic stress tolerance in order to meet the increasing demand for food, feed and alternative fuels. Our unique ability to combine deep understanding of plant genomics with advanced capabilities in computational analysis of scientific data makes Evogene unique in our industry and an attractive proposition to world leading agriculture companies," concluded Mr. Haviv. - XXX - About Evogene Evogene is a world leading plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 15/07/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Hosts-President-of-the-State-of-Israel-Mr-Shimon-Peres Evogene Announces Confidential Submission of Draft Registration Statement for U.S. Public Offering http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Confidential-Submission-of-Draft-Registration-Statement-for-US-Public-Offering Rehovot, ISRAEL - June 4, 2013 - Evogene Ltd. ("Evogene") (TASE: EVGN) today announced plans to conduct a registered public offering of its ordinary shares in the United States. The offering is expected to commence, subject to market conditions, after the U.S. Securities and Exchange Commission completes its review process initiated by Evogene's confidential submission of a draft registration statement. However, there can be no assurances with regard to the timing or the completion of the offering. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. - XXX - This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates","plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 04/06/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Confidential-Submission-of-Draft-Registration-Statement-for-US-Public-Offering Evogene to Collaborate with Chinese Biotechnology Company DBN on Improving Key Rice Traits http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-to-Collaborate-with-Chinese-Biotechnology-Company-DBN-on-Improving-Key-Rice-Traits- Rehovot, Israel & Beijing, China, May 29, 2013 - Evogene Ltd. (TASE: EVGN), a world leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, and Beijing Dabeinong Technology Group Co. Ltd. (DBN) (SZ:220385), a Chinese biotechnology company, today announced a collaboration, focused on improving productivity by increasing fertilizer uptake and drought tolerance in rice. Pursuant to the collaboration agreement, candidate genes discovered and prioritized by Evogene for these key traits will be introduced into DBN's pipeline for the development of improved rice. Financial terms of the agreement were not disclosed. Rice is one of the most important grains for human nutrition and caloric intake, providing more than one fifth of all calories consumed worldwide. Over 50 percent of the world's population is dependent upon rice for 80 percent of its nutrition. China is the world largest consumer and producer of rice, with approximately 25% of all world rice production. Under the collaboration, DBN will be granted a license to candidate genes, identified and prioritized through Evogene's ATHLETE® computational technology and validated in model plants. DBN will introduce and develop the licensed genes in rice as part of its R&D pipeline and have the right to commercialize rice incorporating these genes in China. Evogene will be entitled to receive milestone payments and royalties based on the sale of resulting products. "With China's need to support a fifth of the world's population with less than ten percent of the world's arable land, it is clear that innovative technologies are required to minimize the gap and meet the growing demand for food," stated Mr. Ofer Haviv, Evogene's President and CEO. "We are pleased to cooperate with DBN on developing improved rice for China, the world's largest market for this important crop." "Improving use efficiency of fertilizer and water can increase farmer productivity, while ensuring the sustainability of agriculture", said Dr. Yuping Lu, General Manager of the DBN Biotech Center. "We are pleased to collaborate with Evogene in developing improved rice to bring more innovative products to farmers and to increase our ability to meet the growing food needs in China." - XXX - About DBN DBN is a leading biotechnology company in China. DBN's newly developed Biotech Center specializes in novel gene discovery and evaluation, crop genetic transformation and commercial event selection to product development through its high through-put platforms, greenhouse facilities and crop field test centers. With the strong support from the Central Government and collaborations with many research institutes and companies, DBN is strategically positioning itself to be one of the important players in the global market in the industry. DBN, listed for trading on the Shenzhen Stock Exchange (SZ: 220385), is headquartered in Beijing, China. For additional information, please visit DBN's website at www.dbnbc.com About Evogene Evogene is a world leading plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 29/05/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-to-Collaborate-with-Chinese-Biotechnology-Company-DBN-on-Improving-Key-Rice-Traits- Evogene Reports First Quarter 2013 Financial Results http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-First-Quarter-2013-Financial-Results Rehovot, Israel - May 13, 2013 - Evogene Ltd. (TASE: EVGN), a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the first quarter ended March 31, 2013. Ofer Haviv, Evogene's president and CEO, stated: "The necessity of raising crop productivity in order to meet the rapidly growing need for food, feed and renewable fuel is a key driver in agriculture worldwide. As such, the ability to enhance seed traits, and therefore crop productivity, through an understanding and utilization of plant genomics is expected to be a crucial factor in meeting these critical demands. This is our area of focus, and we believe we have now established Evogene as a recognized leader in this field." "Our long-term, highly focused research and development efforts have established a powerful integrated technology infrastructure based on proprietary scientific understandings of plant genomics. An important aspect of this technology infrastructure is our broad array of computational technologies, capable of integrating and analyzing the vast amounts of genomic data now becoming available through more and more advanced data creation methodologies. These vast new sources and types of biological data provide substantial opportunities for identifying methods for trait improvement. However, they also provide a major challenge, since gaining meaningful knowledge from them requires sophisticated analysis tools, such as the computational technologies that we have established, and believe are unique in the industry. In addition, our infrastructure incorporates strong capabilities for data generation and plant validation systems, allowing us to identify, prioritize and initially validate for trait performance over 1,000 genes per year," added Mr. Haviv. "During the first quarter of 2013, we continued to make progress under our multiple collaborations with leading seed companies worldwide. In addition, Evogene continued to expand its research and development capabilities, strengthening its genomic innovation with the launch of Gene2ProductTM, a proprietary computational platform designed to improve plant trait efficacy and probability of success of novel seed products, and the introduction of a new monocot plant validation system, the Brachypodium." "We are confident that our broadly applicable technology infrastructure provides us with the foundation for continued growth and development. We anticipate that this growth will come from both current and new collaboration partners, and from the leveraging of our core industry leading competences into new areas of advanced agriculture, such as ag-chemicals and second generation feedstock for biodiesel," concluded Mr Haviv. Revenues for the first quarter of 2013 grew to $4.6 million, compared to $4.2 million for the same period in 2012. Evogene's current revenues consist primarily of research and licensing revenues generated under the Company's various collaboration agreements with seed companies. Cost of Revenues includes expenses related to the support of the Company's on-going activities under collaboration agreements with seed companies, all of which provide for future milestone and royalty revenues. Cost of Revenues for the first quarter of 2013 was $2.2 million, compared to $2.1 million for the same period in 2012. Research & Development expenses for the first quarter of 2013, which do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues, were $2.2 million. This compared to $1.5 million for the same period in 2012. The increase in Research & Development expenses mainly relates to the development of new computational technologies, establishing new capabilities for our technology platform and expansion of internal research projects and related headcount. Loss from ordinary operations for the first quarter of 2013 was $0.6 million, compared to a loss from ordinary operations of $0.1 million for the same period in 2012. This increase is mainly attributed to the increase in research & development expenses, as described above. Total Comprehensive loss for the first quarter of 2013 was $0.5 million, compared to a total comprehensive profit of $0.5 million for the same period in 2012. The change from comprehensive profit to comprehensive loss is mainly due to the increase in loss from ordinary operations, as described above, and a decrease in financial income, net, mainly due to fluctuation in currency exchange rates and decline in interest rates. As of March 31, 2013, Evogene had $52.5 million in cash, cash equivalents and short-term marketable securities, compared to $55.1 million as of December 31, 2012. - XXX - About Evogene Evogene is a world leading plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 13/05/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-First-Quarter-2013-Financial-Results Evogene Announces Appointment of Chief Financial Officer http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Appointment-of-Chief-Financial-Officer- Rehovot, Israel, May 01, 2013 - Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the appointment of Ms. Sigal Fattal as the Company's Chief Financial Officer (CFO) effective May 1, 2013. Ms. Fattal has been serving as the Company's Vice President of Finance since her appointment for the role in October 2012. In her new role, Ms. Fattal will hold expanded responsibilities, overseeing corporate finance, legal counsel, operations and purchasing, administration and human resources. She will remain a member of the Company's Executive Team. Ms. Fattal joined Evogene in June 2012, serving as advisor to the Company's Chief Executive Officer (CEO) on corporate matters, and was appointed as Vice President of Finance later that year. Prior to joining Evogene, she held executive accounting and finance positions in the financial sector, mainly with Blue Chip companies, including as CEO of wwCFO Ltd, and as CFO of Cal International, one of Israel's largest credit card companies. Ms. Fattal holds a Bachelor degree in Accounting and Economics, which she completed with honors, and a Master degree in Business, both from Tel Aviv University. "I am delighted to appoint Sigal for the role of CFO. The appointment credits her significant contribution to Evogene's financial operations and executive team, and marks the Company's ongoing growth and expanding operations," said Ofer Haviv, Evogene's President and CEO. "I am confident in her leadership and dedication as she takes on her extended responsibilities overseeing a core aspect of Evogene's corporate operations." - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and seed development. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Israel, with field operations in South America. For additional information, please visit Evogene's website at www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 01/05/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Appointment-of-Chief-Financial-Officer- Evogene Reports Fourth Quarter and Year End 2012 Financial Results http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Fourth-Quarter-and-Year-End-2012-Financial-Results Rehovot, Israel - March 24, 2013 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2012. Ofer Haviv, Evogene's president and CEO, stated: "Our position as a world leading discoverer and developer of improved plant traits was significantly strengthened during the past year. Included in our industry collaborations at year end were substantial collaborations with five of the seven leading seed companies in the world. These collaborations cover many important crops, including the four largest food and feed crops - wheat, corn, rice and soybean." Mr. Haviv continued, "In addition, major efforts were undertaken during 2012 to position us for continued growth and diversification through the further expansion of our unique integrated plant genomics capabilities. We believe that these broadly applicable capabilities provide each of our four operating divisions - yield and abiotic stress, biotic stress, ag-chemicals and seed development - with significant competitive advantages to address critical worldwide food, feed and fuel needs." Mr. Haviv explained, "Among our capabilities expansion achievements during the past year, included the completion of a pilot program for long non-coding RNA, launch of new computational platforms (including Gene2ProductTM), introduction of a new and unique model plant system (Brachypodium), and initial use of a new automated data collection and analysis platform (Phenomix). Combined with our past infrastructure investments and achievements, Evogene in 2013 has the team, the technical capabilities and the industry relationships to not only maintain, but also to enhance and broaden, its strong competitive position in the four markets that we are addressing worldwide." Mr. Haviv concluded, "In addition, we continue to maintain a strong financial position, with increasing revenues and cash equivalents at yearend of over $55 million." Revenues for 2012 were approximately $17.1 million, representing an increase of approximately 15% compared to revenues of $14.9 million for the same period in 2011. This increase in revenues primarily relates to the November 2011 extension of our multi-year collaboration with Monsanto. Revenues for the fourth quarter of 2012 were $4.8 million, compared with $4.7 million for the same period in 2011. At present, revenues consist primarily of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Cost of Revenues includes expenses related to the support of our on-going activities under our various collaborations with seed companies, all of which provide for future potential milestone and royalty revenues. Cost of Revenues for 2012 was $9.6 million, compared with $8.2 million for 2011. This increase in Cost of Revenues results from the increase in activities under our various collaborations as demonstrated by the increase in Revenues for the period. Cost of Revenues expenses for the fourth quarter of 2012 were $2.6 million, compared with $2.7 million for the same period in 2011. Research & Development expenses for 2012 were $7.3 million, compared with $6.4 million for the same period in 2011. Research & Development expenses do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues. Research & Development expenses for the fourth quarter of 2012 were $2.1 million, compared with $1.7 million for the same period in 2011. This increase in R&D expenses relates mainly to development of new computational genomics and validation technologies in support of our four operating divisions and a significant increase in the company's R&D personnel. Loss from ordinary operations for 2012 was $3.2 million, representing no change compared to the same period in 2011. Loss from ordinary operations for the fourth quarter of 2012 was %v.9 million, compared to a loss from ordinary operations of %v.8 million for the same period in 2011. Financial income during 2011 due to publicly traded warrants: During the first two quarters of calendar 2011, Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007. As of May 31, 2011, the date of expiration of these warrants, over 99.9% had been exercised. While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares resulted in non-cash financial income or expense due to their revaluation on our statements of comprehensive profit or loss. Such accounting due to publicly traded warrants was no longer applicable after the second quarter of 2011. Total Comprehensive loss for 2012 was $2.5 million, compared to a total comprehensive profit of %v.6 million for the same period in 2011. Total comprehensive loss for the fourth quarter of 2012 was %v.8 million, compared to a comprehensive loss of %v.9 million for the same period in 2011. As more fully explained in the preceding paragraph, total comprehensive profit for 2011 includes $3.7 million of non-cash financial income relating to publicly traded warrants expired on May 2011, whereas total comprehensive loss for 2012 does not include any such non-cash financial effects due to such warrants. As of December 31, 2012, Evogene had approximately $55.1 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to approximately $58.8 million as of December 31, 2011. Key highlights for 2012: Business Development · Research and discovery activities continued on track under our on-going collaborations with world leading seed companies. · Activities initiated for our ag-chemicals division, focusing on finding new innovative chemical solutions for herbicides and crop enhancers. · Transfer of the Company's seed activities to Evofuel, a newly formed wholly owned subsidiary, with activities and partnerships for development and commercialization of seed products, primarily for biofuels. New collaborations: Rasi Seeds, an Indian Seed Company, to increase yield and drought tolerance in hybrid rice in key and strategic markets for this crop. T6 Industrial S.A., leading Argentinean biodiesel producer, to develop castor bean as a sustainable and cost competitive feedstock for biodiesel in Argentina. Infrastructure and Technologies · Long non-coding RNA (lncRNA) - Completion of a pilot program to develop and validate a platform for identification of long non-coding RNA related genes. Evogene is now validating a new pool of lncRNA related genes under various growth conditions. · Phenomix - Establishment of a new platform enabling the advanced collection, storage and integrated analysis of enormous quantities of phenotypic data directly from the field. · Computational technologies - Launch of new and advanced computational genomics technologies for improving plant performances: ATHLETE® 4.0, a new version of our gene discovery technology; and Gene2Product® 1.0, an integrated platform for optimizing gene function in target crops and increasing the probability of success of biotechnology seed products. · Brachypodium - Disclosure and initial use of our monocot model plant validation system for evaluation of genes for monocot crops, such as wheat, corn and rice. The validation system is utilized by Evogene for evaluation of genes discovered by us, and in certain case, those discovered by our partners. · Discovery and Validation Infrastructure - Completion of an expansion program of over 50% in the company's gene validation & plant growth capacity, including construction of new molecular and tissue culture laboratories and substantial expansion of our greenhouse facilities. - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and seed development. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Israel, with field operations in South America. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 24/03/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Reports-Fourth-Quarter-and-Year-End-2012-Financial-Results Evogene Announces Launch of Model Plant Validation System for Monocot Plants http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Launch-of-Model-Plant-Validation-System-for-Monocot-Plants Rehovot, Israel - February 12, 2013 - Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the launch of a novel monocot model plant validation system for evaluation of candidate genes for monocot crops, such as wheat, corn and rice. The new validation system, which uses Brachypodium as the monocot model plant, enables the efficient and rapid evaluation of the performance of candidate genes for improving traits of interest, such as yield and drought tolerance. The system, which has been a high priority infrastructure development program at Evogene for the past three years, is now fully operational and has been incorporated in certain of Evogene's existing monocot plant collaborations. In addition to utilizing the new validation system in certain existing collaborations based on Evogene discovered genes, Evogene has begun to enter into agreements with its partners to utilize the monocot model system for validating partners' candidate genes in their pipelines. Ag-biotech industry efforts to improve traits of interest in key crops require both the prediction by various methodologies of candidate genes, and then the experimental validation of the actual performance of these predictions in plants. Such validation efforts typically begin with model plant systems that offer a much faster and more efficient high-throughput path to initially evaluate and prioritize candidate genes. The prioritized genes, which pass proof of concept in the model plants, will undergo further evaluation in the target crops, such as corn, wheat and soybean. In the absence of a monocot specific model system in the past, Evogene, consistent with general practice in the industry, has utilized a dicot model plant system - based on Arabidopsis - for the evaluation of both dicot and monocot plants. Evogene's Arabidopsis model system has the capacity to validate 1,000 new genes annually under an array of 15 different assays such as yield, nitrogen deficiency and drought. Now, with the addition of the new monocot Brachypodium dedicated model system, Evogene has the unique capacity to provide within one year from gene discovery, and in a high-throughput manner, a complete array of gene validation in model plant, which is data specific for either monocot or dicot target crops. Evogene's two model plant validation systems strongly complement to its ATHLETETM and related computational based gene discovery capabilities. This combination provides Evogene's researchers and collaborators not only with targeted novel gene discoveries but also with highly specific model systems for the high throughput validation of these gene discoveries, thus resulting in better candidates being selected for further development in the target crops. "The successful implementation of our novel monocot validation system is an important additional achievement as we pursue our mission of providing the ag-biotech industry with a complete solution for plant trait improvement for food, feed and fuel through combining state of the art biotechnology and advanced breeding methods," stated Dr. Hagai Karchi, Evogene's Executive VP R&D and CTO. "Furthermore, we are pleased to see partner's choice to utilize this unique capability, not only with respect to genes we have discovered, but also for use with its other candidate genes." Definitions - Monocot, Dicot and close evolutionary relatives Flowering plants are largely classified as either Monocot or Dicot Phylums characterized by generally different plant morphologies. Monocot plants have one single embryonic seed leaf. Monocot plants include three of the most economically important food crops: corn, rice and wheat as well as some of the largest and most familiar groups of plants, such as lilies, orchids, agaves, palms, and grasses. Dicot plants have two embryonic seed leaves. Dicot plants include important commercial crops such as soybean, cotton, canola and sunflower. In addition, many of the fruits, vegetables, spices, roots and tubers are classified as dicots. - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's discovery infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuels. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Rehovot. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 12/02/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Launch-of-Model-Plant-Validation-System-for-Monocot-Plants Evogene Announces Launch of Gene2Product Computational AgBio Platform http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Launch-of-Gene2Product-Computational-AgBio-Platform Rehovot, Israel - January 29, 2013 - Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the launch of Gene2Product® version 1.0, a unique integrated computational platform for improving trait efficacy by high throughput optimization of gene function in the target crop ('mode of use') as part of the development process for biotechnology seed products. Evogene has already entered into agreements to utilize Gene2Product® to optimize the performance of certain genes it has discovered for use in the development pipelines of its partners. In order to improve the performance of plants, research efforts in the industry have focused primarily on various methodologies to identify the genes that influence the traits of interest, such as yield, drought tolerance, resistance to pests, etc. However, the actual efficacy achieved in the field depends not only on the presence or absence of the gene of interest, but on its optimization with other factors related to the mode of use of such gene. Such factors include: the choice of gene variant for the crop of interest, its interactions with other genes, the tissues in which it is expressed, its level and/or pattern of expression, its performance under changing environmental conditions, and other factors. The Gene2Product® Platform 1.0 provides a robust and high throughput analysis of a large number of genes in parallel in order to optimize their modes of use in the end product. This is accomplished through the use of four interconnected sub-platforms, with the fourth of these sub-platforms targeted for incorporation later this year. Each of these sub-platforms relies on the use of computational modules incorporating advanced algorithms to analyze enormous amounts of relevant data from both public and proprietary sources, with a current comprehensive database in excess of 250 terabytes and growing. This database includes more than 10 different genomic and phenotypic data types originating from over 200 different plant species. The sub-platforms incorporated in the Gene2Product® Platform are as follows: PlaNet (Plant Network) - Improves trait efficacy by predicting appropriate gene combinations, referred to in the seed industry as "gene stacking". Multi-gene stacking is expected to be a key solution for increasing trait efficacy when approaching complex traits, such as yield, which is an emerging need in the industry. The PlaNet sub-platform is designed to provide a set of genes predicted to jointly impact the trait when stacked, utilizing multiple interaction data layers across multiple species. Through the simulation of efficacy, scoring and subsequent ranking of millions of possible multiple gene interactions for a gene of interest, possible stacking combinations are prioritized with respect to their predicted ability to improve a given trait. This sub-platform utilizes, in addition to the enormous amounts of plant data, vast amounts of relevant protein interaction data from other species such as yeast. GeneSpec (Gene Spectrum) - Improves trait efficacy by selecting the preferred functional gene variant for each gene of interest for the crop of interest. The GeneSpec sub-platform analyzes the entire gene variation spectrum (i.e. orthologous, alleles, etc.) for the gene of interest and selects the minimal number of variants representing the entire molecular functional divergence of the gene spectrum across species. This involves the identification and classification of up to 1,000 possible variants per gene through the use of novel algorithms, according to sequence-function and other relationships. Following this, the sub-platform utilizes additional novel algorithms to prioritize the variants in each group according to their predicted ability to affect the trait of interest. RePack (Regulation Package) - Improves trait efficacy by predicting the regulation mode for the gene of interest that will provide the optimal expression pattern. This includes prediction of where in the plant expression would be beneficial and where it would be undesired in respect of tissue, organ, timing, level of expression and other aspects that can impact trait efficacy. The RePack sub-platform uses advanced visualization tools and algorithms to provide insights from various plant species on the expression patterns for a specific gene and its orthologs in specific tissue, treatment and development stage in order to predict the optimal expression pattern for the gene to improve the trait of interest in the target crop. GeneDex (Gene Index) - Targeted for incorporation in Gene2ProductTM during 2013, GeneDex is designed to improve trait efficacy by predicting functional robustness of a gene across different genetic backgrounds (i.e. germplasms) and environmental conditions. GeneDex will provide multiple relative index scores for each gene predicting such gene's contributions with respect to each trait of interest across different combinations of such variables. "We have been extremely pleased by the rapid recognition and appreciation of our ATHLETETM gene discovery platform by leading AgBio companies, as evidenced by our large and growing number of collaborations with such companies for the most important food crops worldwide. Now, with the addition of our complementary Gene2Product® computational platform, we see the opportunity to achieve very substantial improvement in utilizing these discoveries for both greater trait efficacy and probability of success with biotechnology seed products", stated Dr. Hagai Karchi, Evogene's EVP Development and CTO. Mr. Ofer Haviv, Evogene's President and CEO added: "We are pleased to report that Gene2Product® has been successfully implemented in certain of our in-house programs and in our on-going research and development collaboration with Monsanto Company and other partners. Furthermore, we believe it will become a 'must have' component in all of our plant improvement activities." - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's discovery infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuels. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Rehovot. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 29/01/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Announces-Launch-of-Gene2Product-Computational-AgBio-Platform Evogene Strengthens Scientific and General Management Teams http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Strengthens-Scientific-and-General-Management-Teams Evogene (TASE: EVGN) announces that during the past year, it continued to strengthen its scientific management as well as financial and operational management teams by new nominations and recruitments. New scientific management nominations that took place this year include: - Sharon Ayal, PhD, named VP R&D - Biotic Stress Division - Basia Vinocur, PhD, named VP R&D - Yield & ABST Division - Eyal Emmanuel, PhD, named VP R&D - Ag-Chem Division and - Alon Glick, PhD, named Director of Experimental Genomics. Furthermore, during 2012, the following senior employees joined Evogene's team: Ms. Sigal Fattal - VP finance Ms. Fattal has over 16 years of experience at the Financial Sector, mainly with Blue Chip International and public companies. Prior to joining Evogene, during the years 2011-2012, Ms. Fattal served as the CEO of wwCFO Ltd., prior to that during the years 2008-2010, Ms. Fattal held the position of CFO and VP Business Development of Cal International. Ms. Fattal holds a BA in accounting and economics, with honors, and a MBA specializing in finance and marketing, both from Tel Aviv university. Dr. Dana Ichelczik - Project Manager Prior to joining Evogene, during the years 2011-2012, Dr. Ichelczik was responsible for new technology evaluation coordination and additional R&D activities at FuturaGene Ltd. Prior to that, in 2010, she served as a post-doctorate fellow in the department of Fruit Tree Sciences, at the Volcani Center. Dr. Ichelczik holds PhD and MSc degrees in Plant Protection from the Department of Entomology at the Faculty of Agriculture of the Hebrew University of Jerusalem. Dr. Ariel Cohen - Project Manager Prior to joining Evogene, during the years 2010-2012, Dr. Cohen co-founded 'Ensof Biosystems', a company aimed at developing a novel proteomics platform for drug discovery. Prior to that, during the years 2004-2010, Dr. Cohen completed his studies at the Weizmann Institute of Science. His studies focused on proteomic dynamics in live cancer cells. Dr. Cohen's work was published in several high-impact peer-reviewed journals. Dr. Cohen holds a Ph.D., with honors, from the Department of Cell Biology, Weizmann Institute of Science and a B.Sc. in Bioinformatics from the Hebrew University of Jerusalem. Dr. Maya Schushan - Business Development Associate Prior to joining Evogene, during the years 2006-2012, Dr. Schushan completed her Ph.D. studies that focused on bioinformatics structural analysis of trans membrane proteins, including structure-function relationship of human proteins in health and disease. During that time, Dr. Schushan also completed an MBA degree in Management of Technology, Entrepreneurship and Innovation from the Recanati Business School in Tel-Aviv University. Dr. Schushan holds a Ph.D. from the Biochemistry Department and a B.Sc. with honors, both from the Faculty of Life Science in Tel-Aviv University. In addition, Dr. Schushan holds an MBA from the Recanati Business School in Tel-Aviv University. Dr. Ronit Rimon Knopf - Trait Researcher Prior to joining Evogene, during the years 2005-2011, Dr. Knopf completed her Ph.D at the Robert H. Smith Faculty of Agriculture of the Hebrew University. Her studies focused on characterization of rhomboid proteases in chloroplasts. Her M.Sc studies focused on the role of ethylene-producing genes in the sex determination pathway in cucumber. Dr. Knopf holds a M.Sc. and B.Sc. from the Department of Life Sciences of Ben-Gurion University and Ph.D from the Robert H. Smith Faculty of Agriculture of the Hebrew University. Mr. Roy Opperman - IP Manager Prior to joining Evogene, during the years 2011-2012, Mr. Opperman served as the CEO of Forest IP Ltd, which he has founded. The company dealt with innovative patent related data mining and analysis. Prior to that, during the years 2006-2010, Mr. Opperman served as a patent attorney specializing in the Hi-Tech industry, first at the Hi-Tech department of Reinhold Cohn Group and then as an independent consultant. Mr. Opperman holds a B.A. in Computer Science & Economics, with honors, from the Tel-Aviv University, and M.Sc. in Bioinformatics from the Weizmann Institute of Science. Mr. Tal Katz - Director of Operation & Purchasing Mr. Katz has an extensive experience, for over 14 years, in operation, logistics and purchasing, working as a director for various companies both in Israel and abroad. Prior to joining Evogene, during the years 2009-2011, Mr. Katz served as the CEO of Oriental Food Importers Ltd. an import, export, marketing and distribution of Asian food Products Company. Prior to that, during the years 2004-2009, Mr. Katz served as operation and customer service manager at "Metro Motor Marketing (1981) Ltd". Mr. Katz was qualified as a Safety Shift Manager by the British Council, and was qualified as a Navy Firefighter and Mechanic. Ofer Haviv, Evogene's president and CEO said: "In the passing year, we have substantially increased our scientific team and expanded our business field focused on finding new innovative chemical solutions. We have established a scientific management team, led by top PhD researchers and we look forward for continued development both in our human resources and in our collaboration agreements in the company's key fields of activity." - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's discovery infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuels. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Rehovot. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 02/01/2013 http://www.evogene.com/News-Events/Press-Releases/2013/Evogene-Strengthens-Scientific-and-General-Management-Teams Evogene Stock to be Traded in the TA-100, one of the Leading Indices in theTel-Aviv Stock Exchange http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Stock-to-be-Traded-in-the-TA-100-one-of-the-Leading-Indices-in-theTel-Aviv-Stock-Exchange Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, is to be traded in the TA-100 index as of December 16, 2012, in accordance with the Tel Aviv Stock Exchange (TASE) recent announcement. The TA-100 Index is one of the TASE's leading stock market indices, consisting of the 100 companies with the highest market capitalization listed on Tel Aviv. For more details please see announcement by TASE - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's discovery infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuels. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Rehovot, with field operations in Israel, Brazil and Argentina. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 13/12/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Stock-to-be-Traded-in-the-TA-100-one-of-the-Leading-Indices-in-theTel-Aviv-Stock-Exchange Evogene Announces Successful Pilot Program Validating New Source of Novel Genes for Plant Trait Improvement http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Successful-Pilot-Program-Validating-New-Source-of-Novel-Genes-for-Plant-Trait-Improvement- Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the successful completion of a two year pilot program for development and validation of a discovery platform targeted at the identification and use of long non-coding RNA ("lncRNA") related genes for plant trait improvement. Initiated during 2011, the pilot program utilized state-of-the-art high throughput sequencing methodologies to produce a vast amount of genomic data. This data was then analyzed using the Company's proprietary computational genomic technologies in order to identify, assemble and characterize novel lncRNAs, their related genes, and their effect on key plant traits. At present, dozens of these lncRNA related genes are being validated by Evogene under various growth conditions. lncRNA is the largest subgroup within ncRNA and exists in high abundance in plant species. Transcribed from DNA regions, previously known as 'junk DNA', and not coding proteins, these molecules are now recognized as having key roles in determining many of the complex characteristics which play significant roles in plant traits. Therefore lncRNA represents a largely unexplored world of genetic variation both within and between species and provides Evogene with an anticipated additional rich source for novel genes for plant improvement. Evogene's core capabilities and competitive advantages relate to identification and utilization of genes effecting key plant traits. To date, the source for identification of such genes, for Evogene and in general, for the rest of the industry, has focused on DNA regions that encode for proteins. Although, this research area continues to provide Evogene with substantial opportunities for identifying novel genes, the addition of lncRNA related genes as a further significant new gene source, is anticipated to take Evogene's world leading agbio discovery efforts to a new level. Four objectives were achieved in the course of the successful pilot program: the creation of a substantial highly accurate lncRNA genomic data base from a number of different plant species, the development of a discovery platform for accurate identification of lncRNAs and related genes from this data base; linking of these lncRNAs to specific plant traits; and experimental proof, through the use of Evogene's model plant validation system, that lncRNA originating from one plant species can significantly affect traits in other plant species. "As a world leader in developing improved plant traits based on coding genes, which has yielded impressive and growing R&D pipelines of beneficial plant traits for ourselves and our partners, we have now set a goal for Evogene to be a leader in the largely unexplored, but very promising, field of long non-coding RNA as well," stated Dr. Hagai Karchi, Evogene's EVP Development and CTO. "lncRNA is an innovative research field which has great potential for improving key plant traits. Furthermore, we believe this new 'gene reservoir' will provide a substantial opportunity for discovery and beneficial modification of additional plant traits beyond those currently identified, for both internal development and collaboration with our agbio partners." An Introduction to DNA, Genes and RNA DNA (deoxyribonucleic acid) contains the complete "blueprint" for each living organism. Regions of DNA that transcribe (i.e. produce) RNA (ribonucleic acid) are termed "genes". Each RNA can either encode (i.e. produce) a protein (messenger RNA or "mRNA"), or not encode ("ncRNA"). ncRNA has various subgroups such as long non coding RNA ("lncRNA"), micro RNA ("miRNA") and small interfering RNA ("siRNA"). The largest subgroup currently known in the plant kingdom is lncRNA. To date, most commercial efforts worldwide has focused on mRNA, the related genes and the resulting proteins. - XXX - About Evogene Evogene is a world leading discoverer and developer of improved plant traits through the use of integrated plant genomics. Combining proprietary state-of-the-art computational genomic technologies with advanced breeding methods, the company's discovery infrastructure provides a complete solution for plant trait improvement to its four market focused operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuels. In addition to its internal programs, Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene, listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN), is headquartered in Rehovot, with field operations in Israel, Brazil and Argentina. For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 26/11/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Successful-Pilot-Program-Validating-New-Source-of-Novel-Genes-for-Plant-Trait-Improvement- Evogene Reports Third Quarter 2012 Financial Results http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Third-Quarter-2012-Financial-Results Evogene Ltd. (TASE: EVGN) announced today financial results for the third quarter, ended September 30, 2012. Ofer Haviv, Evogene's president and CEO, stated: "As demonstrated by our recently announced launch of our Phenomix Agbio Platform, which enables advanced collection, storage and integrated analysis of phenotypic data directly from field experiments, we continue to significantly enhance and expand our state-of-the-art, world leading computational capabilities and validation platforms for plant genomics." Mr. Haviv continued, "These broad capabilities provide Evogene with a unique, proven and continuously improving ability to accurately predict and validate novel genes for trait improvement in a wide variety of key crops. To date, the company's product focus has been primarily on improving yield and abiotic stress tolerance." Mr. Haviv concluded, "Now, in order to more fully leverage our unique capabilities and infrastructure, the company has created four market driven operating divisions: Yield and abiotic stress, Biotic stress, Ag-chemicals and Biofuel. Each division is led by dedicated R&D and Business Development directors. We are already seeing that this new structure allows both much greater focus and increased productivity with respect to our current programs, and an accelerating identification of new opportunities for our rapidly growing company." Revenues for the first nine months ended September 30, 2012 were $12.3 million, compared to $10.2 million for the same period in 2011, representing an increase of about 20%. Revenues for the third quarter of 2012 were $4.0 million, compared to $3.4 million reported for the same period in 2011, representing an increase of about 18%. This increase in revenues primarily relates to the extension of our collaboration with Monsanto, signed on November 2011. Cost of Revenues include expenses related to the support of our on-going activities under our collaborations with seed companies, all of which provide for future milestone and royalty revenues. Cost of Revenues for the first nine months ended September 30, 2012 was $6.9 million, compared to $5.5 million for the same period in 2011. Cost of Revenues for the third quarter of 2012 was $2.4 million, compared to $2.0 million for the same period in 2011. This increase in Cost of Revenues is in parallel to the increase in revenues. Research & Development expenses for the first nine months ended September 30, 2012, which do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues, were $5.2 million, compared to $4.6 million for the same period in 2011. This increase in R&D expenses primarily relates to increase in the company's internal programs to support future growth, such as the Biofuel program and extensive field experiments for generation of proprietary plant data. Research & Development expenses for the third quarter of 2012 were $1.9 million, compared to $2.0 million for the same period in 2011. Loss from ordinary operations for the first nine months ended September 30, 2012, was $2.2 million, compared to loss from ordinary operations of $2.4 million for the same period in 2011. Loss from ordinary operations for the third quarter of 2012 was $1.1 million, compared to loss from ordinary operations of $1.3 million for the same period in 2011. Financial income during 2011 due to publicly traded warrants: During the first two quarters of calendar 2011, Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007. As of May 31, 2011, the date of expiration of these warrants, over 99.9% had been exercised. While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares resulted in non-cash financial income or expense due to their revaluation on our statements of comprehensive profit or loss. Such accounting due to publicly traded warrants was no longer applicable after the second quarter of 2011. Total comprehensive loss for the first nine months ended September 30, 2012, was $1.8 million, compared to a total comprehensive profit of $1.6 million for the same period in 2011. Comprehensive loss for the third quarter of 2012 was $1.0 million, compared to a comprehensive loss of $2.3 million for the same period in 2011. As more fully explained in the preceding paragraph, the comprehensive profit for the first nine months of 2011 includes $3.7 million of non-cash financial income relating to publicly traded warrants expired on May 2011, whereas total comprehensive loss for the first nine months and third quarter of 2012 does not include any such non-cash financial effects due to such warrants. As of September 30, 2012, Evogene had approximately $54 million in cash and cash equivalents, marketable securities and short term deposits compared to approximately $59 million as of December 31, 2011. The decrease of approximately $5 million during the nine month period relates primarily to increased activities with respect to Evogene's internal research programs and further expansion of its facilities in support of the company's ongoing growth. About Evogene's Operating Divisions Yield and abiotic stress - Utilizing our broad base of proprietary technologies, Evogene is advancing multiple collaborative programs to improve these important traits. These include multiyear collaborations with Monsanto Company in corn, soybean, cotton and canola and with Bayer CropScience in wheat. At present, hundreds of Evogene's discovered genes for improving these traits are undergoing development and validation in our partners' pipelines. Biotic stress - Evogene has been broadening its activities in this field, which includes on-going collaborations with Syngenta for improving soybean nematode resistance and DuPont for soybean rust resistance. We see great potential for expanding our efforts in this field through additional partnerships as well as internal programs. Agro-chemicals - As resistance of pests and weeds to existing chemicals becomes more and more of a challenge, Evogene has been evaluating various paths to leverage its proprietary technologies to identify new and innovative chemicals for global agriculture. In doing so, we see great synergy in combining our capabilities and innovative approach for plant genomics with applied chemistry in the search for new chemical solutions and believe that our extensive knowhow in plant biology provides Evogene with a significant advantage in identifying relevant target proteins. Biofuel - Evogene's wholly owned subsidiary, Evofuel, continues to progress towards its goal of supplying seed for cost competitive biofuel feedstock with current focus on Latin American markets collaborating with SLC Agricola in Brazil and T6 Industrial in Argentina. - XXX - About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 20/11/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Third-Quarter-2012-Financial-Results Evogene Announces Launch of Phenomix Agbio Platform http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Launch-of-Phenomix-Agbio-Platform Evogene announced today the launch of its Phenomix platform. The new platform utilizes advanced proprietary technologies for the collection, storage and integrated analysis of vast amounts of phenotypic data directly from the field. Through the use of Phenomix, Evogene researchers can evaluate crop behavior in environments closely resembling growth conditions existing in commercial agriculture. The two key data types utilized by Evogene's infrastructure for improving plant traits are phenotypic data, that is plant observable characteristics such as morphology, development, biochemical or physiological properties and genotypic data, that is related to the plant's internal biological mechanisms. Evogene currently has one of the world's largest, and continuously increasing, proprietary databases of integrated genomic data from multiple crops. Now with Phenomix, this critical resource is being augmented with vast amounts of fully annotated phenotypic data. More importantly, such phenotypic data is being obtained from crops in the field, mimicking actual commercial growth conditions, and not from controlled greenhouses as is typically the case in agbio research. Since Evogene's gene discovery capabilities rely on the integration and advanced analysis of genotypic and phenotypic data by the Company's computational technology platforms, such as ATHLETE® and EvoBreed®, the addition of the Phenomix data is anticipated to significantly enhance the Company's world leading agbio gene discovery capabilities, allowing even more precise prediction of the effect and level of compatibility of candidate genes under multiple field conditions. Phenomix provides a direct field -to- computer research communication channel which constantly streams physiological, structural and environmental data inputs from the field. The platform integrates a large number of modified sensors, digital imaging and other devices, previously in general used only as stand-alone units in confined greenhouse environments, and makes them usable in open field conditions. The resulting vast amount of data, from both ground level and from the air, is stored, analyzed and correlated with genotypic data through Evogene's computational technology platforms, such as ATHLETE® and EvoBreed®, providing both summaries of the raw data and its analysis in real time to the researcher. The Phenomix platform was recently successfully validated in an Evogene 18 acre field trial of various wheat varieties, demonstrating reliability and completeness of data, reduction of errors and the ability of the researcher to evaluate field experiment progress in real-time. This one field trial involved collection of more than one million high quality phenotypic data points, such as various physical characteristics, growth rate and yield by individual plant. Following this success, the Phenomix platform is now being routinely implemented in all Evogene field trials, further demonstrating its built-in flexibility to adjust to different crops, traits and field locations. "It is well appreciated in the industry that phenotypic data from the field is far more meaningful and valuable for research than data from artificial greenhouse conditions, stated Assaf Kacen, Evogene's EVP Technology Platform. "The development of the Phenomix platform is also a good example of how our constantly improving and expanding internal technological capabilities can complement one another, providing key components for further enhancement of our overall agbio discovery infrastructure." Ofer Haviv, Evogene's President and CEO added, "Phenomix is an important addition to Evogene's unique agbio discovery infrastructure combining state of the art computational platforms, high-quality data and plant scientific know-how. It is this infrastructure that is now allowing us to pursue, in collaboration with leading agbio companies worldwide, our mission to address the global demand for food, feed & fuel through improved plant performance." - XXX - About Evogene: Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 14/11/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Launch-of-Phenomix-Agbio-Platform Evogene to present at the 'CropWorld Global 2012' International conference in London, UK on November 7, 2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-present-at-the-CropWorld-Global-2012-International-conference-in-London-UK-on-November-7-2012- Dr. Hagai Karchi, Evogene's EVP Development and CTO, is to give a presentation at the CropWorld Global 2012 International conference dedicated to the global crop production industry, taking place on November 6-7 at London, UK. The presentation titled 'Utilizing OMICs data to enhance modern crop improvement' will be held on November 7th, and will focus on the following theme of application of the OMICs discipline: OMICs is a powerful and expanding discipline in plant biology for crop and trait improvement that can be applied to GM, Advanced Breeding and Ag-Chemicals. OMICs including genome, proteome, metabolome, transcriptome, interactome, and phenom tools, is currently used for meta data collection, processing and analysis to better us understand biological processes in a broad perspective. Evogene is a world leader in developing improved plant traits for agriculture through the use of plant OMICs data. Since its foundation in 2002, Evogene has focused on providing a complete solution for plant trait improvement by processing vast amounts of public and proprietary OMICs data through its computational technology platforms: ATHLETE® for gene discovery; Gene2Product® for improving gene efficacy; and EvoBreed® for breeding enhancement. These technologies and their deliverables are designed to fully integrate with both GM and breeding pipelines to increase a products' probability of success. Evogene's discovery efforts are focused on improving various traits of high commercial value including yield, drought tolerance, fertilizer utilization and resistance to key diseases. - XXX - About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its shares are traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 31/10/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-present-at-the-CropWorld-Global-2012-International-conference-in-London-UK-on-November-7-2012- Evogene Collaborations with Bayer CropScience and Monsanto Company Nominated for 2012 Agrow Awards http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Collaborations-with-Bayer-CropScience-and-Monsanto-Company-Nominated-for-2012-Agrow-Awards Evogene Ltd. (TASE: EVGN) announced today that its collaborations with Bayer CropScience and Monsanto Company have received two out of the four nominations for the 2012 Agrow Award for Best Industry Collaboration worldwide. The final award will be presented at the annual Agrow Awards ceremony, the most prestigious event for the crop protection industry, next month in London. The collaboration with Bayer CropScience was initiated in January 2011 and constitutes a multiyear collaboration to accelerate the development and introduction of improved wheat varieties through the utilization of a combination of advanced breeding and state of the art genetic modification methods. The collaboration with Monsanto was signed in November 2011 and is an extension to the two companies' multiyear research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola. Ofer Haviv, Evogene's President and CEO, stated: "As a young company currently listed only on the Israeli Tel Aviv Stock Exchange, we are of course very honored and pleased that the joint achievements being accomplished in these collaborations and our rapidly growing role in the worldwide food, feed and fuel industries are being recognized through these two nominations." - XXX - About the Agrow Awards The 2012 Agrow Awards features 15 categories that reward innovation and excellence in diverse areas, ranging from product chemistry and technology, business strategy, to corporate responsibility. The Best Industry Collaboration award recognizes a successful partnership between two companies in the worldwide crop protection or plant biotechnology arena. All forms of collaboration between two parties are eligible, including R&D collaborations, licensing agreements, joint ventures, manufacturing or formulation arrangements, or sales, marketing or distribution collaborations. Eligible partnerships must have been formed within the last two years. The other two nominees in this category for 2012 are the collaborations between Certis USA and Kumiai Chemical and between Makhteshim Agan and ChemChina. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its shares are traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 09/10/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Collaborations-with-Bayer-CropScience-and-Monsanto-Company-Nominated-for-2012-Agrow-Awards Evogene Subsidiary, Evofuel, Appoints Head of Research and Development http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Subsidiary-Evofuel-Appoints-Head-of-Research-and-Development Mr. Shai Leviatov, has been appointed as Head of Research & Development of Evogene's subsidiary, Evofuel, effective September 2nd, 2012. In his role, Mr. Leviatov will oversee Evofuel's R&D activities of plant feedstock development for the biofuel industry, focusing nowadays on the development of improved castor bean seeds as a viable source for production of biodiesel and biojet. For the past four years, Mr. Shai Leviatov served as Head of R&D Israel at Syngenta Seeds, one of the world leading seed companies. Mr. Leviatov managed collaborations with third party companies and academia as part of the global strategy of Syngenta. Mr. Leviatov also served as the global leader for Syngenta breeding for the protected cultivation tomato market in Mediterranean countries, Asia and the Americas and led innovation and technology implementation. Prior to that, Mr. Leviatov served as the Head of tomato breeding team at Zeraim Gedera Seed Company, which was acquired by Syngenta Seeds in 2007. Mr. Leviatov holds B.Sc and M.Sc degrees from the Hebrew University of Jerusalem's Faculty of Agriculture, specializing in plant physiology and genetics. "We are pleased to have Shai Leviatov join our team at Evofuel. With Shai's vast R&D and commercial management experience in the past 20 years, together with his firm and deep understanding of the seed industry and crop development, we strongly believe that he will bring substantial value to our development efforts and operations," said Mr. Assaf Oron, Evofuel's General Manager. "With Evofuel's recently announced progress and expanded development activity in Latin America markets, focusing on Brazil and Argentina, in the upcoming years we intend to intensively address up-scaling of our infrastructure and seed production towards meeting our commercialization goals." 03/09/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Subsidiary-Evofuel-Appoints-Head-of-Research-and-Development Evogene to present at the 'Innovate. Invest. Israel', a Wall Street Journal and Barron's Conference in New York, on September 10 2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-present-at-the-Innovate-Invest-Israel-a-Wall-Street-Journal-and-Barrons-Conference-in-New-York-on-September-10-2012 Ofer Haviv, Evogene's President and CEO , is to present at the 'Innovate. Invest. Israel' conference, hosted by the Wall Street Journal and Barron's, on Monday, September 10, 2012, 13:30, in New York City, as part of the Biomed and biotechnology session. The conference is supported by the Israeli Ministry of Finance. The conference will be discussing Israel's global impact as a leading exporter of technologies, ideas, innovations and entrepreneurial spirit. The conference will be moderated by the best Wall Street Journalists, top-tier guests and panelists which include: Rupert Murdoch, Chairman & CEO of News Corporation, Lewis B. Kaden, Vice Chairman, Citigroup Inc, Rodney Cook, Senior Vice President, International, Noble Energy, Saul Singer, Co-Author, The Start-Up Nation, Daniel Kahneman, Nobel Prize Winner in Economics, Peter Hancock, Chief Executive Officer, Chartis, Dr. Yuval Steinitz, Israeli Minister of Finance, Yuli Edelstein, Israeli Minister of Public Diplomacy & Diaspora Affairs, Prof. Oded Sarig, Director of Capital Market, Insurance and Savings Department, Israel Ministry of Finance, Yair Seroussi, Chairman, Bank Hapoalim, Shai Agassi, Founder, Better Place, Ester Levanon, CEO, Tel-Aviv Stock Exchange, Ed Finn, Editor & President, Barron's and Bret Stephens, Global View Columnist, The Wall Street Journal. 27/08/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-present-at-the-Innovate-Invest-Israel-a-Wall-Street-Journal-and-Barrons-Conference-in-New-York-on-September-10-2012 Evogene Releases Corporate Social Responsibility Policy http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Releases-Corporate-Social-Responsibility-Policy Rehovot, Israel, August 21th, 2012 - Evogene Ltd. (TASE: EVGN) has released its Corporate Social Responsibility (CSR) policy, setting forth the guidelines and values for its social involvement and contribution activities. As part of its commitment to contribute to the community in which it operates, Evogene has set the guidelines for its involvement and the involvement of its employees in promoting social responsibility. Evogene's CSR activity is focusing on three main areas: i) Diversity in human resources; ii) Academic support of disadvantaged students in the field of plant sciences; and iii) Social involvement in the community through volunteering activities, in which company employees take an active role. Evogene's CSR policy released follows past years activities including cooperation with 'All Good' association which provides a variety of employment and leisure initiatives to hundreds of disabled candidates in order to integrate them in the community; and with 'Meshi'- Rehovot, a rehabilitation plant which integrates people with mental disability in the labor market. This cooperation included integration of individuals from these organizations in the company's on-going operations. Furthermore, company employees were involved in volunteering activities during the Israeli holidays to collect, pack and provide food packages for populations in-need. The volunteering activities were conducted in cooperation with 'Hod Israel', a community charity organization and 'Latet', an Israeli humanitarian aid organization. In addition, the company has donated this year scholarships for PhD students at the Hebrew University's Faculty of Agriculture. "We are pleased to take an active and supportive part in the community in which we operate and see great value in promoting our CSR activity while mutually benefiting from the sense of purpose of volunteering as well as promoting individuals with scientific knowledge that may potentially integrate into the company ," Stated Mr. Ofer Haviv, CEO and President of Evogene. "Evogene is committed to supporting educational programs in the Israeli plant science community to advance academic scientific education and support local organizations and institutions that aid disadvantaged populations." 21/08/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Releases-Corporate-Social-Responsibility-Policy Evogene Reports Second Quarter 2012 Financial Results http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Second-Quarter-2012-Financial-Results Rehovot, Israel - August 14, 2012 - Evogene Ltd. (TASE: EVGN) announced today financial results for the second quarter, ended June 30, 2012. Ofer Haviv, Evogene's president and CEO, stated: "Currently, as severe drought is occurring in the United States and South America, negatively impacting supply of agricultural products and key commodities prices, awareness of the critical need to introduce genetic improvements to enhance agricultural crops is becoming even more apparent. As a leading supplier of improved traits to the major seed companies, we are very pleased to see Evogene's continuing progress in addressing this critical challenge through our key fields of activities, while at the same time continuing to invest heavily in additional infrastructure and new technologies for the future. Yield and abiotic stress tolerance - Utilizing our broad base of proprietary technologies, Evogene is advancing multiple collaborative programs to improve these important traits. These include multiyear collaborations with Monsanto Company in corn, soybean, cotton and canola and with Bayer CropScience in wheat. In addition, the company announced during the past quarter a new collaboration with Rasi Seeds, a leading seed company in India, for rice. India and south-east Asia are key markets for our technology and we are excited to expand our presence in this growing region of the world. At present, hundreds of Evogene's discovered genes for improving these traits, are undergoing development and validation in our partners' pipelines. Disease and other biotic stress resistance - Evogene has been broadening its activity in this field, which includes on-going collaborations with Syngenta for improving soybean nematode resistance and Dupont for soybean rust resistance. We see great potential for expanding our efforts in this field through additional partnerships as well as internal programs. Agro-chemicals - Evogene has been evaluating various paths to leverage its proprietary technologies to identify new and innovative chemicals for global agriculture, as resistance of pests and weeds to existing chemicals is becoming more and more of a challenge. In doing so, we see great synergy in combining our capabilities and innovative approach for plant genomics with applied chemistry in the search for new chemical solutions and we believe that our extensive know how in plant biology provides us with a significant advantage in identifying relevant target proteins. Feedstock for Biofuel - Evogene's wholly owned subsidiary, Evofuel, continues to progress towards its goal of supplying seed for cost competitive biofuel feedstock. With our current focus on Latin American markets, we recently announced expansion of Evofuel castor bean varieties development to Argentina through collaboration with T6 Industrial, in addition to our ongoing activities with SLC Agricola in Brazil. T6 is a leading biodiesel producer in Argentina and we consider this partnership as an important step towards establishing large scale production of castor bean as a key feedstock for the biodiesel industry." Mr. Haviv continued, "In order to support these activities, Evogene invests considerable resources in development of its human resources and computational technologies as well as its capabilities in field trials and proprietary plant genomic data generation. During the first half of 2012, Evogene launched ATHLETE® 4.0, a new version of our computational technology for gene discovery, which now incorporates additional computational tools and algorithms and the ability to integrate new data types. In addition, the company has recently completed the largest and one of the most complex field experiments, ever undertaken by us, for genomic and phenotypic data generation for a target field crop." Mr. Haviv concluded, "In each of these broad market areas, we see Evogene as a key contributor to meeting critical food, fuel and feed challenges worldwide, and by doing so, providing significant increases in shareholder value." Revenues for the first six months ended June 30, 2012 were $8.3 million, representing an increase of over 20% compared to $6.8 million for the same period in 2011. Revenues for the second quarter of 2012 were $4.1 million, compared to $3.4 million reported for the same period in 2011. Revenues for the first half and the second quarter of 2012 consist primarily of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Cost of Revenues include expenses related to the support of our on-going activities under our collaborations with seed companies, all of which provide for future milestone and royalties revenues. Cost of Revenues for the first six months ended June 30, 2012 was $4.5 million, compared to $3.6 million for the same period in 2011. Cost of Revenues for the second quarter of 2012 was $2.4 million, compared to $1.8 million for the same period in 2011. This increase in Cost of Revenues primarily relates to the extension of our collaboration with Monsanto, signed November 2011. Research & Development expenses for the first six months ended June 30, 2012, which do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues, were $3.3 million, compared to $2.7 million for the same period in 2011. Research & Development expenses for the second quarter of 2012 were $1.9 million, compared to $1.5 million reported for the same period in 2011. This increase in R&D expenses primarily relates to increase in the company's internal programs to support future growth, such as the Biofuel program and extensive field experiments for generation of proprietary plant data. Loss from ordinary operations for the first six months of 2012 was $1.1 million, compared to loss from ordinary operations of $1.0 million in the same period in 2011. Loss from ordinary operations for the second quarter of 2012 was $1.0 million, compared to loss from ordinary operations of $0.6 million in the same period in 2011. Financial expenses during 2011 due to publicly traded warrants: During the first two quarters of calendar 2011, Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007. As of May 31, 2011, the date of expiration of these warrants, over 99.9% of which had been exercised. While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares resulted in non-cash financial income/expense due to their revaluation on our statements of comprehensive profit or loss. These non-cash financial income/expense due to publicly traded warrants were no longer applicable after the second quarter of 2011. Total comprehensive loss for the first six months ended June 30, 2012, was $0.7 million, compared to a total comprehensive profit of $3.9 million for the same period in 2011. Comprehensive loss for the second quarter of 2012 was $1.2 million, compared to a comprehensive profit of $2.8 million for the same period in 2011. Total comprehensive loss for the first six months and second quarter of 2012 does not include any non-cash financial affects due to exercise of most of the publicly traded warrants as stated above, while the comprehensive profit for the first six months of 2011 includes $3.7 million of such non-cash financial revenues and the comprehensive profit for second quarter of 2011 includes $2.7 million of such non-cash financial revenues. As of June 30, 2012, Evogene had approximately $53 million in cash and cash equivalents, marketable securities and short term deposits, not including trade receivables of $3.9 million, this is compared to approximately $59 million as of December 31, 2011, not including trade receivables of $0.8 million. 14/08/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Second-Quarter-2012-Financial-Results Rasi Seeds and Evogene to Collaborate on Improving Key Traits in Rice http://www.evogene.com/News-Events/Press-Releases/2012/Rasi-Seeds-and-Evogene-to-Collaborate-on-Improving-Key-Traits-in-Rice Attur, Tamilnadu, India, and Rehovot, Israel, June 18th, 2012 - Rasi Seeds and Evogene Ltd. (TASE: EVGN) today announced a collaboration, focused on increasing yield and drought tolerance in rice. Pursuant to the collaboration agreement, candidate genes discovered by Evogene for these key traits will be introduced into Rasi Seeds pipeline for the development of improved hybrid rice. Financial terms of the agreement were not disclosed. Rice is one of the most important grains for human nutrition and caloric intake, providing more than one fifth of all calories consumed worldwide. Over 50 percent of the world's population is dependent upon rice for 80 percent of its nutrition. Much of the world's rice crop is still dependent upon rainfall, therefore changes in weather patterns can alter the delicate balance between world supply and demand, significantly affecting rice trade and price. India is one of the leading producers of rice, having the largest area under rice cultivation worldwide. Under the collaboration, Rasi Seeds will be granted a license to candidate genes, identified and prioritized through Evogene's ATHLETE® computational genomic technology and validated in model plants. Rasi Seeds will integrate the licensed genes into its R&D pipeline and evaluate them in rice field trials. The agreement provides Rasi Seeds the right to commercialize hybrid rice incorporating these genes in India and in additional countries in southern-east Asia. Evogene will be entitled to receive milestone payments and royalties based on the sales of resulting products. "We are pleased to collaborate with Evogene to introduce new technologies and excel our research and development in rice hybrids," stated Dr. M. Ramasami, CMD of Rasi Seeds. "With Rasi's leaderships in hybrid seed products in India, this collaboration serves our goal to expand into a multi-crop quality research to contribute the farming community and the industry, primarily in India. Rasi will continuously invest in R&D and new technologies for the sustainability of food production in India." "We are very pleased to enter into this collaboration with Rasi Seeds, one of the major seed companies in India. India and south-east Asia are key and strategic markets for improved rice seeds and we are excited to have the opportunity to bring our technology to these markets in collaboration with one of the leading companies in the region," stated Mr. Ofer Haviv, Evogene's President and CEO. "Considering the critical importance of rice for human nutrition in this rapidly growing region of the world, we believe that by addressing key traits, such as improved rice yield and drought tolerance, we can contribute significantly to increasing production and thereby benefiting both growers and consumers worldwide." About Rasi Seeds Rasi Seeds (P) Ltd. was initiated by Dr. M. Ramasami in 1973 in Attur located in Salem District, Tamilnadu, India. Rasi Hybrid Seeds has made rapid advances from seed production and supply ventures to a commendable position in Research and Development and transformed Rasi Seeds (P) Ltd. into one of the leading companies in the seed sector. Having 600 inqualified workforce, the company serves large sections of Indian farmers. Rasi has been recognized as the leader in cotton hybrids. Now Rasi is expanding its business in hybrid seeds of maize, pearl millet, rice, wheat, mustard and vegetables. The company has excellent processing facilities and follows efficient seed production techniques, high seed quality and purity standards. The services network provides technical support to several thousand farmers enabling them to produce high quality seeds. Rasi is providing best performing genetics to Indian farmers to reap the benefits. For additional information, please visit Rasi Seed's website at http://www.rasiseeds.com/index.html About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com 18/06/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Rasi-Seeds-and-Evogene-to-Collaborate-on-Improving-Key-Traits-in-Rice Evofuel to present at the 'European Biodiesel 2012' International conference in Krakow, Poland on June 14, 2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evofuel-to-present-at-the-European-Biodiesel-2012-International-conference-in-Krakow-Poland-on-June-14-2012 Assaf Oron, General Manager at Evofuel, is to present at the European Biodiesel 2012 International conference dedicated to the biodiesel industry, taking place on June 13-14 at Krakow, Poland. The presentation will be held on June 14th, as part of the session 'Sustainable Feedstocks for Biodiesel Production: Current & Future Options'. Mr. Oron will present Evofuel's activity for development of 2nd generation feedstock for biofuel, and will focus on the following themes: With growing demand for biofuels in ground, aviation and maritime transportation, feedstock source is a major bottleneck, limiting availability and driving prices of biodiesel up. Evofuel is uniquely positioned to provide a viable feedstock solution for the industry by leveraging world leading plant genomic capabilities together with agro-technique expertise to enable economic, scalable and sustainable production of biofuel agricultural crops. Evofuel is focused on development of high yielding castor bean varieties, supplying the biodiesel and biojet industries, aiming at production costs equivalent to $50/barrel with potential growth on 10's of millions of hectares worldwide. Evofuel collaborates with leading agribusinesses and biofuel companies to facilitate future commercialization of its products in its key target markets, including as Brazilian SLC Agricola and Argentinean T6 Industrial. 10/06/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evofuel-to-present-at-the-European-Biodiesel-2012-International-conference-in-Krakow-Poland-on-June-14-2012 Evogene Announces Nomination of New VP Project Management & New VP Technology Expansion http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Nomination-of-New-VP-Project-Management--New-VP-Technology-Expansion REHOVOT, ISRAEL (May 23, 2012) - Evogene Ltd. (TASE: EVGN) announced today that Mr. Amos Shachar, has been named as the Company's VP Project Management, effective as of May 22th, 2012. In his new position, Mr. Shachar will be responsible for project management at Evogene, overseeing internal and customer facing activities. Mr. Shachar will replace Ms. Sharon Ayal, PhD, who has been named VP Technology Expansion. In her new position, Ms. Ayal will contribute to solidifying Evogene's opportunities to expand the use of its capabilities and technologies to new fields it's exploring, such as ag-chemicals and biotic stresses. Furthermore, Ms. Ayal will be responsible for evaluating new scientific avenues the company could expand into. "We are pleased to have Amos Shachar join our team at Evogene. The management of our various collaborations with seed company partners is a fundamental component in our ongoing operations, combining efforts by a dedicated team of project managers, researchers and bio-informaticians. We are confident that with his skills and extensive background in the field of project management, Amos will significantly contribute to the company in meeting its objectives." said Ofer Haviv, Evogene's President and CEO. "We would like to wish Amos and Sharon the best of luck in their new positions and thank Sharon for leading the project management group from its initiation to being a team of managers, which supports Evogene's multiple collaborations with our various partners. Sharon has been serving at Evogene for over eight years in various roles, such as collaboration manager, trait researcher and most recently as Program Management Officer. This vast experience will allow her to take part in structuring Evogene's future leading computational technologies and in seeking new opportunities for the company." Prior to joining Evogene, Mr. Shachar served as a Program Manager at RADiFlow, a RAD group start-up company, where he led multiyear, million dollar projects, including product planning, development, integration with complex systems and operation activities. Prior to that, Mr. Shachar held a Senior Project Manager position with Nokia Siemens Networks (2008-2011), leading large scale, multiple-team and multidisciplinary projects worldwide. He has substantial R&D development and management experience leading Software, Hardware and Testing Groups (2000-2008) in various technologies and business ventures to successful quality products. Mr. Shachar holds a B.Sc. in Communication Systems Engineering from Ben-Gurion University in Beer Sheva, Israel. 23/05/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Nomination-of-New-VP-Project-Management--New-VP-Technology-Expansion Evogene's Subsidiary, Evofuel, and T6 Industrial to Collaborate on Biodiesel Feedstock Production in Argentina http://www.evogene.com/News-Events/Press-Releases/2012/Evogenes-Subsidiary-Evofuel-and-T6-Industrial-to-Collaborate-on-Biodiesel-Feedstock-Production-in-Argentina- Rehovot, Israel and Rosario, Santa Fe, Argentina, (May 22, 2012) - Evogene Ltd. (TASE: EVGN) and T6 Industrial S.A., a leading biodiesel producer in Argentina, today announced that Evofuel Ltd., Evogene's wholly owned subsidiary, and T6 Industrial S.A., entered a collaboration for development of castor bean seeds as a sustainable and cost competitive feedstock for biodiesel production. Under the collaboration, Evofuel and T6 Industrial S.A aim to evaluate and develop Evofuel's advanced castor bean varieties, displaying high oil yield under rain-fed conditions, for commercial production in Argentina. The companies anticipate initiating field trials in Argentina as well as validating the economics and scalability of using Evofuel's castor bean varieties as a feedstock to supply T6 Industrial's biodiesel facilities. "Our announced collaboration with T6 Industrial is a strategic step towards expanding our activity into additional markets in Latin America, further to our ongoing activity in Brazil, which bears substantial opportunities for large scale commercial production of castor," stated Assaf Oron, General Manager of Evofuel. "We are excited to work with T6 Industrial to provide a viable and economically attractive feedstock solution for the biodiesel market in Argentina." "In the next three years, T6 is planning to lead the international market of 2nd generation Biodiesel; reinforcing its actual worldwide leadership in biodiesel production," declared Gabriel RÍos, General Manager of T6. "T6 Industrial has found the collaboration with Evofuel a strategic alliance in order to obtain the feedstock necessary to produce 2nd generation biodiesel," explained Andres Shocron, Financial Manager. "T6 Industrial will support Evofuel so as to achieve together a successful plantation of castor bean in specific areas of our country." According to the USDA Foreign Agriculture Service, Argentina's 2011 biodiesel production was 2.5 billion liters, with soybean oil being the main feedstock. In addition to significant fluctuations in soybean oil prices, its continuous expansion for biodiesel consumption has spurred a debate on the impact of using food crops for biofuels, raising doubts on the sustainability and long-term feasibility of relying on these sources. Evofuel's castor varieties are aimed at being highly attractive economically with currently available feedstock, such as soybean, enabling sustainable oil production at a cost equivalent to approximately $50 per barrel. About T6 Industrial T6 is an agribusiness company that adds value to the agro-industrial chain in Argentina; specialized in the Oil, Biodiesel and Glycerin Production. T6 initiated the oleo-chemical industry in 2007 with the first production of neutral oil and biodiesel plant, duplicating the production capacity up to 500.000 tons per year in 2011. Nowadays, T6 is the biggest producer of neutral oil, biodiesel and refined glycerin in the country and an important player in the international market for biofuels. In the next few years, T6 Industrial searches to lead the biodiesel market in national and international level. For additional information, please visit www.termina6.com.ar About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com About Evofuel Evofuel Ltd. is engaged in the development and commercialization of seeds for second-generation feedstock for the growing biofuel market. The company applies advanced breeding utilizing world leading plant genomics capabilities together with agro-technique expertise to improve potential biofuel feedstock and enable its efficient and sustainable large scale production. Evofuel is focused on commercialization of high yielding castor bean seeds as a cost competitive, sustainable feedstock source for Biodiesel & Biojet, initially in Brazil. Evofuel was incorporated in January 2012 as a wholly owned subsidiary of Evogene Ltd. (TASE: EVGN), a world leading developer of improved plant traits for a wide diversity of key crops through the use of plant genomics. For additional information, please visit Evofuel's Website at: www.evo-fuel.com 22/05/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogenes-Subsidiary-Evofuel-and-T6-Industrial-to-Collaborate-on-Biodiesel-Feedstock-Production-in-Argentina- Prof. Naama Barkai has joined Evogene's Scientific Advisory Board http://www.evogene.com/News-Events/Press-Releases/2012/Prof-Naama-Barkai-has-joined-Evogenes-Scientific-Advisory-Board- Rehovot, Israel - May 14, 2012 - Evogene is proud to announce that Prof. Naama Barkai has joined its scientific board, commencing on May 14, 2012.Evogene's Scientific Board now consists of four members, including Prof. Avraham Levy, Prof. James Birchler and Prof. Gad Galili. Prof. Naama Barkai a professor in the department of Molecular Genetics and Physics of Complex Systems at the Weizmann Institute of Science in Rehovot, Israel. Her research is at the interface between mathematics and biology and understanding the biological constraints that are imposed on a particular system, and the impact of those constraints on the structural design of the network while developing novel solutions for fundamental biological problems, such as nutrient homeostasis systems and the organization of the cellular transcription programs. Prof. Barkai's group also analyzes networks of gene expression in yeast using microarrays. In 2008, Prof. Naama Barkai was elected a member of the European Molecular Biology Organization (EMBO) and received the FEBS/EMBO Women in Science Award. For additional information on Evogene's Scientific Board please visit: http://www.evogene.com/About-Us/Scientific-Advisors 16/05/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Prof-Naama-Barkai-has-joined-Evogenes-Scientific-Advisory-Board- Evogene Reports First Quarter 2012 Financial Results http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-First-Quarter-2012-Financial-Results Rehovot, Israel - May 15, 2012 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the first quarter, ended March 31, 2012. Ofer Haviv, Evogene's president and CEO, stated: "I am pleased to report that during the past quarter, we continued to successfully meet the targets under our various collaborations with multinational seed companies, including Monsanto, Bayer CropScience and Dupont. These collaborations focus on improving key plant traits for the world's major food crops through the application of Evogene's computational genomics technologies. With respect to our on-going extensions and enhancements of our genomics technologies, during the past quarter we launched an advanced version of ATHLETE TM 4.0 and continued to invest in further development of our Gene2ProductTM and EvoBreedTM platforms. Also, in order to provide the required infrastructure for our continuing growth, we completed a greater than 50% expansion of our R&D facilities, primarily laboratories and plant growth facilities; along with a greater than 30% increase in our professional staff, from 115 people as of the end of 2010 to 150 today. With respect to data generation, capture and analysis, we continued to make substantial investments. These investments are largely focused on establishment of multiple field experiments, automated data collection directly from the field and further enhancing Evogene's capabilities as one of the world leading companies in 'big-data' management of plants genomics." Mr. Haviv continued "In addition, we are continuing to create value through additional growth engines, leveraging Evogene's unique plant genomics capabilities - in the past quarter, we announced the creation of Evofuel as a wholly owned subsidiary. In light of the promising business and scientific viability that this activity has shown, all of Evogene's biofuel program currently focused on Brazil as a main market for the development and commercialization of our castor bean varieties, have now been transferred to this new subsidiary." Revenues for the first quarter of 2012 increased approximately 24% to $4.2 million, compared to $3.4 million for the same period in 2011. Evogene's current revenues consist primarily of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Cost of Revenues include expenses related to the support of our on-going activities under our collaborations with seed companies, all of which provide for future milestone and royalties revenues. Cost of Revenues for the first quarter of 2012 was $2.1 million, compared to $1.7 million for the same period in 2011. This increase in Cost of Revenues primarily relates to the extension of our collaboration with Monsanto. Research & Development expenses for the first quarter of 2012, which do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues, were $1.5 million. This compared to $1.2 million for the same period in 2011. Research & Development expenses mainly relate to the development of new computational technology platforms, expansion of internal research projects and to support our wholly owned subsidiary, Evofuel. Loss from ordinary operations for the first quarter of 2012 was $0.1 million, compared to a loss from ordinary operations of $0.4 million for the same period in 2011. Financial expenses during 2011 due to publicly traded warrants: During the first two quarters of calendar 2011, Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007. As of May 31, 2011, the date of expiration of these warrants, over 99.9% of which had been exercised. While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares resulted in non-cash financial income/expense due to their revaluation on our statements of comprehensive profit or loss. These non-cash financial income/expense due to publicly traded warrants were no longer applicable after the second quarter of 2011. Total Comprehensive profit for the first quarter of 2012 was $0.5 million, compared to a total comprehensive profit of $1.1 million for the same period in 2011. Total comprehensive profit for the first quarter of 2012 does not include any non-cash financial affects due to exercise of most of the publicly traded warrants as stated above, while the comprehensive profit for the first quarter of 2011 includes $1.0 million of such non-cash financial revenues. As of March 31, 2012, Evogene had approximately $57 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to approximately $59 million, as of December 31, 2011. 15/05/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-First-Quarter-2012-Financial-Results Evogene Announces Launch of ATHLETE 4.0 Gene Discovery Computational Technology http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Launch-of-ATHLETE-40-Gene-Discovery-Computational-Technology Rehovot, Israel - April 4, 2012 - Evogene Ltd. (TASE: EVGN) announced today the launch of ATHLETE® 4.0, a new version of its technology for discovery of novel genes for improving plant performances. To date, Evogene has discovered through earlier versions of the ATHLETE® and validated in plants over 3,000 novel genes relating to key plant traits, such as yield, drought tolerance, fertilizer utilization and plant disease resistance. Patents have been filed or granted with respect to all of these discoveries. The new ATHLETE® 4.0 relies on a series of proprietary tools and algorithms, which substantially accelerate Evogene's gene discovery capabilities by integrating multiple levels of plant data types. ATHLETE® 4.0 incorporates genomic data from over 200 plant species and more than 4,000,000 genes, thus enabling a more comprehensive and accurate cross-species discovery capabilities. As with previous versions of ATHLETE®, this version utilizes Evogene's powerful Information Technology (IT) infrastructure, which has been built to support one of the largest agbio-data sets worldwide. Among the new version's proprietary capabilities: EvoCAT - ATHLETE® 4.0 incorporates an enhanced version of Evogene's innovative technology for gene clustering and sequencing assembly, EvoCAT (Evogene Clustering & Assembly Toolbox). This new version of EvoCAT improves Evogene's ability to integrate sequence data from 'next generation' sequencing platforms, which produce huge amounts of sequence data in short DNA sequence fragments )one-tenth the length of previously available data(, representing a major challenge for gene clustering and assembly. To address this challenge the new version of EvoCAT can analyze up to 1,000 times more such sequences. eTrait - ATHLETE® 4.0 incorporates a new version of eTrait - a platform for phenotypic data storage and analysis. This new version represents an additional step towards Evogene's goal to capture accurate, computerized phenotypes directly from the field. The phenotypic data includes numerous plant quantifiable traits, such as leaf color, number of leaves and stem length, which are stored in the platform in a uniform and systematic manner according to the season, plant species, etc. This provides a high level of compatibility data for statistical analysis. The outcome is improved ability to identify which genomic components contribute most to trait improvement and, by the cross analysis of phenotypic data with genomic data, more accurate and rapid discovery of genes. Proteomics - ATHLETE® 4.0 incorporates additional proteomics data, which provides more accurate information about the conditions and quantities of the various proteins produced in the plant. Dr. Hagai Karchi, Evogene's EVP Development and CTO, stated: "ATHLETE® 4.0 provides us with an even more powerful engine to gain valuable knowledge from the enormous amounts of data, both being generated from our field experiments and data becoming publicly available, in order to perform targeted gene discovery and provide our existing and future partners with high quality genes to improve desired plant traits. As a leading company in our field, a key objective being pursued by our scientists - in parallel with their efforts pursuant to our various collaborations with major seed companies - is to continue to invest both in improvements to our broad range of existing capabilities and in new capabilities. The launch of ATHLETE® 4.0 is an excellent example of our success with respect to this objective since this next generation platform contains a significant number of new and improved proprietary technologies." About ATHLETE® ATHLETE® is Evogene's proprietary computational technology for plant gene discovery. ATHLETE® is designed for addressing Evogene's evolving requirements and capacity for gene discovery, thus taking advantage of the data explosion of the 'omics' era for the development of improved seeds and plants. The ATHLETE® is comprised of proprietary algorithmic tools and data mining concepts, resulting in the discovery of a rapid and reliable list of genes relevant to each target trait. The technology is broadly applicable to different traits and crops, according to the needs of our various internal programs and partnerships. Additional information regarding ATHLETE® is available at: www.evogene.com/Technology/Computational-Technologies 04/04/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Announces-Launch-of-ATHLETE-40-Gene-Discovery-Computational-Technology Evogene Expands Research and Development Facilities by Over 50 Percent http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Expands-Research-and-Development-Facilities-by-Over-50-Percent- Rehovot, Israel - April 2, 2012 - Evogene Ltd. (TASE: EVGN) announced today completion of an expansion program of its R&D facilities, resulting in a greater than 50% increase in the company's gene validation & plant growth capacity. The expansion was conducted in two stages: the first stage included reconstruction of new molecular and tissue culture laboratories; and the second stage included substantial expansion of Evogene's greenhouse site. The total costs for this expansion program was approximately $4.5 million The first stage of the program included construction of over 1,100 m2 state-of-the-art molecular and tissue culture laboratories, upgrading and expanding the previous area amount by over 60%. The new laboratories were planned and equipped with Evogene's custom tailored automated instruments for lab processes, with emphasis on cost optimization, international environmental safety standards and energy savings. The second stage of the program included expansion of Evogene's greenhouse site and was focused on doubling the area amount in the Gezer regional area, located nearby Rehovot. This enables Evogene to substantially increase its plant growth and validation capacity. Evogene's plant validation system is today comprised of two key model plants- Arabidopsis for dicots and Brachypodium for monocots. In addition, Evogene has initiated an additional building program to provide new office space to support its personnel increase, mainly trait researchers and computational genomics teams. During the past three years, the company more than doubled its employment level. The new office and related facilities are budgeted to cost approximately $1,000,000. "We are very pleased with the availability of this additional and substantial expansion of our R&D facilities in support of our continuing growth in programs, both internal and under partnerships with seed companies, as well as personnel. In this regard, we see both a continuing increase in the potential for partnerships, and the opportunity to substantially increase the amount and type of research activities that we are capable undertaking with our computational genomic platforms - ATHLETE®, EvoBreed® and Gene2Product®," stated Assaf Kacen, EVP of Technology Platform at Evogene. "With this recent expansion, we are able to clone, transform to model plants and validate in our greenhouses over 1,000 genes per year, thus providing the capacity for continuing rapid growth and expansion." 02/04/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Expands-Research-and-Development-Facilities-by-Over-50-Percent- Evogene Reports Fourth Quarter and Year End 2011 Financial Results http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Fourth-Quarter-and-Year-End-2011-Financial-Results Rehovot, Israel - March 20th, 2012 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2011. Ofer Haviv, Evogene's president and CEO, stated: "During the past year, we were pleased to see key achievements and continued growth in all four current fields of Evogene focus, each of which strongly relies on our unique and proprietary plant genomics technologies and capabilities." Mr. Haviv continued, "With respect to these focus areas, first and foremost, we enhanced our world leading position in the field of improved yield and abiotic stress tolerance traits for key agricultural crops, and continued to provide our partners with genomic discoveries under existing, new and expanded collaborations. Second, in the field of disease and other biotic stress resistance traits, we significantly increased our activities with a new multi-year agreement. Thirdly, having demonstrated economic viability, we created a wholly owned subsidiary to consolidate and expand our activities related to development of non-food feedstock for biofuels. And in our fourth and most recent focus area, agro-chemicals, we are completing a strategic plan for leveraging our technologies and see opportunities for us to develop products for this very substantial industry." Mr. Haviv concluded, "In order to accomplish these goals and to provide for future corporate growth, during the past two years, we more than doubled our professional team and substantially expanded our facilities to create one of the world's largest gene discovery infrastructures. It is important to note that, while accomplishing all of this, most of which relates to potential future revenues and profits, we continued to substantially strengthen our financial base with increased revenues and other cash sources, and ended the year with $59 million in cash resources." Highlights during the year included: Early extension of the collaboration with Monsanto Company, focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola. The collaboration was extended in an additional year and includes Evogene's Gene2ProductTM computational technologies. This extension follows successful completion of the collaboration's third year out of the originally five year program, initiated in 2008. Multiyear collaboration with DuPont to improve resistance to soybean rust, one of the most devastating fungal diseases in soybean. This collaboration further builds on an on-going partnership between the companies, for improving drought tolerance in corn and soybean. Milestone achievement in wheat collaboration with Bayer CropScience AG, signed on December 2010, which utilizes Evogene's ATHLETETM and EvoBreedTM computational technologies. Under this milestone, over 200,000 wheat SNPs were identified as part of the companies' efforts to introduce improved wheat varieties. Advancement of Evogene's yield and drought tolerance corn trait by Biogemma (from the Limagrain Group) to the next phase of development - Phase II. Establishment of Evofuel, a wholly owned subsidiary that focuses on development and commercialization of second-generation feedstock for biofuel. This year we also announced expansion of our agreement with SLC Agricola in Brazil for the development of castor bean seeds as a cost competitive feedstock for biofuels. Establishment of a dedicated team to design a road-map for implementing our genomic technologies and plant science to develop innovative chemicals for agriculture. Expansion of the company's R&D facilities, including laboratories and greenhouse facilities, totaling $4.4 million. This expansion is aimed at increasing the company's plant validation & growth efficiency and capacity by over 50%. Increase of 30% in the company's personnel, mainly driven by appointment of new plant researchers and computational genomics personnel. As of December 31, 2011, Evogene had approximately $59 million in cash, cash equivalents, cash deposits and short-term marketable securities. This includes approximately $16.6 million from the exercise in May 2011 of the then outstanding publicly traded warrants and $12 million from an equity investment made on January 2011 by Bayer CropScience AG pursuant to the wheat collaboration agreement. Revenues for 2011 were approximately $15 million, compared to $12.6 million for the same period in 2010, representing revenues growth of approximately 19%. Revenues for the fourth quarter of 2011 were $4.7 million, approximately equal to the same period for 2010. At present, revenues consist primarily of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Cost of Revenues include expenses related to support of our on-going activities under our collaborations with seed companies, each of which provides for future milestone and royalties revenues. Cost of Revenues for 2011 was $8.2 million, compared with $5.8 million for the same period in 2010. Cost of Revenues expenses for the fourth quarter of 2011 were $2.7 million, compared with $1.6 million for the same period in 2010. These increases in Cost of Revenues primarily relate to the addition of the collaboration agreements with Bayer CropScience, signed on December 2010, and the extension of our collaboration with Monsanto. Research & Development expenses for 2011, which do not include expenses incurred in support of on-going collaborations which, as stated above, are accounted for as Cost of Revenues, were $6.4 million, compared with $5.5 million for the same period in 2010. Research & Development expenses for the fourth quarter of 2011 were $1.7 million, compared with $1.9 million for the same period in 2010. These increases in Research & Development expenses for the year 2011 mainly related to development of new genomic technologies, including Gene2ProductTM, and to support our biofuel activity. Loss from ordinary operations for 2011 was $3.2 million, compared to a loss from ordinary operations of $1.9 million for the same period in 2010. Loss from ordinary operations for the fourth quarter of 2011 was $0.8 million, compared to a profit from ordinary operations of $0.2 million for the same period in 2010. Financial expenses due to publicly traded warrants: During the first half of 2011, Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007. 99.9% of these warrants were exercised by May 31, 2011, their date of expiration. While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares resulted in non-cash financial income/expense due to their revaluation on our statements of comprehensive profit or loss. These non-cash financial income/expense due to publicly traded warrants were no longer applicable after the second quarter of 2011. Total Comprehensive profit for 2011 was $0.6 million, which includes $3.7 million of non-cash financial income due to publicly traded warrants, as described above, compared to a total comprehensive loss of $7.0 million, including $5.4 million of such non-cash financial expenses for the same period in 2010. Total comprehensive loss for the fourth quarter of 2011 was $0.9 million, compared to a comprehensive loss of $3.0 million for the same period in 2010. Total comprehensive loss for the fourth quarter of 2011 does not include any non-cash financial affects due to exercise of most of the publicly traded warrants as stated above, while the comprehensive loss for the fourth quarter of 2010 includes $3.2 million of such non-cash financial revenues. As of December 31, 2011, Evogene had approximately $59 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to approximately $35.8 million as of December 31, 2010. 20/03/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Reports-Fourth-Quarter-and-Year-End-2011-Financial-Results Evogene Awarded First Place in the 'Safety and Hygiene in Agriculture' Contest for 2011 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Awarded-First-Place-in-the-Safety-and-Hygiene-in-Agriculture-Contest-for-2011- Evogene Ltd. (TASE: EVGN) was awarded first place by Israel's national public Institute for Occupational Safety and Hygiene (IIOSH) in a contest for safety and hygiene at work in the field of agriculture for the year 2011. Evogene was chosen from among over 50 Israeli agricultural sites following an extensive screening process. Evogene's company representatives received the award on January 24, in a ceremony that took place in Jerusalem at the Knesset, the house of representatives of the State of Israel, in the presence of the Speaker of the Knesset, Mr. Reuven Rivlin and the Minister of Industry, Trade and Labor, Mr. Shalom Simhon. Compliance with safety criteria is a mandatory element of the ongoing work at Evogene; however Evogene goes a step beyond to ensure a safe work environment for its employees. Over the last year, steps in this aspect included construction of a new laboratory facility with unprecedented safety standards, ergonomic assessment of work stations, and the amounts of hazardous substances were reduced and replaced with safer alternatives. Mr. Assaf Kacen, Evogene's EVP Technology Platform stated: "Evogene's Human Resource is one of our greatest assets. We place great emphasis and efforts on safety and welfare issues, which allow the company to maintain the security of its workers and a safe work environment, while achieving its commercial targets." About the Israel Institute for Occupational Safety and Hygiene (IIOSH) The IIOSH is Israel's national public institution concerned with the workplace safety and health. Its mission includes: (j) safety training and promotion; (ii) assistance in selecting safety representatives, organizing safety committees and guiding their activities; (iii) assisting the Labor Inspectorate in its activity and (iv) advising the Minister of Labor and Welfare on the matters concerning occupational safety and hygiene. View Video Clip Presentation of Safety and Welfare at Evogene 24/01/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-Awarded-First-Place-in-the-Safety-and-Hygiene-in-Agriculture-Contest-for-2011- Evogene's New Recruitments Expand Its Scientific Team http://www.evogene.com/News-Events/Press-Releases/2012/Evogenes-New-Recruitments-Expand-Its-Scientific-Team Evogene (TASE:EVGN) announced today the appointment of 20 new employees in the scientific teams. This Human Resource expansion in the R&D was carried out in Evogene's core scientific areas: Computational Genomics, Development of New Core Technologies, Trait Improvement and Experimental Genomics. 14 of the new team members hold PhD degrees. Ofer Haviv, Evogene's president and CEO stated: "The recruitment of 20 new employees in the scientific and business teams, being announced today, is targeted at supporting mainly our computational genomics capabilities and the scientific research expertise. This growth in Human Resource is expected to enable us to pursue our activities under the collaborations with world leading seed companies that the company has committed to, which significantly increased in the second half of 2011, the further development of new computational technologies with an emphasis on Gene2ProductTM and EvoBreedTM and the preparation for entries into new business fields, such as Ag-chemicals." 10/01/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogenes-New-Recruitments-Expand-Its-Scientific-Team Evogene to Establish Evofuel Ltd. for Developing Advanced Feedstock for Biofuel http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-Establish-Evofuel-Ltd-for-Developing-Advanced-Feedstock-for-Biofuel- Rehovot, Israel (January 1st, 2012) - Evogene Ltd. (TASE: EVGN) today announced that it is establishing Evofuel, a wholly owned subsidiary, to focus on developing seed for advanced second-generation feedstock for biofuel. Included in the activities that are being transferred from the parent company to Evofuel is the development and commercialization of castor bean varieties for Brazil as well as the biofuel research and development activities located in Israel. World production of biodiesel has been substantially increasing in the past years, reaching over 20 billion liters in 2010, however feedstock supply falls short of meeting the required demand and industry economic and sustainability needs. In addition to being the limiting factor for future growth, feedstock, which currently relies mainly on edible oils, such as soybean and canola, currently constitutes approximately 80% of biodiesel production costs. Evogene's biofuel activity, initiated in 2007, targets the development of second generation feedstock to serve as a sustainable, viable and cost efficient source of oil for the growing biodiesel industry. In addition to its activity for development and of advanced castor bean seed, Evofuel intends to broaden its activity to additional potential feedstocks for the biodiesel, biojet and bioethanol markets. "With the biofuel industry's continued growth and tremendous demand for cost competitive feedstock, there is a strong and immediate need for a solution based on designated second generation seed products. The establishment of Evofuel as a separate company, strongly positions it to address this substantial un-met need." stated Ofer Haviv, Evogene's President and CEO, "We are reinforced by the progress and results of our castor seed in Brazil and believe that access to Evogene's leading plant genomics capabilities will provide Evofuel with commercial advantages and opportunities in relevant markets." Evogene recently announced successful completion of field trials for its advanced castor varieties in Brazil in cooperation with SLC Agricola, a leading agribusiness in Brazil. Based on results obtained demonstrating improved yield potential and performance under rain-fed conditions in northeast Brazil, the companies expanded their activity in order to accelerate development of best performing varieties and agronomical practices suitable for commercial scale production. 02/01/2012 http://www.evogene.com/News-Events/Press-Releases/2012/Evogene-to-Establish-Evofuel-Ltd-for-Developing-Advanced-Feedstock-for-Biofuel- Evogene Expands Biofuel Activity in Brazil with SLC Agricola http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Expands-Biofuel-Activity-in-Brazil-with-SLC-Agricola- Expanded Agreement follows Successful Completion of Field Trials Rehovot, Israel and Porto Alegre, Rio Grande Do Sul, Brazil, (December 12th, 2011) -Evogene Ltd. (TASE: EVGN) and SLC Agricola (Bovespa: SLCE3; ADR's: SLCJY; Bloomberg: SLCE3:BZ; Reuters: SLCE3.SA), a leading agribusiness company in Brazil, today announced expansion of their agreement for the development of castor bean seeds as a cost competitive feedstock for biofuels. This expansion follows successful completion of field trials for such varieties in northeast Brazil during 2011. The collaboration between Evogene and SLC Agricola, initiated in 2010, is focused on developing advanced castor seed displaying high oil yield under rain-fed conditions and suitable for sustainable and commercial production in Brazil. In recently completed field trials, proprietary castor varieties developed by Evogene demonstrated improved yield potential and performance compared to existing cultivars. Under the expanded agreement, the companies will continue to collaborate on evaluating Evogene's castor varieties in SLC's farm locations in northeast Brazil to determine the best performing varieties and agronomic practices suitable for commercial scale production. "We are excited with the results achieved and look forward to continuing our joint efforts with SLC Agricola, one of the leading soybean and cotton producers in Brazil. Combining Evogene's world leading capabilities for crop improvement with SLC's agricultural production systems is expected to strongly position our castor varieties as a sustainable and economically viable feedstock solution for the growing biodiesel and biojet markets," stated Assaf Oron, EVP Strategy & Business Development at Evogene. "And, with Brazil's leadership and long term commitment to biofuel as well as its well established agriculture industry, there is a substantial opportunity for large scale commercial production of castor in Brazil." "We are developing a new alternative crop to plant as a second crop after the soybean harvest. Also, it can be another source of oil to maximize the production of biodiesel at the cotton seed oil industry," stated AurÉlio Pavinato, Chief Operator Officer of SLC AgrÍcola S.A." Evogene's castor varieties are targeted at being highly competitive with currently available feedstock for biodiesel, enabling oil production at a cost equivalent to approximately $50 per barrel, compared to much higher costs based on production from existing food crops, such as soybean and canola oils. Furthermore, biodiesel produced from the Evogene's castor varieties is expected to substantially reduce Greenhouse Gas (GHG) emissions - by over 75% compared with conventional diesel, as demonstrated by a Life Cycle Assessment (LCA) conducted. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. About SLC Agricola SLC Agricola SA. is one of the largest land owners and agricultural producers in Brazil, being also the first in its sector (grains and cotton) to list its shares in a stock exchange. It focuses of the production of cotton, soybean and corn, and also on the acquisition and development of farmland in the country for future sale. The Company currently operates 13 production units, in six different states, totaling 250 thousand hectares of planted area at the 2011/12 crop year. The Company's business model is based on a large-scale, modern production system, with standardized production units, thoroughly up-to-date technology and rigorous cost controls, underpinned by social and environmental responsibility. 12/12/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Expands-Biofuel-Activity-in-Brazil-with-SLC-Agricola- Monsanto and Evogene Extend Collaboration on Yield and Stress Research http://www.evogene.com/News-Events/Press-Releases/2011/Monsanto-and-Evogene-Extend-Collaboration-on-Yield-and-Stress-Research Collaboration Adds Evogene's Gene2ProductTM Computational Technologies ST. LOUIS, MO, USA and REHOVOT, ISRAEL (November 29, 2011) - Monsanto Company (NYSE:MON) and Evogene Ltd. (TASE: EVGN) announced today a one-year extension to their five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola. The companies recently announced the successful completion of the collaboration's third year. The collaboration's gene discovery activities to date have been based on Evogene's ATHLETETM computational technology. As part of the extension, Evogene will add its Gene2ProductTM computational technologies to its gene discovery program, offering an additional approach for enhancing trait efficacy and the development of candidate genes identified under the collaboration. Ofer Haviv, Evogene's President and CEO stated, "We are delighted by this extension of our joint work with Monsanto and in particular with the addition of our Gene2Product computational technologies. We expect that by bringing together Monsanto's development expertise and these new Evogene technologies, in addition to those already utilized in the collaboration, the companies will be able to further address some of the key challenges that the seed industry is facing in the discovery and development process for biotechnology products in agriculture." "Continued agricultural innovation is the key to meeting growing global demand, which is why productive collaborations like this one are critical," added Bob Reiter, Vice President and Global Lead of Biotechnology for Monsanto Company. "By combining Evogene's innovative gene discovery technologies with Monsanto's trait development expertise, we'll ultimately be able to better deliver products to help farmers increase their productivity." Additional terms of the collaboration include: Evogene will continue to provide Monsanto with candidate genes discovered by Evogene's computational technologies that are predicted to improve yield, fertilizer utilization and a plant's reaction to environmental stress. The genes will be validated by Evogene in model plants. Monsanto receives exclusive license rights to such candidate genes delivered by Evogene for use in corn, soybean, canola, and cotton. As stated above, Evogene will now begin to apply its Gene2ProductTM computational technologies to optimize trait efficacy and the product development process. Evogene will receive additional research payments related to this addition to the collaboration. Successful candidate genes that emerge from the collaboration will be commercialized by Monsanto through its branded seed and trait licensing businesses, with Evogene entitled to receive both development milestone payments and royalties. As part of the original agreement, Monsanto agreed, via a put option exercisable by Evogene, to invest $12 million toward additional equity in Evogene. This arrangement remains in place under a new put option that is exercisable at $12 per share at a later date. About Monsanto Company Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter® at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at www.monsantoblog.com, or subscribe to our News Release RSS Feed. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. These technologies include ATHLETETM for gene discovery; Gene2ProductTM for improving trait efficacy and probability of successful development of biotechnology seed products; and EvoBreedTM for breeding enhancement. Evogene's plant genomics capabilities combine high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 29/11/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Monsanto-and-Evogene-Extend-Collaboration-on-Yield-and-Stress-Research Evogene Reports Third Quarter 2011 Financial Results http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Third-Quarter-2011-Financial-Results Rehovot, Israel - November 22nd, 2011 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the third quarter ended September 30th, 2011. Ofer Haviv, Evogene's President and CEO, stated "We are very proud of our continuing achievements under our collaborations with major seed companies. These achievements, such as the recent milestone reached under the collaboration with Bayer CropScience for wheat and the successful completion of the third year of our five-year collaboration with Monsanto, are providing further evidence of Evogene's position as a world leader in discovering genes targeted at improving yield and environmental stress traits. In addition to our activities in these key areas of abiotic stress, we are allocating significant resources to both expanding our plant genomic technologies to address additional challenges in product development, and to leveraging these capabilities into other major commercial areas, where they can provide the basis for successful new products." Mr. Haviv continued, "With respect to the expansion of our genomic technologies, we believe that the addition of our recently announced Gene2ProductTM technology will add significant value to our gene discovery capabilities both in our current areas of focus and in new areas. One such area of focus relates to plant diseases and other biotic stress resistance, as demonstrated by the expansion of our collaborative work with Pioneer Hi-Bred to address rust resistance in soybean, which was announced yesterday." Mr. Haviv concluded, "We look forward to reporting additional achievements in these and other areas as we further develop and expand our unique company." Highlights for this quarter with respect to our collaborations include: Expansion of our relationship with Pioneer Hi-Bred, a DuPont Business, addressing important soybean traits, by the signing of a new multiyear collaboration, for improving resistance to soybean rust, one of the most devastating fungal diseases in this important crop. Milestone achievement under our five-year wheat collaboration with Bayer CropScience AG, signed in December 2010, which includes identification of over 200,000 single-nucleotide polymorphisms ("SNP's") in the wheat genome. Joint announcement of the successful completion of the third year of collaboration with Monsanto, covering yield and environmental stress in corn, soybean, cotton and canola. Revenues for the first nine months of 2011 were $10.2 million, compared to $7.9 million for the same period in 2010. Revenues for the third quarter of 2011 were $3.4 million, compared to $2.6 million for the same period in 2010. At present, revenues consist primarily of research and licensing revenues generated under the company's various collaboration agreements. Research & Development expenses for the first nine months of 2011 were $4.6 million, compared to $3.7 million for the same period in 2010. Research & Development expenses for the third quarter of 2011 were $2.0 million, compared to $1.5 million for the same period in 2010. These increases mainly relate to the development of the Gene2ProductTM computational technology, increased efforts focused on additional traits, mainly biotic tolerance traits, and the biofuel program. In addition, Cost of Revenues consists primarily of certain research and development expenses allocated to deliverables under our various collaborations. Such Cost of Revenues for the first nine months of 2011 were $5.5 million, compared to $4.2 million for the same period in 2010. Cost of Revenues for the third quarter of 2011 were $2.0 million, compared to $1.5 million for the same period in 2010. Loss from ordinary operations for the first nine months of 2011 was $2.4 million, compared to loss from ordinary operations of $2.1 million for the same period in 2010. Loss from ordinary operations for the third quarter of 2011 was $1.3 million, compared to loss from ordinary operations of $1.2 million for the same period in 2010. Financial expenses due to publicly traded warrants: Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007, 99.9% of which were exercised by May 31, 2011 (the warrant expiry date). While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares results in non-cash financial income (expense) due to their revaluation on our statements of comprehensive profit or loss. Total Comprehensive profit for the first nine months of 2011 was $1.6 million, which includes $3.7 million of non-cash financial income due to publicly traded warrants, as described above, compared to a total comprehensive loss of $4.0 million, including $2.2 million of such non-cash financial expenses, for the same period in 2010. Total comprehensive loss for the third quarter of 2011 was $2.3 million, compared to a total comprehensive loss of $3.6 million, which includes $3.1 million of such non-cash financial expenses for the same period in 2010. Also as explained above, these non-cash financial income and/or expense amounts due to publicly traded warrants will not be applicable for future quarterly results. As of September 30, 2011, Evogene had approximately $60 million in cash and cash equivalents, marketable securities and short-term deposits, compared to approximately $36 million as of December 31, 2010. The September 30, 2011 amount includes $16.6 million from the exercise of the previously outstanding publicly traded warrants and $12 million from an equity investment in the Company by Bayer CropScience pursuant to a wheat collaboration agreement signed in December 2010. 22/11/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Third-Quarter-2011-Financial-Results DuPont and Evogene Enter Multiyear Collaboration for Soybean Rust Resistance http://www.evogene.com/News-Events/Press-Releases/2011/DuPont-and-Evogene-Enter-Multiyear-Collaboration-for-Soybean-Rust-Resistance Collaboration Expands Existing Relationship to Address Important Soybean Traits DES MOINES, Iowa, and REHOVOT, Israel, November 21st, 2011 - DuPont and Evogene Ltd. today announced a multiyear collaboration to improve resistance to soybean rust, one of the most devastating fungal diseases in soybean. Under the agreement, DuPont business, Pioneer Hi-Bred, and Evogene will collaborate to develop soybean varieties displaying in-plant resistance to rust. Financial terms of the agreement were not disclosed. Soybean is one of the world's most important crops, supplying protein for human and animal consumption and feedstock for oil production. Soybean rust is a severe fungal disease, which causes significant yield losses that can reach up to 80 percent of the affected field. It is estimated that the yield losses caused by soybean rust exceed $1.5 billion annually. Development of new rust-resistant soybean varieties would help growers protect harvestable yield against rust, ultimately improving productivity of agriculture. DuPont and Evogene will jointly generate a genomic database tailored to soybean rust resistance. Evogene will utilize its computational genomic technology, the ATHLETE®, to identify novel genes predicted to improve soybean rust resistance. Pioneer will use proprietary technologies to evaluate the genes in transgenic soybeans, and may advance leads for further development and commercialization. Evogene will be entitled to receive milestone payments and royalties based on the sales of resulting products. "Strong disease resistance has been a cornerstone to the growth of our Pioneer soybean business," said John Bedbrook, vice president, DuPont Agricultural Biotechnology. "Unique science from Evogene is going to help us more effectively tackle soybean rust." "In addition to our well-established and leading position providing novel genes for improving crop yields under normal and abiotic stress conditions, such as drought and reduced fertilizer utilization, we are now increasing our efforts with respect to biotic stress conditions, where the crops are attacked by insects, fungi and other stresses," said Ofer Haviv, Evogene's president and CEO. "Therefore, we are very pleased to enter into this collaboration with Pioneer, one of the world's largest seed businesses and a leading provider of soybean seeds, to utilize our advanced trait discovery technologies to address the important biotic stress condition of soybean rust." Pioneer and Evogene have received an approval in principle for partial funding of the project from the BIRD Foundation, a bi-national foundation funded by the Israeli and American governments, which supports and encourages cooperation between Israeli and American companies in various areas of technology, and provides assistance in locating strategic partners from both countries for developing joint products. About Pioneer Hi-Bred Pioneer Hi-Bred (www.pioneer.com), a DuPont business headquartered in Des Moines, Iowa, is the world's leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere. Science with Service Delivering Success®. About DuPont DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit www.dupont.com. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state-of-the-art biotechnology and advanced breeding methods. Evogene is collaborating with world-leading seed companies to introduce its improved plant traits into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 21/11/2011 http://www.evogene.com/News-Events/Press-Releases/2011/DuPont-and-Evogene-Enter-Multiyear-Collaboration-for-Soybean-Rust-Resistance Evogene to present at the 'WATEC ISRAEL 2011' International conference in Tel-Aviv on November 15 2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-to-present-at-the-WATEC-ISRAEL-2011-International-conference-in-Tel-Aviv-on-November-15-2011 Assaf Oron, EVP Strategy & Business Development at Evogene, is to present at the WATEC ISRAEL 2011 International conference on water technologies, renewable energy and environmental control, taking place on November 15-17 at Tel Aviv exhibition center. The presentation will be given on November 16, as part of the session ',the Israeli model for crossing the valley of death - renewable energy, biofuel, water & energy nexus technologies'. Mr. Oron will present Evogene's Biofuel program, aimed at developing and commercializing seeds of second-generation feedstock to serve as a sustainable, viable and cost efficient source of oil for the growing biodiesel and biojet industries. Evogene's Biofuel program is currently focusing on developing castor bean varieties, displaying high oil yield under rain-fed conditions, without competing with food crops, and suitable for fully mechanized management. Utilizing advanced plant breeding and agro- technique tools, Evogene's improved castor bean varieties are expected to substantially improve the economics of biodiesel, enabling oil feedstock production cost equivalent to approximately $50 per barrel, compared to an equivalent soybean oil price of $150 per barrel today. 28/10/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-to-present-at-the-WATEC-ISRAEL-2011-International-conference-in-Tel-Aviv-on-November-15-2011 Bayer CropScience and Evogene Achieve Milestone in Wheat Genetics Research http://www.evogene.com/News-Events/Press-Releases/2011/Bayer-CropScience-and-Evogene-Achieve-Milestone-in-Wheat-Genetics-Research- Over 200,000 SNPs identified in wheat genome as part of effort to improve wheat traits through advanced breeding Rehovot, Israel, September 26th, 2011 -Evogene Ltd. (TASE:EVGN) and Bayer CropScience AG have reached a milestone in their joint research collaboration in wheat. Utilizing Evogene's proprietary tools, more than 200,000 single-nucleotide polymorphisms ('SNPs') across the wheat genome were identified as part of the companies' efforts to improve wheat through the application of advanced breeding techniques. SNPs are single-nucleotide substitutions of one base in the genome and a powerful type of molecular marker for trait improvement. Identifying SNPs across the wheat genome is an essential step towards improving desired traits in wheat through advanced breeding. The wheat genome is both complex and very large - approximately five times the size of the human genome - which creates a major challenge for breeders in implementing advanced breeding techniques. The identification of a significant number of SNP markers improves the overall understanding of the wheat genome and therefore facilitates the utilization of this knowledge to deliver desirable improvements in wheat. In December 2010, Bayer CropScience and Evogene entered into a five-year collaboration, aimed at accelerating the development and introduction of improved wheat varieties. The collaboration is focusing on improving wheat yield, drought tolerance and fertilizer use efficiency utilizing a combination of advanced breeding and state of the art genetic modification methods. The successful creation of the genome-wide SNP dataset for wheat was enabled by the use of Evogene's proprietary assembly tools and algorithms for highly reliable SNP identification, designed specifically for the wheat genome. Furthermore, the dataset was obtained from a broad collection of wheat lines from multiple locations world-wide. This SNP dataset has significantly boosted the genetic data available for the efforts of the collaboration. This dataset is being integrated into Evogene's EvoBreed technology platform to broaden and accelerate the implementation of advanced breeding approaches for wheat. "We want to improve wheat to tackle issues like climate change and the decline of mineral resources used for fertilizer," said Mathias Kremer, Head of the BioScience business group of Bayer CropScience. "This research milestone is an important step towards that goal, and will enable Bayer CropScience to deliver improved wheat varieties to growers sooner." Ofer Haviv, Evogene's President & Chief Executive Officer stated: "We are very proud of this technological breakthrough, which we achieved in a relatively short period. The identification of the SNPs is a key to enhancing native traits utilizing genomics-guided, efficient and precise breeding tools. Our newly-discovered SNP dataset significantly expands our understanding of the wheat genome, which we anticipate will facilitate our joint work with Bayer CropScience to introduce improved wheat varieties." About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 6.830 billion (2010), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 20,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. These technologies include ATHLETE for gene discovery; Gene2Product for improving trait efficacy and probability of successful development of biotechnology seed products; and EvoBreed for breeding enhancement. Evogene's plant genomics capabilities combine high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 26/09/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Bayer-CropScience-and-Evogene-Achieve-Milestone-in-Wheat-Genetics-Research- Evogene and Monsanto Mark Completion of Third Year of Five-Year Collaboration http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-and-Monsanto-Mark-Completion-of-Third-Year-of-Five-Year-Collaboration Evogene Discovered Genes now being evaluated in Monsanto R&D Pipeline REHOVOT, ISRAEL and ST. LOUIS, MO, USA (September 22, 2011) - Evogene Ltd. (TASE: EVGN) and Monsanto Company (NYSE:MON) announced today the successful completion of the third year of their research and development collaboration. The goal of this five-year collaboration agreement is to discover genes that could enhance crop yield for farmers in corn, soybean, cotton and canola. Under the collaboration, Evogene is focused on identifying key plant genes related to yield, environmental stress, and fertilizer utilization for further evaluation and potential development and commercialization by Monsanto. During the initial three years of collaborative work, Evogene utilized its computational genomics technology, the ATHLETE, to successfully discover genes, predict, and provide validation in model plants, to address the objectives of the collaboration. A number of the genes discovered by Evogene are now undergoing evaluation in target crops in Monsanto's research and development pipeline. During the remaining two years, as more performance data for these initial genes are obtained, further discovery and validation work will also be conducted, potentially leading to even more new genes and potential product candidates for growers. "As populations grow and as diets and climates shift around the world, more than ever the global community is relying on the success of farmers in every part of the world," said Bob Reiter, Vice President and Global Lead of Biotechnology for Monsanto Company. "By partnering with research companies like Evogene, we hope to bring more tools to farmers faster than we could solely through our own internal research. We view collaborations such as the one with Evogene as central to our future success in helping farmers increase productivity. And ultimately, their success is our success." Ofer Haviv, Evogene's President and CEO stated "Our relationship with Monsanto has been a substantial and important component of our company's trait research and discovery activities during these past three years. Therefore, we are extremely pleased to see both the promising results to date and the excellent collaborative environment that has been established by our two companies. We look forward to continuing this productive collaboration as we utilize our innovative and continuously improving predictive capabilities to deliver novel genes that, under Monsanto's development program, will hopefully result in future products for farmers." About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. These technologies include ATHLETE 3.0 for gene discovery; Gene2Product for improving trait efficacy and probability of successful development of biotechnology seed products; and EvoBreed for breeding enhancement. Evogene's plant genomics capabilities combine high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. About Monsanto Company Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter® at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at www.monsantoblog.com, or subscribe to our News Release RSS Feed. This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," "scheduled," "potentially" and "intends," and they describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Cautionary Statements Regarding Forward-Looking Information: Certain statements contained in this release are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent Form 10-K Report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results. 22/09/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-and-Monsanto-Mark-Completion-of-Third-Year-of-Five-Year-Collaboration Evogene Reports Second Quarter 2011 Financial Results http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Second-Quarter-2011-Financial-Results Highlights for quarter include development of new Gene2Product technology and infrastructure expansion As of end of quarter, Evogene had over $60 million in cash, including approximately $16 million received from exercise of public warrants and $12 million investment by Bayer CropScience Rehovot, Israel - August 10th, 2011 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the second quarter ended June 30th, 2011. Ofer Haviv, Evogene's president and CEO, stated:"2011 has been a year of both execution and expansion. With respect to execution, we are continuing to successfully provide our partners with genomic discoveries under our various collaborations, including agreements with most of the world's leading seed companies. With respect to expansion, we are substantially enhancing and expanding our infrastructure for the future, in terms of capabilities, people and physical facilities. Furthermore, we are very pleased with Evogene's current financial stability: as of June 30, 2011, we had over $60 million in cash, representing an increase of more than $25 million during the first half of 2011, including amounts received from the exercise of public warrants and the Bayer CropScience investment." Mr. Haviv continued, "An important key component of our expansion is our new Gene2Product technology that focuses the power of our proven industry leading computational genomic capabilities on optimizing trait efficacy and the product development process of novel genes in our partners' pipelines. The first component of the Gene2Product technology, RePack, has been commercially launched, with additional components under development and planned for introduction during the coming months. We are very excited about the potential that this powerful new capability has to substantially improve the probability of success, in terms of both quality of performance and quantity, of biotechnology seed products resulting from industry-wide development efforts." Revenues for the first six months ended June 30, 2011 were $6.8 million representing an increase of approximately 28% compared to $5.3 million for the same period in 2010. Revenues for the second quarter of 2011 were $3.4 million, representing an increase of approximately 30% compared to $2.6 million reported for the same period in 2010. Revenues for the first half and the second quarter of 2011 consist of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Research & Development expenses for the first six months ended June 30, 2011 were $2.7, compared to $2.2 million for the same period in 2010. Research & Development expenses for the second quarter of 2011 were $1.5 million, compared to $1.3 million reported for the same period in 2010. These increases mainly relate to the development of the Gene2Product computational genomic technologies and increased efforts focused on additional traits, mainly biotic tolerance traits. Loss from ordinary operations for the first six months of 2011 was $1 million, compared to loss from ordinary operations of $0.9 million in the same period in 2010. Loss from ordinary operations for the second quarter of 2011 was $0.6 million, compared to loss from ordinary operations of $0.7 million in the same period in 2010. Financial expenses due to publicly traded warrants: Evogene had approximately 4.5 million publicly traded warrants outstanding, which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007, 99.9% of which were exercised by May 31, 2011 (the warrant expiry date). While these warrants were outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares results in non-cash financial income (expense) due to their revaluation on our statements of comprehensive profit or loss. This will not be applicable for future quarterly results. Comprehensive profit for the first six months ended June 30, 2011, was $3.9 million, which includes $3.7 million of non-cash financial revenues due to previously outstanding publicly traded warrants, as described above, compared to a total comprehensive loss of $0.4 million, including $0.9 million of non-cash financial revenues for the same period in 2010. Comprehensive profit for the second quarter of 2011 was $2.8 million, which includes $2.7 million of non-cash financial revenues, compared to a comprehensive profit of $3.4 million, including $4.5 million of such non-cash financial revenues for the same period in 2010. As of June 30, 2011, Evogene had $61.0 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to $35.8 million as of December 31, 2010. The June 30, 2011 amount includes $16.6 million from the exercise of the publicly traded warrants (including $13 million received in the second quarter of 2011) and $12 million from an equity investment in the Company by Bayer CropScience pursuant to a wheat collaboration agreement signed in December 2010. About Gene2Product The Gene2Product technology consists of a number of computational genomic components, under development by Evogene, to improve the probability of successful development of biotechnology seed products. Utilization of Gene2Product is complimentary and additive to use of ATHLETE for gene discovery. The aim of Gene2Product is to improve trait efficacy through optimizing gene 'mode of use' in the pipelines of seed companies utilizing computational genomics and includes the following components: RePack to improve trait efficacy by optimization of gene regulation; PlaNet to improve trait efficacy by multiple gene stacking; GeneDex to improve trait efficacy through genes stable to different environments and genetic backgrounds; and GeneSpec to improve trait efficacy by selecting the preferred allele for each gene. 10/08/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Second-Quarter-2011-Financial-Results Evogene To Publish a Scientific Paper: Sequencing of Melon Fruit http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-To-Publish-a-Scientific-Paper-Sequencing-of-Melon-Fruit Rehovot, Israel, July 12, 2011 - Evogene Ltd. (TASE: EVGN) in cooperation with the Department of Vegetable Research at Neve Ya'ar Research Center, DYN Diagnostics Ltd., Department of Statistics at The Hebrew University of Jerusalem and the Department of Vegetable Research at the Volcani Research Center, published a scientific paper acknowledging their success in assembling a melon transcriptom and predicting the expression levels of melon genes based on next generation sequencing techniques. The research was conducted as part of an ongoing Program to identify genes to improve melon fruit quality traits, such as flavor and aroma. The research, initiated on 2006, was supported by the Office of the Chief Scientist in the Israeli Ministry of Industry, Trade, and Labor through Magnet Program and the Israeli Bio-TOV Consortium. The research work included the use of innovative sequencing techniques in order to sequence high-quality nonbiased cDNA of melon's flesh and peel transcriptoms as well as utilizing advanced and precise computational assembly and digital expression tools, developed by Evogene. The results, which were validated by a comparative amplification process, indicated that deep sequencing data can be used to predict the expression level of melons genes through Evogene's technology. The full article was published in the latest issue of The Plant Genome and is here by attached. 12/07/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-To-Publish-a-Scientific-Paper-Sequencing-of-Melon-Fruit Evogene Announces Publication of a Scientific Paper: Sequencing of Melon Fruit Transcription as towards Identifying Flavor and Aroma Genes http://www.evogene.com/News-Events/Press-Releases/%sYear/Evogene-Announces-Publication-of-a-Scientific-Paper-Sequencing-of-Melon-Fruit-Transcription-as-towards-Identifying-Flavor-and-Aroma-Genes- 12/07/2011 http://www.evogene.com/News-Events/Press-Releases/%sYear/Evogene-Announces-Publication-of-a-Scientific-Paper-Sequencing-of-Melon-Fruit-Transcription-as-towards-Identifying-Flavor-and-Aroma-Genes- Evogene Announces Exercise of the Company's Series 2 Warrants http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Announces-Exercise-of-the-Companys-Series-2-Warrants Rehovot, Israel, June 1st, 2011 - Evogene Ltd. (TASE: EVGN) announced today that it has received $16.6 million from the exercise of the company's series 2 warrants. The warrants, which expired May 31, 2011, were issued in June 2007 as part of the company's initial public offering on the Tel Aviv Stock Exchange and as part of an investment agreement signed with AquAgro Fund L.P on April 2008. Ofer Haviv, Evogene's president and CEO, stated: "We greatly appreciate these additional votes of confidence from our existing and new investors, as represented by these further investments in our Company, resulting in the exercise of 99.9% of the outstanding series 2 warrants," Mr. Haviv continued. "Evogene has maintained a rapid pace of growth and development since our IPO and we expect to continue this progress in the coming years. This includes continued progress in our current and future collaborations, as well as further expansion of our core technologies and its commercial applications." As of March 31, 2011, Evogene had $50.1 million in cash, cash equivalents, cash deposits and short-term marketable securities. This includes $3.6 million of the $16.6 million that has been received from the exercise of series 2 warrants; the remaining $13 million were received after March 31, 2001. 01/06/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Announces-Exercise-of-the-Companys-Series-2-Warrants Evogene presents at the 'Innovation and Entrepreneurship' Kinneret Panel in Kinneret College http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-presents-at-the-Innovation-and-Entrepreneurship-Kinneret-Panel-in-Kinneret-College Ofer Haviv, President and CEO at Evogene, will present at the "Innovation and Entrepreneurship" Kinneret Panel on May 25th, at the Kinneret Engineering School. The panel will be hosted by Dr. Giora Yaron, the chairman of the Advisory Committee to the Kinneret Engineering School and an entrepreneur. The discussion will include issues of bio-med and medicine as the growth engines for Israel and how the new developments in these two areas require a solid scientific infrastructure which exists in the Academic Institutes, integration of these capabilities with applied R&D capabilities, and marketing and sales which will lead to breakthroughs. Mr. Haviv will discuss the need for interdisciplinary work in these fields, and will use the application methods at Evogene as an example. About Kinneret College The Kinneret College, is located on the southern shores of the Sea of Galilee in northern Israel. The College was established in 1965 by the regional council of the kibbutzim in the area. The students in the College come from all parts of Israel but especially from the Galilee. This is reflected in the multi-cultural and multi-faith background of the student population: Jewish and Arab, secular and religious. The College has been affiliated with the Bar Ilan University for many years and continues to award Bar Ilan degrees in the social sciences and humanities. However, since 2004 the College has also had independent academic status and empowered to grant degrees in a number of fields of Engineering, Communication Studies and Management of Tourism by the Israel Council for Higher Education. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company is focusing on providing a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods, based on its computational genomic technologies: ATHLETE 3.0 for gene discovery; RePack for gene expression optimization and EvoBreed for breeding enhancement. Evogene's technology also combines high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 22/05/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-presents-at-the-Innovation-and-Entrepreneurship-Kinneret-Panel-in-Kinneret-College Evogene Reports First Quarter 2011 Financial Results http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-First-Quarter-2011-Financial-Results Rehovot, Israel - May 17, 2011 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the first quarter ended March 31, 2011. Ofer Haviv, Evogene's president and CEO, stated: "This past quarter saw substantial efforts directed in three primary areas as we continue our rapid progress. First, and foremost, we continued to meet our obligations under our on-going collaborations with world leading seed companies, including Bayer CropScience, Biogemma, Monsanto, Pioneer/Dupont, and Syngenta. Secondly, very substantial efforts were devoted to establishing our new wheat collaboration with Bayer, signed during December of last year, and which is targeted at improving wheat varieties utilizing a combination of advanced breeding and genetic modification methods. And lastly, we continued to build our infrastructure for the future, including ongoing construction programs to increase our research capacity by more than 50%, including facilities for expanded gene validation, data experiments and plant growth. This increased capacity will allow us to both significantly increase the number of research programs we can support and enable the introduction of new technologies now under development." Mr. Haviv continued: "With respect to our financial results, we are of course pleased to see the substantial increase in both current revenues and financial strength in order to support our continued growth." Revenues for the first quarter of 2011 were $3.4 million, representing an increase of approximately 26% compared to $2.7 million reported for the same period in 2010. Revenues consist of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Research & Development expenses for the first quarter of 2011 were $1.2 million, including non-cash financial expenses of $205 thousand for amortization of deferred compensation. This compares with $0.94 million for the same period in 2010, including such non-cash financial expenses of $97 thousand. These increases in Research & Development expenses relate to the development of new genomic technologies, expansion of the company's internal projects and to support our biofuel program. Loss from ordinary operations for the first quarter of 2011 was $399 thousand, including non-cash financial expenses of $665 thousand for amortization of deferred compensation. This compares to a profit from ordinary operations of $181 thousand for the same period in 2010, including such non-cash financial expenses of $370 thousand. Financial expenses due to publicly traded warrants: As of March 31, 2011, Evogene had approximately 3.5 million publicly traded series 2 warrants outstanding which were issued in 2007 as part of its IPO on the Tel Aviv Stock Exchange. These warrants will expire, if not previously exercised, at the end of this month (May 31, 2011). Although not impacting the actual financial status of the Company or its cash balances, any change as of the end of a reporting period in the market price of the Company's ordinary shares results in non-cash financial income (expense) due to revaluation of warrants on our statements of comprehensive income and a corresponding decrease or increase in the non-cash liability related to traded warrants on our balance sheets, which has an effect on Evogene's comprehensive profit as detailed hereunder. Comprehensive profit for the first quarter of 2011 was $1.1 million, which includes $1.0 million of non-cash financial revenues due to publicly traded warrants, as described above, compared to a total comprehensive loss of $3.7 million, including $3.6 million of such non-cash financial expenses for the same period in 2010. Cash Status: As of March 31, 2011, Evogene had $50.1 million in cash, cash equivalents, cash deposits and short-term marketable securities, including $12 million received in January 2011 pursuant to the Bayer CropScience agreement signed in late 2010, compared to $35.8 million as of December 31, 2010. Financial Tables 17/05/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-First-Quarter-2011-Financial-Results Evogene presents at the 'Genomics in Business 2011' congress in Amsterdam, Netherlands, April 3-5, 2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-presents-at-the-Genomics-in-Business-2011-congress-in-Amsterdam-Netherlands-April-3-5-2011 Assaf Oron, EVP Strategy & Business Development at Evogene, presented at the Genomics in Business 2011 congress in Amsterdam, the Netherlands on April 4th, in the session on commercial applications, business approaches and development. Mr. Oron discussed Evogene's business model in lead discovery collaborations in the agro industry which includes wheat collaboration with Bayer CropScience, and future perspectives on biotech industry developments, business models and competitiveness. 'Genomics in Business' is an international conference for executive management, entrepreneurs, start-ups, leading scientists and financial experts from the agro-food industry. 'Genomics in Business 2011' showcases successful scientific and business models in the agro-food industry. By convening international front running companies and visionary scientists, the conference participants discuss and explore the newest genomics technologies and their translation to commercial applications, with an eye towards developing new business opportunities. for the complete presentation press here. 07/04/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-presents-at-the-Genomics-in-Business-2011-congress-in-Amsterdam-Netherlands-April-3-5-2011 Evogene and Zeraim Gedera Extend Collaboration for Development of Salt Tolerant Tomato Varieties http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-and-Zeraim-Gedera-Extend-Collaboration-for-Development-of-Salt-Tolerant-Tomato-Varieties Evogene Ltd. (TASE: EVGN) and Zeraim Gedera, announced today a further extension of their joint program for the development of salt tolerant tomato varieties. The first salt tolerant tomato varieties developed under this program, initiated in 2004, were commercially launched in 2010. Salinity is a key limiting factor affecting approximately 20% of all irrigated cultivated land worldwide and is caused by poor irrigation practices and continuing accumulation of salts in greenhouse soil. "It is our pleasure to announce the continuation of our long term collaboration with Evogene in developing salt tolerance tomato rootstocks. Evogene, with its unique systems and innovative solutions, has been a key partner for this unique and complex project" says Shai Leviatov, Head of Zeraim Gedera R&D. "Salt tolerance in key crops like tomatoes is one of the possible solutions" he adds. "We are delighted to build on our success to date under our collaboration with Zeraim Gedera, a leading company in the development of vegetable varieties" stated Dr. Hagai Karchi, Evogene's EVP Development and CTO. "With salinity being a major challenge in today's agriculture, the tomato varieties being developed under this collaboration are expected to offer improved solutions to allow growers worldwide to maintain high yields under disadvantageous soil conditions." About Zeraim Gedera Zeraim Gedera, is one of the world's leading companies in vegetable varietal development. Since its establishment in 1952, the Company is known for its expertise in developing innovative, added value varieties, enabling farmers to plant the seeds of fresh produce sought by consumers around the world. In Zeraim, a dedicated team of in-house breeders conducts intensive research and field studies in order to develop varieties that will meet market demands. Some of the leading breeding programs are conducted in conjunction with leading Israeli Agricultural Research Institutes & companies. For additional information, please visit Zeraim Gedera website at www.zeraim.com. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company is focusing on providing a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods, based on its computational genomic technologies: ATHLETE 3.0 for gene discovery; RePack for gene expression optimization and EvoBreed for breeding enhancement. Evogene's technology also combines high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 28/03/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-and-Zeraim-Gedera-Extend-Collaboration-for-Development-of-Salt-Tolerant-Tomato-Varieties Evogene Reports Fourth Quarter and Year End 2010 Financial Results http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Fourth-Quarter-and-Year-End-2010-Financial-Results Rehovot, Israel - March 15, 2011 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2010. Ofer Haviv, Evogene's president and CEO, stated: "Although revenues for calendar year 2010 increased by more than 25% from 2009, clearly the key accomplishments from a strategic standpoint were those supporting our growing leadership position in the discovery and licensing of agbio traits to the industry. In this regard, during 2010 we were very proud to see greatly increased industry recognition, substantial enhancement and expansion of our discovery capabilities and further evidence of the quality of our results." Highlights during the year included: The signing of a multiyear collaboration with Bayer CropScience AG, to improve wheat yield, drought tolerance and fertilizer use efficiency, utilizing a combination of advanced breeding and genetic modification methods. Evogene will receive approximately $20 million in the form of upfront fees and annual research payments over the term of the agreement and will additionally be entitled to milestone payments and royalties on product commercialization. In addition, Bayer CropScience made an equity investment of $12 million in Evogene equity. Substantial enhancement of our discovery infrastructure and capacity, with the launch of ATHLETE 3.0 incorporating new computational capabilities as well as the introduction of two new computational discovery platforms, EvoBreed and RePack. These computational platforms will allow the introduction of novel products into the seed industry and open new commercial opportunities for Evogene. The advancement to the next stage of development of an Evogene yield and drought tolerance trait for corn as part of Evogene's collaboration agreement with Biogemma. This achievement follows a three year collaborative program and field trials. Successful completion of a second year of our multiyear collaboration with Monsanto, covering key traits for corn, soybean, cotton in canola. Continued progress in our Biofuel Program, including positive results in a pilot project conducted with NASA and UOP demonstrating that biojet produced from castor varieties under development by Evogene meets key international standards for alternative aviation fuels. Mr. Haviv continued, "As we continue to partner on the basis of our core technology, we remain committed to our strategy of broadening its applicability to new areas in plant genomics. In this regard, we were pleased to see the introduction of our EvoBreed technology, applicable to advanced breeding, which will be utilized initially through our wheat collaboration with Bayer CropScience AG announced on December 2010. We enthusiastically look forward to the remainder of 2011 and the next few years as we continue to further build our unique offering to the Ag industry." Revenues for 2010 were $12.6 million, compared to $10 million for the same period in 2009. Revenues for the fourth quarter of 2010 were $4.7 million, compared to $2.6 million for the same period in 2009. Revenues for all such periods consist of research and licensing revenues generated under the company's various collaboration agreements with seed companies. Research & Development expenses for 2010 were $5.5 million, including non-cash financial expenses of $0.8 million for amortization of deferred compensation. This compares with $2.6 million for the same period in 2009, including such non-cash financial expenses of $0.2 million. Research & Development expenses for the fourth quarter of 2010 were $1.8 million, including non-cash financial expenses of $0.3 million for amortization of deferred compensation. This compares with $1 million for the same period in 2009, including such non-cash financial expenses of $0.1 million. These increases in Research & Development expenses relate to the development of new genomic technologies, the establishment of genomic and breeding infrastructure for wheat and to support our biofuel program. Research & Development expenses do not include expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Loss from ordinary operations for 2010 was $1.9 million, including non-cash financial expenses of $2.6 million for amortization of deferred compensation. This compares to a profit from ordinary operations of $0.3 million for the same period in 2009, including such non-cash financial expenses of $1 million. Profit from ordinary operations for the fourth quarter of 2010 was $0.2 million, including non-cash financial expenses of $0.8 million for amortization of deferred compensation. This compares to a loss from ordinary operations of $0.5 million for the same period in 2009, including such non-cash financial expenses of $0.4 million. Financial expenses due to publicly traded warrants: As of December 31, 2010 Evogene had approximately 4.3 million publicly traded series 2 warrants outstanding which were issued in 2007 as part of its IPO on the Tel Aviv Stock Exchange. Such warrants will expire if not previously exercised on May 31, 2011. Although not impacting the actual financial status of the Company or its cash balances, as long as these warrants are outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares will result in non-cash financial income (expense) due to revaluation of warrants on our statements of comprehensive income and a corresponding decrease or increase in the non-cash liability related to traded warrants on our balance sheets. Comprehensive loss for 2010 was $7 million, which includes $5.4 million of non-cash financial expenses due to publicly traded warrants, as described above, compared to a total comprehensive loss of $3.4 million, including $4.8 million of such non-cash financial expenses for the same period in 2009. Total comprehensive loss for the fourth quarter of 2010 was $3 million, which includes $3.2 million of such non-cash financial expenses, compared to a comprehensive loss of $0.4 million, which includes $0.1 million of such non-cash financial revenues for the same period in 2009. Cash Status: As of December 31, 2010, Evogene had $35.8 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to $38.2 million as of December 31, 2009, not including $12 million received in January 2011 pursuant to the Bayer CropScience agreement signed in late 2010. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company is offering a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods, based on its computational genomic technologies: ATHLETE for gene discovery; RePack for gene expression optimization; EvoBreed for breeding enhancement. Evogene's technology also combines high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com Financial Tables 15/03/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Reports-Fourth-Quarter-and-Year-End-2010-Financial-Results Evogene Continues to Expand Its Scientific Team and Senior Recruitments http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Continues-to-Expand-Its-Scientific-Team-and-Senior-Recruitments- Rehovot, Israel - March 9, 2011 - Evogene (TASE:EVGN) announced today new appointments of six trait researchers, castor plant growth manager, image processing specialist, business development manager & director of operation & purchasing. Ofer Haviv, Evogene's president and CEO stated: "As Evogene continues its growth, we are broadening and strengthening our plant genomics capabilities and partnerships. To achieve our targets, we are reinforcing our scientific teams' expertise and professional know-how, and maintain for a consecutive year an increase of our staff by over 30%. I would like to welcome the new members to our team." The senior employees joining Evogene's team are: Dr. Avishag Levi-Barshalom - Trait Researcher Prior to joining Evogene, Dr. Avishag Levi-Barshalom completed her Ph.D. studies at the Plant Sciences Department of the Faculty of Agriculture of the Hebrew University of Jerusalem. Her studies focused on characterizing drought-resistance in cotton for productivity and drought-related traits. In the years 1999-2001, Dr. Levi-Barshalom was employed as a cotton breeder by Hazera Genetics R&D department. Dr. Levi-Barshalom holds a B.Sc. and M.Sc. degrees from the Faculty of Agriculture of the Hebrew University of Jerusalem. Dr. Avital Adato - Trait Researcher Prior to joining Evogene, during the years 2007-2010, Dr. Avital Adato was an associate researcher in the Plant Sciences Department of the Weizmann institute of Science, where she studied various aspects of plant surface. During the years 2002-2005 Dr. Adato was a post-doctorate fellow and associate researcher in the Pasteur Institute in Paris, where she studied the protein network underlying Usher syndrome (hereditary disease effecting both hearing and sight) in human and mice. Prior to joining the Pastuer Institute Dr. Adato was a post-doctorate fellow in the Molecular Genetics Department of the Weizmann Institute of Science where she combined bioinformatics and molecular approaches to study the genetics of Usher syndrom. Dr. Adato holds a B.Sc. and M.Sc. from the Faculty of Agriculture at the Hebrew University of Jerusalem, and a Ph.D. from the Human Genetics Department of the Sackler Faculty of Medicine at the Tel Aviv University. Dr. Inbal Dangoor - Trait Researcher Prior to joining Evogene, during the years 2002 - 2010, Dr. Dangoor completed her M.Sc. and Ph.D. studies at the Plant Sciences Department of the Weizmann institute of Science. Her studies focused on in vivo characterization of redox-regulated protein complexes in the chloroplast. Dr. Dangoor holds a B.Sc. from the Faculty of Agriculture of the Hebrew University of Jerusalem (Cum Laude). Dr. Michal Shoresh - Trait Researcher Prior to joining Evogene, during the years 2007-2011, Dr. Shoresh served as a Research Scientist studying plant responses to abiotic stress, in the Institute of Soil, Water and Environmental Sciences, Agricultural Research Organization, The Volcai Center. During the years 2005-2007, Dr. Shoresh was a post-doctoral research associate at Cornell University, studying plant response to microorganisms using 'Omics' methods. Dr. Shoresh was a post-doctoral research fellow in the field of plant response to microorganisms and biocontrol at The Otto Warburg Center for Biotechnology, The Hebrew University of Jerusalem, during the years 1999-2001, and at the Dept. of Biological Chemistry, The Weizmann Institute of Science, during the years 2002-2005. Dr. Shoresh holds a Ph.D. degree from the faculty of Life Sciences, Molecular Microbiology and Biotechnology Department in Tel Aviv University. Dr. Noa Matarasso - Trait Researcher Prior to joining Evogene, during the years 2005-2006, Dr. Matarasso served as a Research Scientist in the department of Fruit Tree Sciences, Agricultural Research Organization, The Volcai Institute. During the years 2006-2009, Dr. Matarasso was part of the founding group of Recogene Ltd., serving as a Senior Scientist & Project leader taking part in developing molecular tools for the company's technology platform. Prior to joining Recogene Ltd. Dr. Matarasso was a post doctorate fellow in the field of Prostate Cancer Genetics in the Genetic Institute of Tel-Aviv Sourasky Medical Center, The Human Genetics Departement of Sackler Faculty of Medicine at Tel Aviv University. Dr. Matarasso holds a M.Sc. and Ph.D. degrees from the faculty of Life Sciences, Plant Sciences Department in Tel Aviv University. Dr. Ehud Katz - Trait Researcher Prior to joining Evogene, during the years 2005-2010, Dr. Ehud Katz was a post doctorate fellow in the Plant Sciences Department of the University of California at Davis where he studied molecular determinants affecting Citrus fruit quality by using high-throughput label-free LC-MS/MS based shot-gun proteomics. He also studied sugar transport into the vacuole and sugar homeostasis during Citrus fruit development. During the years 2003-2005 Dr. Katz was a post-doctorate fellow in the Faculty of agriculture at the Hebrew University of Jerusalem, where he studied flowering induction and flower development of Passiflora edulis and the mechanism by which CONSTANS, the photoperiodic flowering pathway regulator is regulating its' targets in Arabidopsis. Dr. Katz holds a B.Sc., M.Sc. and Ph.D. from the Faculty of Agriculture at the Hebrew University of Jerusalem. Mr. Rafi Lotem - Castor Plant Growth Manager Mr. Lotem has extensive experience as a professional manager in various agricultural fields in countries worldwide (Asia, Africa and Europe). Prior to joining Evogene, during the years 2008-2010, Mr. Lotem served as the General Manager of Oryol - Rav Agro, a multinational company in Russia, which operates large scale wheat growth projects. Mr. Lotem was in charge of all agronomic aspects and management activities. Mr. Lotem holds a B.A. degree in Business & Management from the Tel-Aviv School of Business & Management, and a Practical Engineer degree from the Ruppin Academic Center School of Agriculture. Ms. Ruth Sher- Image Processing Specialist Ms. Ruth Sher has extensive experience as a software developer, focusing on algorithms for image processing and computer vision. Prior to joining Evogene, she has worked at Elbit Systems - Elop (2003-2009), and at Image Navigation - DenX (1997-2003, 2010) Ms. Sher holds a M.Sc. in Computer Science and a B.Sc. in Computer Science and Mathematics from the Hebrew University of Jerusalem. Mr. Roy Livneh- Business Development Manager Mr. Livneh has an extensive record of business development, marketing and sales, and account management positions, in NASDAQ traded and start-up companies, with vast experience in the international market. Prior to joining Evogene, during the years 2000-2007, Mr. Livneh worked in Saifun Semiconductors (SFUN), serving in his last role as VP Business Development, and for the past years Mr. Livneh was an entrepreneur and a business consultant for a few high-tech companies. Mr. Livneh holds a M.B.A. from Tel Aviv University and a B.Sc. in Industrial Engineering and Management from the Technion (CUM LAUDA). Yacov Wuhl - Director of Operation & purchasing Prior to joining Evogene, Mr. Wuhl served as Director of Operation at Hazera Genetics R&D department (1997- 2006); in addition, he was responsible for construction and purchasing at Hazera Genetics (2006-2010). Mr. Wuhl holds a Practical Engineer degree from the Ruppin Academic Center School of Agriculture. 09/03/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Evogene-Continues-to-Expand-Its-Scientific-Team-and-Senior-Recruitments- Evogene presented at the 2007 Beltwide conference, New Orleans Louisiana, January 12th, 2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-presented-at-the-2007-Beltwide-conference-New-Orleans-Louisiana-January-12th-2007- On January 12th, 2007 Evogene gave a lecture at the annual Beltwide conference in New Orleans, Louisiana. Dr. Hagai Karch, Evogene's VP Development and CTO, gave a lecture on "Novel Genes for Improving Fiber Quality Validated Through Tomato Seed Hair as a Unique Model System". Novel Genes for Improving Fiber Quality Validated Through Tomato Seed Hair as a Unique Model System 15/02/2011 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-presented-at-the-2007-Beltwide-conference-New-Orleans-Louisiana-January-12th-2007- Biogemma Advances Evogene's Yield and Drought Tolerance Trait in its Corn Development Pipeline http://www.evogene.com/News-Events/Press-Releases/2011/Biogemma-Advances-Evogenes-Yield-and-Drought-Tolerance-Trait-in-its-Corn-Development-Pipeline Rehovot, Israel and Paris, France - January 19, 2011 - Evogene Ltd. (TASE: EVGN) and Biogemma SAS today announced that Biogemma will be advancing a yield and drought tolerance corn trait licensed from Evogene to the next phase of development - Phase II. A number of candidate genes were evaluated by both companies through a joint, multi-year research and development program, initiated in 2006. Positive genes validated in this stage will be further evaluated and integrated by Biogemma through its corn yield and drought development pipeline As a result of the achievement of this milestone, Biogemma maintains worldwide exclusive commercialization rights for corn to certain Evogene's discovered yield and drought tolerance genes. "Today's announcement marks the next step in our collaboration with Evogene. This is an important milestone on the development of improved maize varieties incorporating Evogene's genes for yield and drought tolerance," stated Pascual Perez, Biogemma's CEO. "The additional results obtained this summer across our drought field evaluation network provided further evidence of the role of these genes. We are excited by the opportunities that these results offer us to develop new corn varieties with improved performance under drought conditions," said Christophe Sallaud, Head of the Transgenesis Department of Biogemma. "We are delighted by Biogemma's decision to advance Evogene's yield and drought tolerance trait to the next phase of development in its corn pipeline. Biogemma is a leading crop biotechnology company and we are very pleased to be collaborating with the company by providing our trait technology for such an important crop," stated Ofer Haviv, Evogene's President and CEO. "Furthermore, in addition to the obvious importance of this event with respect to our collaboration with Biogemma, this progress further validates Evogene's plant genomics technologies, which are resulting in the discovery of novel genes to serve as attractive leads for the improvement of traits in major food crops." About Biogemma Biogemma is a leading biotech company in Europe involved in Genomics applied to Field crops. Result of the merger of the biotech activity of three major seed companies, Vilmorin & Cie (Limagrain Group), Euralis and RAGT, with the help of two financial institutions Sofiproteol and Unigrains and the support of the technical agency Arvalis, the company is developing R&D programs with its partners, in field crops (Corn, Wheat, Sunflower and Oilseed rape), focused on yield improvement, biotic and abiotic stress resistance and specialty grain compounds. 19/01/2011 http://www.evogene.com/News-Events/Press-Releases/2011/Biogemma-Advances-Evogenes-Yield-and-Drought-Tolerance-Trait-in-its-Corn-Development-Pipeline Bayer CropScience and Evogene Sign Collaboration Agreement to Improve Wheat Seed http://www.evogene.com/News-Events/Press-Releases/2010/Bayer-CropScience-and-Evogene-Sign-Collaboration-Agreement-to-Improve-Wheat-Seed Focus on yield, drought tolerance and fertilizer use efficiency Use of both advanced breeding and genetic modification methods Monheim, Germany, and Rehovot, Israel - December 13, 2010 - Bayer CropScience AG and Evogene Ltd. have entered into a five-year collaboration to accelerate the development and introduction of improved wheat varieties. Improvements will be pursued for wheat yield, drought tolerance, fertilizer use efficiency and certain other wheat traits utilizing a combination of advanced breeding and state of the art genetic modification methods. Bayer will have exclusive rights to commercialize in wheat the traits resulting from this collaboration. The collaboration further builds on an on-going partnership between Bayer CropScience and Evogene, which was initiated in 2007 and expanded in 2009, for increasing rice productivity and yield. In a separate agreement, Bayer CropScience will make an equity investment of USD 12 million in Evogene at a price of approximately USD 7 per ordinary share. On a global basis, wheat is the largest crop in terms of cultivated area and one of the most important food crops. The critical need to provide sufficient wheat to meet the needs of the growing world population is widely recognized. Significant efforts are being directed towards addressing this challenge, primarily through programs attempting to increase yields and to sustainably reduce required inputs, such as water and fertilizer. The collaboration will utilize Evogene's ATHLETE, RePack and EvoBreed computational genomic technologies for the identification of genetically modified and native traits to improve yield, drought tolerance, fertilizer utilization and certain other characteristics in wheat. Bayer CropScience will utilize its capabilities in breeding and product development to incorporate genetically modified and native traits identified by Evogene, into its wheat pipeline for developing elite varieties displaying improved performance. The resulting improved wheat varieties will be commercialized by Bayer CropScience. Evogene will receive approximately USD 20 million in the form of upfront fees and annual research payments over the term of the agreement. Furthermore, the company will receive development milestone payments and royalties on the commercialization of any resulting products. Further details of the agreement were not disclosed. "The wheat industry is facing challenges, such as changing climate, the decline of mineral resources used for fertilizer and the need to increase crop yields. We look forward to working together with Evogene in the area of wheat research to help tackle these issues," said Lykele van der Broek, Chief Operating Officer of Bayer CropScience. "Being market and innovation Leader in the crop protection market for Cereals, we aim to become the partner of choice to wheat growers and the wheat industry and will offer superior integrated solutions to improve cereal production in a sustainable way." "We are very pleased by this major expansion of our relationship with Bayer CropScience, a worldwide leader in innovative crop science, and we are confident that this joint effort will result in meaningful contributions to meeting the needs of the wheat industry," stated Ofer Haviv, Evogene's President and CEO. "A unique aspect of this collaboration is the synergistic combination of the two research approaches for trait improvement: advanced breeding and biotechnology. By combining these two approaches in one truly collaborative program utilizing an array of Evogene's leading computational genomic technologies and Bayer CropScience's proven product development expertise, we anticipate opportunities for significantly enhanced results." Key figures about wheat: - Approximately 25 percent of global agricultural land is utilized for wheat cultivation, making wheat the largest food crop worldwide in terms of area. - Wheat is the second most-produced cereal crop after corn with more than 650 million tons produced every year. - Wheat productivity is increasing at less than 1 percent annually, while the annual global demand is growing at approximately double that percentage. - Main wheat producing regions are Australia, the Black Sea Region, China, the EU, India and North America. About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.5 billion (2009), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 18,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com. About Evogene Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company is focusing on providing a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods, based on its computational genomic technologies: ATHLETE 3.0 for gene discovery; RePack for gene expression optimization and EvoBreed for breeding enhancement. Evogene's technology also combines high throughput plant validation systems, field experiments and proprietary genomic data creation. Evogene is collaborating with world leading seed companies to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. 13/12/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Bayer-CropScience-and-Evogene-Sign-Collaboration-Agreement-to-Improve-Wheat-Seed Evogene Reports Third Quarter 2010 Financial Results http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Third-Quarter-2010-Financial-Results Rehovot, Israel - November 18th, 2010 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the third quarter, ended September 30th, 2010. Ofer Haviv, Evogene's president and CEO, stated: "During the past quarter, we continued to progress as planned under our current collaborations with world leading seed companies. In addition, in order to support these collaborations as well as prepare for anticipated future collaborations, significant efforts and investments were made in both improving and broadening our ATHLETE 3.0, RePack and EvoBreed genomic technologies, including their application to wheat as an additional target crop. Guiding these efforts is our focus on creating a complete and comprehensive solution for improving plant genetics, through the synergistic combination of 'state of the art' biotechnology and advanced breeding approaches." Revenues for the first nine months of 2010 were $7.9 million, compared to $7.4 million for the same period in 2009. Revenues for both the third quarter of 2010 and of 2009 were $2.6 million. Revenues for all such periods consist substantially of research revenues generated under the company's various collaboration agreements with seed companies. Research & Development expenses for the first nine months of 2010 were $3.7 million, including non-cash financial expenses of $0.7 million for amortization of deferred compensation. This compares with $1.5 million for the same period in 2009, including such non-cash financial expenses of $0.2 million. Research & Development expenses for the third quarter of 2010 were $1.5 million, including non-cash financial expenses of $0.4 million for amortization of deferred compensation. This compares with $0.7 million for the same period in 2009, including such non-cash financial expenses of $0.1 million. These increases in Research & Development expenses relate to the development of new genomic technologies, the establishment of genomic and breeding infrastructure for wheat, increased efforts related to additional traits and to support our biofuel program. Research & Development expenses do not include expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues. Loss from ordinary operations for the first nine months of 2010 was $2.1 million, including non-cash financial expenses of $1.7 million for amortization of deferred compensation. This compares to a profit from ordinary operations of $0.7 million for the same period in 2009, including such non-cash financial expenses of $0.6 million. Loss from ordinary operations for the third quarter of 2010 was $1.2 million, including non-cash financial expenses of $0.9 million for amortization of deferred compensation. This compares to a loss from ordinary operations of $0.1 million for the same period in 2009, including such non-cash financial expenses of $0.3 million. The increase in loss from ordinary operations for both the first nine months and third quarter periods of 2010 compared to 2009 is primarily due to the previously mentioned increases in Research & Development expenses and non-cash financial expenses. Financial expenses due to publicly traded warrants: Evogene has approximately 4.5 million publicly traded warrants outstanding which were issued in 2007 as part of its IPO on the Tel Aviv Stock Exchange. Such warrants will expire if not previously exercised on May 31, 2011. Although not impacting the actual financial status of the Company or its cash balances, as long as these warrants are outstanding, any change as of the end of a reporting period in the market price of the Company's ordinary shares will result in non-cash financial income (expense) due to revaluation of warrants on our statements of comprehensive income and a corresponding decrease or increase in the non-cash liability related to traded warrants on our balance sheets. Comprehensive loss for the first nine months of 2010 was $4.0 million, which includes $2.2 million of non-cash financial expenses due to publicly traded warrants, as described above, compared to a total comprehensive loss of $3.0 million, including $5.0 million of such non-cash financial expenses for the same period in 2009. Total comprehensive loss for the third quarter of 2010 was $3.6 million, which includes $3.1 million of such non-cash financial expenses, compared to a comprehensive profit of $2.1 million, which includes $1.3 million of such non-cash financial revenues for the same period in 2009. As of September 30, 2010, Evogene had $35.9 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to $38.2 million as of December 31, 2009. About Evogene Evogene is a world leading developer of improved plant traits for the agriculture and biofuel industries through the use of plant genomics. The company's technology platform is based on a unique computational core technology for gene discovery, the ATHLETE 3.0, and high throughput systems for gene validation. Evogene's development programs focus on the improvement of high-commercial value plant traits, such as yield, biotic and a-biotic stresses tolerance and the improvement of plants specifically for biofuel uses. Evogene is collaborating with world leading seed companies in order to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. This press release contains "forward-looking statements". These statements include words like "may," "expects," "believes," "scheduled" and "intends," and they describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Financial Tables 18/11/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Third-Quarter-2010-Financial-Results Evogene Reports Second Quarter 2010 Financial Results http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Second-Quarter-2010-Financial-Results Rehovot, Israel - August 10th, 2010 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the second quarter, ended June 30th, 2010. Ofer Haviv, Evogene's president and CEO, stated: "During the past quarter, we continued to progress under our current collaborations with world leading seed companies, including Bayer CropScience, Biogemma/Limagrain, Monsanto, Pioneer/Dupont and Syngenta. To support these collaborations and as part of the company's growth strategy, we successfully continued the planned expansion and enhancement of our R&D capabilities. These efforts relate both to our infrastructure in terms of professional staff, state of the art equipment and facilities and on-going improvements to our key discovery technologies - ATHLETE, RePack and EvoBreed. In addition, we substantially increased our plant trait validation capacity and today have the capacity to validate in model plants hundreds of genes per year. With respect to our activity in biofuels with world leading entities, such as NASA, the Air Force Research Laboratory and Honeywell's UOP, we were very pleased to announce, this past quarter, the successful feasibility demonstration that biojet produced from castor varieties that we have been developing meets international standards for alternative aviation fuels." Mr. Haviv continued: "An exciting new program for us involves wheat, one of the world's most important commodity crops. For the past year, we have been exploring establishing a program for the use of both advanced genomic and breeding techniques for improving this crop, and more recently began to create the required crop specific infrastructure. We consider wheat to be a strategic crop of interest to Evogene and in the coming months will expand our activity in this field, initially through the focusing of our existing trait capabilities for improving yield, drought tolerance and fertilizer utilization." Revenues for the first six months ended June 30, 2010 were $5.3 million, compared to $4.8 million for the same period in 2009. Revenues for the second quarter of 2010 were $2.6 million, compared to $2.4 million reported for the same period in 2009. Revenues for the first half and the second quarter of 2010 consist almost entirely of research revenues generated under the company's various collaboration agreements with seed companies, which also provide for future development milestones and royalty payments on sales of resulting improved products. Research & Development expenses, which do not include expenses related to the company's discovery and validation activities associated with on-going collaborations and which are accounted for as Cost of Revenues, continued to increase. Research & Development expenses were $2.2 for the first six months ended June 30, 2010, compared to $0.8 million for the same period in 2009. Research & Development expenses for the second quarter of 2010 were $1.3 million, compared to $0.4 million reported for the same period in 2009. These increases primarily relate to development of new core computational technologies, such as ATHLETE 3.0, RePack and EvoBreed; increased efforts focused on additional traits, such as plant diseases, pests and other biotic tolerance traits; establishment of genomic and breeding infrastructure for wheat; and our biofuels program. Loss from ordinary operations for the first six months of 2010 was $913 thousand, compared to a profit from ordinary operations of $860 thousand in the same period in 2009. Loss from ordinary operations for the second quarter of 2010 was $732 thousand, compared to a profit from ordinary operations of $236 thousand in the same period in 2009. The loss from ordinary operations in the first half and second quarter of 2010 is mainly due to increase in Research & Development expenses, as stated above. Evogene has approximately 4.5 million publicly traded warrants outstanding which were issued as part of its IPO on the Tel Aviv Stock Exchange in May 2007 and expire in May 31, 2011. Although not impacting the actual financial status of the Company or its cash balances, as long as these warrants are outstanding, an increase in the market price of Evogene's ordinary shares will require a non-cash financial charge to our income statement and an increase in a corresponding non-cash liability related to traded warrants on our balance sheet. Likewise, a decrease in the market price of our ordinary shares will result in non-cash financial revenue on our income statement and a corresponding reduction in the non-cash liability related to traded warrants shown on our balance sheet. Comprehensive loss for the first six months ended June 30, 2010, was $358 thousand, which includes $0.9 million of non-cash financial revenues as described above, compared to a total comprehensive loss of $5.1 million, including $6.3 million of non-cash financial expenses for the same period in 2009. Total comprehensive profit for the second quarter of 2010 was $3.4 million, or $0.12 per share, which includes $4.5 million of non-cash financial revenues, compared to a comprehensive loss of $3.8 million, or $0.14 per share, which includes $4.7 million of non-cash financial expenses for the same period in 2009. As of June 30, 2010, Evogene had $35.6 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to $38.2 million as of December 31, 2009. Financial Tables 10/08/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Second-Quarter-2010-Financial-Results Evogene Announces Launch of ATHLETE 3.0 Gene Discovery Technology http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Announces-Launch-of-ATHLETE-30-Gene-Discovery-Technology New version of world leading plant gene discovery technology includes new tools, data and integration methodologies Rehovot, Israel - August 2, 2010 - Evogene Ltd. (TASE: EVGN) announced today the launch of ATHLETE 3.0, a next generation version of its world leading technology for discovery of novel genes for the improvement of plant performances. To date, Evogene discovered through the ATHLETE and validated in plants over 1500 novel genes relating to key plant traits. ATHLETE 3.0 enables more comprehensive and accurate cross-species discovery of genes, based on genomic data of over 130 plant species. ATHLETE 3.0 relies on a series of unique, new and enhanced tools which substantially accelerate gene discovery, in addition to incorporating additional types and quantities of data compared with the previous version. Additional New Data Layers - ATHLETE 3.0 incorporates new data types and additional layers of biological data. These include protein to protein interactions, transcription networks, SNPs data, Metabolomics levels and non-coding RNA data as well as phenotypic data based on large scale field experiments. ATHLETE 3.0 data mining tools now perform across all these data layers and cross-species, giving unprecedented data resolution to improve prediction reliability. More Plant Species and Genome Sequences - ATHLETE 3.0 integrates key data types of over 130 plant species and over 20 full sequenced annotated genome sequences. ATHLETE 3.0 also supports next generation sequencing data, allowing more effective prediction of new genes based on high throughput analysis of enormous amounts of short sequence data. Advanced Computational Analysis Tools - ATHLETE 3.0 incorporates new data mining tools, algorithms and methods to improve prediction capabilities. These include tools for genome wide association studies, unique analysis of phenotypic data, gene to gene interaction maps and further improvements of expression analysis tools. The ATHLETE 3.0 is now being integrated into Evogene's gene discovery programs, providing novel genes for the improvement of key traits, such as yield, drought, fertilizer utilization and plant diseases to Evogene's collaborators, which include world leading seed companies. Dr. Hagai Karchi, Evogene's EVP Development and CTO, stated: "We have been working continuously to improve the ATHLETE tools to further enhance Evogene's position at the forefront of plant genomics. These improvements, which are supported, among others, by an increase in our plant biology and bioinformatics professional staff, enable us to adjust our technology and gain knowledge from the enormous amounts of data becoming available today. The ATHLETE is a key component of our current collaborations with world leading seed companies, and we believe that with the availability of ATHLETE 3.0, we shall accelerate our capabilities to provide our partners with high quality candidate genes to improve desired key plant traits." About ATHLETE ATHLETE is Evogene's proprietary computational technology, which allows rapid discovery and prioritization of hundreds of plant genes relevant to a target trait of choice. The technology is applicable for different traits, including yield, stress tolerance and agronomic traits, and various crops. A gene discovery process utilizing the ATHLETE technology lasts approximately 6 to 9 months, and includes: (1)Trait Understanding and development of trait improvement strategies; (2)Database Assembly of a wide, comparative genomic data from various sources; and (3) Data Mining using proprietary algorithmic tools Since the launch of the first version of the ATHLETE in 2006, Evogene has been continuously investing in the development of new tools and methodologies in order to enhance its prediction capabilities. ATHLETE 3.0 is an advanced next generation version of ATHLETE being introduced in 2010, incorporating more and additional data types and enhanced computational tools and methodologies. 02/08/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Announces-Launch-of-ATHLETE-30-Gene-Discovery-Technology Evogene Castor Oil Demonstrates Suitability as Biojet Feedstock http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Castor-Oil-Demonstrates-Suitability-as-Biojet-Feedstock Analysis conducted in collaboration with NASA, AFRL, and Honeywell's UOP REHOVOT, ISRAEL (July 7, 2010) - Evogene Ltd. (TASE: EVGN) announced today that biojet(1) produced from castor varieties under development by Evogene, meets the key international standards for alternative aviation fuels. The analysis was conducted by Evogene, Inc., a fully owned US subsidiary of Evogene, Ltd., in collaboration with NASA, the US National Aeronautics and Space Administration, the Air Force Research Laboratory and Honeywell's UOP, a leading international developer and licensor of refining process technology. As previously disclosed, in April 2009 Evogene Inc. entered into a feasibility agreement with NASA, to evaluate the potential use of castor oil as a viable and sustainable feedstock for production of biojet fuel. Under said agreement, biojet produced from Evogene castor oil through UOP's technology, is expected to under go additional advanced testing by NASA and the U.S. Air Force Research Laboratory. The results being announced today demonstrate that such biojet meets the major ASTM D7566(2) fuel specifications requirements for alternative aviation fuels containing Synthesized Hydrocarbons. The D7566 fuel specification is written for fuels produced using the Fischer-Tropsch process; however, specifications for alternative aviation fuels containing Bio Synthesized Paraffinic Kerosene (biojet) are expected to be approved for commercial airline use before the end of 2010 or early next year. "A diverse range of feedstocks is critical to creating a sustainable biofuels infrastructure," said Jim Rekoske, general manager of Renewable Energy & Chemicals at Honeywell's UOP. "Castor oil has proven to be a viable second-generation source, and we believe it has the potential to be an important contributor to the production of aviation biofuels." "We are pleased to see this feasibility support in castor oil as a viable second-generation feedstock for biofuels. In addition to the positive properties analysis being reported today, Evogene recently announced the results of a Life Cycle Analysis of biodiesel produced from its castor, showing that such biodiesel reduces greenhouse gases emissions by 90% compared to petroleum diesel in the U.S.," stated Mr. Ofer Haviv, Evogene's President and CEO. "We highly value our joint efforts with NASA, AFRL and UOP, world leading entities in this field, for this project in developing castor oil biofuels." Based on public sources, a key objective of the aviation industry is obtaining viable and sustainable second-generation feedstock for biojet production, with the additional objective of reducing life-cycle emissions. Presently, it is believed that biojet will be one of the most common mid-term solutions for the aviation industry as it could be used as a drop-in replacement for jet fuel and would not require redesign of the engine or airplane. As previously disclosed, Evogene is focusing on development of high yielding castor varieties, suitable for cost-efficient growth on semi-arid lands, using fully mechanized production. The economic target of Evogene's castor development program is for its varieties to be price competitive without government subsidies at an oil price equivalent to $45 per barrel. Evogene is currently testing its castor varieties in field trials in the southern U.S. and northeastern Brazil. (1) Biojet is a plant-based alternative to aviation fuels, also known as Bio Synthesized Paraffinic Kerosene (Bio-SPK) and Hydroprocessed Renewable Jet (HRJ). (2) International standard and fuel specifications, covering the manufacture of aviation fuel that consists of conventional and synthetic blending components. 07/07/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Castor-Oil-Demonstrates-Suitability-as-Biojet-Feedstock Evogene Reports First Quarter 2010 Financial Results http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-First-Quarter-2010-Financial-Results Rehovot, Israel - May 13, 2010 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the first quarter ended March 31, 2010. Ofer Haviv, Evogene's president and CEO, stated: "During the past quarter, we continued to progress under our current collaborations with world leading seed companies, including Bayer CropScience, Monsanto, Pioneer/Dupont and Syngenta. In addition, during the past quarter, we announced a continuation agreement with Biogemma, a company in the Limagrain group, for development and commercialization by Biogemma of Evogene's yield and drought tolerance genes in corn. This new agreement follows results of a joint evaluation of the genes in corn field trials in both the United States and Israel." Mr. Haviv continued: "In addition, during the past quarter, we continued to enhance our R&D capabilities, primarily with new computational techniques and tools being developed for the ATHLETE core technology for gene discovery - which is the basis for most of our current activities; the RePack core technology under development for prediction of biological regulatory features of genes; and the EvoBreed core technology under development for significantly accelerating breeding processes through the incorporation of advanced computational tools. We also achieved progress in our biofuel program, which is currently focused on the development of castor as feedstock for biodiesel and biojet fuels. This progress included expanding the field evaluation of the castor lines under development to the target locations for future commercialization - Texas and Brazil - and demonstrating the sustainability of castor growth through the completion of a Life Cycle Analysis." Revenues for the first quarter of 2010 were $2.7 million, compared to $2.4 million reported for the same period in 2009. Loss from ordinary operations for the first quarter of 2010 was $181 thousand, compared to a profit from ordinary operations of $624 thousand in the same period in 2009. The loss from ordinary operations in the first quarter of 2010 is mainly due to increase in Research & Development expenses, which totaled $939 thousand in the first quarter of the year compared to $340 thousand in the first quarter last year. Such increase in Research & Development expenses is due to the expansion of the company's internal projects, mainly development of new core computational technologies and resulting increase in staff to support these projects. Total comprehensive loss for the first quarter of 2010 was $3.7 million, or $0.14 per share, compared to $1.4 million, or $0.06 per share, in the same period in 2009. The comprehensive loss for the first quarter of 2010 includes $3.6 million of non-cash financial expenses, compared to $1.5 million for the same period in 2009. These non-cash charges are due primarily to the revaluation for accounting purposes of the publicly traded options issued in the 2007 IPO due to the increase in market price of the Company's ordinary shares during such time periods. As of December 31, 2009, Evogene had $37.8 million in cash, cash equivalents, cash deposits and short-term marketable securities, compared to $38.2 million as of December 31, 2009. 13/05/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-First-Quarter-2010-Financial-Results Life Cycle Analysis of Evogene Castor Bean based Biodiesel Shows 90 percent Emissions Reduction Compared to Petroleum http://www.evogene.com/News-Events/Press-Releases/2010/Life-Cycle-Analysis-of-Evogene-Castor-Bean-based-Biodiesel-Shows-90-percent-Emissions-Reduction-Compared-to-Petroleum REHOVOT, ISRAEL (April 8, 2010) - Evogene Ltd. (TASE: EVGN) today announced the results of a Life Cycle Assessment (LCA) of biodiesel produced from castor bean varieties being developed by the Company. The assessment shows that such biodiesel reduces Greenhouse Gases (GHG) emissions by 90% compared to petroleum diesel in the U.S. The results are based on Evogene's objectives for castor bean varieties, aimed at increasing crop yields to 4-5 ton/ha on semi-arid lands - at present focusing on Texas and Brazil - and therefore providing the additional benefit of not competing with food use of arable land. The LCA was conducted by Symbiotic Engineering, a company specializing in GHG and sustainability management and providing tools to evaluate 'green' projects and products, and was peer-reviewed by Dr. Arunprakash Karunanithi from the University of Colorado, Denver. "The results of the LCA strengthen our belief in castor bean as a viable and sustainable second-generation feedstock for biofuel production. Based on our project objectives, the castor bean varieties we are developing have a potential to address the immediate need for sustainable, widely available and cost efficient solutions for the biofuel industry," stated Mr. Assaf Oron, Evogene's EVP Strategy and Business Development. "We are keen to pursue the needs of the biofuel industry through castor bean breeding and evaluation of our varieties in field trials, recently established in Texas and Brazil." The assessment evaluates the environmental impact of biodiesel produced from the castor bean varieties being developed by Evogene as compared to conventional petroleum diesel and biodiesel originating from soybean. Results show that Evogene's castor bean biodiesel production and use Reduces net GHG emissions by 90% in the U.S. and more than 75% in Brazil compared with conventional diesel, if grown in non-arable or semi-arid land. Exceeds the GHG savings achieved with soybean biodiesel, with reductions for the U.S. of 43% compared to soybean. Castor Bean (Ricinus Communis) is a non-edible crop with naturally high oil content in its seeds and its growth requires relatively low inputs. As previously disclosed, Evogene is focusing on development of high yielding castor bean varieties, suitable for cost-efficient growth on semi- arid lands in southern U.S. and northeastern Brazil, using fully mechanized production. The economic target for Evogene is to be price competitive without government subsidies at an oil price equivalent to $45 per barrel. 08/04/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Life-Cycle-Analysis-of-Evogene-Castor-Bean-based-Biodiesel-Shows-90-percent-Emissions-Reduction-Compared-to-Petroleum Biogemma Licenses Yield and Drought Tolerance Genes from Evogene for Commercialization in Corn http://www.evogene.com/News-Events/Press-Releases/2010/Biogemma-Licenses-Yield-and-Drought-Tolerance-Genes-from-Evogene-for-Commercialization-in-Corn The Agreement is in Continuation of the Parties' 2006 Joint Research Agreement Rehovot, Israel and Paris, France, March 16, 2010 - Evogene Ltd. (TASE: EVGN) and Biogemma SAS today announced the signing of a licensing agreement for the development and commercialization by Biogemma of hybrid corn lines, displaying improved yield and drought tolerance. The improved corn lines will incorporate certain Evogene discovered genes which have been jointly evaluated by the parties through a collaboration initiated in 2006. Under the newly signed licensing agreement, Biogemma receives worldwide exclusive commercialization rights to the genes for corn; financial terms of the agreement were not disclosed. Pursuant to the earlier 2006 joint research agreement, corn lines incorporating various Evogene discovered genes were validated by Biogemma and Evogene in field trials in the USA and Israel during 2008 and 2009. Pascual Perez, CEO for Biogemma stated, "We were pleased to see that the results of the Evogene's leads confirmed our interest in the Evogene discovered genes for our major target crop: maÏze. We are also very satisfied with the efficient research collaboration that has been established by the two companies and which allowed us to rapidly finalize this important Proof of Concept. Under the newly signed agreement and commercial license, we will now focus our efforts on developing the improved maÏze product for the benefits of our seed company shareholders." Ofer Haviv, Evogene's President and CEO stated, "Improved plant yield and drought tolerance are perhaps the most critical needs in today's worldwide agriculture, and as such are key targets for Evogene's agbio trait program. We therefore are extremely pleased by Biogemma's decision to continue the validation and further development of our genes in corn and consider this as a very positive outcome of the parties' joint collaborative efforts." About Evogene Evogene is a world leading developer of improved plant traits for the agriculture and biofuel industries through the use of plant genomics. The company's technology platform is based on a unique computational core technology for gene discovery, the ATHLETE, and high throughput systems for gene validation. Evogene's development programs focus on the improvement of high-commercial value plant traits, such as yield, biotic and a-biotic stresses tolerance, and the improvement of plants specifically for biofuel uses. Evogene is collaborating with world leading seed companies in order to introduce its technology into key commercial crops. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com. About Biogemma Biogemma is a leading biotech company in Europe involved in Genomics applied to Field crops. Result of the merger of the biotech activity of three major seed business companies, Vilmorin & Cie (Limagrain Group), Euralis and RAGT and with the help of two financial institutions Sofiproteol and Unigrain with the support of the technical agency Arvalis , the company is developing R&D programs with its partners, in field crops ( Corn, Wheat, Sunflower and Rapeseed ), focused on yield improvement, biotic and abiotic stresses and specialty grain compounds. 16/03/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Biogemma-Licenses-Yield-and-Drought-Tolerance-Genes-from-Evogene-for-Commercialization-in-Corn Evogene Reports Fourth Quarter and Annual 2009 Financial Results http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Fourth-Quarter-and-Annual-2009-Financial-Results Rehovot, Israel - March 10, 2010 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2009. Ofer Haviv, Evogene's president and CEO, stated: "We are extremely pleased to see the continuing rapid growth and development of our company. During the past year, we continued to advance under our current collaborations, entered into new collaborations with world leading seed companies, substantially increased our infrastructure and capacity and furthered the evaluation of our castor bean lines being developed for biodiesel uses. In addition, during 2009, significant resources were allocated, and during 2010 will continue to be allocated, to enhancements and new applications for our gene discovery core technology - the ATHLETE - and to the pursuit of two new core technologies based on our proprietary genomic understandings, systems and tools." Among our achievements during 2009 were: A new three year collaboration with Bayer CropScience AG, focusing on rice yield improvement. The agreement strengthens an existing collaboration for rice, established in 2007. A new collaboration with Syngenta Biotechnology for Soybean nematode (soil parasites) resistance, significantly expanding our activity in the important field of biotic stresses (e.g. diseases and insect resistance). Completion of a first collaboration year under the five year agreement signed with Monsanto on August 2008 and entry into the second year of the collaboration. Expansion of field trials in Texas and Brazil for the company's castor bean lines being developed as a feedstock for biodiesel production. The completion of a corporate infrastructure expansion program to substantially increase the company's R&D and administrative facilities, including construction of a new greenhouse site. The further building of the professional team of the company, with approximately 85% of the staff committed to research and development activities. Revenues for the year ended December 31, 2009 were $10 million, compared to $3.4 million reported for the same period in 2008. Revenues for the fourth quarter of 2009 were $2.6 million, compared to $2.3 million for the same period in 2008. Revenues for the year ended and fourth quarters of 2008 and 2009 include revenues generated mainly under the collaboration with Monsanto. Profit from ordinary operations for the year ended December 31, 2009 was $266 thousand, compared to a loss from ordinary operations of $4.1 million in the same period in 2008. Loss from ordinary operations for the fourth quarter of 2009 was $481 thousand, compared to a profit from ordinary operations of $836 thousand in the same period in 2008. Included in the comprehensive loss for year ended December 31, 2009 were $4.8 million of non-cash financial expenses, compared to $247 thousand for the prior year. These non-cash charges are due primarily to the revaluation for accounting purposes of the publicly traded options issued in the 2007 IPO due to the change in market price of the Company's ordinary shares during such time periods. After taking into account these non-cash charges, total comprehensive loss for the year ended December 31, 2009, was $3.4 million, or $0.13 per share, compared to $4.5 million, or $0.22 per share, in the same period in 2008. Mr. Haviv continued: "With regards to our financial results, in 2009 there was a substantial growth in revenues due primarily to our collaborations with Monsanto, Bayer and Syngenta. Consistent with this, a substantial portion of our research and development activities during the year were in support of these collaborations and therefore these expenses are being accounted for as cost of revenues. We anticipate that for 2010, non-collaboration research and development expenses will increase, mostly due to the planned development of the company's new core technologies." As of December 31, 2009, Evogene had $38.2 million in cash, cash equivalents, cash deposits and short-term marketable securities, an increase of approximately $9 million compared to $29.4 million as of December 31, 2008. This increase is mainly due to the exercise in the third quarter of 2009 of substantially all of the company's Series 1 options that were issued as part of the company's initial public offering on the Tel Aviv Stock Exchange in June 2007. 10/03/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Reports-Fourth-Quarter-and-Annual-2009-Financial-Results Evogene Establishing Biofuel Feedstock Field Trials in Texas and Brazil http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Establishing-Biofuel-Feedstock-Field-Trials-in-Texas-and-Brazil Rehovot, Israel (February 1, 2009) - Evogene Ltd. (TASE: EVGN) announced yesterday the establishment of field trials in Texas, USA and northeastern Brazil, for the evaluation of its proprietary castor bean lines. These castor bean lines, designed for higher yield and growth on semi-arid land, are being developed by Evogene to serve as a sustainable and cost efficient second-generation feedstock for biofuel production. Having recently completed two years of field trials under semi-arid conditions in Israel, the purpose of the field trials in Texas and Brazil is to evaluate the lines when grown in the two main target locations for future commercial growth, and further develop them to local conditions. The semi-arid land potentially available for castor commercial growth in these areas is estimated at over 10 million hectares and the climate conditions are suitable for this purpose. The field trials will be operated in collaboration with Texas AgriLife Research, part of the Texas A&M System in the U.S., and South Cone Agriculture in Brazil. "During the past few years, in addition to our well-established and rapidly growing agbio trait activities, our biofuel activity has grown with the castor project being a key component," stated Mr. Ofer Haviv, Evogene's President and CEO. "Both the USA and Brazil have strong potential in terms of land availability, commitment to biofuels and ability to develop large scale agriculture industries. We look forward to working with the professional teams at Texas AgriLife Research and South Cone Agriculture to test our castor lines and further develop them towards commercialization." Mr. Haviv continued, "Consistent with our increased focus on castor project, the company recently announced that the collaboration with Orfuel, a US subsidiary of Ormat Industries, for the development of improved feedstock sources for biodiesel production, has been terminated. The field trials being announced today are a continuation of that effort, but moving forward now as a part of Evogene's proprietary biofuel program." The biodiesel market in the U.S. and Brazil is growing rapidly, with production of 2.5 and 1.3 billion liters respectively, which combined represented in 2008 more than one-third of the global biodiesel production. The Brazilian government is heavily promoting the production of biodiesel and recently announced the adoption of a legal mandate for use of 5 percent biodiesel blended with diesel fuel. In addition, currently both the U.S. and Brazil have surplus industrial capacity to produce biodiesel, however the major bottleneck of the industry remains feedstock supply to meet the required demand. Mr. Haviv concluded: "There is an immediate need for a sustainable, widely available and cost efficient second-generation plant feedstock for biofuels. We believe that the castor bean varieties Evogene is developing can provide a solution for the industry." About Evogene Evogene is a world leading developer of improved plant traits. The company's proprietary product development platform combines state of the art computational gene discovery technology (The 'ATHLETE'), plant and field validation capabilities and unique selection systems. Evogene's current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com. About The Texas A&M System/Texas AgriLife Research Texas A&M was established in 1876 as Texas' first public institution of higher learning. Today it has a 5,000-acre campus boasting world-class research programs and award-winning faculty. As one of the world's leading research institutions, The Texas A&M System makes significant contributions to the storehouse of knowledge, including many to science and technology. Research conducted within the system represents an annual investment of more than $582 million, which ranks third nationally for universities without a medical school and underwrites approximately 3,500 sponsored projects. Part of the Texas A&M System, Texas AgriLife Research is the state's premier research agency in agriculture, natural resources and the life sciences. Collaborative research spans various scientific disciplines and is conducted throughout Texas, the U.S. and numerous countries worldwide. This research creates basic, fundamental and applied contributions, in many cases resulting in economic benefit to the state, nation and world. About South Cone Agriculture South Cone Agriculture, Plc (SCA) is an Irish company engaged in the development of large scale agro-industrial plantations targeting the biofuels and chemical industries. Its activities are carried out in South America and are soon to be expanded to Africa. SCA's focus is on origination of oilseeds, mainly castor, jatropha and crambe - high value oils with special chemical characteristics. 01/02/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Establishing-Biofuel-Feedstock-Field-Trials-in-Texas-and-Brazil Evogene Continues to Strengthen Scientific and Management Teams http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Continues-to-Strengthen-Scientific-and-Management-Teams Rehovot, Israel (February 1, 2010) - Evogene (TASE:EVGN) announces that during the past months, it continued to strengthen its scientific and management teams by the appointment of additional Program Managers, a Business Development Manager, Computational Genomics Scientists and a Seed Production Agronomist, alongside additional staff in the different units of the company's technology platform. Ofer Haviv, Evogene's president and CEO said: "During 2009, we substantially increased our staff by more than 30%, and are today proud to have 100 employees, with approximately 85% committed to research and development activities. This continuous expansion is geared towards supporting the company's R&D activities for internal projects and on-going collaboration agreements, including significantly strengthening and increasing our gene discovery and validation capabilities." The senior employees joining Evogene's team are: Mr. Chanan Lavi - Business Development Manager Prior to joining Evogene, Mr. Lavi served as Business Development Manager at IAI - Israel Aerospace Industries. Prior to that, Mr. Lavi was employed by SanDisk where he was a Director of Business Development and before that had held several other business and financial positions at SanDisk and MSystems (NSDQ:FLSH) until it was acquired by SanDisk Corp (NSDQ:SNDK). Mr. Lavi holds an M.A. (Cum Laude) and B.A. (Summa Cum Laude) in Economics and Business Management from the Hebrew University of Jerusalem. Dr. Avner Levy - Program Manager Prior to joining Evogene, Dr. Levy worked as a post-doctorate fellow at the University of Michigan, Ann Arbor, MI, USA (2007-2009). During the years 2006-2007 throughout his Ph.D. studies, Dr. Levy worked as a crop breeder in both the Faculty of Agriculture, the Hebrew University of Jerusalem and in a private seed company. Dr. Levy holds a Ph.D. (2006) and a M.Sc. (2000) from the Department of Genetics, Faculty of Agriculture of the Hebrew University of Jerusalem. Dr. David Panik - Program Manager Prior to joining Evogene, Dr. Panik completed his post-doctoral fellowship at the Weizmann Institute of Science in the lab of Dr. Asaph Aharoni. Major focus of his work was the metabolism of the plant surfaces. He did his PhD at the Pharmacology Department of the Hebrew University of Jerusalem in the field of endocannabinoids. In addition, Dr. Panik holds B.A. and M.Ss. (1997) in Pharmaceutical Sciences from Sankt-Petersburg State Chemical and Pharmaceutical Academy, Russia. Dr. Limor Poraty-Gavra - Program Manager Prior to joining Evogene, during the years 2002 - 2009, Dr. Poraty completed her M.Sc. and Ph.D. studies at the Faculty of Life Science, Plant Sciences Department in Tel-Aviv University. During that time she visited at the Swiss Federal Institute of Technology Zurich for gene expression studies. In addition, Dr. Poraty took part in the development of a method for reducing lignin content in the plant, which is registered as a patent by "Ramot at Tel Aviv University Ltd". Mr. Yinon Plesser - Seed Production Agronomist Prior to joining Evogene, Mr. Plesser worked as an experimental and up-scaling seed production manager at "Hazera Genetics" (2006- 2010). In addition, he served as an assistant tomato breeder at "Hazera Genetics"(2005-2006). Mr. Plesser holds a B.Sc. (2005) from the Plant Science Department of the Faculty of Agriculture of the Hebrew University of Jerusalem. Dr. Chanan Rubin - Senior Computational Genomics Scientist Prior to joining Evogene, Dr. Rubin worked as a post-doctorate fellow at the National Institute of Health in Bethesda, Maryland, as a researcher in the field of epigenetics (2008-2009). His Ph.D. at the Weizmann institute of Science focused on the study of signal transduction networks and cancer biology (2002-2007). Dr. Rubin's work was published in several high-impact peer-reviewed journals. During the years 1998-2000 he worked as a software engineer at Compugen, developing tools for the company's bioinformatic platform. Dr. Rubin holds a B.Sc. in math and computer science from the Tel-Aviv University and an M.Sc. and Ph.D. in Biology from the Weizmann Institute of Science, Rehovot. Ms. Yaara Unger - Computational Genomics Scientist Prior to joining Evogene, Ms. Unger worked as a REALTIME embedded software engineer at ECI (2007-2010), as a computational biology scientist at Proteologics (2006-2007) and as a client-side software engineer at Brighthaul (2004). Ms. Unger holds a M.Sc. (2006) from the Faculty of Biology, Weizmann Institute of Science and a B.Sc. (Cum Laude) in Computer Science and Computational Biology (2003) from the Hebrew University of Jerusalem. 01/02/2010 http://www.evogene.com/News-Events/Press-Releases/2010/Evogene-Continues-to-Strengthen-Scientific-and-Management-Teams Evogene Completes Substantial Facilities Expansion http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Completes-Substantial-Facilities-Expansion Rehovot, Israel - November 30, 2009 - Evogene Ltd. (TASE: EVGN) announced today the successful completion of its previously announced program to substantially increase the company's R&D and administrative facilities. During the past year, the company has developed and is now operating a new greenhouse site at Kibutz Naan, Israel for model and target plant growth. The site is comprised of 15 state of the art greenhouses with cutting edge equipment for plant validation assays. In addition, the company completed the expansion of its existing facilities in Rehovot, which included substantial increases to all computational and lab-based components of its gene discovery and plant validation platform, including molecular biology and tissue culture, in addition to new administrative offices. Ofer Haviv, Evogene's President and CEO stated: "Since Evogene's formation in 2002, the company has established a powerful technology platform that enables highly accurate and rapid computational discovery and plant validation of candidate genes, linked to desired plant traits. During the past two years, we significantly increased our gene discovery and validation capabilities in terms of gene quantities and efficiency and entered into several new collaborations. In addition, during this time period we more than doubled the size of our technological team, which now consists of more than 80 persons from all the required scientific disciplines." Ofer Haviv continued, "With the completion of this facilities expansion, we now have the facilities and equipment that will allow us to both support our existing collaboration agreements and provide us with the opportunity to pursue additional collaborations in the coming years." For more information on Evogene's new greenhouses site and platform, please click here. 30/11/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Completes-Substantial-Facilities-Expansion Evogene Reports Third Quarter 2009 Financial Results http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Third-Quarter-2009-Financial-Results Rehovot, Israel - November 19, 2009 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the third quarter, ended September 30, 2009. Ofer Haviv, Evogene's president and CEO stated: "During the third quarter of 2009, we continued advancing our R&D activities under our existing collaboration agreements with world leading seed companies. In order to support these and anticipated new collaborations, along with our own internal programs, we recently completed a significant expansion of our capacity in terms of staffing, facilities and equipment. This included a new greenhouse site for model and target plant growth at Kibutz Naan in Israel, and expansion of our molecular biology and tissue culture labs. With this significantly increased computational gene discovery and plant validation capacity and our strong cash position, we enthusiastically look forward to the continuing growth of our company." Revenues for the first nine months ended September 30, 2009 were $7.4 million, compared to $1.1 million for the same period in 2008. Revenues for the third quarter of 2009 were $2.6 million, compared to $0.9 million for the same period in 2008. Revenues for the first nine months and third quarter of 2009 include revenues generated mainly under the collaboration with Monsanto. Profit from ordinary operations for the first nine months of 2009 was $747 thousand, compared to a loss from ordinary operations of $5.0 million in the same period in 2008. Loss from ordinary operations for the third quarter of 2009 was $113 thousand, compared to a loss from ordinary operations of $2.3 million in the same period in 2008. Total comprehensive loss for the first nine months ended September 30, 2009, was $3.0 million, or $0.11 per share, as a result of $5.0 million of non-cash financial expenses due to revaluation of certain non-employee options, primarily options issued in the 2007 IPO. These revaluations for accounting purposes reflect changes in the fair market value of Evogene ordinary shares and the market value of the options. This is compared to a total comprehensive loss of $9.1 million, or $0.44 per share, in the same period in 2008, including non-cash financial expenses of $4.3 million due to the revaluation of options. Total comprehensive profit for the third quarter of 2009 was $2.1 million, or $0.07 per share, as a result of $1.3 million of non-cash financial income due to revaluation of certain non-employee options, primarily options issued in the 2007 IPO. This is compared to a total comprehensive loss of $7.6 million, or $0.35 per share, including non-cash financial expenses of $4.8 million due to the revaluation of options. As of September 30, 2009, Evogene had approximately $39 million in cash, cash equivalents, cash deposits and short-term marketable securities, an increase of $10 million compared to $29 million as of December 31, 2008. This increase is mainly due to the exercise in the previous quarter of the company's outstanding Series 1 options that were issued as part of the company's IPO in June 2007. Financial Tables 19/11/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Third-Quarter-2009-Financial-Results Evogene Names New VP of Technology Platform http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Names-New-VP-of-Technology-Platform REHOVOT, ISRAEL (August 31, 2009) - Evogene Ltd. (TASE: EVGN) announced today that Mr. Assaf Kacen, has been named as the Company's VP of Technology Platform, effective August 31, 2009. Prior to joining Evogene, Assaf Kacen held a position of Product manager at Nokia Siemens Networks (2008-2009). He has substantial R&D management experience leading Lateral Software Groups with multiple teams of engineers (2004-2008), implementing advanced development procedures and management methods with proven results. Assaf served in the Israeli Air Force, where he held a variety of command and management positions. Assaf holds an MBA from Interdisciplinary Center, with a specialization in Finance and a B.Sc in Communication Systems Engineering from Ben-Gurion University. "We are pleased to have Assaf Kacen join our team at Evogene. Assaf's experience in R&D platform management coupled with his operational excellence makes him a strong leader for our technology platform," said Ofer Haviv, Evogene's President and CEO. "For the past three years, Dr. Tamara Byk has led the establishment of the Company's powerful technology platform. During this period, we significantly strengthened the platform infrastructure: the professional technology platform team grew from 20 people to more than 50; we doubled the number of platform departments; tremendously increased the platform's gene validation capacity and greatly improved processes related to our gene validation. The exceptional capabilities and potential of the technology platform team have been demonstrated through our accelerating R&D programs and our technological and commercial achievements." Assaf Kacen stated, "I am very excited to join Evogene and take part in the Company's growth. The fundamental role of Evogene's technology platform makes this new position a great challenge for me. I am confident that working together with the platform's talented team will allow us to support the R&D programs and provide the essentials for the Company to meet its goals." Tamara Byk, stated, "I am proud to have been a part of the achievement and progress of Evogene in the recent years. It was a great challenge for me to lead Evogene's technology platform, which includes the Bioinformatics, Molecular Biology, Tissue Culture & Plant Transformation units as well as the Plant Growth units, in a period of accelerated growth and substantial expansion of the Company's R&D programs and collaborative activities. I look forward to continuing to be involved in the Company's consulting capacity." 31/08/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Names-New-VP-of-Technology-Platform Evogene Reports Second Quarter 2009 Financial Results http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Second-Quarter-2009-Financial-Results Rehovot, Israel - August 13, 2009 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the second quarter, ended June 30, 2009. Ofer Haviv, Evogene's president and CEO stated: "During the second quarter of 2009, our accelerating growth and development continued with new collaborations with world leading agro-biotech companies, important enhancements to our discovery methodologies and further broadening of the scope of our R&D activities. These achievements included the recently announced initiation of a collaboration with Syngenta Biotechnology, focusing on identifying plant genes for resistance to soybean nematode, one of the most devastating and yield limiting pests of soybean. This collaboration is the first where we will be focusing our gene discovery capabilities in the critical area of pest protection for major field crops." Mr. Haviv continued: "In addition, we greatly appreciate the vote of confidence expressed by our investors through the recent exercise of 99.6% of the company's outstanding Series 1 options. These options were issued as part of the company's IPO in June 2007, and with the approximately $9 million received from this exercise, Evogene ended the quarter with cash and cash equivalents of $39 million." Revenues for the first six months ended June 30, 2009 were $4.8 million, compared to $202 thousand for the same period in 2008. Revenues for the second quarter of 2009 were $2.4 million, compared to $88 thousand for the same period in 2008. Revenues for the first six months and second quarter of 2009 include revenues generated mainly under the collaboration with Monsanto. Profit from ordinary operations for the first six months of 2009 was $860 thousand, compared to a loss from ordinary operations of $2.7 million in the same period in 2008. Profit from ordinary operations for the second quarter of 2009 was $236 thousand, compared to a loss from ordinary operations of $1.5 million in the same period in 2008. Total comprehensive loss for the first six months ended June 30, 2009, was $5.1 million, or $0.2 per share, as a result of $6.3 million of non-cash financial expenses due to revaluation of certain non-employee options, primarily options issued in the 2007 IPO. These revaluations for accounting purposes reflect changes in the fair market value of Evogene ordinary shares and the market value of the options. This is compared to a total comprehensive loss of $1.5 million, or $0.12 per share, in the same period in 2008, including non-cash financial revenues of $0.5 million due to the revaluation of options. Total comprehensive loss for the second quarter of 2009 was $3.8 million, or $0.14 per share, as a result of $4.7 million of non-cash financial expenses due to revaluation of certain non-employee options, primarily options issued in the 2007 IPO. This is compared to a total comprehensive loss of $0.9 million, or $0.06 per share, including non-cash financial revenues of $0.3 million due to the revaluation of options. As of June 30, 2009, Evogene had $39 million in cash, cash equivalents, cash deposits and short-term marketable securities compared to $29.4 million as of December 31, 2008. Financial Tables 13/08/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Second-Quarter-2009-Financial-Results Syngenta and Evogene to Collaborate on Soybean Nematode Resistance http://www.evogene.com/News-Events/Press-Releases/2009/Syngenta-and-Evogene-to-Collaborate-on-Soybean-Nematode-Resistance REHOVOT, ISRAEL (June 26, 2009) - Evogene Ltd. (TASE: EVGN) today announced a collaboration with Syngenta Biotechnology, Inc. focusing on identifying plant genes related to soybean nematode resistance. Under the agreement, Syngenta will receive exclusive licensing rights to candidate genes discovered by Evogene for use in soybean. Soybean nematode is a soil parasite which attacks the roots of developing plants, and is one of the most devastating and yield limiting pests of soybean. Soybean growers may lose more than 20 percent of their yield to this pest, while defenses against it are limited. It is estimated that soybean nematode causes losses in the United States alone exceeding one billion dollars annually. "We are very pleased by this collaboration with Syngenta and we look forward to working with the Syngenta team on this key trait for soybean," stated Ofer Haviv, Evogene's President and CEO. "Plant pest protection traits, such as nematode resistance, have a strong impact on farm productivity hence Evogene intends to expand use of its predictive technologies for gene discovery in this field," Mr. Haviv concluded. "Syngenta is a leader in advanced breeding to bring our grower customers the best choices to protect yield against soybean pests," stated Roger Kemble, Head Syngenta Crop Genetics Research. "This collaboration complements our in-house trait discovery program, creating new sources of genes for biotech traits to strengthen our current offering." Under this collaboration agreement, Evogene will provide Syngenta with candidate genes discovered by Evogene's computational gene discovery technology, the 'ATHLETE', that are predicted to improve nematode resistance. Syngenta will evaluate candidate genes in its soybean research and development program. Syngenta may commercialize improved soybean seeds developed through this collaboration. Specific details of the agreement were not disclosed. 26/06/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Syngenta-and-Evogene-to-Collaborate-on-Soybean-Nematode-Resistance Evogene to present at the ISMB-ECCB 2009 in Stockholm-Sweden on June 30, 2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-to-present-at-the-ISMB-ECCB-2009-in-Stockholm-Sweden-on-June-30-2009 Maital Ashkenazi, Senior Computational Genomics Scientist at Evogene, presented at the ISMB/ECCB 2009 in Stockholm, Sweden on June 30th, 2009, as part of Cytoscape Birds of a Feather (BoF) meeting. ISMB is the annual meeting of the International Society for Computational Biology (ISCB). ISMB/ECCB 2009 conference is one of the largest and most important computational biology events globally. 23/06/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-to-present-at-the-ISMB-ECCB-2009-in-Stockholm-Sweden-on-June-30-2009 Evogene announces results of exercise of the company's series 1 options http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-announces-results-of-exercise-of-the-companys-series-1-options Rehovot, Israel - June 2, 2009 - Evogene Ltd. (TASE: EVGN) announced today that it has received $9 million from the exercise of the company's series 1 options (expiration date May 31, 2009). The options were issued in June 2007 as part of the company's initial public offering on the Tel Aviv Stock Exchange. Ofer Haviv, Evogene's president and CEO stated: "We welcome this vote of confidence of our investors in the company with the exercise of 99.6% of the issued series 1 options. " 02/06/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-announces-results-of-exercise-of-the-companys-series-1-options Evogene Strengthens its Scientific and Management Teams http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Strengthens-its-Scientific-and-Management-Teams Rehovot, Israel - May 24th, 2009 - Evogene (TASE:EVGN) announces that during the past six months, it has significantly strengthened its scientific and management teams by the appointment of additional Program Manager, Business Development Manager, Director of IP, Director of Operation, Senior Computational Genomics Scientist, Plant Growth Unit Manager and Seed-Bank Manager, next to additional manpower in the different units of the company's technology platform. During the past year, Evogene continued with its technical, commercial and financial progress, and entered into multi-year collaborations with leading international seed companies: In August 2008, Evogene signed a 5 year collaboration agreement with Monsanto Company for yield and drought improvement in key commercial crops, and in April 2009, Evogene signed a three year collaboration agreement with Bayer CropScience for yield improvement in rice. In order to support its R&D programs and these new and previous collaboration agreements, the company decided to strengthen its professional team. Ofer Haviv, Evogene's president and CEO said: "During the past year, we experienced a tremendous growth, both in our human resources and in our research and administrative facilities. Following a growth of more than 50% in our human resources, we are today proud to employ 75 employees from various disciplines - bioinformaticians, biologists, breeders, agronomists and others. Our team is a great contributor to our progress and achievements, and we are certain that our expanded team will allow us to further meet the objectives in our two main fields of activity -improved plant traits and improved feedstock for biofuels." The senior employees who joined Evogene's team are: Dr. Dror Shalitin - Program Manager Prior to joining Evogene, Dr. Shalitin worked for 2 years as a senior scientist at the 'Institute for Myeloma and Bone Cancer Research', West Hollywood, CA, USA (2006-2007). During the years 2000-2005, Dr. Shalitin worked first as a post-doctorate fellow and then as a Research-Associate at the University of California Los-Angeles. His scientific findings were published in standing journals such as Nature, Plant Cell and PNAS. Dr. Shalitin holds a Ph.D. (2001) and a M.Sc. (1994) from the Department of Field Crops and Genetics, and the Department of Plant Pathology (respectively), Faculty of Agriculture of the Hebrew University of Jerusalem. Mr. Eran Kosover - Business Development Manager Prior to joining Evogene, Mr. Kosover was in charge of Sales & Marketing in Atera Networks, an Israeli Hi-tech IT Security company (2005-2008). Prior to that, Mr. Kosover worked as a Project Manager in various Strategic Consulting projects for Teva Pharmaceuticals divisions, mainly Teva EU (2002-2005). Mr. Kosover holds an M.A. in Economics from the Tel Aviv University Berglas School of Economics (2006); and a B.A. in Economics and Management from the Tel Aviv University (2002). Mr. Gil Kalmanovich - Director of IP Prior to joining Evogene, Mr. Kalmanovich worked as the IP manager at COMVERSE Ltd. Prior to that, Mr. Kalmanovich worked as the IP Manager at Rosettagenomics (2005-2007). Mr. Kalmanovich is a licensed Israeli Patent Attorney since 2004. Mr. Kalmanovich holds a M.Sc. in Bioinformatics from Bar-Ilan University (Cum Laude) and a M.BA. from the Interdisciplinary Institute in Rishon Le-Zion. Mr. Assaf Elias - Director of Operation Prior to joining Evogene, Mr. Elias worked in two startups companies as COO (2005-2008). Prior to that, Mr. Elias worked at Compugen as Operation and Purchasing Manager (2000-2005). Mr. Elias holds a M.BA. from the College of Management and a B.Sc. in Chemistry from Bar-Ilan University. Ms. Maital Ashkenazi - Senior Computational Genomics Scientist Prior to joining Evogene, Ms. Ashkenazi worked as a senior software engineer at UCmore (2000-2001), as a project leader at Comverse (1999-2000) and as a consultant for SPL WorldGroup (1997-1998). In addition to her role in Evogene, Ms. Ashkenazi is a core developer for the open source organization Cytoscape, and mentors students through their coding projects in the Google Summer of Code program. Ms. Ashkenazi holds a M.Sc. (Cum Laude) in Plant Science, Genomics and Bioinformatics (2008) and a B.Sc. (Cum Laude) in Plant Science (2005) from the Hebrew University of Jerusalem. Ms. Haya Rak-Yahalom - Model Plant Growth Unit Manager Prior to joining Evogene, Ms. Rak-Yahalom worked at "Hen" nurseries as an Agronomist and a production manager (1994-2009). In addition she worked in developing data base for "Yanai" nurseries (2003). She also performed various consulting jobs and worked as a landscape architect (2002-2009). Ms. Rak -Yahalom holds a B.Sc. Agr. (1987) from the Faculty of Agriculture of the Hebrew University of Jerusalem. Ms. Michal Stein - Seed Bank Manager Prior to joining Evogene, Ms. Michal Stein worked as a Regulatory Document Specialist at CTI Clinical Trial & Consulting Services Inc., USA (2006-2008). In addition, she managed the Germination Laboratory at "Hazera Genetics", Israel. Ms. Stein holds a M.Sc. (1993) and a B.Sc. (1991) from the Plant Protection Department of the Faculty of Agriculture of the Hebrew University of Jerusalem. 24/05/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Strengthens-its-Scientific-and-Management-Teams Evogene Reports First Quarter 2009 Financial Results http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-First-Quarter-2009-Financial-Results Rehovot, Israel - May 19, 2009 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the first quarter ended March 31, 2009. Ofer Haviv, Evogene's president and CEO stated: "We are very pleased to conclude additional quarter of growth and progress in the two main fields of our activity - improved traits for a wide diversity of key commercial crops and improved feedstock for biofuels. In the first quarter of 2009 we continued, as planned, with our R&D activities under our collaborations with leading international ag-biotech companies, including the five year agreement with Monsanto Company, initiated in August 2008. Furthermore, in April this year, we announced a three year agreement with Bayer CropScience for yield improvement in rice." Mr. Haviv continued "During this quarter we greatly strengthened the capacity of our technology platform for gene discovery and plant validation through significant expansion of our molecular lab, tissue culture rooms, greenhouses and office space." Revenues for the first quarter of 2009 were $2.4 million, compared to $114 thousand for the same period in 2008. Revenues for the first quarter of 2009 include revenues generated mainly under the collaboration with Monsanto. Profit from ordinary operations for the first quarter of 2009 was $624 thousand, compared to a loss from ordinary operations of $1.2 million in the same period in 2008. Total comprehensive loss for the first quarter of 2009 was $1.4 million, or $0.06 per share, including financial expenses of $1.7 million due to revaluation of options and obligation to the Office of Chief Scientist. This is compared to a total comprehensive loss of $0.7 million, or $0.06 per share, including financial revenues of $182 thousand due to revaluation of options and obligation to the Office of Chief Scientist in the same period in 2008. As of March 31, 2009, Evogene had $30 million in cash, cash equivalents, cash deposits and short-term marketable securities. Financial Tables 19/05/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-First-Quarter-2009-Financial-Results Bayer CropScience and Evogene Enter a Multi-Year Collaboration for Rice Yield Improvement http://www.evogene.com/News-Events/Press-Releases/2009/Bayer-CropScience-and-Evogene-Enter-a-Multi-Year-Collaboration-for-Rice-Yield-Improvement- MONHEIN AM RHEIN, GERMANY and REHOVOT, ISRAEL (April 21, 2009) - Bayer CropScience AG and Evogene Ltd. (TASE: EVGN) today announced a three-year collaboration focused on increasing rice productivity and yield. Pursuant to the collaboration agreement, key candidate genes discovered by Evogene for yield enhancement will be introduced into Bayer CropScience's rice R&D pipeline for the development of high yielding hybrid rice. The agreement strengthens and expands the companies' existing research and development collaboration for rice, established in 2007. Rice is one of the most important grains for human nutrition, providing more than one fifth of all calories consumed worldwide. Rice is the cereal with the second highest worldwide production after maize. For a number of years the growth rate of rice production has been slower than population growth, which triggered the need for rice varieties displaying improved yields. Dr. Michiel van Lookeren Campagne, Head of Research at BioScience, a business operations unit of Bayer CropScience, welcomes the expanded business relationship with Evogene. "Advantages in yield and yield stability of our superior hybrids have been the basis of our leadership position in rice hybrid seeds. The integration of the full breadth of Evogene's proprietary yield improvement gene technology into our rice R&D pipeline will allow us to keep offering top-of-the-line innovation to our customers, especially with regard to ensuring higher yields in difficult climatic conditions." "We are very pleased by this expansion of our rice collaboration with Bayer CropScience on yield improvement," stated Mr. Ofer Haviv, Evogene's President and CEO. "This important trait has been, and will remain, a key focus area for Evogene, and the new agreement represents an important addition to our rapidly expanding programs in this area. In addition, we believe that these types of broader, longer term collaborations with world leading ag-biotech companies, such as Bayer CropScience, are the most efficient way for Evogene to continue progressing towards its goal of being the leading trait provider to the seed industry," Mr. Haviv concluded. Under the terms of the collaboration: Evogene will provide Bayer CropScience with candidate genes, discovered by Evogene, that are predicted to improve yield; Evogene's computational technology, the 'ATHLETE', will be used for the gene discovery process, and the genes will be validated by Evogene in model plants; Bayer CropScience will integrate the licensed genes into its R&D pipeline and evaluate them in rice; Bayer CropScience will be granted an exclusive commercialization license to the candidate genes for use in rice; Evogene will receive annual research payments and is entitled to development milestones and royalty payments based on sales of any resulting products. Bayer CropScience and Evogene have been collaborating since June 2007 to increase productivity and yield in rice. About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.4 billion (2008), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of more than 18,000 and is represented in more than 120 countries. About Evogene Evogene is a world leading developer of improved plant traits. The company's proprietary product development platform combines state of the art computational gene discovery technology (The 'ATHLETE'), plant and field validation capabilities and unique selection systems. Evogene's current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com. 21/04/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Bayer-CropScience-and-Evogene-Enter-a-Multi-Year-Collaboration-for-Rice-Yield-Improvement- Evogene Reports Fourth Quarter and Annual 2008 Financial Results http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Fourth-Quarter-and-Annual-2008-Financial-Results Results include initial activities under Monsanto Agreements Rehovot, Israel - March 11, 2009 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2008. These results include initial activities under the Monsanto Collaboration Agreement and the Monsanto Investment Agreement, both signed in August 2008. Ofer Haviv, Evogene's president and CEO stated: "We are very pleased with our continuing and accelerated progress during 2008, further strengthening our position as a leader in improved traits for a wide diversity of key commercial crops and improved feedstock for biofuels. We are proud of the company's commercial, technical and financial progress during the past year, all of which were achieved during a period of rapid corporate expansion and a challenging financial environment." Evogene's key achievements for the year included: Initiation of a multi-year collaboration with Monsanto Company, the world's leading seed company, to improve yield in corn, soybeans, canola and cotton. Pursuant to this collaboration, Evogene received a $5 million initial payment and expects to receive annual research payments totaling approximately $30 million during the next five years plus milestone payments and royalties based on seed sales incorporating Evogene discovered genes. Investment agreement with Monsanto, pursuant to which Monsanto purchased an $18 million equity stake in Evogene, and shall be obligated, subject to certain Evogene diligence requirements under the collaboration and at Evogene's request, to purchase in the future an additional $12 million of Evogene equity. Successful field trial results for Evogene discovered genes in corn. The field trials, conducted as part of Evogene's collaboration with Biogemma SAS, demonstrated that corn containing Evogene discovered genes displayed significant yield increases under both normal and drought conditions. Continued progress under collaborations with other leading international ag-biotech companies, including new agreements signed during 2008 with Vilmorin and Viterra. Expansion, as planned, of our activities in the field of biofuels. Substantial increases in our R&D capabilities and capacities, including significant strengthening of Evogene's professional staff and additions to our facilities and infrastructure to support the Company's rapidly growing R&D programs and collaboration activities. This includes construction of state-of-the-art greenhouses, additional laboratory space and offices, and computational equipment. Mr. Haviv continued: "With respect to our financial status, during 2008 we substantially strengthened our balance sheet through the signing of the collaboration and investment agreements with Monsanto. We ended the year with $29 million in cash, plus more than an additional $30 million in expected future payments under existing agreements." Revenues for the year ended December 31, 2008 were $3.4 million, compared to $251 thousand for the same period in 2007. Net loss for the year ended December 31, 2008 was $4.8 million, or $0.22 per share, compared to a net loss of $4.9 million, or $0.29 per share, for the same period in 2007. Revenues for the fourth quarter of 2008 were $2.4 million, compared to $67 thousand for the same period in 2007. Net profit for the fourth quarter of 2008 was $4.6 million, including financial income of $3.9 million (including $3.6 million financial income due to revaluation of index linked publicly traded Options according to the IFRS) and a profit of $800 thousand from ordinary operations. This is compared to a net loss of $1.3 million, including financial expenses of $76 thousand (including $295 thousand financial expenses due to revaluation of Options) and a loss of $1.2 million from ordinary operations, for the corresponding quarter of 2007. Revenues for the year ended December 31, 2008 and the fourth quarter of 2008 include revenues generated under the collaboration with Monsanto. As of December 31, 2008, Evogene had $29 million in cash, cash equivalents, cash deposits and short-term marketable securities. 11/03/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-Reports-Fourth-Quarter-and-Annual-2008-Financial-Results Evogene is to present at the 'BIO International Convention 2009' in Atlanta, USA on May http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-is-to-present-at-the-BIO-International-Convention-2009-in-Atlanta-USA-on-May Dr. Hagahi Karchi, Evogene's EVP and CTO, is to present at the 'BIO International Convention 2009' in Atlanta, USA on May 19th. Dr. Karchi will present Evogene's computational approach for discovery genes controlling yield and yield stability, as part of the workshop "Saving Harvests, Lives & Livelihoods: Breakthroughs in Plant Stress Tolerance Technologies". 19/02/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-is-to-present-at-the-BIO-International-Convention-2009-in-Atlanta-USA-on-May Publication of an article co-authored by Evogene and The Hebrew University of Jerusalem http://www.evogene.com/News-Events/Press-Releases/2009/Publication-of-an-article-co-authored-by-Evogene-and-The-Hebrew-University-of-Jerusalem Rehovot, Israel - January 15th, 2009 - Evogene announces the publication of an article co-authored by Evogene and Scientists at The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture, Faculty of Agricultural, Food & Environmental Quality Sciences of The Hebrew University of Jerusalem. The article was published on January 2009 in the 'New Phytologist' Journal. The article - 'Improving plant stress tolerance and yield production: is the tonoplast aquaporin SlTIP2;2 a key to isohydric to anisohydric conversion?' - is describing the physiological mechanism of an a-biotic stress gene discovered by Evogene's computational platform, the 'ATHLETE'. 15/01/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Publication-of-an-article-co-authored-by-Evogene-and-The-Hebrew-University-of-Jerusalem Evogene announces plans to invest approximately $2 million to expand its facilities http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-announces-plans-to-invest-approximately-2-million-to-expand-its-facilities- Rehovot, Israel - January 8th, 2009 - Evogene (TASE:EVGN) announced today plans to invest approximately $2 million (8 million Israeli shekels) to expand its research and administrative facilities during 2009 to support its rapidly expanding R&D programs and collaboration activities. This investment consists of an estimated $1.2 million (4.5 million Israeli shekels) for construction of state-of-the-art greenhouses for model and target plant growth, and approximately $0.7 million (2.5 million Israeli shekels) related to the company's existing facilities in Rehovot, including expansion of its molecular biology labs, tissue culture rooms, computational infrastructure and offices. 08/01/2009 http://www.evogene.com/News-Events/Press-Releases/2009/Evogene-announces-plans-to-invest-approximately-2-million-to-expand-its-facilities- Evogene and Biogemma Show Increased Corn Yield in Field Trials http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Biogemma-Show-Increased-Corn-Yield-in-Field-Trials Corn Containing Evogene Discovered Genes Show Significant Yield Increases under Both Normal and Drought Conditions Rehovot, Israel and Paris, France, December 9, 2008 - Evogene Ltd. (TASE: EVGN) and Biogemma SAS, today announced results of field trials for corn hybrids containing a number of genes predicted by Evogene to increase yield and drought tolerance. The field trials, conducted in several sites in the United States and in Israel, demonstrate that corn hybrids containing certain of these genes displayed significant yield increases under both normal and drought conditions compared to control corn hybrids under the same conditions. Evogene and Biogemma intend to expand their efforts to further evaluate the best performing of these genes in corn through additional field trials during 2009, aimed at selection of the most suitable candidates for the next phase of development towards commercialization. The field trials for which results are now being reported were conducted as part of a collaboration initiated in 2006 between Evogene and Biogemma to develop corn with improved yield and tolerance to drought conditions. This collaboration is financially supported by the Eureka, a pan-European network for market-oriented industrial R&D. Included in the field trials were Evo133 and Evo137, two genes predicted by Evogene in 2003 to improve yield and drought through the use of its computational technology platform, the 'ATHLETE', and subsequently validated in model plants. These genes were introduced and expressed in corn utilizing Biogemma's technologies. These positive results in corn follow Evogene's announcement of December 2007 of field trial results for Evo133 demonstrating significant yield improvements in tomato plants under both normal and stress conditions. Ofer Haviv, Evogene's President and CEO stated, "We are extremely pleased by these successful results from this first field trial of Evogene discovered genes in one of the most important crops worldwide for both food and alternative energy uses. Also, in addition to the potential value represented by these genes for corn and other crops, this is a significant milestone for our company in the validation of the ability of our unique in silico discovery platform - the 'ATHLETE' - to accurately predict and select genes associated with important traits of interest in agbio. Therefore, we enthusiastically look forward to continuing our joint efforts with Biogemma in corn and with our other partners, as we move forward with both further gene discovery and the validation of Evogene discovered genes in important target crops." Pascual Perez, CEO for Biogemma stated, "We are very happy with these first year field trials showing important preliminary results for yield improvement under normal and drought conditions. Next year's experiments which will be done in more geographic locations are looked with high interest. Our corn genetic transformation pipeline and its specific proprietary technologies has allowed Biogemma to quickly and properly assess Evogene's leads in different hybrid backgrounds within two years of the initiation of our fruitful collaboration. When the collaboration was initiated in 2006, combining Biogemma's and Evogene's expertise seemed extremely promising and we see today that the good complementary skills , the two companies' know how and IP portfolio open the way to develop commercial improved corn for our shareholders. Biogemma will continue to rely on its efficient transgenic platforms for corn and wheat, to give value to the genes discovered on our genomic platforms or developed in partnerships." About Evogene Evogene is a world leading developer of improved plant traits. The company's proprietary product development platform combines state of the art computational gene discovery technology (The 'ATHLETE'), plant and field validation capabilities and unique selection systems. Evogene's current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com. About Biogemma Biogemma is a leading biotech company in Europe involved in Genomics applied to Field crops. Result of the merger of the biotech activity of three major seed business companies, Vilmorin Company ( Limagrain Group), Euralis and RAGT and with the help of two financial institutions Sofiproteol and Unigrain with the support of the technical agency Arvalis , the company is developing R&D programs with its partners, in field crops ( Corn, Wheat, Sunflower and Rapeseed ), focused on yield improvement, biotic and abiotic stresses and specialty grain compounds. 09/12/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Biogemma-Show-Increased-Corn-Yield-in-Field-Trials Evogene and Bayer CropScience to Evaluate Additional Genes for Rice Yield Improvement http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Bayer-CropScience-to-Evaluate-Additional-Genes-for-Rice-Yield-Improvement Rehovot, Israel, December 2, 2008 - Evogene Ltd. (TASE: EVGN) today announced strengthening its on-going collaboration with Bayer CropScience to increase yield in rice. In June 2007, the two companies announced a collaboration to increase rice productivity and yield. Pursuant to the collaboration agreement between the companies, Bayer CropScience has recently exercised its option to exclusive licensing rights in rice to additional candidate genes discovered by Evogene. The candidate genes, which were predicted by Evogene's computational technology (the "ATHLETE") to improve yield, displayed yield improvement when validated by Evogene in model plants, and will be evaluated by Bayer CropScience in rice. 02/12/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Bayer-CropScience-to-Evaluate-Additional-Genes-for-Rice-Yield-Improvement Evogene Reports Third Quarter 2008 Financial Results http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Third-Quarter-2008-Financial-Results Results for 2008 Periods Include Substantial Non Cash Accounting Charges Rehovot, Israel - November 27, 2008 - Evogene Ltd. (TASE: EVGN) announced today its financial results for the third quarter ended September 30, 2008. Ofer Haviv, Evogene's president and CEO stated: "We are very pleased by our continuing progress and the achievements of the past quarter highlighted by: A multiyear collaboration agreement with Monsanto Company. The agreement provides Monsanto with exclusive licensing rights in a number of crops to candidate genes that are predicted to improve plant yield, discovered by Evogene during the next five years. Evogene expects to receive approximately $35 million over the research term of the collaboration in the form of upfront and annual research payments. Evogene is also entitled to development milestone and royalties on future sales of seeds incorporating Evogene licensed genes. The continued progress under our collaborations with other leading international companies." Mr. Haviv continued: "With respect to our financial status, available resources were substantially increased during the past quarter through the signing of an investment agreement with Monsanto, pursuant to which they have purchased for $18 million an approximately 13.6% equity interest in Evogene, and have agreed to purchase, subject to certain diligence requirements under the collaboration agreement, $12 million of additional Evogene equity in the future. We ended the past quarter with $32 million in cash, cash equivalents, cash deposits and short-term marketable securities (including the equity purchase by Monsanto)." "Another significant effort during the past quarter" Mr. Haviv reported, "was the continued expansion of our R&D infrastructure to support our rapidly growing activities in the two areas of strategic interest to our company - improved plant traits and biofuels. This effort included the investment in new 'state of the art' green-houses, additional lab and computational equipment and increasing our professional staff". The financial results for the first nine months and the third quarter of 2008 include the following substantial non-cash charges: $4.6 million to financial expenses due to revaluation of tradable options and obligation to the Office of Israeli Chief Scientist, compared to $942 thousand for the first nine months of 2007; and for the third quarter of 2008, such non-cash charge to financial expenses was $5.2 million compared to $246 thousand for the third quarter of 2007. $1.5 million to R&D expenses for the first nine months of 2008 relating to the potential liability for future reimbursement of certain success based governmental grants received in the past by the company, compared to $262 thousand for the first nine months of 2007; and for the third quarter of 2008 such non-cash charge to R&D expenses was $1.2 million compared to $181 thousand for the third quarter of 2007. $504 thousand to loss from ordinary operations for the first nine months of 2008 relating to amortization of deferred compensation compared to $465 thousand for the first nine months of 2007; and for the third quarter of 2008 such non-cash charge to loss from ordinary operations was $182 thousand, compared to $200 thousand for the third quarter of 2007. Revenues for the first nine months of 2008 were $1.1 million, compared to $184 thousand for the same period in 2007. Revenues for the third quarter of 2008 were $870 thousand, compared to $39 thousand for the same period in 2007. The revenues for the first nine months and the third quarter of 2008 include revenues generated in the first month (September 2008) of the recently signed collaboration with Monsanto. Including the applicable non-cash charges as stated above, loss from ordinary operations for the first nine months of 2008 was $5.0 million, compared to $2.7 million for the same period in 2007. Loss from ordinary operations for the third quarter of 2008 was $2.3 million compared to $1.2 million for the same period in 2007. Including the applicable non-cash charges as stated above, financial expenses for the first nine months of 2008 were $4.5 million, compared to $885 thousand for the same period in 2007. Financial expenses for the third quarter of 2008 were $4.8 million compared to $277 thousand for the same period in 2007. Including the applicable non-cash charges as stated above, net loss for the first nine months of 2008 was $9.4 million, or $0.46 per share, compared to a net loss of $3.6 million, or $0.22 per share, for the same period in 2007. Including the applicable non-cash charges as stated above, net loss for the third quarter of 2008 was $7.1 million or $0.33 per share, compared to a net loss of $1.4 million, or $0.07 per share, for the same period in 2007. As of September 30, 2008, Evogene had $32.1 million in cash, cash equivalents, cash deposits and short-term marketable securities. This includes Monsanto's initial investment of $18 million and an upfront payment pursuant to the research collaboration agreement. 27/11/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Third-Quarter-2008-Financial-Results Leviev Group, Evogene and Orfuel to Establish a Biodiesel Company in Namibia, Africa http://www.evogene.com/News-Events/Press-Releases/2008/Leviev-Group-Evogene-and-Orfuel-to-Establish-a-Biodiesel-Company-in-Namibia-Africa Namibia and Rehovot, Israel, September 10, 2008 - L.L Biofuel Namibia (PTY) Ltd. of the Leviev Group and Evogene Ltd. (TASE:EVGN) today announced that together with Orfuel Inc., a US subsidiary of Ormat Industries Ltd (TASE:ORMAT), they have signed an agreement to establish a new company focused on the growth of specialized castor plants for use as feedstock for biodiesel. The new company will be headquartered in Namibia, with operations in Namibia and possibly other locations in Africa. According to the terms of the agreement, the new company will examine various castor varieties in field tests in Namibia, and following the selection of best performing varieties, the new company will work to commercialize and grow the selected varieties on a commercial scale in Namibia, and possibly in other locations in Africa. Evogene will provide the new company with the castor varieties for evaluation, and will utilize its knowledge and capabilities in plant growth. The Leviev Group will provide access to lands for crop growth in Namibia and logistical infrastructure for the project. In addition, the Leviev Group will contribute its experience and knowledge in establishing projects in Namibia and in other southern African countries. The castor varieties to be supplied by Evogene will be selected from varieties being developed in a previously announced collaboration between Evogene and Orfuel, initiated in September 2007. Under this collaboration, which has received a grant from the BIRD Foundation (Israel-US Binational Industrial Research and Development Foundation), Evogene and Orfuel are jointly developing non edible plants, such as castor, for biodiesel commercial production. A special focus of this collaboration is that these plants can be grown commercially in non arable areas. Castor is a high oil yielding crop and there are vast non arable lands available in Namibia that potentially could be used for this purpose. Thus it is anticipated that the cost of biodiesel feedstock produced using specialized castor crops grown in Namibia is expected to be significantly lower than cost of biodiesel produced from crops currently used for this purpose, such as soybean and canola. Eli Nefussy, CEO of the Leviev Group in Namibia, stated: "Innovation is one of the key elements guiding the business strategy of the Leviev Group. Renewable energy and alternative fuels are fields of high importance to the Leviev Group. I am confident that the experience of the Leviev Group in Africa together with the technology and knowledge of Evogene and Orfuel through the utilization of arable lands will result in breakthroughs in these fields. We are pleased to be partners in such an innovative project, and hope that this collaboration will be a significant layer in creating renewable resources." "This collaboration fits well into Evogene's business model in the field of biodiesel, and constitutes an additional stage towards commercialization of the plants developed through the joint project with Orfuel in one of the potential target locations," stated Ofer Haviv, Evogene's president and CEO. "We are convinced that with our extensive capabilities in plants together with the vast experience of the Leviev Group in Africa, we will be able to develop improved feedstock addressing the needs of the alternative fuel industry." About Leviev Group The activity of Leviev Group, to which L.L Biofuel Namibia (PTY) Ltd. belongs, includes various companies worldwide (in America, Europe, Africa, far east and other), which deal with real-estate, green construction, construction and infrastructures, mining, diamonds, international trade, energy and oil and other. The Leviev Group has been operating in Africa for several years, and has extensive experience in the continent in various fields. The Group is active in Namibia through mining, diamond refinement, constructions, infrastructure and agriculture. About Evogene Evogene is a leading developer of improved plants for the ag-biotech and biofuel industries. The Company's proprietary product development platform combines world leading computational gene discovery technologies, high throughput selection systems and advanced breeding methods. The platform's computational biology component - the ATHLETE - is based on Compugen's (Nasdaq: CGEN) in-silico predictive discovery capabilities. Evogene's current programs focus on yield under normal and various environmental stress conditions (such as drought), fertilizer utilization and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the ag-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com About Orfuel For additional information, please visit www.ormat.com 10/09/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Leviev-Group-Evogene-and-Orfuel-to-Establish-a-Biodiesel-Company-in-Namibia-Africa Monsanto and Evogene Collaborate on Yield and Stress Research http://www.evogene.com/News-Events/Press-Releases/2008/Monsanto-and-Evogene-Collaborate-on-Yield-and-Stress-Research Collaboration focuses on identifying key genes to help farmers produce more, while conserving more ST. LOUIS, MO, USA and REHOVOT, ISRAEL (August 28 , 2008) -Monsanto Company (NYSE:MON) and Evogene Ltd. (TASE: EVGN) have entered into a five- year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization. The agreement is intended to enhance research efforts to discover and deliver novel, yield-enhancing technologies at a time of increasing demand for grain globally. "We have been very impressed with Evogene's discovery capabilities, particularly their computer-based, predictive biology efforts," said Robb Fraley, Monsanto's Chief Technology Officer. "We look forward to building upon our strong relationship with Evogene to deliver products to farmers' fields that help meet the needs for increased food, fiber and energy while protecting the environment." "In view of Monsanto's leading position in the seed business and its history of delivering innovative products to farmers, we look forward to this expansion of our gene discovery collaboration," said Mr. Ofer Haviv, Evogene's President and CEO. "The collaboration reflects the companies' shared vision of delivering value to farmers through the development of yield-enhanced crops." Under the terms of this collaboration: - Evogene will provide Monsanto with candidate genes discovered by Evogene's computational platform that are predicted to improve yield, fertilizer utilization and a plant's reaction to environmental stress. The genes will be validated in model plants. - The collaboration will provide Monsanto access to new genes strengthening its entire gene discovery program. Monsanto will receive exclusive licensing rights to such genes in a number of crops, including corn, soybean, canola, and cotton. - Monsanto will evaluate the licensed genes in its research and development pipeline. Products that emerge from the joint development will be commercialized by Monsanto through its branded and licensed businesses. - Evogene expects to receive approximately $35 million over the research term of the collaboration in the form of an upfront payment and annual research payments, in consideration for the performance of the research. - Evogene is also entitled to development milestone and royalty payments based on sales of any resulting products. Monsanto believes this new collaboration will help support its commitment to double yields in its core crops by 2030 and strengthen its ongoing work with Evogene. In September of 2007, the two companies announced a collaboration to improve nitrogen use efficiency in corn, soybeans, canola and cotton. In a separate agreement, Monsanto has purchased an $18 million (USD) equity stake in Evogene and has agreed to purchase an additional $12 million in the future, subject to certain Evogene diligence requirements. Martin Gerstel, Chairman of Evogene, stated, "Having the world's leading agriculture company as a major collaborator moving forward is clearly a transforming event in the history of our company, and we welcome Monsanto as a shareholder. Furthermore, with this new financial commitment, we are now convinced that Evogene has the resources required to aggressively pursue our two primary areas of interest - improved plants for agriculture and novel feedstocks for biofuels." About Evogene Evogene is a leading developer of improved plants for the ag-biotech and biofuel industries. The company's proprietary product development platform combines state of the art computational gene discovery technologies, plant and field validation capabilities and unique selection systems. The platform's computational biology component - the ATHLETE - is based on Compugen's (Nasdaq: CGEN) in-silico predictive discovery capabilities. Evogene's current programs focus on yield under normal and various environmental stress conditions (such as drought), fertilizer utilization and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the ag-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com. About Monsanto Company Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information, please visit the company's web site at http://www.monsanto.com. Monsanto and Evogene Related Information 28/08/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Monsanto-and-Evogene-Collaborate-on-Yield-and-Stress-Research Evogene and FuturaGene's Wholly Owned Subsidairy, CBD Technologies Ltd. Collaborate to Improve Cotton Fiber Properties http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-FuturaGenes-Wholly-Owned-Subsidairy-CBD-Technologies-Ltd-Collaborate-to-Improve-Cotton-Fiber-Properties Evogene Ltd. (TASE: EVGN) and CBD Technologies Ltd. (CBD Tech), a wholly owned subsidiary of FuturaGene (LSE: FGN) to collaborate on the improvement of cotton fiber properties. Under the agreement signed between the parties, CBD Tech gains rights in cotton to certain promoters (genetic elements which activate gene expression) discovered by Evogene for evaluation in CBD Tech's research & development program. The promoters were discovered by Evogene utilizing its in-silico gene discovery platform, the "ATHLETE." Improving cotton fiber properties is of major interest to the cotton industry. High quality cotton fibers are essential for better yarn performances and optimal utilization through modern spinning technologies, hence produce higher value per pound for the farmer. Cotton fiber is constituted of 100% cellulose. As CBD Tech's cell wall modifying technology has shown demonstrable cellulose polymer and fiber improvement in tree species, this collaboration is aimed at combining Evogene's promoters with CBD Tech's cell wall modifying genes in order to enhance cotton fiber properties. About Evogene Evogene is a leading developer of improved plants for the ag-biotech and biofuel industries. The Company's proprietary product development platform combines world leading computational gene discovery technologies, high throughput selection systems and advanced breeding methods. The platform's computational biology component - the ATHLETE - is based on Compugen's (Nasdaq: CGEN) in-silico predictive discovery capabilities. Evogene's current programs focus on yield under normal and various environmental stress conditions (such as drought), fertilizer utilization and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the ag-biotech and alternative energy industries. Evogene's headquarters in Rehovot, Israel, and is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com About FuturaGene PLC FGN is a leading agricultural biotechnology company focused on research, development, and commercialization of technologies that play key roles in substantially improving agronomic traits of value in plants. In particular the Company is focused on the development and commercialization of modified plants for improving yields, processability and environmental sustainability in the forestry, biofuels and agricultural sectors. FuturaGene licenses intellectual property from leading universities in its strategic fields of interest and is exploiting the synergies of these technologies with the cell wall modification platform of its wholly owned subsidiary, CBD Technologies, Inc. (CBD Tech) in forestry, food and biofuel crops. CBD Tech has pioneered a modality for altered cell walls, resulting in enhanced growth and biomass, increased cellulose, improved fiber properties, improved digestibility and processability, and increased yield properties and has secured broad intellectual property covering plants with modified cell walls showing such altered properties. More information is available at www.futuragene.com 15/08/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-FuturaGenes-Wholly-Owned-Subsidairy-CBD-Technologies-Ltd-Collaborate-to-Improve-Cotton-Fiber-Properties Evogene Reports Second Quarter 2008 Financial Results http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Second-Quarter-2008-Financial-Results Rehovot, Israel - August 14, 2008 - Evogene Ltd. (TASE: EVGN) reports financial results for the second quarter ended June 30, 2008. "Our initial collaborations with the leading agbio companies in the world are confirming the uniqueness and potential value of the predictive biology driven gene discovery and validation platform that has been established at Evogene. We are now expanding our R&D capacity in terms of both physical infrastructure and scientific and management expertise to support current and anticipated new activities," stated Ofer Haviv, President and CEO. "During the past quarter, we were pleased to announce our collaboration with Vilmorin, the fourth largest seed company in the world, to improve yield and yield stability in tomatoes, and to welcome AquAgro Fund L.P, a venture capital fund focused on innovative water, agriculture, food and alternative energy technologies, as a significant shareholder," Mr. Haviv concluded. Revenues for the first six months of 2008 were $212,000*, compared to $141,000** for the same period in 2007. Operating loss for the first six months of 2008 was $2.8 million*, and the net loss for that period was $2.4 million*, or $0.12* per share. Operating loss for the first six months of 2007 was $1.5 million**, and the net loss for that period was $2.0 million**, or $0.15** per share. Revenues for the second quarter of 2008 were $89,000*, compared to $125,000** for the second quarter of 2007. Operating loss for the second quarter of 2008 was $1.5 million*, and the net loss for that quarter was $1.2 million*, or $0.06* per share. Operating loss for the second quarter of 2007 was $772,000**, and the net loss for that quarter was $1.9 million**, or $0.13** per share. As of June 30, 2008, Evogene had $10.6 million in cash, cash equivalents, cash deposits and short-term marketable securities. *Converted from New Israeli Shekels (NIS) at the exchange rate on June 30, 2008 (3.352NIS = $1.00) for the convenience of readers. ** Converted from New Israeli Shekels (NIS) at the exchange rate on June 30, 2007 (4.249 NIS = $1.00) for the convenience of readers. 14/08/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Second-Quarter-2008-Financial-Results Evogene Strengthens its Scientific and Management Teams due to Expansion in R&D Programs and Collaboration Agreements http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Strengthens-its-Scientific-and-Management-Teams-due-to-Expansion-in-RD-Programs-and-Collaboration-Agreements Rehovot, Israel - August 7th, 2008 - Evogene (TASE:EVGN) announces that during the first half of 2008 it has significantly strengthened its scientific and management teams by the appointment of two additional program managers, additional plant growth manager, a senior bioinformatician and a new IP manager. Evogene has made tremendous progress during the last year, and in order to support its growing pipeline of R&D programs and collaboration agreements, the company had to strengthen its professional team. Ofer Haviv, Evogene's president and CEO said: "Since its foundation, Evogene has worked to build one of the strongest platforms for gene discovery in the industry. Our team is an integral part of the platform, and we are now proud to employ more than 50 qualified employees from a wide range of disciplines - bioinformaticians, biologists, breeders, agronomists and others. We are certain that these individuals, together with our existing team, will allow us to achieve our commitment to be a leading provider of genes for improving key plant traits to our current and future partners." The most significant additions to Evogene's team are: Dr. Daphna Blachinsky - Program Manager Prior to joining Evogene, Dr. Blachinsky worked for 4 years as a field trial manager at Agrogreen - Minrav, a company that develops and manufactures biological control agents for agriculture. During the years 1996-2001, Dr. Blachinsky worked in the Ministry of Agriculture as a plant protection adviser. Dr. Blachinsky holds a Ph.D. (2004) and a M.Sc. (1996) from the Department of Plant Science and the Department of Plant Diseases, respectively, of the Faculty of Agriculture of the Hebrew University. Dr. Zur Granevitze - Program Manager Prior to joining Evogene, Dr. Granevitze initiated and managed a collaboration program between the Faculty of Agriculture of the Hebrew University of Jerusalem and the industry (2005-2006). In addition, He developed a DNA based gender sorting method for poultry in collaboration with the Faculty of Agriculture of the Hebrew University of Jerusalem and a U.S. based private company (2006-2007). Dr. Granevitze did his PhD on genetics of populations (2008), a M.Sc (2003) and a B.Sc (2000) from the Faculty of Agriculture of the Hebrew University of Jerusalem, and did his postdoc research in system biology at Bar-Illan University (2008). Dr. Yoav Herschkovitz - IP Manager Prior to joining Evogene, Dr. Herschkovitz trained as a patent attorney in the Jeruslaem branch of Luzzatto & Luzzatto patent attorney firm, and worked in the R&D and Engineering departments of a diagnostics based biotech company. Dr. Herschkovitz did his post doctoral study in the field of biocontrol of weedy infestations in the Department of Plant Science of the Weizmann Institute. Dr. Herschkovitz holds a Ph.D. from Department of Plant pathology and Microbiology of the Faculty of Agriculture of the Hebrew University (2005) and a M.Sc. (1998) and a B.Sc. from the Department of Molecular microbiology and biotechnology of the Faculty for life Sciences of the Tel Aviv University. Ms. Sarah Pollock - Senior Bioinformatician Prior to joining Evogene, Ms. Pollock worked in Yadata (recently purchased by Microsoft) as a senior data analyst. Prior to that, Ms. Pollock worked at Compugen (1997-2000, 2001-2007), where her last position was Bioinformatics Director, R&D; and at Pfizer, France (2000) as Chief Bioinformatics researcher. Ms. Pollock had been leading research projects in Genetics, Genomics & Diagnostics and Drug Discovery. Ms. Pollock holds a M.Sc. in Pharmacology and Physiology from Tel Aviv University (Suma Cum Laude - Interdisciplinary Program for Outstanding Students - Direct Masters program). Mr. Ialon Irijimovich - Head of Model Plant Growth Unit Prior to joining Evogene, Mr. Irijimovich worked as an agronomist in nurseries specializing in producing vegetables, herbs and flower seedlings (2006-2008, 1993-2003). During the years 2003-2006, Mr. Irijimovich worked at Boyce Thompson Institute, Cornell, NY as a plant grower at the greenhouse facilities aside researchers growing different varieties of plants, such as Arabidopsis, Tobacco, Corn, Rice, Tomatoes and others. Mr. Irijimovich holds a B.Sc. (1987-1990) from the Faculty of Agriculture of the Hebrew University of Jerusalem, Rehovot. 07/08/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Strengthens-its-Scientific-and-Management-Teams-due-to-Expansion-in-RD-Programs-and-Collaboration-Agreements Evogene to Present at the Annual Agricultural Biotechnology International Conference 'ABIC', August 24-27th, 2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Present-at-the-Annual-Agricultural-Biotechnology-International-Conference-ABIC-August-24-27th-2008 Evogene will participate at the Annual Agricultural Biotechnology International Conference (ABIC), which will be held in Cork, Ireland on August 24-27th 2008. The annual conference is one of the most important events in the field of agricultural biotechnology, and provides a discussion forum on the latest cutting-edge scientific advances in agricultural biotechnology research and future directions of agricultural biotechnology. The theme of ABIC 2008 is Agricultural Biotechnology for a Competitive and Sustainable Future, and it will be dealing with the way agricultural biotechnology R&D will impact sustainable social and economic development at times when global agricultural production faces significant challenges. Evogene will give a lecture on its proprietary computational gene discovery platform, the ATHELET (Agro Traits Harvest LEeads TEchnology), which enables the rapid and reliable discovery of candidate genes with high relevance to a target trait of interest. print page 14/07/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Present-at-the-Annual-Agricultural-Biotechnology-International-Conference-ABIC-August-24-27th-2008 Evogene to Collaborate with Vilmorin for Tomato Yield Improvement http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Collaborate-with-Vilmorin-for-Tomato-Yield-Improvement Rehovot, Israel (May 28, 2008) - Evogene Ltd. (TASE: EVGN) today announced a collaboration with Vilmorin, a French seed breeder and the mother company of 'Hazera Genetics', to improve yield and yield stability in tomatoes. Under the agreement, Evogene has licensed to Vilmorin the rights to certain genes discovered by Evogene, which have demonstrated improved yield and yield stability in tomatoes. The financial terms of the agreement were not disclosed. Vegetables are the world's most important source of micronutrients and an essential component of the world's food supply. The significant and continuous growth of world population and improvements in quality of life, combined with an on-going loss of land available for farming, has created an immediate and rapidly increasing need for greater output of vegetables. The development and introduction of vegetables with improved yield and yield stability can contribute to both a more sustainable food supply, and greater stability of growers' income. The candidate genes licensed to Vilmorin under this collaboration were discovered by Evogene using its advanced in-silico gene discovery technology, the 'ATHLETE'. These genes have already undergone three years of field trials in tomatoes, displaying consistent improvements in yield of over 20% under both normal and environmental stress conditions. Through the collaboration, Vilmorin will evaluate the influence of the licensed genes on yield improvement in its elite varieties. "We are very pleased to collaborate with Vilmorin, a world leading breeder of elite vegetable seeds," stated Mr. Assaf Oron, Evogene's VP Strategy and Business Development. "The licensed genes have shown significantly improved performance in tomatoes, and we strongly believe in the potential to jointly develop yield enhanced varieties based on Vilmorin's elite germplasm." Mr. Oron concluded. About Evogene Evogene is a leading developer of improved plants for the ag-biotech and biofuel industries. The Company's proprietary product development platform combines world leading computational gene discovery technologies, high throughput selection systems and advanced breeding methods. The platform's computational biology component - the ATHLETE - is based on Compugen's (Nasdaq: CGEN) in-silico predictive discovery capabilities. Evogene's current programs focus on yield under normal and various environmental stress conditions (such as drought), fertilizer utilization and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the ag-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com About Vilmorin Listed on Euronext Paris, Vilmorin is the fourth largest seed company in the world, and an expert in the creation of novel vegetable and field crop plants. Based on a sustainable, responsible vision of its development, its strategy is a successful combination of research and international growth. For more information, please visit website at www.vilmorin.info 28/05/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Collaborate-with-Vilmorin-for-Tomato-Yield-Improvement Evogene Reports First Quarter 2008 Financial Results http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-First-Quarter-2008-Financial-Results Rehovot, Israel - May 21, 2008 - Evogene Ltd. (TASE: EVGN) reports financial results for the first quarter ended March 31, 2008. "Evogene continues to demonstrate accelerating progress towards its goal of being the leading provider of improved plants for the ag-biotech and biofuel industries under milestone and revenue sharing agreements," stated Ofer Haviv, Evogene's President and CEO. "Evogene discovered genes are now being introduced into four major food crops: Corn, Rice, Soybean and Canola through collaborations with leading international seed companies, such as: Bayer CropScience, DuPont/Pioneer, Limagrain and Monsanto, and during the past quarter we announced a collaboration with Viterra, a leading provider of seed varieties in Canada, to develop canola with improved yield and environmental stress tolerance. With current developments in world population and food supplies, dramatic rise in commodities prices and global climate changes, we strongly believe that improving yields under various conditions is a major step towards coping with critical agricultural problems caused by these trends," Mr. Haviv concluded. Revenues for the first quarter of 2008 were $116,000*, compared to $17,000** for the first quarter of 2007. Operating loss for the first quarter of 2008 was $1.2 million, and the net loss for that quarter was $1.1 million (including financing income of $190,000 due to implementation of the International Financial Reporting Standards), or $0.07 per share. Operating loss for the first quarter of 2007 was $738,000, and the net loss for that quarter was $218,000 (including financing income of $494,000 due to implementation of the International Financial Reporting Standards), or $0.015 per share. As of March 31, 2008, Evogene had $9 million in cash, cash equivalents, cash deposits and short-term marketable securities. *Converted from New Israeli Shekels (NIS) at the exchange rate on March 31, 2008 (3.553 NIS = $1.00) for the convenience of readers. ** Converted from New Israeli Shekels (NIS) at the exchange rate on March 31, 2007 (4.155 NIS = $1.00) for the convenience of readers. 21/05/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-First-Quarter-2008-Financial-Results Evogene announces $2,000,000 private investment by AquAgro venture fund http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-announces-2000000-private-investment-by-AquAgro-venture-fund Rehovot, Israel - April 30, 2008 - Evogene Ltd. (TASE: EVGN) today announced that AquAgro fund L.P, a venture capital fund focused on innovative water, agriculture, food and alternative energy technologies will invest $2,000,000 in the Company in a private placement. AquAgro will acquire 1,107,700 newly issued ordinary shares at a price of 6.5 NIS ($1.86) per share, and will in addition receive 651,584 warrants to purchase 651,584 ordinary shares at a price of 11.05 NIS ($3.16) per share. Under the terms of the recently signed investment agreement, Evogene will also obtain the right, exercisable at its election until May 31 , 2011, to issue additional ordinary shares to AquAgro at a price of 4.5NIS per share, up to a total additional NIS investment by AquAgro in Evogene equivalent at such time to $2,000,000. "In view of AquAgro's investment focus and their managers' expertise in these fields, we are very pleased to have them join Evogene as a major shareholder, holding approximately five percent of the Company's shares after this purchase", stated Ofer Haviv, Evogene's President and CEO. "The two organizations fully share a commitment to address major problems already facing the critically important worldwide alternative energy and food and feed fields, and these problems are certain to become more extreme in view of continuing population growth and global climate changes", Mr. Haviv concluded. "The AquAgro fund is focusing on food and 'smart' agro in view of its managers' long term experience in these fields and the understanding that food and water are the next fields to adopt new technologies," stated Nir Belzer, Managing Partner of the Fund. "We seek out established companies with excellent growth and development potential, and therefore we are extremely enthusiastic about this investment in Evogene , a company we are confident is bringing a unique and powerful approach to key problems in these fields." About Evogene Evogene is a leading developer of improved plants for the ag-biotech and biofuel industries. The Company's proprietary product development platform combines world leading computational gene discovery technologies, high throughput selection systems and advanced breeding methods. The platform's computational biology component - the ATHLETE - is based on Compugen's (Nasdaq: CGEN) in-silico predictive discovery capabilities. Evogene's current programs focus on yield under normal and various environmental stress conditions (such as drought), fertilizer utilization and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the ag-biotech and alternative energy industries. Evogene's headquarters in Rehovot, Israel, and is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene's website at www.evogene.com About AquAgro AquAgro Fund, L.P. is a venture capital fund focused on Israel's innovative water and agriculture technologies, as well as other innovative clean technologies. The Fund was formed by Gaon Agro Industries, AquAgro GbR Germany and Ainsbury Properties Ltd. together with Hillel Milo and Nir Belzer who have extensive investment experience with Israeli technology companies and proven track record of providing superior returns to investors. The Fund Managers bring substantial experience in the field of R&D, marketing and management of the portfolio, and are assisted by a team of experienced research and operational personnel. 30/04/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-announces-2000000-private-investment-by-AquAgro-venture-fund Evogene Was Elected to Exhibit at the ''Facing Tomorrow'' Exhibition, Accompanying the Presidential Convention in May, 2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Was-Elected-to-Exhibit-at-the-Facing-Tomorrow-Exhibition-Accompanying-the-Presidential-Convention-in-May-2008 Evogene was elected to exhibit at the "Facing Tomorrow" exhibition, which will take place in Jerusalem, May 13-15, 2008 alongside the first annual presidential convention. Evogene was elected as one of the 60 initiatives that will present their activity in the exhibition, all were developed by Israeli entrepreneurs and have the potential to change "the face of tomorrow" of Israel and the world. The presidential convention is the first international convention initiated and led by Israel's president, Mr. Shimon Peres, for Israel's 60th Independence celebrations. The convention will be a gathering of more than 2000 of the world's leading politicians, key figures in the business world, finance, science, technology, culture, and others. Among the participants: George W. Bush, U.S President; Tony Blair, former UK prime minister; Henry Kissinger, former US secretary of state; Sergey Brin, founder of Google; Mark Zuckerberg, founder of the online social networking Facebook; Tata Ratan, head of the Tata group. Facing tomorrow will look at trends and developments that are mapping the future in a broad spectrum of fields: economics, technology, environment, research and development, etc. The convention and the exhibition will be covered by the international media. Evogene Introduction, Presidential Convention, May 2008 29/04/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Was-Elected-to-Exhibit-at-the-Facing-Tomorrow-Exhibition-Accompanying-the-Presidential-Convention-in-May-2008 Evogene to Present at a Panel on Energy Challenges of the 21st Century with U.S. Department of Energy, May 6th, 2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Present-at-a-Panel-on-Energy-Challenges-of-the-21st-Century-with-US-Department-of-Energy-May-6th-2008 Evogene will participate at a special panel entitled "The Energy Challenges of the 21st Century" at the Herzliya Interdisciplinary Center (IDC) campus. The panel, which will take place on May 6th 2008 , will consist of top energy experts from Israel and the U.S., including delgates from the U.S. Department of Energy (DOE) and the International Energy Agency (IEA). Mr. Assaf Oron, Evogene's VP Strategy and Business Development, will present Evogene's activity in the field of biofuels and improved plants to address key agricultural problems. NETL Delegation - Conference, The Hertzelia Interdisciplinary Center, May 6, 2008 29/04/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-to-Present-at-a-Panel-on-Energy-Challenges-of-the-21st-Century-with-US-Department-of-Energy-May-6th-2008 Evogene Reports Fourth Quarter and Annual 2007 Results http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Fourth-Quarter-and-Annual-2007-Results Rehovot, Israel - March 13, 2008 - Evogene Ltd. (TASE: EVGN) today reported financial results for the fourth quarter and year-end December 31, 2007. "All of us at Evogene are very pleased by the significant progress we made during 2007 towards strengthening our position as world leaders in developing improved plants for the ag-biotech and biofuel industries," stated Ofer Haviv, Evogene's President and CEO. "This progress was achieved in all fronts of our business, including substantial enhancements of our computational gene discovery, validation and development platform; the discovery of hundreds of novel candidates genes of interest in our various programs and further validation of selected genes by us and our partners; the integration of groups of our discovered genes in the pipeline of leading ag-biotech companies through deals and collaborations, and a rapidly growing list of partners, such as Bayer CropScience, Monsanto Company, and Pioneer Hi-Bred; the utilization of our plant capabilities for the field of biofuels, especially through the joint biodiesel program with Orfuel, a subsidiary of Ormat; and the strengthening of our financial situation through the public offering of Evogene shares on the Tel Aviv Stock Exchange." Mr. Haviv continued "Based on this progress and momentum - and the growing recognition of Evogene's unique and innovative capabilities in the ag-biotech and biofuel fields - we enthusiastically look forward to continuing this progress during 2008 and future years." Revenues for the year ended December 31, 2007 were $268,000*, compared to $114,000** for the same period in 2006. Net loss for the year ended December 31, 2007 was $3.6 million (including a non-cash charge of $656,000 for amortization of deferred compensation), or $0.21 per share, compared with a net loss $2.7 million (including $59,000 of deferred compensation), or $0.22 per share, for the same period in 2006. Revenues for the fourth quarter of 2007 were $69,000, compared to $34,000 for the fourth quarter of 2006. The net loss for the fourth quarter of 2007 was $1 million (including a non-cash charge of $147,000 for amortization of deferred compensation), or $0.05 per share, compared with a net loss of $534,000 (including $13,000 of deferred compensation), or $0.04 per share, for the corresponding quarter of 2006. As of December 31, 2007, Evogene had $9.2 million in cash, cash equivalents, cash deposits and short-term marketable securities. *Converted from New Israeli Shekels (NIS) at the exchange rate on December 31, 2007 (3.846NIS = $1.00) for the convenience of readers. ** Converted from New Israeli Shekels (NIS) at and the exchange rate on December 31, 2006 (4.225NIS = $1.00) for the convenience of readers. 13/03/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-Reports-Fourth-Quarter-and-Annual-2007-Results Evogene and Viterra obtain a grant from the CIIRDF foundation for financial support of a joint project to improve canola yields http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Viterra-obtain-a-grant-from-the-CIIRDF-foundation-for-financial-support-of-a-joint-project-to-improve-canola-yields On March 11th, 2008 Evogene Ltd. (TASE: EVGN) and Viterra (TAX:VT), a leading supplier of agricultural products and services in Canada, signed a co-operation and project funding agreement with the CIIRDF (Canada-Israel ndustrial Research and Development Foundation), to obtain a grant from the foundation for financial support of a joint project of Evogene and Viterra. A principle approval for the grant was obtained in February 13th, 2008. The agreement with CIIRDF was signed following the signature of a collaboration agreement between Evogene and Viterra in February 13th,2008, for the joint development of canola with improved yield and tolerance to abiotic stress. The CIIRDF was established in 1994 to promote collaborative R&D between firms in Israel and in Canada. CIIRDF is involved in three broad complementary activities, including promoting and marketing the benefits of joint Canadian-Israeli R&D collaboration, matching companies in one country seeking a research partner in the other and supporting projects by contributing up to 50% of the joint R&D costs. 12/03/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Evogene-and-Viterra-obtain-a-grant-from-the-CIIRDF-foundation-for-financial-support-of-a-joint-project-to-improve-canola-yields Viterra and Evogene to Develop Canola with Improved Yield and Stress Tolerance Traits http://www.evogene.com/News-Events/Press-Releases/2008/Viterra-and-Evogene-to-Develop-Canola-with-Improved-Yield-and-Stress-Tolerance-Traits REGINA, SASKATCHEWAN, CANADA and REHOVOT, ISRAEL (February 13th, 2008) -Viterra (TSX: VT) and Evogene Ltd. (TASE: EVGN) today announced a joint collaboration to develop canola with improved yield and tolerance to abiotic stress. Under the three year collaboration, the companies will assess a number of Evogene discovered gene candidates in trials involving Viterra's elite canola lines. These varieties will be evaluated under normal and stress conditions. Abiotic stress refers to environmental factors, such as drought, extrme cold or heat that can have harmful effects on plants. Abiotic stress conditions have a significant impact on limiting worldwide crop productivity, especially under challenging and often variable seasonal climatic global conditions. With the rapid increase in demand for canola oil worldwide, improving abiotic stress tolerance could significantly expand the geographical regions where canola is grown, minimizing the impact stress conditions have on productivity. "We are very pleased to work with Evogene to bring innovative solutions to the canola market. Our Company has an ongoing commitment to plant breeding that benefits our farm customers as well as our end-use customers. We believe this particular initiative will go a long way to improving canola yields and yield stability," said Mayo Schmidt, Viterra's President and CEO. The candidate genes covered in this agreement were discovered by Evogene utilizing its in-silico gene discovery platform, the "ATHLETE." These genes have been evaluated in model plants, showing improved yield under both normal and adverse environmental conditions. "We have been working with global ag-biotech companies to introduce these genes into major field crops. We recently announced successful third year field trial results for one of these candidate genes - Evo133. It is with this momentum that we go into our collaboration with Viterra, sharing that common goal to develop canola with improved yields and enhanced performance under a variety of conditions," said Ofer Haviv, Evogene's President and CEO. Viterra, a leading provider of seed varieties in Canada, will evaluate the effect of these genes in its proprietary canola lines in field trials in Western Canada, the most important canola growing region in the world. The companies also intend to sign a co-operation and project funding agreement with the Canada-Israel Industrial Research and Development Foundation (CIIRDF) in which CIIRDF will provide financial support for the project. Development, testing and evaluation on Viterra's canola varieties will begin this spring and take place over the next several years. The financial terms of the agreement were not disclosed. About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current trait development portfolio includes: abiotic stress tolerance and yield, improving nitrogen use efficiency, enhancement of cotton fiber quality, increasing yield for canola and soybean and plant manufacturing of therapeutic proteins. Evogene was created in 2002 by the spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's website at www.evogene.com About Viterra Viterra - Canada's largest agribusiness - is built on the foundation of its heritage companies, Saskatchewan Wheat Pool Inc. and Agricore United. The new company has extensive facility operations and distribution capabilities across Western Canada, with operations in the United States and Japan. Well-positioned geographically and with business segment diversity, Viterra serves its customers with a wide range of proprietary seed varieties, fertilizer, equipment, a full line of crop protection products, extensive agronomic and financial services and the largest network of grain handling and marketing resources in Canada. This provides the company's destination customers in Europe, Asia, Latin America and other regions with a secure source of supply of high quality crops, including identity preserved varieties bred to customer specifications. Viterra is focused on business sector management, technology leadership, strategic customers and markets, and emerging opportunities. For additional information, please visit Viterra's website at www.viterra.ca About the CIIRDF Foundation The Canada-Israel Industrial Research and Development Foundation (CIIRDF) was established in 1994 to promote collaborative R&D between firms in both countries. With a sophisticated research base to draw on in each country, Canadian and Israeli companies are well suited to form productive partnerships. CIIRDF is involved in three broad complementary activities including promoting and marketing the benefits of joint Canadian-Israeli R&D collaboration, matching companies in one country seeking a research partner in the other and supporting projects by contributing up to 50% of the joint R&D costs. For additional information, please visit CIIRDF's website at www.ciirdf.ca 13/02/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Viterra-and-Evogene-to-Develop-Canola-with-Improved-Yield-and-Stress-Tolerance-Traits Prof. James Birchler has joined Evogene's Scientific Advisory Board http://www.evogene.com/News-Events/Press-Releases/2008/Prof-James-Birchler-has-joined-Evogenes-Scientific-Advisory-Board- Rehovot, Israel - January 29th, 2008 - Prof. James Birchler has joined the Scientific Advisory Board of Evogene Ltd. (TASE:EVGN). Prof. James Birchler is Professor of Biological Science at the University of Missouri, Columbia, where his studies focus on maize genetics, cytogenetics and genomics with a special interest in the mechanisms of heterosis, gene dosage response, engineered minichromosomes and gene silencing. He joined the University of Missouri in 1991 after serving as an associate professor at Harvard University since 1985. Evogene's Scientific Advisory Board now consists of three members: Prof. Avraham Levy, Chairman, Prof. James Birchler and Prof. Gad Galili Prof. Avraham Levy is leading a research group in the Plant Sciences Department at the Weizmann Institute of Science, Israel, studying the dynamics of plant genomes via DNA recombination and genome duplication. Prof. Gad Galili is the Head of the Department of Plant Sciences at the Weizmann Institute of Science, Israel. He is a leading researcher in the field of plant metabolic pathways. 29/01/2008 http://www.evogene.com/News-Events/Press-Releases/2008/Prof-James-Birchler-has-joined-Evogenes-Scientific-Advisory-Board- Evogene and Orfuel obtain a $1M grant from the BIRD foundation for financial support of a joint project in the field of alternative energy http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Orfuel-obtain-a-1M-grant-from-the-BIRD-foundation-for-financial-support-of-a-joint-project-in-the-field-of-alternative-energy On December 19 , 2007 Evogene Ltd. (TASE: EVGN) and Orfuel Inc, a US subsidiary of Ormat Industries Ltd (TASE:ORMAT), signed an agreement with the BIRD Foundation (Israel-US Binational Industrial Research and Development Foundation) to obtain a grant from the foundation for financial support of a joint project of Evogene and Orfuel in the field of alternative energy. A principle approval for the grant was obtained on July 25th, 2007. The Evogene and Orfuel joint project is aimed at providing substantially improved feedstock sources for biodiesel production. The companies collaborate to develop non edible plants, displaying improved oil yield and capable of being grown in non arable lands, thus addressing the key problems facing the industry. In addition to the other benefits, these plants are expected to significantly decrease feedstock costs for biodiesel production. The parties obtained an approval for a one million US dollars grant from the BIRD foundation, which constitute half of the initial budget allocated to the project. The project is expected to last three years. The BIRD Foundation works to encourage cooperation between Israeli and American companies in various areas of technology. The BIRD Foundation supports projects of up to 50 percent of a project's budget without receiving any rights in the participating companies or in the projects themselves. The financial assistance is repaid under the terms and schedule of the agreement with the foundation; however the foundation does not demand that the investment be repaid if the project fails to reach the sales stage. The BIRD Foundation works in full cooperation with the Chief Scientist's Office at the Ministry of Trade, Industry and Employment in Israel, and with the U.S. Commerce Department's National Institute of Standards and Technology (NIST). 20/12/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Orfuel-obtain-a-1M-grant-from-the-BIRD-foundation-for-financial-support-of-a-joint-project-in-the-field-of-alternative-energy Successful Third Year Field Trial of Evogene's Candidate Gene for Improving Yield and Abiotic Stress Tolerance http://www.evogene.com/News-Events/Press-Releases/2007/Successful-Third-Year-Field-Trial-of-Evogenes-Candidate-Gene-for-Improving-Yield-and-Abiotic-Stress-Tolerance Rehovot, Israel, December 19, 2007 - Evogene Ltd. (TASE: EVGN) today announced successful third year field trial results for Evo133, one of its candidate genes for improving plant yield and tolerance to abiotic stress conditions. Transgenic tomato plants over expressing Evo133 demonstrated an increase of up to 25% under normal conditions, and up to 20% under abiotic stress conditions compared to control plants under the same conditions. Results from this third field trial are consistent with two previous field trials conducted in 2005 and 2006. Evo133 is one of a group of genes discovered by Evogene in 2003, which were predicted to provide improved plant yield and tolerance to abiotic stress conditions, such as drought, salt and heat stress. These genes were predicted in silico using Evogene's unique computational gene discovery platform, the ATHLETE, and then experimentally validated in model plants. Evo133 was further validated in field trials in transgenic tomato plants, and has now successfully completed its third year of such trials. Evogene has entered into collaborations with leading ag-bio companies for the evaluation of Evo133 in major field crops. To date, these collaborations include Bayer CropScience for rice, Biogemma SAS for corn, Mertec LLC for soybean and CIRAD (Centre de CoopÉration Internationale en Recherche Agronomique pour le DÉveloppement), a French Research Institute, for cotton. In addition, Evogene is itself further developing Evo133 in canola using recently established "in house" transformation capabilities. Initial results from these efforts by Evogene and its collaborators are expected during 2008 in corn and canola, and 2009 in soybean and cotton. Abiotic stress conditions, such as drought, salty water, soil salinity and heat stress currently have a massive impact on crop productivity and agricultural supply, and this impact is continuing to increase due to global warming and climate changes. Therefore, developing plants displaying improved tolerance to abiotic stress would have an enormous economic potential, and is one of the main goals for leading seed companies. "The successful third year field trials for Evo133 are another demonstration of the unique value of Evogene's ATHLETE gene prediction platform, combining plant trait understandings with advanced and proprietary computational biology", said Dr. Hagai Karchi, Evogene's VP development and CTO. "An important feature of ATHLETE is that it is a constantly improving platform. For example, Evogene has already used ATHLETE to complete a second round of gene discovery for improving plant abiotic stress tolerance, with the resulting discovery of a number of additional candidate genes for this important trait", Dr. Karchi concluded. Ofer Haviv, Evogene's President and CEO added "With respect to our business model, we are delighted that leading seed and ag-biotech companies are recognizing the potential of Evo133 and other genes in our rapidly increasing inventory of gene discoveries for important traits. As we have previously stated, we intend to continue focusing our gene discovery and validation efforts mainly on increasing yield, improving drought tolerance and Nitrogen use efficiency, in addition to our efforts in the field of biofuels." 19/12/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Successful-Third-Year-Field-Trial-of-Evogenes-Candidate-Gene-for-Improving-Yield-and-Abiotic-Stress-Tolerance Evogene Reports Third Quarter 2007 Results http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Reports-Third-Quarter-2007-Results Rehovot, Israel - November 19th, 2007 - Evogene Ltd. (TASE: EVGN) today reported financial results for the third quarter ended September 30, 2007, the Company's first full quarter as a public company. "Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries, and our current commercialization efforts are targeted at integrating Evogene discovered genes into the product pipelines of world leading companies in these industries under revenue sharing agreements" stated Ofer Haviv, Evogene's President and CEO. "Therefore we were of course extremely pleased to announce during the last few months the signing of crop trait agreements with the two leading companies in the global seed market - Monsanto and Pioneer, a DuPont business. In addition, during this past quarter, we expanded our activity in the bio-diesel field - which we consider an important engine for our company's growth - through a collaboration with Orfuel, a subsidiary of Ormat, a leading alternative energy company. We are very proud of the growing recognition of the commercial potential offered by Evogene's unique capabilities as demonstrated by our growing list of collaborations with industry leading companies" Mr. Haviv concluded. Revenues for the nine months ended September 30, 2007 were $191,000*, compared to $79,000** for the same period in 2006. Net loss for the nine months ended September 30, 2007 was $2.4 million (including a non-cash charge of $473,000 for amortization of deferred compensation), or $0.15 per share, compared with a net loss $2.1 million (including $45,000 of deferred compensation), or $0.18 per share, for the same period in 2006. Revenues for the third quarter of 2007 were $41,000 compared to $46,000 for the third quarter of 2006. The net loss for the third quarter of 2007 was $1.05 million (including a non-cash charge of $198,000 for amortization of deferred compensation), or $0.05 per share, compared with a net loss of $589,000 (including $12,000 of deferred compensation), or $0.04 per share, for the corresponding quarter of 2006. Evogene continues to invest in R&D focusing on further enhancements of its core proprietary discovery platform which combines state-of-the-art computational genomics, molecular biology and advanced breeding methods, and on the discovery and validation of a number of promising genes in major areas of interest to the industry. Net research and development expenses for the first nine months of 2007 were $1.69 million compared to $1.16 million for the first nine months of 2006 representing an increase of more than 40% from the prior year as the Company continues to expand it's R&D operations, and representing approximately 65% of the Company's total expenses for the first nine months of 2007. As of September 30, 2007, Evogene had $9.3 million in cash, cash equivalents, cash deposits and short-term marketable securities. *Converted from New Israeli Shekels (NIS) at the exchange rate on September 30th, 2007 (4.013NIS = $1.00) for the convenience of readers. **Converted from New Israeli Shekels (NIS) at and the exchange rate on September 30th, 2006 (4.302NIS = $1.00) for the convenience of readers. 19/11/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Reports-Third-Quarter-2007-Results DuPont and Evogene Collaborate to Increase Drought Tolerance in Corn and Soybeans http://www.evogene.com/News-Events/Press-Releases/2007/DuPont-and-Evogene-Collaborate-to-Increase-Drought-Tolerance-in-Corn-and-Soybeans DES MOINES, Iowa, and REHOVOT, Israel, Oct. 30, 2007 - DuPont and Evogene Ltd. today announced a research collaboration to improve drought stress tolerance primarily in corn and soybeans. Under the agreement, DuPont business Pioneer Hi-Bred has exclusive rights to several genes discovered by Evogene for improving these traits. The financial terms of the agreement were not disclosed. "Drought has an enormous impact on crop productivity and quality as well as cost of production. It's the one agronomic pressure that negatively affects growers in every country around the world, every year," said William S. Niebur, vice president -- DuPont Crop Genetics Research and Development. "We look forward to creatively combining our technologies to develop superior products that use water more efficiently, leading to greater productivity, profitability and sustainability of agricultural systems." Drought causes global crop losses in excess of $8 billion annually. The impact of drought will likely increase, based on predictive models used to study the effects of ongoing climate changes. Improving corn and soybean tolerance to drought stress will help maximize grower yield and income, as well as provide more grain for the food, feed, fuel and materials value chains. The candidate genes were discovered by Evogene's most advanced in-silico gene discovery technology called the "ATHLETE." Pioneer will evaluate the licensed genes in its elite corn and soybean germplasm to measure the benefit in its commercial products. "We are pleased to collaborate with Pioneer, a world leader in developing and supplying corn and soybean seed varieties. This collaboration reinforces the value of our gene discovery tools and will help us determine the utility of our candidate genes," said Ofer Haviv, Evogene president and CEO. "This collaboration is a significant milestone for us." Pioneer is taking multiple approaches to drought tolerance that include conventional breeding, molecular breeding and transgenic programs. The collaboration with Evogene is complementary to the drought tolerance work already under way at Pioneer. About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, improving nitrogen use efficiency, enhancement of cotton fiber quality, increasing oil yield for the biodiesel industry and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's website at www.evogene.com About Pioneer & DuPont Pioneer Hi-Bred, a DuPont business, is the world's leading source of customized solutions for farmers, livestock producers and grain and oilseed processors. With headquarters in Des Moines, Iowa, Pioneer provides access to advanced plant genetics in nearly 70 countries. DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation. 30/10/2007 http://www.evogene.com/News-Events/Press-Releases/2007/DuPont-and-Evogene-Collaborate-to-Increase-Drought-Tolerance-in-Corn-and-Soybeans Evogene will present at 'The Greenberg Traurig Global Resources Conference', October 31st, 2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-will-present-at-The-Greenberg-Traurig-Global-Resources-Conference-October-31st-2007 On October 31st 2007, Evogene will present at 'The Greenberg Traurig Global Resources Conference' in Tel-Aviv, Israel. The presentation will be given during a panel discussion 'A Look at what's Ahead for Alternative and Renewable Energy Technologies'. Mr. Assaf Oron, Evogene's VP Strategy and Business Development, will present Evogene's activity in the field of biodiesel and improved plants to address global warming, such as drought tolerant plants. The Greenberg Traurig conference is in conjunction with the WATEC (Water Technologies & Environmental Control) gathering, which is aimed at introducing water and environmental technologies form the Israeli industry and academy, together with capital and international strategic bodies. Evogene - For a greener World, Global Resources Conference, October 31st 2007 29/10/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-will-present-at-The-Greenberg-Traurig-Global-Resources-Conference-October-31st-2007 Evogene Participated at the Energy Forum Workshop of the 'Samuel Neaman Institute', October 16th, 2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Participated-at-the-Energy-Forum-Workshop-of-the-Samuel-Neaman-Institute-October-16th-2007 On October 16th 2007, Evogene participated at a workshop of the Energy Forum of The Samuel Neaman Institute at 'The Technion-Israel Institute of Technology'. The workshop is a part of a research program, "The Policy and National Planning of Israel's Position at The Bio-Etahnol World Market", which is conducted in the Institute. The participants in the workshop were Israeli companies that are active in the energy industry, such as "Ormat", "ICG" and other figures from the industry, government, finance and academia. The Samuel Neaman Institute is an independent public-policy research institute, established in 1978 in order to assist in the search for solutions to national problems in science and technology, education, economy and industry. Through its research, workshops and publications, the Institute serves as a link between academia and decision makers in government, public institutions and industry. Dr. Hagai Karchi, Evogene's VP Development and CTO, was elected to serve at a committee, which will finalize the forum's conclusions and recommendations for the Israeli government. 16/10/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Participated-at-the-Energy-Forum-Workshop-of-the-Samuel-Neaman-Institute-October-16th-2007 Monsanto and Evogene Collaborate on Nitrogen Use Efficiency Research http://www.evogene.com/News-Events/Press-Releases/2007/Monsanto-and-Evogene-Collaborate-on-Nitrogen-Use-Efficiency-Research ST. LOUIS, MO, USA and REHOVOT, ISRAEL (September 25 , 2007) -Monsanto Company (NYSE:MON) and Evogene Ltd. (TASE: EVGN) today announced a collaboration to improve nitrogen use efficiency in corn, soybeans, canola and cotton. Under the agreement, Monsanto gains exclusive rights to a number of genes discovered by Evogene that help plants maintain yield with lower applications of nitrogen. Monsanto will work to evaluate the use of those genes in its research and development pipeline. The potential candidates from Evogene are complementary to the nitrogen utilization genes already in testing in Monsanto's pipeline and could provide the opportunity to further a series of upgrades for this key target area. The financial terms of the agreement were not disclosed. Nitrogen fertilizer represents one of the largest input costs in agriculture; it accounts for approximately one-fifth of the operating costs for a corn producer. In the US alone, farmers spend more than $3 billion annually on nitrogen fertilizer application of corn fields, with plants typically absorbing less than half of the nitrogen fertilizer applied. "Improving nitrogen use efficiency in crops has immense value not only for farmers but also for our environment," said Fred Below, professor of crop physiology at the University of Illinois. "These improvements provide the greatest opportunity for increased profitability, while also offering a new way to reduce the environmental impact of corn production." "Monsanto is continually innovating new technologies to help farmers get more out of every seed and to do more with less, including maximizing the nitrogen efficiency of crops," said Steve Padgette, Monsanto's vice president of biotechnology. "We look forward to working with Evogene to continue delivering valuable products to farmers' fields that reduce agriculture's impact on the environment." "Monsanto is acknowledged worldwide for its excellent capabilities in delivering innovative technology to farmers," said Mr. Ofer Haviv, Evogene's President and CEO. "Therefore we are obviously delighted Monsanto has chosen our computational gene discovery technology for the development of its next generation of improved crop traits." About Monsanto Company Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information, please visit the company's web site at http://www.monsanto.com. About Evogene (TASE: EVGN) Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and Biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, improving nitrogen use efficiency, enhancement of cotton fiber quality, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's Website at www.evogene.com 25/09/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Monsanto-and-Evogene-Collaborate-on-Nitrogen-Use-Efficiency-Research Evogene and Ormat Industries subsidiary Announce Biodiesel Collaboration http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Ormat-Industries-subsidiary-Announce-Biodiesel-Collaboration REHOVOT and YAVNE, ISRAEL (September 24 , 2007) - Evogene Ltd. (TASE: EVGN) and Orfuel Inc, a US subsidiary of Ormat Industries Ltd (TASE:ORMAT) today announced a collaboration in the field of alternative energy and biofuels, aimed at providing substantially improved feedstock sources for biodiesel production. Biodiesel is an alternative to diesel fuel, based on oil derived from plants. Biodiesel use in the US and Europe has rapidly increased in the past few years, currently exceeding 4.5 billion liters annually. Since at present the main plant feedstocks for biodiesel production are soybean and canola, the increasing demand for biodiesel has resulted in rising prices for these important food crops and other commodities. The increasing demand for biodiesel has also resulted in substantial usage of arable farm land for non food purposes. This situation has led to an increasing need to develop alternative feedstock to serve the rapidly expanding biodiesel industry. Evogene and Orfuel will collaborate to develop non edible plants displaying improved oil yield and capable of being grown in non arable lands, thus addressing the key problems facing the industry. In addition to the other benefits, these plants are expected to significantly decrease feedstock costs for biodiesel production. Under the terms of the collaboration, Evogene will utilize its advanced biotechnological capabilities (such as gene and molecular marker discovery), in the development of the enhanced crops which will then be evaluated in field trials conducted by Orfuel in the expected target locations. In addition, Orfuel will evaluate suitability and methodologies for using such crops for biodiesel production. Upon project completion, Evogene and Orfuel intend to establish a joint venture aimed at commercialization of the developed plants. The companies obtained approval in principle for a grant from the BIRD Foundation (Israel-US Binational Industrial Research and Development Foundation) for financial support of the project. "For many reasons, there is an enormous and growing need for alternative feedstocks for the biodiesel industry, and we are convinced that with our advanced plant biotechnological capabilities we will be able to develop appropriate crops for this purpose" stated Mr. Martin Gerstel, Evogene's Chairman "With respect to the collaboration being announced today, Ormat has continuously demonstrated its capability to translate advanced technology into world leading products in the field of alternative energy and therefore we are extremely pleased to have them as our partner" Mr. Gerstel concluded. "Practically this is a return to Ormat's core: Utilizing the energy from the sun, however, this time for the production of fuels rather than electricity." Stated Mr. Lucien Y. Bronicki, Ormat's Chairman, "We are convinced that the synergy between Evogene and Ormat will produce the type of "fruits" necessary to allow an environmentally friendly solution in the field of biofuels." Dr. Eitan Yudilevich, Executive Director, BIRD Foundation said: "The decision to substantially support this project is in line with BIRD's policy of promoting projects in the area of alternative, renewable and clean energy and with BIRD's high involvement in these fields (e.g. Bio-Fuel and the Hydrogen Technology). BIRD Foundation has already invested in such projects and will encourage similar new initiatives." About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, improving nitrogen use efficiency, enhancement of cotton fiber quality, increasing oil yield for the biodiesel industry and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's Website at www.evogene.com About Ormat Industries For information on Ormat Industries see www.ormat.com About the BIRD Foundation The BIRD (Binational Industrial Research and Development) Foundation works to encourage cooperation between Israeli and American companies in the various areas of technology, and provides free assistance in locating strategic partners from both countries for developing joint products. During its 30 years, the BIRD Foundation has invested in more than 740 projects that have yielded direct and indirect revenues of roughly $8 billion. The BIRD Foundation supports projects without receiving any rights in the participating companies or in the projects themselves. Any financial assistance is repaid as royalties from sales. The Foundation provides support of up to 50 percent of a project's budget, beginning with R&D and ending with the initial stages of sales and marketing. The Foundation shares the risk and does not demand that the investment be repaid if the project fails to reach the sales stage. The BIRD Foundation works in full cooperation with the Chief Scientist's Office at the Ministry of Trade, Industry and Employment in Israel, and with the U.S. Commerce Department's National Institute of Standards and Technology (NIST). 24/09/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Ormat-Industries-subsidiary-Announce-Biodiesel-Collaboration Evogene Elects Two External Directors to Board of Directors http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Elects-Two-External-Directors-to-Board-of-Directors Rehovot, Israel - September 18th, 2007 - Evogene Ltd. (TASE: EVGN) announces that yesterday, at its Annual Meeting of Shareholders, Dr. Michael Anghel and Dr. Rafi Hofstein were elected to serve as external directors of the Company. Dr. Michael Anghel serves as a member of various boards of major Israeli corporations, including Partner Ltd., Syneron Medical Ltd., ECI Telecom Ltd., and Scopus Ltd. Previously, Dr. Anghel served on the management of the Discount Investment Corporation and as CEO of Discount Capital Markets, the investment banking arm of the Israel Discount Bank. He was actively involved in the founding and management of various technology and communications enterprises, including Cellcom and Tevel. Dr. Anghel holds a B.A. (Economics) from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. from Columbia University in New York. Dr. Rafi Hofstein is President and CEO of Hadasit Ltd., the Technology Holdings Company of Hadassah Medical Organization. Previously, he served as the President of Mindsense Biosystems Ltd. and as Business Unit Director of Ecogen Inc. in Langhorne PA, after serving as the Scientific Director of its Israel office. Dr. Hofstein received his PhD and Master of Science in life-sciences and chemistry from the Weizmann Institute of Science, and completed postdoctoral training at the Harvard Medical School in Boston, MA, in the departments of biological chemistry and neurobiology. Following yesterday's election by the shareholders, Evogene's board of directors consists of seven members: Dr. Angel, Martin Gerstel, Dr. Hofstein, Dr. Adina Makover, Leon Recanati, Dr. Simcha Sadan and Dr. Eli Zangvil. 18/09/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Elects-Two-External-Directors-to-Board-of-Directors Evogene licenses transformation technology from Midwest Oilseeds, Inc. http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-licenses-transformation-technology-from-Midwest-Oilseeds-Inc- Rehovot, Israel and Adel, Iowa - September 4th, 2007 - Evogene Ltd (TASE: EVGN) and Midwest Oilseeds, Inc. announced the signature of a licensing agreement for plant transformation technologies. Through the agreement, Evogene shall receive access to Midwest Oilseeds' advanced gene transformation technologies applicable for leading commercial crops such as corn, soybean and canola. Evogene uses a proprietary computational gene discovery platform to discover key genes related to agricultural traits and validates them through model and target plants. Transformation is the process of inserting the genes into the genome of plants to create plants expressing the desired trait. The transformation technology licensed-in intends to allow Evogene to more efficiently validate its candidate genes and further advance in the trait development pipeline. Evogene's pipeline includes groups of genes targeted at improving agricultural traits such as: yield, yield stability via tolerance to abiotic stress (mainly drought and salinity), nitrogen use efficiency, enhancement of cotton fiber quality and improved oil yield for biodiesel production. Ofer Haviv, Evogene's President and CEO stated: "We are pleased to add this advanced transformation technology to our product development platform and expect it to allow us better flexibility and efficiency through the development pipeline." Joseph Saluri, Vice-President for Midwest Oilseeds stated: "The Aerosol Beam Injector technology is a great tool for the advancement of biotechnology and traits. We are confident that this technology will assist Evogene in bringing its new traits to the marketplace." About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, improving nitrogen use efficiency, enhancement of cotton fiber quality, increasing oil yield for the biodiesel industry and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's website at www.evogene.com About Midwest Oilseeds, Inc. Midwest Oilseeds, Inc. is focused on delivering the highest-yielding soybean germplasm in the seed industry. As the soybean genetics supplier of first choice to the seed industry, Midwest Oilseeds supplies a substantial portion of the soybean genetics planted in the United States today. Midwest Oilseeds' world-class soybean research and testing system includes operations throughout the Midwestern United States, as well as in Florida, Hawaii, Puerto Rico, Chile and Argentina. Stine Biotechnology, which is a wholly owned subsidiary of Midwest Oilseeds, Inc., has been granted a United States patent on a proprietary transformation technology for the introduction of DNA into plant cells. This new transformation system is known as Aerosol Beam Injection. For additional information, please visit www.stineseed.com 04/09/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-licenses-transformation-technology-from-Midwest-Oilseeds-Inc- Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Zeraim-Gedera-Salt-Tolerant-Tomato-Collaboration-Advances-to-Second-Phase- Rehovot and Gedera, Israel - September 3rd ,2007 - Evogene Ltd. (TASE: EVGN) and Zeraim Gedera Ltd, which was recently acquired by Syngenta S.A., announced today that their joint program for the development of salt tolerant tomato varieties has successfully completed the first phase with experimental varieties currently undergoing field trials in target locations worldwide. Under a recently signed follow-on agreement, the parties intend to further develop the experimental varieties towards commercialization and develop additional varieties for new target markets. The use of massive irrigation practices and water sources of high salinity levels in tomato growing areas have caused a reduction in tomato yield and in severe cases the abandoning of such areas. The tomato varieties developed through this collaboration are expected to allow growers to maintain high yields under severe growing conditions displaying high salt concentrations of water and soil. Zeraim Gedera's breeding program is based on its leading tomato germplasm and utilizes Evogene's advanced selection tools. These selection tools include proprietary selection assays and molecular marker for salt tolerance, developed based on Evogene's computational gene discovery platform. "We are very pleased with the successful completion of the first phase and Zeraim Gedera's choice to continue the joint development." stated Ofer Haviv, Evogene's President and CEO "We are very excited about the potential of the new tomato varieties being developed based on Zaraim Gedera's world leading varieties". Mr. Haviv concluded. Ohad Zuckerman, CEO of Zeraim Gedera stated: "Zeraim Gedera views this collaboration as a first step towards future collaborations with Evogene for developing improved varieties that will strengthen our competitive position in vegetables. This is the first agreement we signed since the closing of Syngenta's acquisition, and an initial step towards enhancing our involvement in the Israeli R&D institutes and private companies such as Evogene". About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current trait development portfolio includes: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the biodiesel use and plant manufacturing of therapeutic proteins. Evogene was created in 2002 by the spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's website at www.evogene.com About Zeraim Gedera Zeraim Gedera is one of the world's leading companies in vegetable varietal development. Since its establishment in 1952, the Company is known for its expertise in breeding high quality vegetable varieties, and in developing and marketing of its vegetable seeds world-wide. The company was lately acquired by Syngenta, a world-leading agribusiness, which purchased all of the company's shares from Markstone Capital Partners, an Israeli private equity group. Zeraim Gedera focuses on six vegetable products: tomatoes, sweet peppers, watermelons, melons, squash and cucumbers, and has longstanding research and breeding relationships with leading research institutes and universities in Israel and world-wide. As a result of massive investments in R&D, outstanding breeding capabilities and a strong presence in major markets world-wide, such as Spain, Turkey, Mexico, USA and China, Zeraim Gedera has displayed rapid growth in the past few years. For additional information, please visit Zeraim Gedera's website at www.zeraimgedera.com 03/09/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-Zeraim-Gedera-Salt-Tolerant-Tomato-Collaboration-Advances-to-Second-Phase- Evogene Reports Second Quarter 2007 Financial Results http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Reports-Second-Quarter-2007-Financial-Results Rehovot, Israel - August 30th, 2007 - Evogene Ltd. (TASE: EVGN) today reported financial results for the second quarter ended June 30, 2007. "During the past five years - initially as a division of Compugen, and then as a private company - Evogene created a unique, powerful and continuously improving agbio discovery and development capability." stated Ofer Haviv, Evogene President and CEO. "Now, in our first quarterly report as a public company, we are pleased to focus on the accelerating commercialization of this broadly applicable capability. During the past few months, we announced collaborative activities with Ormat Ltd., a leading company in the field of alternative energy, for development of crops for biodiesel use; with Bayer CropScience, a world-wide leader in agbio, which exclusively licensed the rights to certain genes discovered by Evogene for increasing the productivity and yield of a Bayer core crop under drought and other stress conditions; and with Rahan Meristem Ltd., a world-wide leading producer and marketer of banana plantlets, for development of banana plants with resistance to a key banana disease." "We welcome our new shareholders and enthusiastically look forward to reporting our continuing progress and growth." Mr. Haviv concluded. Revenues for the quarter were $129,000* compared to $10,500 for the second quarter of 2006. The net loss for the quarter was $738,000 (including a non-cash charge of $225,000 for amortization of deferred compensation), or $0.05 per share, compared with a net loss of $836,000 (including $13,000 of deferred compensation), or $0.06 per share, for the corresponding quarter of 2006. Revenues for the first six months ended June 30, 2007 were $146,000, compared to $34,000 for the same period in 2006. Net loss for the first six months of 2007 was $1.4 million (including a non-cash charge of $282,000 for amortization of deferred compensation), or $0.1 per share, compared with a net loss $1.6 million (including $31,000 of deferred compensation), or $0.15 per share, for the same period in 2006. As of June 30, 2007, Evogene had $9.9 million in cash, cash equivalents, cash deposits and short-term marketable securities, an increase of $6.6 million from $3.3 million as of March 31, 2007, reflecting the net proceeds from the IPO on TASE completed in June. * Converted from New Israeli Shekels (NIS) at the exchange rate on August 28th, 2007 (4.125NIS = $1.00) for the convenience of readers. 30/08/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-Reports-Second-Quarter-2007-Financial-Results Evogene and CIRAD expand their cotton collaboration http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-CIRAD-expand-their-cotton-collaboration- Rehovot, Israel - July 24th, 2007 - Evogene Ltd., a publicly quoted plant biotechnology company (TASE: EVGN) and CIRAD, a French scientific organization, announce the expansion of their multi-year collaboration signed in 2004. The goal of the new project is to introduce Evogene's candidate gene, EVO133, into cotton and to validate its improvement for drought tolerance. Cotton is the third largest genetically modified crop by its importance, after soybean and corn, and provides 40% of the global fiber requirements. Cotton is grown on about 35 million hectares worldwide, 10 million hectares (28%) of which are grown with GM varieties. Cotton is largely grown in marginal agricultural areas where precipitations are low and drought resistance is often the first limiting factor for yield. Drought resistance is one of the key factors which can help dry areas stay competitive in the global cotton market. EVO133 is Evogene's candidate gene for yield, and yield stability under drought, heat and salinity conditions. EVO133 has been tested in three seasons of field trials in processing tomato varieties and has demonstrated its potential to increase yield under normal conditions, reduce yield penalty under drought conditions as well as under salinity and heat stresses. The validation of EVO133 is also advancing in other target crops under other collaborations, which have been announced publicly, namely in Corn with Biogemma and Soybean with Mertec. Ofer Haviv, Evogene President and CEO stated: "Having identified EVO133 as a candidate for yield and yield stability, we are excited to advance towards obtaining promising results in the cotton crop. CIRAD's decades of experience in developing cotton varieties around the globe, makes it a very attractive partner for this project". Bernard Hau, Head of the CIRAD Cotton Research Unit stated: "The search for rustic varieties resisting to drought corresponds to the demand of the developing countries and its importance will increase with climate change. CIRAD is pleased to have established a partnership with the Israeli company EVOGENE, a partner offering new tools to efficiently address this theme. Part of this project is financed by the EUREKA initiative through the French National Agency for Research (ANR)." About CIRAD CIRAD, the "Centre de coopÉration internationale en recherche agronomique pour le dÉveloppement", is the French Agricultural Research Centre for international Development. Its mission is to contribute to the economic development of the tropical and subtropical regions through research on agriculture, training, and dissemination of its results. It employs 1,850 people, including 950 senior staff, working in French overseas departments and some fifty other countries. Its budget amounts to approximately 180 million Euros. CIRAD has three research departments: the Biological Systems Department, the Performance of Tropical Production and Processing Systems Department and the Environments and Societies Department. CIRAD operates through its own research centres, collaborating with national agricultural research systems, universities and international centres, as well as development projects. CIRAD runs a Cotton Research Unit with a staff of 40 including 30 researchers and 10 technicians, in Africa, the Americas, South East Asia and Montpellier (France). For more information www.cirad.fr About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and Biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Evogene was created in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's Website at www.evogene.com 24/07/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-and-CIRAD-expand-their-cotton-collaboration- Professor Nina V. Fedoroff, the U.S. Secretary of State’s new Science and Technology Adviser, resigns from Evogene’s Scientific Advisory Board http://www.evogene.com/News-Events/Press-Releases/2007/Professor-Nina-V-Fedoroff-the-US-Secretary-of-States-new-Science-and-Technology-Adviser-resigns-from-Evogenes-Scientific-Advisory-Board U.S. Secretary of State, Condoleezza Rice, has named Professor Nina V. Fedoroff, a member of Evogene's Scientific Advisory Board (SAB), to be her new Science and Technology Adviser. The appointment was announced on July 18th 2007, two days after President George W. Bush announced that Prof. Fedoroff will receive the 2006 National Medal of Science and Technology, the Nation's highest honor for science and technology. The Medals will be presented by President Bush during a White House awards ceremony on July 27th, 2007. Prof. Nina Fedoroff, the Willaman Professor of Life Sciences and Evan Pugh Professor in the Biology Department and the Huck Institutes of the Life Sciences at Pennsylvania State University, has been a member of Evogene's SAB since 2002. In order to avoid a possible conflict of interest with her new duties, Prof. Fedoroff informed the company that she is resigning from Evogene's SAB effective immediately. Evogene is proud to have one of its SAB members named for such a senior position, and would like to thank Prof. Fedoroff for her contribution in shaping Evogene's technology direction, and wishes Prof. Fedoroff success in her new role. Prof. Avi Levy, Chairman of Evogene's SAB and Dr Hagai Karchi, Evogene's founder and CTO will initiate a search for a new member to replace Prof. Fedoroff in Evogene's SAB print page 22/07/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Professor-Nina-V-Fedoroff-the-US-Secretary-of-States-new-Science-and-Technology-Adviser-resigns-from-Evogenes-Scientific-Advisory-Board Rahan Meristem and Evogene to Collaborate on Key Banana Disease http://www.evogene.com/News-Events/Press-Releases/2007/Rahan-Meristem-and-Evogene-to-Collaborate-on-Key-Banana-Disease Rehovot and Rosh Hanikra, Israel - July 10th, 2007 - Evogene Ltd. (TASE: EVGN) and Rahan Meristem announced today that they will be collaborating to develop bananas displaying resistance to Black Leaf Streak Disease (also known as Black Sigatoka), the most damaging disease threatening banana plantations. Under a recently signed agreement the parties will combine their research and development capabilities to develop the resistant bananas and subsequently market them jointly. Evogene will utilize its novel computational gene discovery technology to discover genes which confer resistance to the disease. Rahan Meristem, the world's leading banana plantlet producer and marketer, will develop and assess the resistant bananas based on its existing leading banana varieties. Black Leaf Streak Disease is the most costly and damaging foliar disease to the export-banana industry. The pathogen causes large lesions that eventually cover the entire surface of the leaves, resulting in devastating yield losses. Currently, the only way to control the disease is through frequent - often more than 50 times per year - oil and fungicide applications. The frequency of spraying is on the incline from year to year. In some tropical areas the cost of spraying accounts for more than 35% of total production costs, amounting to more than $1,300 annually per hectare. The world cost of spraying banana plantations against this single disease per annum surpasses $500 Million. .Also, fungicides are reported to possibly cause environmental and detrimental health effects in the major producing countries of Central America, The Caribbean Islands and Far East. "We are extremely pleased to have the opportunity to work with Rahan Meristem, a world leading banana producer and marketer," stated Mr. Ofer Haviv, Evogene's President and CEO. "Success in this project will not only provide significant financial rewards, but also address a growing environmental problem in certain banana growing countries." Mr. Haviv concluded. "We look forward to the joint work with Evogene, a leader in gene discovery for key traits in agriculture. The partnership between Rahan Meristem and Evogene will greatly increase the probability of reaching a biotechnological solution to the most important problem in the banana industry - Black Leaf Streak Disease" said Dr. Eli Khayat, Rahan Meristem's Scientific Director. About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and Biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Evogene was created in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, is based on Compugen's proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007. For additional information, please visit Evogene's website at www.evogene.com. About Rahan Meristem (1998) LTD Rahan Meristem is a plant biotechnology and propagation company specializing in tissue culture, molecular genetics and breeding. The company exists since 1974 and is currently the largest producer of banana plantlet by tissue culture global wide. Rahan Meristem's selected clones are currently in demand in all tropical regions where desert banana fruit are produced for the export markets. The selection lines "Gal" and "Jaffa" have gained a demand in tropical and subtropical regions of Latin America, Middle East, Africa, and the Far East. 10/07/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Rahan-Meristem-and-Evogene-to-Collaborate-on-Key-Banana-Disease Evogene & SunGene, a BASF Plant Science company, to collaborate on next generation plant-biotechnology enabling technologies http://www.evogene.com/News-Events/Press-Releases/2007/Evogene--SunGene-a-BASF-Plant-Science-company-to-collaborate-on-next-generation-plant-biotechnology-enabling-technologies- Rehovot, Israel and Gatersleben, Germany - June 26th, 2007 - Evogene Ltd. (TASE: EVGN) and SunGene GmbH, a BASF Plant Science company, announced today their collaboration to develop next generation enabling technologies for the precise bioengineering of crops. The collaboration is supported under the Israel-Germany BioDisc program by the Office of the Chief Scientist of the Israeli Ministry of Science and Technology and by the German Federal Ministry of Education and Research. The BioDisc program aims at intensifying contacts between the two countries in areas such as future technologies with high potential. Currently, plant biotechnology provides methods for the introduction of target genes by which a high number of plants have to be analyzed. The goal of this collaboration is to enable the introduction of target genes into plant DNA in a new way by using integration sites that are especially suitable for the insertion of new genes. This will further increase efficiency in plant biotech research and development by reducing the number of plants that have to be analyzed. Biotech crops have had a tremendous impact on agriculture since the first product launch in 1996. In 2006, the number of farmers growing biotech crops exceeded 10 million and the annual area of biotech crops grown exceeded 100 million hectares - more than the surface area of France and Germany combined. Biotech seeds are broadly adopted in soybean, corn, cotton and canola and their sales were valued at over $6 billion and generated over $60 billion worth of agricultural produce. With an unprecedented 60-fold increase during the first decade of adoption it is one of the fastest adopted technologies in recent history. Nevertheless, experts in the field expect that more precise bioengineering methodologies would significantly increase the adoption of bioengineered crops by providing the potential for streamlining and simplifying the current processes. Mr. Ofer Haviv, Evogene's President and CEO, stated: "We are pleased to enter a multi-year collaboration with SunGene, which is dedicated to developing tools for precise engineering of plant genomes. We anticipate that all our projects will benefit from those tools. We are very excited about being able to work with a world class organization in our field like BASF Plant Science group." Dr. Jens Lerchl, SunGene's Managing Director, stated: "We are looking forward to a fruitful cooperation with Evogene, an organization known as being committed to develop improved methodologies in plant biotechnology. We will create synergies to both parties' benefit by combining expertise of the companies including BASF Plant Science which is BASF´s plant biotech company." About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology industry through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Until its spin-off as a separate company in 2002, Evogene was the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, was based on Compugen's proprietary LEADS computational platform. For additional information, please visit Evogene's Website at www.evogene.com. About SunGene - a BASF Plant Science company SunGene is a daughter company of BASF Plant Science. In order to take advantage of the possibilities of plant biotechnology, BASF, the chemical company, founded BASF Plant Science in 1998 as its own biotechnology company. BASF Plant Science coordinates a research and development platform in Europe and North America with about 700 employees among which SunGene is focusing on Metabolic Engineering of valuable plant compounds and Enabling Technologies. BASF Plant Science is working to optimize crops for the following sectors: more efficient agriculture, renewable raw materials for specialty products and healthier nutrition for humans and animals. These include, for example, plants with improved agronomic characteristics, a higher content of vitamins or omega-3 fatty acids for preventing cardiovascular diseases as well as plants with a higher nutritional value for animals. 26/06/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene--SunGene-a-BASF-Plant-Science-company-to-collaborate-on-next-generation-plant-biotechnology-enabling-technologies- Evogene presented at the New York-Israel Alternative and Renewable Energy Conference, New York, June 19th, 2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-presented-at-the-New-York-Israel-Alternative-and-Renewable-Energy-Conference-New-York-June-19th-2007 On June 19th 2007, Evogene gave a lecture at the New York-Israel Alternative and Renewable Energy & Cleantech Conference in New York. In the conference participated leading Israeli companies in the renewable energy field, such as "Ormat" and "Solel Solar Systems", and other leading figures from Industry, government, finance and academia. Mr. Assaf Oron, Evogene's VP Strategy and Business Development, gave a lecture on Evogene's leading developed products in crop biotechnology aimed at the biofuel industry. Evogene's Biofuel Activity, Alternative and Renewable Energy Conference, New York, June 19th 2007 19/06/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-presented-at-the-New-York-Israel-Alternative-and-Renewable-Energy-Conference-New-York-June-19th-2007 Bayer CropScience and Evogene to Collaborate on Crop Yield Improvement http://www.evogene.com/News-Events/Press-Releases/2007/Bayer-CropScience-and-Evogene-to-Collaborate-on-Crop-Yield-Improvement Rehovot, Israel and Monheim am Rhein Germany - June 18, 2007 -Evogene Ltd. (TASE: EVGN) and Bayer CropScience announced today a collaboration to increase the productivity and yield of a Bayer CropScience core crop, especially with regard to stress conditions such as drought. Under a recently signed agreement, Bayer CropScience, has exclusively licensed the rights to certain genes discovered by Evogene which have demonstrated improved plant yield and other performance enhancements in various plant species. Evogene is to receive an initial fee, success-based milestone payments and royalties on sales. "It is Evogene's goal to collaborate with the leading companies worldwide in creating plant varieties with improved traits based on our discoveries", stated Mr. Ofer Haviv, Evogene's President and CEO. "Therefore we are obviously delighted to begin this collaboration with Bayer CropScience for the improvement of this core crop." Mr. Haviv concluded. Dr. Michiel van Lookeren Campagne, Head of Research at BioScience, a business operations unit of Bayer CropScience, welcomes the new business relationship with Evogene. "Advantages in yield and yield stability have been the basis for the fast adoption of our superior hybrids. The integration of these discovered genes into our R&D pipeline can allow us to offer further benefits to our customers, especially with regard to ensuring high yields in difficult climatic conditions." About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agro-biotechnology industry through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Until its spin-off as a separate company in 2002, Evogene was the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in-silico technology, the ATHLETE, was based on Compugen's proprietary LEADS computational platform. For additional information, please visit Evogene's Website at www.evogene.com. About Bayer CropScience Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 5.7 billion (2006), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer Crop-Science has a global workforce of about 17,900 and is represented in more than 120 countries. 18/06/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Bayer-CropScience-and-Evogene-to-Collaborate-on-Crop-Yield-Improvement Evogene completes its Initial Public Offering on the Tel-Aviv stock exchange http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-completes-its-Initial-Public-Offering-on-the-Tel-Aviv-stock-exchange Raises approximately $8,000,000 including exercise of warrants from existing shareholders Rehovot, Israel - June 12th, 2007 - Evogene Ltd. announced today that it has completed an Initial Public Offering on the Tel Aviv Stock Exchange (TASE: EVGN). The company sold units consisting of ordinary shares, Series 1 warrants and Series 2 warrants. In total, 3,800,000 shares, 3,900,000 Series 1 warrants and 3,400,000 Series 2 warrants were sold in the offering. In addition, existing shareholders exercised warrants for approximately 2,000,000 ordinary shares, bringing the total new capital raised to approximately $8,000,000. The Series 1 warrants included in the IPO are exercisable until May 31st, 2009 at a price of 8.45 NIS ($2.02) per share; the Series 2 warrants are exercisable until May 31st, 2011 at a price of NIS 11.05 ($2.64) per share. The full exercise of both series of warrants would approximately generate an additional $16,800,000 of capital. Ofer Haviv, Evogene President and CEO stated: "We are very pleased to have completed this IPO which is a significant milestone for the company. The capital raised will enable us to expand our gene discovery efforts, to advance our products towards commercialization, to widen our activities in the field of Biofuels and to be full partners with leading companies worldwide in the development of products arising out of our unique and broadly applicable discovery capability". 13/06/2007 http://www.evogene.com/News-Events/Press-Releases/2007/Evogene-completes-its-Initial-Public-Offering-on-the-Tel-Aviv-stock-exchange The Evogene Biogemma corn abiotic stress project receives Eureka labeling and funding http://www.evogene.com/News-Events/Press-Releases/2007/The-Evogene-Biogemma-corn-abiotic-stress-project-receives-Eureka-labeling-and-funding The Evogene Biogemma collaboration announced in June 2006 and targeted at developing drought tolerant corn has been endorsed by EUREKA at the NPC meeting in Catania on 24/01/2007. The three year project designated E! 3739 CORNSTRESS received the Eureka label and will be funded under the Eureka scheme 24/02/2007 http://www.evogene.com/News-Events/Press-Releases/2007/The-Evogene-Biogemma-corn-abiotic-stress-project-receives-Eureka-labeling-and-funding Evogene Participates In Israeli Agbio Consortium http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Participates-In-Israeli-Agbio-Consortium Rehovot, Israel - November 28th, 2006 - Evogene Ltd. announced today its participation in the BIOTOV MAGNET Israeli research consortium. The Israeli MAGNET program (Generic Pre-Competitive Technologies and Research and Development) finances research consortia to develop enabling technologies in targeted high potential industries. The BIOTOV consortium is focused on enabling the expression of secondary metabolites in plants that can improve or restore taste or flavor in fruits and vegetables, as well as the enrichment of such fruits and vegetables for producing nutraceuticals. The consortium consists of a group of Israeli companies and academic institutes active in the field of agro-biotechnology, seed and flavors, including, in addition to Evogene, the two leading Israeli seed companies Hazera Genetics (TASE: HQS) and Zeraim Gedera, Rahan Meristem Ltd. a leading producer of banana plantlets and Frutarom Industries (TASE: FRUT; LSE:FRUT) a leading producer of flavors and fragrances. The academic institutes participating include the Hebrew University in Jerusalem, the Vulcani Institute (Agricultural Research Organization) and the Weizmann Institute of Science. A budget of approximately US$1.9 million has been approved for the first year of activity, of which the Israeli government will provide 66%. The consortium members estimate that a total budget of about US$9 million will be required over a three year period. Dr Eli Opper, Israeli Chief Scientist in the Ministry of Industry, Trade and Labor stated: "The target of the MAGNET consortium program is to support industry focused companies and academic institutions in the development of broadly applicable technologies to increase the competitiveness of targeted industry sectors. In this case, we are pleased to provide R&D support in the expanding area of agro-biotechnology for the development of healthier and tastier foods and food ingredients. The agro-biotechnology industry in Israel is relatively small, but the companies involved have proven to be both competitive on a world-wide basis and innovative. We have found that one of the most effective mechanisms we can use to support activities in highly competitive and rapidly growing international markets such as agbio is through the co-operative efforts fostered by Magnet consortia." Evogene's role in the consortium will be to design, create and integrate the genomic and metabolomics databases from public sources and the proprietary data generated by the consortium participants and to further develop computational biology tools to provide lead gene candidates for validation by the consortium participants. Dr Hagai Karchi, Evogene's CTO stated: "We are pleased to participate in this consortium of leading Israeli participants in the agbio field. Our participation in the BIOTOV consortium provides Evogene with the ability to develop additional state-of-the art database integration tools as well as access to significant proprietary data sources and relationship building. In addition, Evogene's role of database design, integration and the development of additional computational biology tools allows us to further develop our capabilities in systems biology". 28/11/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Participates-In-Israeli-Agbio-Consortium Evogene Establishes US Subsidiary in Boston http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Establishes-US-Subsidiary-in-Boston Rehovot, Israel - November 14th, 2006 - Evogene Ltd. announced today the establishment of Evogene Inc. as a subsidiary based in Boston, MA. The initial role for the subsidiary will be to co-ordinate Evogene's activities in North America with its licensees, with the expectation that in the future it would also manage field trials for Evogene products. Ofer Haviv, Evogene's CEO stated: "The North American market is the leading market in the field of agro-biotechnology both in terms of market share and the development of new improved crops. Essentially all major agbio companies are either located there or have substantial operations. For that reason we felt that it was essential for us to establish a presence to meet the needs of our current and future partners". 14/11/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Establishes-US-Subsidiary-in-Boston Evogene Strengthens its Scientific & Business Management Teams http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Strengthens-its-Scientific--Business-Management-Teams Rehovot, Israel - August 30, 2006 - Evogene announces that during the first half of 2006 it significantly strengthened its scientific and business management capabilities. Following its successful $7 second capital raising announced in March 2006, in order to continue the development of its computational biology tools and to support its growing pipeline of collaborations both signed and currently being negotiated, Evogene made significant additions to its scientific and business management teams during the first half of 2006. The most significant additions to the Evogene team are mentioned below: Mr. Assaf Oron: Director of Strategy and Business Development Mr. Oron has a mixed business and scientific background. Prior to joining Evogene, was managing ChondroSite Ltd., a biotechnology company developing tissue engineered products in the field of Orthopedics (2004-2006). Mr. Oron has over 5 years of experience in strategic consulting at POC Ltd., a leading Israeli management consulting company, where he served as senior project manager working with leading companies in the Israeli industry. Mr. Oron holds a M.Sc. in Biology and B.Sc. degrees in Economics and Chemistry from Tel Aviv University. Dr Tamara Byk-Tennenbaum: Director of the Technology Platform Prior to joining Evogene, Dr Byk has held management and research positions in the biotechnology industry in Israel as Head of the Life Science Research Unit at Procognia (2004-2006), and senior researcher at Quark Biotech Inc (QBI) (2000-2004). Dr Byk held various research and post doctoral positions including at the Weizmann Institute (Israel), and two INSERM research laboratories in Paris and Villejuif (France) (1992-2000). Dr Byk holds a Ph.D. (1992) and a M.Sc. (1986) in Biochemistry as well as a B.Sc. in chemistry (1983) from the Hebrew University of Jerusalem. Dr Eyal Emmanuel: Program Director - Biodiesel Prior to joining Evogene, Dr Emmanuel worked as a researcher at the Life Science Research Israel Co. In parallel, with his studies Dr Emmanuel also participated in commercial pepper breeding projects of the Faculty of Agriculture of the Hebrew University of Jerusalem (1995-1998) and also performed bioinformatics and data mining projects for Evogene (2001-2003). Dr Emmanuel holds a Ph.D. (2005) and a M.Sc. (2000) from the Department of Plant Science of the Weizmann Institute as well as a B.Sc. from the Faculty of Agriculture of the Hebrew University. Mr. Alex Diber: Department Manager - Computational Genomics Prior to joining Evogene, Mr. Diber worked for 12 years at Compugen joining the company in 1994 as one of its early employees initially as Software Engineer then evolving to Team Leader, Software Architect and in the last 6 years as Senior Bioinformatics Scientist. Mr Diber has been leading research projects related to integration and analysis of multiple data sources like genomic, expression, chip, pathway, protein-protein interaction and drug-related data. Mr Diber holds a B.A. in Computer Science for the University Ben Gurion University of the Negev (Cum Laude). Dr Ron Vunsh: Tissue Culture & Plant Transformation Prior to joining Evogene, Dr Vunsh was Senior Scientist at Fertiseed (2005-2006), the manager of the "Plant Transformation Center" of the Weizmann Institute (1995-2005), Senior Scientist and Manager of a commercial banana micropropagation laboratory owned by Rahan Meristem (1993-1995), Research Associate at the Volcani Institute (1989-1991), Scientific Manager of A.L. Research and development a plant micropropagation company (1987-1989) and Senior Scientist and Scientific Manager of the "International Genetic Sciences Partnership" (1983-1987). Dr Vunsh holds a Ph.D. (1981) from the Department of Plant Science of the Weizmann Institute, a M.Sc. in Biochemistry (1976) and a B.Sc. in Chemistry (1972) from the University of Tel Aviv. Dr Vunsh also performed post-doctoral research at the University of Illinois (1981-1983). Ofer Haviv, President and CEO for Evogene stated: "We are pleased to welcome such talented and experienced individuals to strengthen our team and ramp up our capabilities at a time where we are expanding our research pipeline and starting to sign significant partnerships". I am certain each and every one of these individuals will significantly contribute to Evogene's development. 30/08/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Strengthens-its-Scientific--Business-Management-Teams Evogene and Biogemma enter collaboration to develop drought tolerant corn http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-and-Biogemma-enter-collaboration-to-develop-drought-tolerant-corn Evogene and Biogemma enter collaboration to develop drought tolerant corn Rehovot, Israel and Paris, France - July 25, 2006 - Evogene and Biogemma announced today a collaboration to jointly develop commercial corn lines with improved tolerance to drought. Corn, one of the three global crops which "feed the world", matures during the peak summer months and requires significant amounts of water for optimum yield. Summer heat waves and drought spells are a major concern, often significantly reducing corn yield and creating billions of dollars in lost revenues for the growers. With the threat of global warming, scientists are facing a major hurdle: creating a more sustainable agriculture which will produce enough food with less water in order to feed a constantly growing population. Therefore, one of the most attractive target traits in the agro-biotechnology field is limiting yield losses in crops due to 'less than optimal' environmental conditions. For the past few years Evogene has been very active in this area. To date, and as part of Evogene's abiotic stress tolerance program, the company has identified a set of novel gene candidates that have been shown to provide high tolerance to adverse environmental conditions in a number of model crops. Drought resistance is known to be one on the most difficult traits to assess. Biogemma has developed different genomic approaches to define the best product. It includes gene candidates, expression and germplasm interaction in particular. Ofer Haviv, President and CEO for Evogene stated: "We have been extremely pleased with our accomplishments to date in predicting and validating important genes for abiotic stress, and look forward to collaborating with Biogemma's world class agro-biotechnology team in the development of drought resistant corn. Michel Debrand, CEO for Biogemma "We have identified Evogene to be one of the most promising biotech research companies, especially in the area of plants tolerant to drought. Combining the expertise of Biogemma and Evogene is extremely exciting. We believe we will be very successful. About Biogemma Biogemma is a leading biotech company in Europe involved in Genomics applied to Field crops. Result of the merger of the biotech activity of three major seed business companies, and with the help of two financial institutions, the company is developing R&D programs with its partners, mainly in corn and wheat focused on biotic and abiotic stresses and specialty grain compounds. For additional information, please visit Biogemma's Website at www.biogemma.com. About Evogene Evogene's mission is to be a world leader in delivering improved plant traits to the agbio industry through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene's current product development portfolio includes such traits as abiotic stress tolerance and yield, enhancement of cotton fiber quality; improving nitrogen use efficiency, and plant manufacturing of therapeutic proteins. Until its spin-off as a separate company in 2002, Evogene was the agbio division of Compugen Ltd. (Nasdaq: CGEN). Evogene's core in silico technology was built on Compugen's proprietary LEADS platform and it maintains a license for its use in the agbio field. For additional information, please visit Evogene's Website at www.evogene.com. 25/07/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-and-Biogemma-enter-collaboration-to-develop-drought-tolerant-corn Biogemma & Evogene participate in European Research Consortium http://www.evogene.com/News-Events/Press-Releases/2006/Biogemma--Evogene-participate-in-European-Research-Consortium Biogemma & Evogene participate in European Research Consortium The goal of the consortium is targeted gene integration in plants (TAGIP) Rehovot, Israel and Paris, France - June 13th, 2006 - Evogene Ltd. and Biogemma announced today their participation in the TAGIP European FP6 research consortium. The TAGIP consortium is focused on enabling the targeted integration of genes in plants. The consortium, led by Professor Avi Levy of the Weizmann Institute of Science, includes, in addition to the two commercial partners, six academic institutions. The academic partners are: Prof. Karel Angelis of the Institute of Experimental Botany of the Czech Academy of Sciences (Czech Republic), Prof. Barbara Hohn of the Friedrich Miescher Institute of Basel (Switzerland), Prof. Jerzy Paszkowski of the University of Geneva (Switzerland), Prof. Holger Puchta of Karlsruhe University (Germany) and Prof. Charles White of the Centre National de la Recherche Scientifique (France). The coordination of the consortium is ensured by OSM-Dan Ltd. managed by Dr Pnina Dan. Dr Hagai Karchi, Evogene's VP of R&D stated: "We are pleased to participate in this consortium with such an elite group of partners. The TAGIP partnership will provide Evogene with additional state-of-the art tools for precise engineering of plant genomes. We anticipate that all our projects can benefit from those tools, in particular, we will evaluate the use of the technology for our Plant Manufactured Protein project." Dr Pascual Perez, Biogemma's Research Coordinator: "The technology is designed to allow the introduction of genes in plants in a targeted area of the genome, which can significantly improve the speed at which modified plants can be developed, minimizing the transformation position effect, and thereby simplifying the regulatory process. This program is therefore of particular interest for the whole seed industry." About Evogene Evogene is a biotechnology company focused on developing high-value commercial products based on plant genomics. The company is merging state-of-the-art predictive computational biology and molecular biology with the most advanced breeding technologies. Evogene's current product development portfolio is focused on: improving abiotic stress tolerance and yield in key crops such as corn, soya, cotton, tomato and canola; enhancing fiber development in cotton; improving nitrogen use efficiency for key crops and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 by Drs. Hagai Karchi and Rafi Meissner as a plant biotechnology spin-off of Compugen Ltd. (Nasdaq: CGEN) and has a broad license to utilize certain Compugen technology in the agbio field. For additional information, please visit Evogene's Website at www.evogene.com. About Biogemma Biogemma is a leading biotech company in Europe involved in Genomics applied to Field crops. The company is developing R&D programs with its partners, mainly in corn and wheat focused on biotic and abiotic stresses and specialty grain compounds. For additional information, please visit Biogemma's Website at www.biogemma.com. 13/06/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Biogemma--Evogene-participate-in-European-Research-Consortium Evogene Completes $7 Million Financing http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Completes-7-Million-Financing Rehovot, Israel - March 1st, 2006 - Evogene Ltd. announced today that it has completed its second round of financing, raising $7 million from existing and new investors from Israel, Europe and North America. Evogene previously announced the initial $1.75 million of this round which was in the form of a convertible bridge loan from existing investors. Ofer Haviv, President and CEO stated: "We appreciate the continuing support and confidence shown by our initial investors and are pleased to welcome new investors as we broaden the ownership base of the company." Mr. Haviv continued, "Although a relatively young company, Evogene is developing an attractive pipeline of improved plant traits and is currently in discussions with a number of leading agbio companies about various forms of collaboration and licensing arrangements" 01/03/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-Completes-7-Million-Financing Evogene gave a lecture at the 2006 Beltwide Cotton Conference in San Antonio, Texas, on Friday, January 6, 2006 in the Cotton Improvement Session. http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-gave-a-lecture-at-the-2006-Beltwide-Cotton-Conference-in-San-Antonio-Texas-on-Friday-January-6-2006-in-the-Cotton-Improvement-Session Presented by Dr Sharon Ayal, Cotton Project Leader Evo 101: A new gene candidate with a key role to modulate cotton Fiber 06/01/2006 http://www.evogene.com/News-Events/Press-Releases/2006/Evogene-gave-a-lecture-at-the-2006-Beltwide-Cotton-Conference-in-San-Antonio-Texas-on-Friday-January-6-2006-in-the-Cotton-Improvement-Session Evogene announces soybean collaboration with Mertec, LLC http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-announces-soybean-collaboration-with-Mertec-LLC Rehovot, Israel - November 16, 2004 - Evogene Ltd. announced today an agreement with Mertec, LLC for the development and marketing of soybean seeds with improved traits. The two companies will bring newly developed traits from Evogene to the market in soybean varieties developed by Mertec. Mertec will market the co-developed soybean varieties using their strong industry channels. Financial terms were not disclosed. Joseph H. Merschman, Mertec's President, said: "We are excited about our partnership with Evogene. This collaboration strengthens our ability to deliver innovative products to our dealers and farmer customers." Dr Hagai Karchi, CEO for Evogene, stated: "We are very pleased to have the opportunity to collaborate with Mertec, an industry leading soybean germplasm and seed supplier. Soybean is the most widespread biotechnology enhanced crop globally, and we are confident that certain traits in our existing development pipeline will provide the basis for significant improvements." About Evogene Ltd Evogene's mission is to become a leading developer of improved traits in plants. The Company's high-throughput platform combine state-of-the-art computational genomics, molecular biology and advanced classical breeding methods in order to accelerate, direct and mimic the natural evolution process. Evogene's current product development efforts are focused on enhanced fiber in cotton; abiotic stress tolerance and nitrogen use efficiency for various crops; and a unique plant platform for the production of therapeutic proteins. For additional information, please visit Evogene's Website at www.evogene.com. About Mertec, LLC Mertec, LLC, based in West Point, Iowa, is a leading breeder and developer of soybean germplasm for the seed trade. Mertec has an extensive line-up of soybean germplasm for the maturities in the United States. Mertec has entered into strategic relationships with biotech and life science companies to deliver the latest traits and technologies to farmer growers in Mertec's high yielding soybean germplasm. 16/11/2005 http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-announces-soybean-collaboration-with-Mertec-LLC Evogene gave a lecture at the Genomics in Business Congress in Holland on Tuesday, October 4, 2005 in the Applied Bioinformatics Session. http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-gave-a-lecture-at-the-Genomics-in-Business-Congress-in-Holland-on-Tuesday-October-4-2005-in-the-Applied-Bioinformatics-Session- Presented by Dr Rodrigo Yelin, Director of Computational Genomics "From Genomic Data to Improved Traits" 06/09/2005 http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-gave-a-lecture-at-the-Genomics-in-Business-Congress-in-Holland-on-Tuesday-October-4-2005-in-the-Applied-Bioinformatics-Session- Evogene completes $1.75 Million Private Placement http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-completes-175-Million-Private-Placement Rehovot, Israel - May 31st, 2005 - Evogene Ltd. announced today that it has received $1.75 million in new capital from its existing as well as new investors from Israel, France and North America. Ofer Haviv, President and CEO stated: "We are pleased to benefit from the continuing support and confidence from our current investors and are pleased to welcome the new investors to Evogene. We believe that this additional investment will help us in establishing Evogene as a leading developer of plant agro-biotechnology traits and to speed up the development of our unique plant platform for the production of therapeutic proteins". 31/05/2005 http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-completes-175-Million-Private-Placement Evogene Appoints Ofer Haviv as President and CEO http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-Appoints-Ofer-Haviv-as-President-and-CEO Rehovot, Israel - May 31st, 2005 - Evogene today announced the appointment of Ofer Haviv as President and Chief Executive Officer. Previously, Haviv was the Company's Chief Operating and Financial Officer. Dr Hagai Karchi, who co-founded Evogene in 2002 and has served as CEO since that time, has been appointed Chief Scientific Officer. In addition, the company announced a number of changes to its Board of Directors. Martin Gerstel, chairman of Compugen Ltd, the parent company of Evogene has been appointed Chairman, Leon Recanati, Chairman and CEO of GlenRock Israel has been elected a director, and Professor Ilan Chet, President of the Weizmann Institute, has been appointed as a special advisor to the Board. Mr. Gerstel stated, "We are extremely pleased to be adding these distinguished leaders to the Evogene family. This is another important step which, along with the financing also announced today, helps position the Company to obtain the maximum future value from our broad technology base and our four lead programs". Mr. Ofer Haviv said: "I want to thank Hagai for providing the leadership in establishing an excellent foundation - in terms of research directions, scientific talent, technologies and initial projects - on which I am confident we can now build a substantial, and unique, multidisciplinary plant biotechnology company. I very much look forward to his continuing contributions as we aggressively pursue this opportunity." Dr .Hagai Karchi said: "Having lead the development of the company and its technologies since founding it together with Dr Rafi Meissner, moving forward I believe it is appropriate for me to concentrate on our technologies and products, the areas where I believe I can have the most impact. Having worked closely with Ofer for the past few years, there is no doubt in my mind that he is the right person to lead Evogene as we begin to focus on commercializing our initial programs." Mr. Martin Gerstel Mr. Gerstel has served as the chairman of Compugen Ltd since August 1997. Prior to relocating to Israel in 1994, Mr. Gerstel was co-chairman and CEO of ALZA Corporation, which he helped found in 1968. Mr. Gerstel is also the co-founder and co-chairman of Itamar Medical, chairman of Keddem Bioscience, and serves as a director of Symyx Technologies, Yissum Ltd, Yeda Ltd and the Foundation for the United States National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University, and is an advisor to the Burrill Life Science Funds and the board of the Israel-U.S. Bi-national Industrial Research and Development (BIRD) Foundation. Mr. Gerstel holds a B.S. from Yale University and an MBA from Stanford University. Dr Leon Recanati Dr Leon Recanati is the founder and CEO of GlenRock Israel, a private Equity group. Until May 2003, Leon was CEO and Chairman of IDB Holding Corporation, one of the largest investment groups in Israel. Also, Leon was Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Until 1997, Leon was chairman of Delek Israel Fuel Corporation and Super-Sol, in addition to several other positions in a variety of operating companies in Israel. Born in Israel, Leon is the third generation of the Recanati family - a driving force in the Israeli economy and Israeli society since pre-statehood days. Leon received his BA and M.B.A. from The Hebrew University of Jerusalem, and an Honorary Doctorate from the Technion Institute of Technology and Tel Aviv University. Leon's personal involvement in organizations and diverse causes has earned him a reputation as one of Israel's outstanding community leaders. He is Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association, and Chairman of Tel-Aviv University's Development Committee. He also is an active member of the Board of Governors of Tel-Aviv University and the Hebrew University of Jerusalem, The Technion, Weizmann Institute, The Chaim Herzog Center for Middle East Studies and Diplomacy at Ben-Gurion University, the Tel Aviv Museum of Art, the Jewish Agency, and Chairman of Tapuah - The Israeli Society for the Advancement of the Information Age. Professor Ilan Chet Since 2001, Professor Ilan Chet is the President of the Weizmann Institute of Science. Since 2000, he is a member of the Advisory Panel of NATO Science Program and since 1998, a member of the External Advisory Group (EAG) to the European Union Research. He is chairman of the Rothschild Prize Committee and Chairman of the Committee for scientific research prizes of the national lottery of Israel. Form 1992 to 2001, VP of R&D of the University of Jerusalem; from 1984 to 94; Visiting Professor at numerous Universities; from 1986 to 89, Dean, Faculty of Agriculture; from 1983 to 86, Director, Otto Warburg Center of Biotechnology in Agriculture; from 1981 to 83, Head of the Dept. of Plant Pathology and Microbiology, Faculty of Agriculture, Hebrew Univ. 1978, Professor of Microbiology; 1975, Assoc. Professor of Microbiology; 1972, Sr. Lecturer in Microbiology Prof. Chet holds a PhD, Hebrew Univ. Jerusalem (1968); an MSc (Hons), Hebrew Univ. of Jerusalem (1964) and a BSc (Hons), Faculty of Agriculture (1962). 31/05/2005 http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-Appoints-Ofer-Haviv-as-President-and-CEO Evogene to enter a research collaboration with the Faculty of Agriculture of the Hebrew University on improved taste and aroma of tomatoes http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-to-enter-a-research-collaboration-with-the-Faculty-of-Agriculture-of-the-Hebrew-University-on-improved-taste-and-aroma-of-tomatoes Evogene to enter a research collaboration with the Faculty of Agriculture of the Hebrew University on improved taste and aroma of tomatoes Rehovot, Israel - May 24th 2005 - Evogene Ltd and BonTom - Breeding & Research Group of the Faculty of Agriculture of the Hebrew University of Jerusalem, announced today a research collaboration agreement to jointly develop tomato varieties with improved taste and high impact aroma. Over the years as a result of the efforts to increase tomato yields, the original taste and aroma of tomatoes has been greatly reduced. Many efforts are invested in the attempt to regain taste and aroma to the tomato fruit without losing productivity, but with only modest success. The new endeavor collaboration is based on Evogene's expertise in computational genomics and its proprietary tomato genomics database, and on BonTom's rich gene pool of tomato and the genetics and breeding capabilities of the Faculty of Agriculture tomato breeding team. This joint effort is directed at isolating genomic markers that can track key taste and aroma genes for use in breeding programs. The partners will use the new markers & knowledge developed during the collaboration as tools to improve tomato varieties. Dr Hagai Karchi of Evogene, stated: "The access to the extensive tomato germplasm and the multi-year breeding experience of The Faculty of Agriculture is the perfect complement to quickly create value via our advanced gene and marker discovery tools." About Evogene Evogene is a biotechnology company focused on developing high-value commercial products based on plant genomics. The company is merging state-of-the-art predictive computational biology and molecular biology with the most advanced breeding technologies. Evogene's current product development portfolio is focused on: improving abiotic stress tolerance and yield in key crops such as corn, soya, cotton and canola: enhancing fiber development in cotton; improving nitrogen use efficiency and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 by Drs. Hagai Karchi and Rafi Meissner as a plant biotechnology spin-off of Compugen Ltd (Nasdaq: CGEN). For additional information, please visit Evogene's Website at www.evogene.com. About BonTom - Seed Breeding & Research Group BonTom, based in the Faculty of Agriculture of the Hebrew University of Jerusalem, Israel, is a leading provider of tomato varieties and one of the largest breeders group of tomatoes in the world. The group is best known for its long shelf life varieties as well as for many Cherry tomato cultivars with excellent yield and flavor. BonTom, led by Prof. Nachum Kedar and Prof. Haim Rabinowitch, has an assortment of promising new products that enable seed companies to offer growers and customers better tomato varieties. With substantial investment in research and development and a staff of more than 30 research and development employees, BonTom has a powerfull capability to invent, develop and sustain innovative tomato varieties. 24/05/2005 http://www.evogene.com/News-Events/Press-Releases/2005/Evogene-to-enter-a-research-collaboration-with-the-Faculty-of-Agriculture-of-the-Hebrew-University-on-improved-taste-and-aroma-of-tomatoes Evogene to evaluate plant-based production of Compugen therapeutic protein candidates http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-to-evaluate-plant-based-production-of-Compugen-therapeutic-protein-candidates Rehovot, Israel - October 25th, 2004 - Evogene Ltd., a pioneer in plant biotechnology, announced today an agreement with Compugen Ltd. (Nasdaq: CGEN), a genomics based drug and diagnostics discovery company, to evaluate the production of three of Compugen's therapeutic protein candidates using Evogene's proprietary "Plant Made Pharmaceutical" (PMP) platform. Under the agreement, Compugen will supply the sequence information of three therapeutic protein candidates. The proteins were discovered through the use of its powerful predictive models and discovery engines, and underwent further in-house wet validation. Evogene will study the feasibility of producing these therapeutic protein candidates using its proprietary plant-based protein production platform. The advent of recombinant DNA technology has resulted in numerous breakthrough biopharmaceutical products in areas such as cancer, autoimmune disease and cardiovascular disease. More than ninety approvals or new indications for biopharmaceuticals have been granted by the FDA since 2000, and more than 1000 protein-based therapeutics are at various stages of development, with 200-300 in late stage clinical trials. Currently, mammalian cell culture is the dominant method for the manufacture of biological products, but mammalian cell culture production is complex and costly. It is characterized by long process development and scale-up times (3-5 years), high and rigid capital requirements ($250M -$500M) and elevated operating costs. The use of modified plants for human protein production is an area of great interest in the industry, and a number of companies are attempting to create platforms for this purpose. Production of human proteins in plants potentially has substantial economic and qualitative benefits, including reduced health risks from pathogen contamination (such as prions responsible for mad-cow disease) and mammalian viruses (such as HIV and Hepatitis B), lower capital requirements and operating costs, faster scale up and much greater production flexibility. In addition to providing these potential advantages of protein production in plants, Evogene's proprietary platform addresses two of the major bottlenecks inherent in most plant protein production platforms now in development by others: harvesting and extraction of the target protein and its subsequent purification. The uniqueness of Evogene's platform is that it is based on utilizing the existing machinery of a specific plant tissue that naturally produces a very high concentration of a native protein, and the plant tissue allows easy harvesting and extraction of the protein. An additional advantage is that the plant platform has been designed to be grown under containment conditions. Ofer Haviv, COO & CFO for Evogene, stated: "We are pleased to have the opportunity to validate the development of our plant based protein production platform on Compugen's novel therapeutic protein candidates with real application potential." 25/10/2004 http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-to-evaluate-plant-based-production-of-Compugen-therapeutic-protein-candidates Evogene and Zeraim Gedera to jointly develop salt tolerant tomato varieties http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-and-Zeraim-Gedera-to-jointly-develop-salt-tolerant-tomato-varieties Rehovot, Israel - September 20th 2004 - Evogene Ltd, a pioneer in plant biotechnology, and Zeraim Gedera, a leading Israeli seed company, today announced the signature of a collaboration agreement for the joint development and commercialization of salt tolerant tomato rootstocks and seed varieties. The collaboration includes the joint development by the partners of tomato lines tolerant to high salinity levels. The leading tomato growing areas in the world such as California and the Mediterranean area rely heavily on irrigation. Due to massive irrigation practice and the use of water sources with increasing salinity levels, many of these major growing areas are becoming affected by accumulated soil salinity, which requires the development of tomato lines with good performance in these conditions. The project will make use of tomato genetic material pre-selected by Evogene through its unique high throughput system, which enables the selection of plants highly tolerant to salinity. The partners will jointly develop high salinity tolerant tomato lines with the required commercial performance. The partners will also use Evogene's genomic marker discovery using its computational genomics capabilities to track the salinity performance of the developed products. Zeraim Gedera will be responsible for the breeding of the varieties and rootstocks by contributing its existing commercial tomato germplasm and implementing its extensive breeding experience. Zeraim Gedera will also take care of producing the seed and marketing the developed tomato varieties in the target markets. Ofer Haviv, COO for Evogene, stated: "We are very pleased to enter into this cooperation with a company with established leading tomato marketing capabilities. This cooperation validates Evogene's business model to become a leading provider of improved plant traits together with seed companies". Ohad Zuckerman, CEO of Zeraim Gedera stated: "This project is a great example of synergy between companies with complementing capabilities. Initially, we planned to enter this market by ourselves, using traditional breeding. By joining hands with Evogene we believe our return on investment will be better since Evogene's technology will shorten our time-to-market". About Evogene Evogene Ltd. mission is to become a leading developer of 'improved trait plants' via a proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced classical breeding methods. This objective is accomplished through the development of high-throughput, economically efficient platforms that accelerate, direct and mimic the natural evolution process. Evogene's current research efforts are focused in three areas: key trait improvements in cotton; gene discovery for abiotic stress tolerance and plant nutrient uptake; and a proprietary platform for the production of therapeutic proteins in plants. Initiated in 1999 as a division of Compugen (NASDAQ: CGEN); Evogene was established as a separate company in 2002 by Compugen and founders Drs. Hagai Karchi and Rafi Meissner. For additional information, please visit Evogene's Website at www.evogene.com. About Zeraim Gedera Zeraim Gedera established in 1952, breeds high quality vegetable varieties and markets the seeds of such varieties worldwide. Company's breeding programs are aimed at developing fruit qualities attractive to consumers such as specific visual traits, long shelf life, superior taste and nutritional values together with traits important to the growers such as high yield and resistance to various diseases and pests. Zeraim Gedera maintains a very strong IP position in Tomato developments. The Company is a "green" company, which uses Biotechnology as a tool to upgrade its present and future R&D activities but does not breed transgenic varieties. Zeraim Gedera focuses on the "high end" of both the growers and the consumers in various markets in the Mediterranean Basin, China, North America and selected markets in South America and Asia. For additional information, please visit Zeraim Gedera's website at www.zeraimgedera.com. 20/09/2004 http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-and-Zeraim-Gedera-to-jointly-develop-salt-tolerant-tomato-varieties Evogene and CIRAD sign a Frame Agreement for collaboration for the development of abiotic stress tolerant cotton http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-and-CIRAD-sign-a-Frame-Agreement-for-collaboration-for-the-development-of-abiotic-stress-tolerant-cotton Rehovot, Israel - June 9th, 2004 - Evogene Ltd, a privately owned pioneer in plant biotechnology, and CIRAD, a French scientific organization, announce the signature of a multi-year collaboration for the development of abiotic stress tolerant cotton. Evogene is an emerging company focused on the improvement of crops and the production of plant derived products. The company is unique in merging state-of-the-art predictive computational biology and molecular biology with the most advanced classical breeding technologies. CIRAD (Centre de Cooperation Internationale en Recherche Agronomique pour le Developement) is the French Agricultural Research Centre for international Development for the tropics and subtropics. The multiyear collaboration includes technology exchanges, screening by Evogene in high abiotic stress conditions in Israel of a broad collection of wild cotton germplasm from CIRAD and introduction into cotton of proprietary gene constructs discovered by Evogene using its predictive computational biology capabilities. Each partner will be free to exploit the product of the joint collaboration in certain geographic areas and with third parties consistent with the fulfillment of its mission. Julien Meissonnier, VP of Business Development for Evogene, stated: "We are very pleased to enter a long term cooperation with CIRAD which has first class cotton research activities and decades of experience in developing cotton varieties adapted to difficult climates". Dr Raphael Meissner, VP and Head of R&D, stated: "In collaboration with CIRAD we will be able to get the best performance in cotton and add value to Evogene's constructs for improved abiotic stress tolerance discovered and already validated in other plants." Jacques Pages, Head of Cirad Cotton research program looks forward to promising perspectives: "Research activities in which we are engaging with Evogene are based upon the most advanced techniques in the field of molecular biology and gene operating process. The goal at stake is to improve cotton resistance to drought stress. This scope is clearly in CIRAD's mandate to contribute through scientific knowledge and its application to the improvement of southern farmers' living conditions. The project will also give opportunity to both partners to master techniques that could lead to numerous applications. It will eventually strengthen collaboration between French and Israeli scientists within the international scientific community". About CIRAD CIRAD, the "Centre de cooperation internationale en recherche agronomique pour le d?veloppement", is the French Agricultural Research Centre for international Development. Its mission is to contribute to the economic development of the tropical and subtropical regions through research on agriculture, training, and dissemination of its results. It employs 1,850 people, including 950 senior staff, working in French overseas departments and some fifty other countries. Its budget amounts to approximately 180 million Euros. CIRAD has seven research departments: annual crops; perennial crops; fruit and horticultural crops; animal production and veterinary medicine; forestry; land, environment and people; and advanced methods for innovation in science. CIRAD operates through its own research centres, collaborating with national agricultural research systems, universities and international centres, as well as development projects. CIRAD runs a cotton program with a staff of 50 including 40 researchers and 10 technicians, in Africa, the Americas, South East Asia and Montpellier (France) (for more information www.cirad.fr). About Evogene Evogene Ltd. is a pioneer in integrating predictive computational biology and plant genomics with classical breeding to generate improved crops and new agricultural biotechnology products. This objective is accomplished through the development of high-throughput, economically efficient platforms that accelerate, direct and mimic the natural evolution process. Evogene's current research efforts are focused in three areas: key trait improvements in cotton; gene discovery for abiotic stress tolerance and plant nutrient uptake; and a proprietary platform for the production of therapeutic proteins in plants. Evogene's activities were initiated in 1999 as a division of Compugen (NASDAQ: CGEN); in 2002 Evogene was created as a separate company founded by Compugen and Drs. Hagai Karchi and Rafi Meissner. For additional information, please visit Evogene's Website at www.evogene.com. 30/06/2004 http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-and-CIRAD-sign-a-Frame-Agreement-for-collaboration-for-the-development-of-abiotic-stress-tolerant-cotton Evogene completes second closing of initial private placement http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-completes-second-closing-of-initial-private-placement- Rehovot, Israel - February 25th, 2004 - Evogene Ltd. announced today that it has completed a second closing of its initial private placement in the amount of $1.5 million bringing the total for the first round to $3.5 million. The first closing took place in March 2003. The second closing was restricted to the group of United States, European and Israeli investors that participated in the first closing. Evogene is an emerging company focusing on the improvement of crops and the production of plant derived products. The company is unique in merging state-of-the-art predictive computational biology and molecular biology with the most advanced classical breeding technologies. Its computational biology activities include a license to use Compugen's (Nasdaq: CGEN) LEADS computational biology research engine in the field of agro-biotechnology. Hagai Karchi, Ph.D., chief executive officer of Evogene Ltd, said "We are extremely pleased with our progress to date and this additional funding will allow us to accelerate our activities related to potential agreements with agro-biotechnology partners as well as the development of our main internal projects: key trait improvements in cotton, gene and promoter discovery in monocots (rice, maize and cereals) and a proprietary platform for the production of therapeutic proteins in plants". Ofer Haviv, CPA, chief operating officer of Evogene, added, "We are very pleased with this additional vote of confidence from our investors, almost all of whom participated in this second closing". 25/02/2004 http://www.evogene.com/News-Events/Press-Releases/2004/Evogene-completes-second-closing-of-initial-private-placement- Evogene’s Fourth Quarter and Full Year 2015 Earnings Announcement Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Fourth-Quarter-and-Full-Year-2015-Earnings-Announcement-Schedule http://www.evogene.com/News-Events/Press-Releases/2015/Evogenes-Fourth-Quarter-and-Full-Year-2015-Earnings-Announcement-Schedule